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1. Resumen 
 
La hipófisis es una glándula endocrina de pequeño tamaño pero de vital importancia 
localizada en la base del cerebro y constituida por dos regiones, una glandular, la 
adenohipófisis, compuesta por los lóbulos anterior e intermedio, y otra de origen neural, la 
neurohipófisis o lóbulo posterior. La adenohipófisis está compuesta por cinco tipos de células 
endocrinas productoras de hormonas entre las que se encuentran las células somatotropas, 
lactotropas, corticotropas, gonadotropas y tirotropas, las cuales sintetizan y secretan hormona 
del crecimiento (GH), prolactina (PRL), corticotropina (ACTH), hormona foliculoestimulante 
(FSH) y luteinizante (LH), y tirotropina (TSH), respectivamente. La hipófisis es responsable del 
control de múltiples funciones biológicas (crecimiento, reproducción, metabolismo, respuesta 
al estrés, etc.) y está regulada por una compleja red de señales moduladoras que actúan a 
través de diversos receptores para integrar y procesar toda la información recibida con el fin 
de controlar la síntesis y secreción de las diferentes hormonas hipofisarias. Específicamente, 
esta regulación fina es ejercida por señales centrales (GHRH, GNRH, CRH, TRH, somatostatina, 
dopamina, etc.) y periféricas (glucocorticoides, adipoquinas, hormonas tiroideas, testosterona, 
estrógenos, ghrelina, obestatina, etc.) y el adecuado balance entre todas estas señales 
aseguran el apropiado funcionamiento de la glándula y, por lo tanto, del organismo.  
La alteración neoplásica de algunos de los tipos celulares hipofisarios da lugar al 
desarrollo de los tumores neuroendocrinos hipofisarios, los cuales constituyen el 15% de 
todos los tumores cerebrales. Diversos estudios han descrito que estos tumores se generan a 
partir de una expansión monoclonal de células alteradas genéticamente y que la desregulación 
de los factores reguladores mencionados previamente tendría un papel importante en dicha 
transformación. Desde un punto de vista clínico, los tumores hipofisarios se clasifican en 
tumores hipofisarios no funcionantes (NFPTs), gonadotropinomas (FSH/LHomas), 
prolactinomas (PRLomas), somatotropinomas (GHomas), corticotropinomas (ACTHomas) y 
tirotropinomas (TSHomas). Aunque la cirugía trans-esfenoidal es la primera opción de terapia 
para pacientes con tumores hipofisarios, en muchos casos no se consigue un control adecuado 
de la enfermedad y es necesario el uso de terapias farmacológicas. En este sentido, los 
análogos de somatostatina (octreótido, pasireótido y lanreótido) y los agonistas de dopamina 
(cabergolina) son las opciones terapéuticas que se emplean actualmente en la práctica clínica. 
Sin embargo, aunque estos fármacos han demostrado tener una alta eficacia reduciendo el 
tamaño tumoral y la hipersecreción hormonal, distintos estudios demuestran que muchos 
pacientes son (o se vuelven) resistentes a estos tratamientos. Por ello, es necesaria la 
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búsqueda de nuevas opciones terapéuticas que enriquezcan el conjunto de fármacos 
actualmente disponibles para tratar estas patologías tumorales.  
 
En este sentido, una de las estrategias actuales para la generación de nuevos fármacos es 
la síntesis de derivados químicos de drogas actuales (análogos de somatostatina, agonistas de 
dopamina) que presenten mayor afinidad, potencia y/o eficacia que los actuales. 
Adicionalmente, una fuente para la identificación de nuevos fármacos es el reposicionamiento 
de drogas que están actualmente en el mercado y que son clínicamente seguras, como el caso 
de las biguanidas (como la metformina) y las estatinas, ya que son tratamientos 
farmacológicos que se emplean actualmente en la práctica clínica para controlar alteraciones 
metabólicas causadas por condiciones patológicas como las diabetes, la obesidad o la 
hipercolesterolemia y que podrían ejercer acciones directas a nivel de la glándula hipofisaria 
modulando su función bajo condiciones normales y/o patológicas. Finalmente, cabe también 
destacar que aunque la causa inicial de la aparición de los tumores neuroendocrinos 
hipofisarios aún no se ha esclarecido totalmente, estudios recientes sugieren que la alteración 
de los procesos fisiológicos de splicing alternativo y la aparición de variantes aberrantes de 
splicing es una característica común en la mayoría de las patologías tumorales y, por lo tanto, 
podría representar una nueva vía para la identificación de nuevas dianas para el diagnóstico, 
pronostico y/o tratamiento de las patologías tumorales. 
 
Por todo esto, el objetivo principal de esta Tesis ha sido profundizar en un conocimiento 
celular, molecular y clínicamente relevante de la regulación fisiopatológica de la glándula 
hipofisaria, y de los tumores neuroendocrinos hipofisarios, a través de la identificación de 
nuevos factores y mecanismos involucrados en la respuesta funcional a diferentes terapias 
farmacológicas.  
 
En primer lugar, los resultados obtenidos en esta Tesis Doctoral demuestran que las 
biguanidas (metformina, buformina y fenformina), familia de compuestos antidiabéticos, 
ejercen efectos directos en células derivadas de diferentes tipos de tumores hipofisarios, 
reduciendo la proliferación celular y la secreción hormonal, e incrementando la apoptosis en 
GHomas, al menos en el caso de la metformina. Todos estos efectos parecen estar mediados 
por la modulación de mecanismos dependientes ([Ca2+]i y ruta PI3K) e independientes de 
AMPK (ruta de ERK). Además, evaluamos la posible asociación entre el tratamiento con 
metformina y diversos parámetros clínicos en pacientes con tumores hipofisarios. Sin 
embargo, el uso de metformina no se relacionó con ninguna de las variables clínicas 
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determinadas en nuestra cohorte de pacientes, lo cual podría ser debido al limitado número 
de pacientes tratados con este fármaco. De forma paralela, encontramos que la metformina 
puede afectar directamente a las células somatotropas, corticotropas y gonadotropas 
normales de dos especies de primates (Papio anubis y Macaca fascicularis), alterando la 
secreción hormonal, la expresión génica y la señalización celular, todo ello sin afectar a la 
viabilidad celular. Así, el efecto de la metformina sobre la secreción de GH, ACTH y FSH se 
produjo a través de las rutas de mTOR, PI3K y de la movilización de Ca2+ intracelular. Además, 
la ruta de la MAPK también fue esencial para las acciones de la metformina sobre la secreción 
de GH. Estos resultados podrían tener una gran relevancia translacional puesto que las 
acciones inhibidoras de la metformina sobre la secreción de GH y ACTH podrían ser 
beneficiosas desde el punto de vista metabólico ya que varios estudios han demostrado que el 
incremento de los niveles circulantes de GH y de glucocorticoides puede desencadenar 
resistencia a la insulina, intolerancia a la glucosa y diabetes mellitus.  
 
En la misma línea, durante el desarrollo de esta Tesis también se han estudiado los 
efectos directos de la simvastatina (compuesto de la familia de las estatinas usado en clínica 
para reducir la hipercolesterolemia) sobre parámetros funcionales relevantes en cultivos 
primarios de diferentes tipos de tumores hipofisarios y líneas celulares, así como su efecto en 
cultivos primarios de células hipofisarias normales procedentes de una especie de primate 
(Papio anubis). Nuestros resultados demuestran que la simvastatina puede reducir la viabilidad 
celular y la secreción hormonal en células de tumores hipofisarios a través de la modulación de 
MAPK. Sin embargo, la combinación de simvastatina con metformina o análogos de 
somatostatina no resultó en ningún efecto aditivo de estos fármacos. Al igual que en el caso de 
la metformina, exploramos la posible asociación entre el tratamiento con estatinas y diversos 
parámetros clínicos en pacientes con tumores hipofisarios. En este caso, los resultados 
revelaron que los pacientes tratados con estatinas mostraron una tendencia a un menor 
crecimiento extraselar que los pacientes no tratados. En cambio, ningún otro parámetro se 
relacionó con el uso de estatinas. En relación con las células hipofisarias normales, la 
simvastatina redujo la secreción de ACTH, GH, PRL, FSH y LH, sin alterar la expresión génica o la 
viabilidad celular. Estos efectos fueron mediados a través de mTOR y PI3K, y también a través 
de MAPK en el caso de los efectos sobre ACTH, GH y PRL.  
 
Por otro lado, en esta Tesis hemos identificado y caracterizado, por primera vez, el efecto 
de dos agonistas específicos del receptor de somatostatina tipo 3 (SST3) sobre parámetros 
funcionales clave en cultivos primarios de NFPTs. Así, nuestros resultados demuestran que 
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estos compuestos pueden reducir la viabilidad celular, la secreción de cromogranina-A e 
incrementar la apoptosis, siendo BIM-355 el compuesto más potente. Además, BIM-355 
también redujo el crecimiento tumoral en un modelo preclínico de tumor hipofisario de ratón. 
El estudio de diferentes rutas de señalización reveló que BIM-355 ejerce sus efectos a través 
de la modulación de las rutas MAPK, PI3K-Akt/mTOR y JAK/STAT. Curiosamente, encontramos 
una proporción de NFPTs no respondedores a estos fármacos, en los cuales sólo la expresión 
de SST3 (a nivel de ARNm y de proteína), pero no de otros receptores de somatostatina, fue 
capaz de discriminar entre las dos poblaciones (respondedores y no respondedores). Así, este 
estudio proporciona un conjunto sólido de pruebas que demuestran que el SST3 tiene un papel 
funcional y relevante y con potencial terapéutico en la fisiopatología de los NFPTs.  
 
Otra aproximación realizada en esta Tesis ha sido el estudio de los efectos directos de un 
nuevo compuesto quimérico, conocido como BIM-065 (nueva generación de dopastatina), 
capaz de unirse a los receptores de somatostatina tipo 2 (SST2) y 5 (SST5) y al receptor de 
dopamina tipo 2 (D2) sobre diferentes tipos de tumores hipofisarios y líneas celulares. En este 
sentido, BIM-065 redujo la viabilidad celular y la secreción hormonal e incrementó la apoptosis 
en diferentes tipos de tumores hipofisarios. Además, el estudio de diferentes rutas de 
señalización en la línea celular AtT-20 reveló que una incubación breve con BIM-065 (10 min) 
aumenta los niveles de fosforilación de Akt, lo cual fue seguido de una clara reducción de la 
proteína antiapoptótica Bcl-2 (lo que apoya el incremento de apoptosis observado en 
respuesta a BIM-065). En cambio, una incubación a largo plazo (24h) con BIM-065 provocó un 
aumento en los niveles de fosforilación de ERK1/2. De acuerdo con los resultados descritos en 
la literatura, estos resultados podrían sugerir que este compuesto quimérico modula ERK1/2 y 
Akt a través de la activación preferencial de la señalización dopaminérgica. Más importante 
aún, y en contraste con datos previos de otros compuestos quiméricos, el tratamiento con 
BIM-065 no generó ningún efecto estimulador en las células tumorales analizadas.  
 
Finalmente, nuestros resultados también indican que la maquinaria celular responsable 
del procesamiento y la regulación del proceso de splicing (spliceosoma y factores de splicing) 
se encuentra diferencialmente desregulada en diferentes tipos de tumores hipofisarios en 
comparación con hipófisis normal. Estos resultados también revelaron una huella específica de 
componentes desregulados de la maquinaria de splicing capaz de discriminar entre cada tipo 
tumoral y el tejido hipofisario sano. Además, se encontraron varios componentes 
desregulados (SRSF1, RNU11, RNU4ATAC y RNU6ATAC) de forma común en todos los tumores 
hipofisarios analizados, lo cual podría sugerir la existencia de alteraciones comunes en la 
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maquinaria de splicing que podrían estar implicadas en la tumorigenesis de estas patologías y, 
de hecho, abre el camino hacia la identificación de nuevas dianas terapéuticas comunes 
basadas en la desregulación de estos elementos. Más aún, nuestro estudio también demuestra 
que la alteración farmacológica del splicing con fármacos específicos, como el pladienolide-B 
(compuesto dirigido contra SF3B1, un componente clave involucrado en el ensamblaje del 
spliceosoma), es capaz de reducir la viabilidad celular y la secreción hormonal en células de 
tumores hipofisarios.  
 
En resumen, los resultados de esta Tesis proporcionan una información novedosa y 
relevante acerca de los efectos antitumorales que ejercen sobre diferentes tipos de tumores 
neuroendocrinos hipofisarios distintos fármacos, algunos de ellos utilizados en la práctica 
clínica habitual con otras indicaciones, y otros que son nuevos fármacos dirigidos contra 
receptores de somatostatina/dopamina, y que, en conjunto, sugieren que estos compuestos 
podrían llegar a ser opciones terapéuticas prometedoras en el tratamiento de pacientes con 
tumores neuroendocrinos hipofisarios. Además, esta Tesis demuestra que la alteración 
específica de la maquinaria de splicing podría estar involucrada en la génesis de los tumores 
hipofisarios y podría proporcionar nuevas herramientas para mejorar el diagnóstico, 
pronóstico y las opciones terapéuticas para estas patologías.  
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2. Summary 
 
The pituitary gland is a small but functionally crucial endocrine organ localized at the base 
of the brain and is comprised by two distinct regions, one of glandular nature, the 
adenohypophysis, comprised by the anterior and intermediate lobes, and another of neural 
origin, the neurohypophysis or posterior lobe. The adenohypophysis is mainly composed by 
five hormone-producing endocrine cells including somatotropes, lactotropes, corticotropes, 
gonadotropes and thyrotropes, which are responsible for the synthesis and secretion of 
growth hormone (GH), prolactin (PRL), corticotropin (ACTH), follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH), and thyrotropin (TSH), respectively. The pituitary gland is 
responsible for the control of multiple biological functions (i.e. growth, reproduction, 
metabolism, stress response, etc.) and is modulated by a complex network of regulatory 
signals that act through different cellular receptors to integrate and process the information at 
the intracellular signal transduction level to finely control synthesis and secretion of the 
different anterior pituitary hormones. This fine regulation is exerted by central (GHRH, GNRH, 
CRH, TRH, somatostatin, dopamine, etc.) and peripheral signals (glucocorticoids, adipokines, 
thyroid hormones, testosterone, estrogens, ghrelin, obestatin, etc.) and the adequate balance 
among all these regulatory signals ensure the appropriate function of the pituitary gland and, 
therefore, of the whole organism.  
The neoplastic alteration of these pituitary cells may lead to the development of pituitary 
neuroendocrine tumors (PitNETs), which represent 15% of all brain tumors. Several studies 
have reported that these tumors arise from a monoclonal expansion of genetically altered cells 
and that the dysregulation of regulatory central and peripheral factors mentioned above may 
play a crucial role in this transformation. From a clinical point of view, PitNETs are classified in 
non-functioning pituitary tumors (NFPTs), gonadotropinomas (FSH/LHomas), prolactinomas 
(PRLomas), somatotropinomas (GHomas), corticotropinomas (ACTHomas) and 
thyrotropinomas (TSHomas). To date, transsesphenoidal surgery is considered the first-line 
therapeutic option for patients harboring PitNETs; however, in many cases, there is an 
inadequate disease control and it is necessary to use subsequent pharmacological therapy. 
Particularly, somatostatin analogues (octreotide, pasireotide and lanreotide) and dopamine 
agonists (cabergoline) are the main therapeutic medical options currently available. However, 
although these drugs have demonstrated a great efficacy inducing tumor shrinkage and 
reducing hormone hypersecretion, several studies have shown that some patients are (or 
become) unresponsive to these treatments. For this reason, the search for new therapeutic 
options to enrich the pharmacological arsenal to treat PitNETs patients is urgently necessary.  
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In this sense, one of the current strategies to the generation of novel therapeutic 
compounds is the synthesis of chemical derivatives of current drugs (somatostatin analogues 
and dopamine agonists) that could exhibit higher affinity, potency and/or efficacy. An 
additional source for the identification of novel therapeutic compounds is the repositioning of 
currently available drugs that have been proved to be clinically safe, as it is the case of 
biguanides (as metformin) or statins. Indeed, they are pharmacological treatments currently 
used in the clinical practice to control metabolic alterations due to pathological conditions 
such as diabetes, obesity or hypercholesterolemia, and could therefore also exert some 
actions at the pituitary gland and modulate its function under normal and/or pathological 
conditions. Finally, it should be also noted that although the primary initiating cause of PitNETs 
development is still unclear, recent studies suggest that altered alternative splicing and 
appearance of aberrant splicing variants is a common feature of most tumor pathologies and 
could, therefore, represent a novel avenue for the identification of novel targets for the 
diagnostic, prognostic and treatment of PitNETs. 
 
Thence, general aim of this study was to gain deeper cellular, molecular and clinically-
relevant knowledge on the (patho)physiological regulation of the pituitary gland, and of 
PitNETs, through the identification of novel factors and mechanisms involved in the functional 
response to different pharmacological therapies, including hormone release and the 
development and progression of pituitary tumor pathology.  
 
Firstly, the findings presented herein demonstrate that biguanides (metformin, buformin 
and phenformin) exert direct antiproliferative and antisecretory actions in different PitNETs 
cell types, and that metformin also increases apoptosis in GH-secreting PitNETs. All these 
actions were mediated through the modulation of AMPK-dependent ([Ca2+]i kinetics and PI3K-
Akt pathway) and independent (ERK pathway) mechanisms. Moreover, we evaluated the 
putative association between treatment with metformin and clinical parameters in patients 
harboring different PitNETs subtypes. However, metformin use was not apparently related to 
any clinical variable determined in our cohort of patients, which could be due to the limited 
number of patients treated with metformin. In parallel, we also found that metformin impacts 
directly on pituitary somatotrope, corticotrope and gonadotrope cells at the secretory, gene 
expression and signaling levels, without altering cell viability, in normal pituitary cells from two 
non-human primate species (Papio anubis and Macaca fascicularis). In particular, we found 
that the effect of metformin on GH, ACTH and FSH release were mediated through mTOR, PI3K 
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and intracellular Ca2+ mobilization. Additionally, the actions of metformin on GH secretion also 
involved MAPK pathway. Interestingly, these findings could have translational relevance in that 
the decrease on GH and ACTH secretion could be a beneficial metabolic action of MF to 
improve whole body homeostasis, inasmuch as several studies have reported that increased 
circulating levels of GH and glucocorticoids can lead to worsening of insulin resistance, glucose 
intolerance and diabetes mellitus.  
 
We also explored during this Thesis the direct effects of simvastatin on functional 
parameters in primary cell cultures from different PitNETs subtypes and cell lines, as well as in 
primary normal pituitary cell cultures from Papio anubis. Our results demonstrated that 
simvastatin reduced cell viability and hormone secretion in PitNETs cells through the 
modulation of MAPK signaling pathway. Remarkably, combination therapy of simvastatin with 
metformin or SSAs did not show additive effects in AtT-20 and GH3 cells, suggesting shared 
mechanisms of action between these drugs. Moreover, we also explored the putative 
association between treatment with statins and clinical parameters of patients harboring 
different PitNETs subtypes. In this case, the analysis revealed that patients treated with statins 
showed a trend to have less extrasellar growth compared with patients not treated with 
statins. None of the other clinical parameters evaluated herein revealed significant 
associations with the use of statins. Regarding normal pituitary cells, simvastatin also reduced 
ACTH, GH, PRL, FSH and LH secretion, without altering hormone gene expression or cell 
viability. In this case, these effects were mediated trough mTOR and PI3K pathways, and the 
actions on ACTH, GH and PRL secretion also required MAPK pathway.  
 
On the other hand, we identified and characterized, for the first time, the effect of two 
somatostatin receptor type 3 (SST3)-specific agonists on key functional parameters in primary 
cell cultures from NFPTs, where this receptor is overexpressed compared with other 
somatostatin receptors subtypes. Our results showed that these compounds reduced cell 
viability and chromogranin-A secretion, and increased apoptosis, being BIM-355 the most 
potent compound. Furthermore, BIM-355 also reduced tumor growth in a preclinical mouse 
model of PitNET. The study of different signaling pathways revealed that BIM-355 exerted its 
actions through the modulation of MAPK, PI3K-Akt/mTOR and JAK/STAT pathways. 
Importantly, we found a proportion of NFPTs unresponsive to these drugs, which was 
associated to the presence of SST3, in that only SST3 expression (at mRNA and protein levels), 
but not the other SST-subtypes, was able to discriminate between responsive and 
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unresponsive tumors. Thus, this study provided compelling evidence demonstrating that SST3 
has a relevant functional role and therapeutic potential in the pathophysiology of NFPTs. 
 
Additionally, we evaluated the direct effects of a new chimeric SST2/SST5/D2 compound, 
called BIM-065 (new dopastatin class), in different PitNETs subtypes and pituitary cell lines. 
BIM-065 acted mostly reducing cell viability and hormone secretion and increasing apoptosis 
in the different PitNETs subtypes. The study of different signaling pathways in AtT-20 cells 
revealed that short-term incubation with BIM-065 (10 min) increased phospho-Akt, which was 
also followed by a clear reduction of anti-apoptotic protein Bcl-2 (supporting the increase of 
apoptosis observed in PitNETs cells). In contrast, long-term incubation (24h) upregulated 
phospho-ERK1/2 levels. Based on the literature, these results might suggest that BIM-065 
modulate ERK1/2 and Akt through the preferential activation of the D2/dopaminergic-
signaling. Most importantly, in contrast to previous data with other chimeric compounds, 
treatment with BIM-065 did not evoke any stimulatory action in the tumor cells analyzed. 
  
Finally, our results also indicate that the cellular machinery responsible for the processing 
and regulation of the splicing process (spliceosome and splicing factors) is differentially 
dysregulated in PitNETs compared to normal pituitary glands (NPs). These results also revealed 
a unique fingerprint of spliceosome components in each PitNET subtype that accurately 
discriminate between them and NPs. Furthermore, we also found several components (SRSF1, 
RNU11, RNU4ATAC and RNU6ATAC) that were commonly dysregulated in all PitNETs analyzed 
which may suggest the existence of common driver alterations in pituitary tumorigenesis and 
may pave the way toward the identification of common therapeutic targets based on the 
dysregulations of these key elements. Indeed, our study also demonstrated that the 
pharmacological disruption of the splicing process with specific drugs, such as pladienolide-B 
(compound able to directly target to SF3B1, a key component involved in the assembly of the 
spliceosome), produced the reduction of cell viability and hormone secretion in PitNETs cells. 
 
In summary, the results of this Thesis provide novel and relevant information about the 
antitumor effects of different drugs currently used in clinical practice, as well as of new drugs 
targeting specific somatostatin/dopamine receptors, in different PitNETs, suggesting that 
these compounds could become a promising option to treat patients harboring PitNETs. In 
addition, this Thesis demonstrate that the alteration of the splicing machinery could be 
involved in the tumorigenesis of PitNETs and could also provide new tools to identify novel 
diagnostic, prognostic and potential therapeutic targets in this pathology.  
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3. Introduction 
 
3.1 The pituitary gland 
 
The pituitary gland is a small endocrine organ localized at the base of the brain, in a 
depression of the sphenoid bone named the sella turcica. It is functionally and anatomically 
connected to the hypothalamus through the median eminence, and it is constituted by two 
distinct portions: a glandular component or adenohypophysis and a neural portion or 
neurohypophysis. The adenohypophysis comprises the anterior lobe (pars distalis), the 
intermediate lobe (pars intermedia; poorly developed in humans), and the pars tuberalis; 
whereas, the neurohypophysis is constituted by the posterior lobe (pars nervosa) and the 
infundibulum [1, 2](Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pituitary gland anatomy. The pituitary is constituted by the neurohypophysis, which is composed by 
axonal terminals surrounded by pituicytes, and the adenohypophysis, which is composed by folliculostellate cells 
and five hormone-producing epithelial cell types. Adapted from [2]. 
 
The neurohypophysis is developed from the embryonic neuroectodermal layer and is 
constituted by axonal terminals of the hypothalamus supraoptic and paraventricular nuclei, 
which are surrounded by pituicytes (modified glial cells) that contribute to regulate 
neurohypophysial hormone release. Thus, oxytocin and vasopressin are hypothalamic 
hormones stored and released from this lobe to the systemic circulation [1]. In addition, 
hypothalamic factors reach the pituitary gland through hypophysial portal circulation to 
regulate adenohypophysial cells. These hypophysiotropic hormones comprise stimulatory 
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factors such as growth-hormone releasing hormone (GHRH), gonadotropin releasing hormone 
(GNRH), corticotropin releasing hormone (CRH) or thyrotropin releasing hormone (TRH), and 
inhibitory factors such as somatostatin (SRIF) or the monoamine dopamine (DA), which, 
together with peripheral signals derived from target organs, regulate the synthesis and 
secretion of the pituitary hormones [1-3].  
 
The adenohypophysis is developed from the Rathke’s pouch, which is derived from the 
roof of the stomodeum, and is considered the “master gland” of the endocrine system, as it is 
involved in the control of an ample range of critical physiological functions, including growth, 
puberty, reproduction, lactation, metabolism and stress, through the integration of multiple 
central, peripheral and intracellular signals [1, 4]. The anterior pituitary gland is composed by 
folliculostellate (FS) cells (non-endocrine cells; ~5-10% of total pituitary cells) and five 
hormone-producing endocrine cells including somatotropes (~40-50% of cell population), 
lactotropes (~15%), corticotropes (~15-20%), gonadotropes (~10%), and thyrotropes (~5%) 
(Figure 1), which are responsible for the synthesis and secretion of growth hormone (GH; 
regulates bone and muscle growth and maintains lean body mass in adults), prolactin (PRL; 
stimulates breast milk production and regulates gonadal function), corticotropin (ACTH; 
stimulates glucocorticoids synthesis by the adrenal gland), follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH; both FSH and LH regulate germ-cell development and sexual 
hormone synthesis/release by the gonads), and thyrotropin (TSH; stimulates thyroid hormones 
production by the thyroid gland), respectively [1, 3, 5]. On the other hand, FS cells are non-
endocrine cells located in the parenchymal tissue of the adenohypophysis. These cells have a 
star-like morphology and produce many factors involved in the control of the behavior of 
surrounding cells and the gland itself. In addition, FS cells constitute an intra-pituitary 
regulatory deposit of cell residues due to their ability to effect phagocytosis [1, 6]. 
 
3.2  Important modulators of pituitary cell function. 
 
The pituitary gland is finely modulated by a complex network of multiple regulatory 
signals that act through specific receptors to integrate and process the information at the 
intracellular signal transduction level to finely control synthesis and secretion of the different 
anterior pituitary hormones. The primary control of pituitary secretion is mainly exerted by 
the hypothalamus through the hypothalamic hormones. However, nowadays, it is well 
accepted that the precise regulation of the pituitary gland is exerted by both central 
(hypothalamic) and peripheral signals [4].  
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Regarding the central modulators, a plethora of stimulatory and inhibitory factors have 
been discovered. Classical stimulatory factors include GHRH, GNRH, CRH and TRH, which are 
responsible of GH, FSH/LH, ACTH and TSH secretion, respectively. TRH, and under some 
circumstances GHRH, also stimulate PRL [4]. In addition, other central stimulatory factors 
have been described such as ghrelin, which stimulates GH, PRL and ACTH release; pituitary 
adenylate cyclase activating polypeptide (PACAP), that stimulates GH, PRL and ACTH release; 
kisspeptin, that stimulates GH and FSH/LH; cortistatin, a neuropeptide that can stimulate GH 
and PRL release at low concentrations; and melatonin, produced by the pineal gland, which 
stimulates GH, PRL and FSH/LH release [4]. On the other hand, there are several important 
inhibitory factors, including the peptide somatostatin (SRIF), which primarily inhibits GH 
release from somatotropes but can also inhibit other pituitary hormones; and the monoamine 
dopamine (DA) which inhibits primarily PRL secretion but can also reduce GH and TSH release. 
In addition, there are other inhibitors such as neuropeptide Y, which can inhibit GH and 
FSH/LH release, and cortistatin, able to inhibit GH and also ACTH secretion [4].  
Additionally, a high number of peripheral modulators (see section 1.2.3) [4] and 
environmental cues, like the circadian rhythm oscillations related to light/dark or sleep/wake 
cycles, have been also reported to regulate pituitary hormone secretion [7].  
 
3.2.1 Somatostatin and somatostatin receptors. 
 
Somatostatin, also known as somatotropin release-inhibiting factor (SRIF), is a peptide 
originally isolated in 1973 from ovine hypothalamus owing to its ability to inhibit GH secretion 
[8]. The SRIF gene is encoded on human chromosome 3 [9], and its transcribed mRNA is 
translated into a 116-amino acid precursor protein, pre-pro-somatostatin, that is processed to 
give rise to two main bioactive isoforms: the most abundant is the cyclic tetradecapeptide 
somatostatin-14 (SRIF-14), usually referred to as SRIF, whereas somatostatin-28 (SRIF-28) is 
an extended 28-amino acid peptide, also cyclic , and can also be processed to generate SRIF-
14 (Figure 2) [10-13]. In addition, mammalian processing of pre-pro-somatostatin can give rise 
to another non-cyclic amidated peptide with 13-amino acid, named neuronostatin [14]. 
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Figure 2: Somatostatin gene derived peptides including somatostatin-28, somatostatin-14 and neuronostatin. SRIF-
14 exerts its actions through the binding to five classical somatostatin receptors.  
 
SRIF is widely distributed throughout the central nervous system (CNS) and peripheral 
tissues, where it exerts numerous physiological actions including the modulation of cognitive 
functions through the regulation of neurotransmission, inhibition of pituitary hormone release, 
regulation of gastrointestinal tract by inhibiting endocrine and exocrine secretions, motility, 
blood flow, absorption and growth, inhibition of pancreatic enzymes and neuropeptides, and it 
is also able to inhibit cell proliferation of tumoral and normal cells [15-18].  
SRIF exerts all its actions by binding to five different receptors, named SST1-5, which 
belong to the seven transmembrane G protein-coupled receptor superfamily [10-13, 19] 
(Figure 2). Taking into account that each SST subtype has been associated with the activation 
of specific signaling pathways to convey different SRIF functions, and that most tissues often 
co-express different SST subtypes, the precise action of SRIF is highly dependent on the precise 
amount of the different SSTs, the possible interaction between them, as well as the specific set 
of signaling pathways activated in response to SRIF [10-12, 19, 20].  
In addition to the canonical, full length SST1-5, two novel SST5 truncated variants have 
been reported, which were named SST5TMD4 and SST5TMD5 due to the number of 
transmembrane domains (TMDs) [21]. To date, several reports have demonstrated that the 
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presence of these variants have functional consequences in different tissues [22-27]. 
Moreover, although the expression of both receptors is very low in normal tissues, SST5TMD4 
is highly frequent in pituitary neuroendocrine tumors (PitNETs) [21]. Thus, the presence of 
SST5TMD4 has been related with sinus invasion, poor pharmacological response to 
somatostatin analogues (SSAs) and with an increase on the aggressiveness of GH-secreting 
PitNETs [23].  
 
3.2.2 Dopamine and dopamine receptors. 
 
Dopamine (DA) is a catecholamine neurotransmitter widely distributed in the mammalian 
brain. DA is synthetized from the aromatic amino acid tyrosine, and is involved in an ample 
range of central and peripheral functions including cognition, emotion, food intake, locomotor 
activity, positive reinforcement, hormone secretion, cardiovascular regulation, vascular tone, 
renal function, and gastrointestinal motility [28, 29].  
DA exerts its functions through binding to five different receptors, named D1-5, which 
belong to the seven transmembrane G protein-coupled receptor superfamily [28]. Moreover, 
DA receptors can be divided into D1-like receptors (D1 and D5) and D2-like receptors (D2, D3 and 
D5) based on its functions. Thus, D1-like receptors can induce the production of cyclic 
adenosine monophosphate (cAMP) and activate cAMP-dependent protein kinase (PKA), and 
D2-like receptors can reduce the accumulation of cAMP through interaction with Gi/G0 proteins 
[30]. Additionally, D2 has been reported to have two alternative splicing isoforms named short 
and long isoforms (D2S and D2L), which differ by only 29 amino acids, and which have been 
associated with different functions. Moreover, D2S is expressed in the pituitary gland at higher 
levels than D2L [31].  
As mentioned above regarding SSTs, the functions triggered by DA depend on the specific 
subtypes and amount of DA receptors present in the tissue and the possible interactions 
between them and with other receptors such as SSTs, since heterodimerizations between 
these two types of receptors have been reported [32].  
 
3.2.3 The pituitary as a metabolic sensor: Influence of metabolic cues in the control 
of pituitary function. 
 
As mentioned earlier, not only central modulators but also a broad range of peripheral 
factors are involved in the precise control and regulation of pituitary hormone secretion under 
normal and pathological conditions. Among them, several reports have demonstrated that 
glucocorticoids are able to inhibit (in a short-time incubation) and stimulate (in a long-time 
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incubation) GH secretion [33, 34], and also to inhibit ACTH, PRL and TSH secretion in vivo and 
in vitro in humans and non-human primates [35, 36]. In the same line, thyroid hormones (T3 
and T4) regulate TSH secretion through a direct negative feedback on pituitary gland [37], and 
also play a direct role in the regulation of somatotropes [38]. On the other hand, adipokines 
(leptin, resistin and adiponectin) comprise a family of cytokines mainly released from the 
adipose tissue. Adiponectin has been associated with the inhibition of GH and ACTH secretion 
and the stimulation of PRL release. Resistin can stimulate GH and ACTH secretion, and leptin 
can stimulate GH and FSH/LH release [39]. In the same line, free fatty acids (FFAs) have also 
been described as regulators of pituitary function. Thus, the elevation of plasma FFAs produces 
a strong inhibition of GH secretion in humans and non-human primates [40, 41]. Additionally, 
insulin and IGF1 can directly regulate somatotrope function under normal conditions [33], and 
IGF1 is also able to regulate PRL and TSH secretion [42, 43]. Because insulin and IGF1 are 
regulated by nutritional status, changes in circulating GH levels observed during starvation or 
obesity may in part be mediated by direct action of these hormone on somatotrope function 
[4]. In addition, other metabolic regulators involved in the control of pituitary gland are 
inhibins, activins, estrogens, testosterone, obestatin, follistatin, endothelin or opioids [4]. 
Therefore, based on all the information described above regarding the direct regulation of the 
function of different pituitary cells by multiple metabolic factors, it is reasonable to propose 
that pharmacological treatments currently used in the clinical practice to control metabolic 
alterations due to pathological conditions such as diabetes, obesity or hypercholesterolemia 
(e.g. metformin and statins), could also exert some actions at the pituitary gland and modulate 
its function under normal and pathological conditions.  
 
 
3.3 Pituitary neuroendocrine tumors (PitNETs). 
 
PitNETs represent approximately 15% of all brain tumors with a prevalence ranging from 1 
in 865 persons to 1 in 2,688 persons [44, 45]. These tumors are usually accompanied by severe 
comorbidities related to mass effects and to an inadequate secretion of pituitary hormones, 
e.g. growth abnormalities, sexual dysfunctions, infertility, amenorrhea, galactorrhea, hypo- or 
hyperthyroidism, hypogonadism, hypopituitarism, etc. [5]. Although these tumors have been 
classically considered as a benign pathology (thus the term adenoma), because they very 
rarely metastatize, a recent consensus of the “International Pituitary Pathology Club” 
proposed a reclassification to accept the nomenclature “pituitary neuroendocrine tumors 
(PitNETs)” instead of “pituitary adenomas”. The main reason to propose this change is based 
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on the great number of behaviors of this pathology that are far from being “benign”, and in 
fact can cause severe comorbidities, despite the lack of metastasis. Additionally, the term 
“adenoma” is not considered appropriate to address invasive and aggressive pituitary tumors 
that cannot be surgically resected or controlled with therapy [46].  
 
3.3.1 Pituitary tumorigenesis. 
 
Several studies have reported that PitNETs arise from a monoclonal expansion of 
genetically altered cells, and that the external hypothalamic or peripheral factors could play a 
role potentiating their transformation [47-49]. Although the primary initiating cause of PitNETs 
remains unclear, several reports have demonstrated that there are numerous factors related 
with an increased proliferative potential of precursor cells for tumor formation and tumor 
growth, such as genetic or epigenetic events, paracrine growth factor disruption or even an 
altered intrapituitary microenvironment [49, 50]. Moreover, the use of transgenic mouse 
models has demonstrated that the overexpression or inactivation of cell cycle regulators is 
enough to trigger pituitary tumorigenesis (Figure 3) [51, 52].  
 
 
 
 
 
 
 
 
 
  
 
Figure 3: Cascade of pituitary tumorigenesis. Adapted from [49]. 
 
 
Although the classic oncogenes are rarely mutated in PitNETs [53], a growing set of 
pituitary-specific cellular disruptors has been described to be associated with pituitary 
tumorigenesis (Figure 4). Importantly, the vast majority of PitNETs have a sporadic origin, but a 
small percentage (5%) are due to familial tumor syndromes such as Carney syndrome, familial 
isolated pituitary adenomas, multiple endocrine neoplasia type I or type 4, etc. [49, 54]. 
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Figure 4: Main pituitary-specific cellular disruptors associated with molecular pathogenesis of PitNETs. Green boxes: 
pituitary tumorigenesis due to mutations (bold gene names represent tumor suppressor genes, gene names that 
are not bold represent oncogenes). Orange boxes: pituitary tumorigenesis due to altered gene expression. Adapted 
from [54]. 
 
 In addition to all these disruptors, other epigenetic alterations can relevantly influence 
the development of tumors and cancer. Indeed, recent studies suggest that altered alternative 
splicing and, consequently, appearance of abnormal or aberrant splicing variants, is a 
common feature of most tumor pathologies, including PitNETs [23-25, 27, 55-58]. The cellular 
machinery that controls and carries out alternative splicing is the spliceosome, a 
ribonucleoprotein complex that recognizes specific sequences that determine the exact 
localization of the exon-intron junctions [59]. This complex machinery is comprised by proteins 
and ribozymes that act cooperatively in an extraordinarily dynamic fashion, and is organized 
into two systems, the major and the minor spliceosome. The major spliceosome is composed 
by a main core comprised by five small nuclear RNAs (snRNAs: U1, U2, U4, U5 y U6), which 
cooperate with more than 300 auxiliary proteins, the so-called splicing factors (i.e., SF2/ASF, 
RBM5 o FBP11), in the precise recognition of the target [60, 61] (Figure 5). The minor 
spliceosome comprises U11, U12, U4atac, U5 and U6atac snRNAs. Thus, the splicing process is 
jointly executed by a discrete set of polypeptides associated with one or more snRNAs to form 
stable ribonucleoproteins (snRNPs), and multiple associated splicing factors comprising this 
intricate cellular machinery, which dynamically cooperate among them to finely regulate all 
the process [62]. Consequently, abnormal alteration of spliceosome function can compromise 
the natural splicing process of an ample range of genes, originating the appearance of 
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multiple, often aberrant splicing variants, which could be directly associated with the 
development/progression of tumor pathologies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Model of spliceosome assembly and catalysis. Adapted from [59].  
 
 
3.3.2 Classification of PitNETs. 
 
PitNETs have been classically classified by combining histopathological features (e.g. 
hormone content) and ultrastructural characteristics (e.g. densely or sparsely granulated) of 
pituitary tumor cells [3, 63, 64]. However, the new classification proposed by the World Health 
Organization (WHO) has incorporated the role of transcription factors in tumor differentiation 
according to cellular lineage(s), regulation of specific pituitary hormone production, and 
possible tumorigenesis [44] (Table 1). In addition to this canonical anatomo-pathological 
classification formulated by WHO, a prognostic clinicopathologic classification has recently 
been proposed based on large series of PitNETs [65]. This classification incorporates different 
parameters, including tumor size, tumor type, and tumor grade (Table 2) [65].  
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Table 1: Pathological classification of pituitary neuroendocrine tumors. Adapted from [44]. 
 
Tumor types Morphological variants Pituitary hormones by 
immunohistochemistry 
Transcription factors and 
other co-factors 
Somatotrope tumors 
Densely granulated somatotrope tumor 
Sparsely granulated somatotrope tumor 
Mammosomatotrope tumor 
Mixed somatotrope-lactotrope tumor 
 
GH, -subunit 
GH 
GH + PRL (in same cells)  -subunit 
GH + PRL (in different cells)  -
subunit 
Pit-1 
Pit-1 
Pit-1, ER 
Pit-1, ER 
 
Lactotrope tumors 
Sparsely granulated lactotrope tumor 
Densely granulated lactotrope tumor 
Acidophil stem cell tumor 
PRL 
PRL 
PRL, GH (focal and variable) 
Pit-1, ER 
Pit-1, ER 
Pit-1, ER 
Thyrotrope tumors  -TSH, -subunit Pit-1, GATA2 
Corticotrope tumors Densely granulated corticotrope tumor 
Sparsely granulated corticotrope tumor 
Crooke’s cell tumor 
ACTH 
ACTH 
ACTH 
Tpit 
Tpit 
Tpit 
Gonadotrope tumor  -FSH, -LH, -subunit (various 
combinations) 
SF-1, GATA2, ER 
Null cell tumor  None None 
Plurihormonal tumors Pit-1-positive plurihormonal tumor 
(previously termed Silent subtype 3 tumor) 
Tumors with unusual 
immunohistochemical combinations 
 
GH, PRL, -TSH  -subunit 
 
Various combinations 
Pit-1 
 
The combined use of both WHO classifications and the a newly proposed comprehensive 
clinicopathological classification of PitNETs could provide an improved indicator for the clinical 
behavior of patients and to predict the probability of post- operative remission or tumor 
progression, which could help clinicians to choose the best post-operative therapy [65].  
 
Table 2: Prognostic clinicopathologic classification of PitNETs. Adapted from [65] 
Clinicopathologic classification of PitNETs 
The classification is on the following 3 characteristics: 
1. Tumor size into micro (<10 mm), macro (10 mm), and giant (>40 mm) by MRI 
2. Tumor type into GH, PRL, ACTH, FSH/LH, and TSH by immunohistochemistry 
3. Tumor grade based on the following criteria: 
- Invasion defined as histologic and/or radiological (MRI) signs of cavernous or 
sphenoid sinus invasion 
- Proliferation considered based on the presence of at least 2 of the following 3 
criteria: 
Mitosis: n greater than 2 per 10 high-power field. 
Ki-67: greater than or equal to 3% 
p53: positive (>10 strongly positive nuclei per 10 high-power field 
        The 5 grades are the following: 
        Grade 1a: noninvasive tumor 
        Grade 1b: noninvasive and proliferative tumor 
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        Grade 2a: invasive tumor 
        Grade 2b: invasive and proliferative tumor 
        Grade 3: metastatic tumor (cerebrospinal or systemic metastases) 
 
From a clinical point of view, approximately 65% of all PitNETs are functioning or 
hormone-secreting, whereas 35% are non-functioning tumors [66]. Non-functioning tumors or 
non-functioning pituitary tumors (NFPTs) comprise about 22-54% of all PitNETs and usually 
derive from cells of the gonadotrope lineage that synthesize, but not oversecrete, FSH and/or 
LH, although they can hypersecrete their common -subunit [67]. In addition to those of a 
gonadotrope origin, there also NFPTs comprised by silent (containing but not oversecreting) 
ACTH, GH and rarely PRL cells [68]. NFPTs are often macroadenomas at diagnosis and are 
associated with secondary symptoms related to mass effects including headaches, 
hypopituitarism, visual defects and cranial nerve palsy [69]. On the other hand, a small 
proportion of gonadotrope-derived tumors are functional, and secrete FSH and/or LH. The 
clinical presentation of these gonadotropinomas (FSH/LHomas) is similar to NFPTs, but can 
also produce a mild or moderate elevation of prolactin levels due to pituitary stalk 
compression, and as rare manifestations may cause ovarian hyperstimulation, testicular 
enlargement or pituitary apoplexy [70]. Prolactinomas (PRLomas) comprise about 47-66% of 
all PitNETs and are associated with hyperprolactinemia, impaired fertility, decreased libido, 
amenorrhea, and galactorrhea. In addition, these tumors produce symptoms related to mass 
effects such as headache, visual disturbances and hypopituitarism [71]. Somatotropinomas 
(GHomas) arise from GH-secreting cells and represent 10-15% of PitNETs. Depending on the 
age of the patient, these tumors produce gigantism in children/adolescents, or acromegaly in 
adult patients, due to a GH hypersecretion, which generates an increase on IGF1 production by 
the liver. The main consequences of a long-term GH and IGF1 exposure include a number of 
severe morbidities such as acral changes, gigantism, prognathism, arthritis, osteopenia, 
vertebral fractures, organs growth, hypertension, heart disorders, diabetes, insulin resistance, 
hypogonadism, etc. [3, 72]. Corticotropinomas (ACTHomas) are composed by ACTH-secreting 
cells and represent 10-15% of all PitNETs. These tumors produce Cushing’s disease (CD), a rare 
endocrine condition due to a chronic exposure to elevated glucocorticoid levels induced by 
ACTH hypersecretion. The clinical symptoms associated to these tumors can be also severe 
and include obesity, hypertension, diabetes, dyslipidemia, muscle weakness, and emotional 
disturbances, among others [3, 73]. Thyrotropinomas (TSHomas) account for less than 1% of 
all pituitary neoplasms. These tumors are diagnosed when TSH is unusually elevated or when is 
normal in a hyperthyroid patient with increased serum T4 levels. Most of them are large and 
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invasive at diagnosis, and present symptoms associated to mass effects (headache, visual 
defects and hypopituitarism) and thyroid dysfunctions [74]. Finally, pituitary carcinomas are 
very rare, as they account for just 0.2% of all PitNETs. These aggressive tumors are defined by 
the presence of craniospinal and/or systemic metastases. The early identification of these 
tumors is crucial since they are associated with higher morbidity and mortality [75].  
 
3.3.3 Therapeutic options for PitNETs.  
 
Surgical treatment is considered the first-line therapeutic option for patients harboring 
PitNETs, with the exception of PRLomas, where dopamine agonists are the treatment of choice 
[76]. Tumor removal is usually performed using transsphenoidal surgery (transnasal), whereas 
craniotomy is only recommended in patients with extrasellar tumors [77]. In this line, 
microscopy transsphenoidal approach has been classically used for PitNETs surgery. However, 
in the last decade, endoscopic transsphenoidal approach has been increasingly used to remove 
these lesions. In fact, endoscopic approach has been associated with higher gross tumor 
removal and lower incidence of septal perforation in patients with PitNETs compared to 
microscopic approach [78]. The surgical success is higher in patients with microadenomas (<10 
mm), but in many cases there are an inadequate disease control after surgery and subsequent 
pharmacological therapy and/or radiotherapy is necessary.  
 
3.3.3.1 Somatostatin analogues (SSAs). 
 
Most PitNETs express SST1-5 at adequate levels to be responsive to SRIF or somatostatin 
analogues (SSAs), and consequently to reduce hormone secretion and, less frequently, cell 
proliferation [19, 79-81]. Although the potent and inhibitory effects of native somatostatin are 
widely known, its clinical usefulness is limited due to its short-half life (less than 3 min) [82]. 
Based on this information, synthetic SSAs were developed by different pharmaceutical 
companies (Table 3). Thus, octreotide and lanreotide, analogues with preferential targeting to 
a single receptor, SST2, and less affinity to SST5 and the rest of SSTs, were the first generation 
of SSAs. These SSAs were first used for the treatment of GHomas and TSHomas to control 
hormone secretion, reduce tumor volume and ameliorate clinical symptoms [83-86]. In fact, 
octreotide and lanreotide have been largely used in the treatment of patients harboring 
PitNETs and other neuroendocrine tumors (NETs) [87, 88]. Nevertheless, a number of studies 
have reported that a proportion of patients are, or become, resistant or poorly responsive to 
these single-receptor-targeted analogues [19, 89]. Consequently, a second generation of SSAs 
with a multireceptor binding affinity was developed based on the notion that targeting several 
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SSTs simultaneously, like the natural ligand, SRIF, may be more effective in those unresponsive 
patients or those who escape to the therapy. The most studied compound in this group is 
pasireotide, which binds with high affinity to SST5, SST2, SST3 and SST1 , and is accordingly often 
referred to as a multi- of pan-SST agonist [90] (Table 3). However, the biological action of SSAs 
does not solely depends on their biding affinity to the different SSTs. Indeed, pasireotide 
modulates intracellular trafficking of SSTs in a distinct manner than SRIF or octreotide, 
particularly producing a rapid recycling of SST2 to the membrane after endocytosis. Instead, 
SST3 is rapidly down-regulated after long-term exposure to SSA (octreotide or pasireotide), 
which suggests an early loss of response in PitNETs with a predominant SST3 expression [91]. 
Interestingly, octreotide and pasireotide display both similar and distinct in vitro effects in 
primary cell cultures from PitNETs, and cell-type specific actions have been recently proposed 
for pasireotide, acting through SST2 in patients responsive to first-generation SSAs and acting 
(also) through SST5 in patients with unsatisfactory response to first-generation SSAs (low SST2 
expression levels) [92-94]. Moreover, although pasireotide has demonstrated high tolerability 
and efficacy in clinical trials, a hyperglycemia secondary to pasireotide treatment was found in 
most patients. Thus, patients under this treatment have to be monitored for glycemia control 
and treated with antidiabetic therapy [95].  
 
Table 3: Binding affinities (IC50) of somatostatin and somatostatin analogues. Adapted from [96, 97].  
 
 
 
 
 
 
 
3.3.3.2 Dopamine agonists. 
 
In addition to SSTs, PitNETs often express notable amounts of dopamine receptors (D1-5), 
specially D2 [80]. In line with this, DA agonists developed to selectively target for D2 have been 
classically considered the first-line therapy for PRLomas [98]. Based on its chemical nature, DA 
agonists can be classified in two groups: the ergot derivatives (bromocriptine, pergolide and 
cabergoline) and the non-ergot derivatives (quinagolide). Bromocriptine was the first drug 
introduced 25 years ago into clinical practice to treat PRLomas. This treatment presents 
properties as D2 agonist and D1 antagonist and, importantly, demonstrated to control 
hyperprolactinemia in 70-90% of PRLomas and to reduce tumor size, although its use was 
Compound SST1 SST2 SST3 SST4 SST5 
SRIF-14 0.93 0.15 0.56 1.50 0.29 
Octreotide 280 0.38 7.10 >1000 6.30 
Lanreotide 2129 0.75 98 1826 12.7 
Pasireotide 9.3 1.0 1.5 >1000 0.16 
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associated with several adverse effects. Even so, bromocriptine is prescribed as the best 
alternative to cabergoline in patients with hyperprolactinemia [76]. On the other hand, 
cabergoline is considered the therapy of choice to treat PRLomas, since this compound has 
higher affinity to bind to D2 (Table 4), fewer side effects, and a longer half-life than 
bromocriptine [30]. In fact, in a large study, cabergoline treatment controlled PRL levels in 86% 
of patients, reduced tumor mass in >80% of patients and even produce the total tumor 
disappearance in 26-36% of cases [76].   
 
 
Table 4: Binding affinities (IC50) of DA and its agonists. Adapted from [97].  
 
 
 
 
 
In this context, it is also worth to mention that D2 is not only present in lactotropes, but 
is expressed in all pituitary cell types, and, accordingly, clinical and in vitro data suggest that 
cabergoline may also be effective as second-line of treatment in selected patients with 
persistent/recurrent Cushing’s disease, acromegaly or NFPTs [99-101].  
 
3.3.3.3 Chimeric compounds. 
 
There is ample evidence that SSTs and DA receptors are highly expressed in most 
pituitary cell types. Interestingly, a number of reports have also demonstrated that certain 
subtypes of SSTs and DA receptors can form homodimers and heterodimers, which results in 
changes in the functional, pharmacological and signaling properties of the receptors involved 
[32, 102, 103]. This information, coupled to the fact that there are patients that are or become 
partially or totally unresponsive to classical SSAs, and that the combination of SSAs and DA 
agonists had been found to be more effective than the treatment with each individual 
compound in some cases, led to the concept that the development of chimeric compounds 
able to bind both SSTs and DA receptors could represent a promising therapeutic option to 
treat this type of patients. This led to the development of the so-called dopastatins. In 
particular, BIM-23A387, a chimeric SST2-D2 molecule (Table 5), was the first drug developed to 
target both receptor families and demonstrated an enhanced potency to suppress GH 
secretion in GHomas compared with octreotide. Moreover, its higher efficacy was mainly 
attributed to its dopaminergic activity [104, 105]. Another compound of this class is BIM-
23A760, the first termed as dopastatin, and was designed with higher binding affinity to bind 
Compound D2S D2L 
Dopamine 350 320 
Bromocriptine 4.5 3.9 
Cabergoline 0.53 0.41 
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to SST2, SST5 and D2 [106] (Table 5). This compound can induce a greater suppression of GH 
secretion than octreotide in cell cultures from human partially responsive GHomas [106]. 
Moreover, in addition to its action on GHomas, BIM-23A760 demonstrated to control different 
pituitary hormonal secretions and to reduce cell proliferation and increase apoptosis in 
different PitNET subtypes, including ACTHomas, NFPTs or PRLomas [20, 107-109].  
 
Table 5: Binding affinities (IC50) of chimeric compounds. ND, not done. *IC50 for both D2 isoforms. Adapted from [97, 
104]. 
 
 
However, treatment with BIM-23A760 also revealed the existence of two pituitary cell 
populations that oppositely responded to the drug (one showing an inhibitory response, and 
another with a stimulatory response) [109]. Moreover, a Phase IIb study using chronic 
administration of BIM-23A760 to acromegalic patients showed a profound dopaminergic effect 
that was caused by a metabolite accumulated in the circulation, which interfered with the 
activity of the parent compound [110]. For these reasons, BIM-23A760 was withdrawn from 
clinical development.  
 
3.4 Non-human primates as suitable model to study pituitary physiology.  
 
There is ample evidence that the quality and appropriateness of the experimental model 
employed to test a given scientific question represent the fundamental keys that determine 
the value and applicability of the results and information generated in research. To date, the 
vast majority of the information generated on the effects of different compounds on the 
function of normal pituitary gland and on their role in the proper control of normal pituitary 
physiology has been gathered in rodent models. However, this information is often not 
comparable, applicable or “translatable” to the human physiology, and in fact, in part due to 
this “species gap”, there are still a number of aspects about the regulation of human pituitary 
physiology that remain unclear. In this scenario, non-human primate models can provide a 
unique, close-to-human, normal pituitary model to investigate the direct actions of putative 
regulators of adenohypophyseal cell function. In line with this notion, our laboratory and 
others have used non-human primate models to achieve this valuable information, in that 
these samples may reproduce physiological conditions or indicate specific regulations of 
primate lineage that could not be determined with the use of other models [39, 111-116]. In 
particular, baboons (Papio sp.) and rhesus monkeys (Macaca mulatta and Macaca fascicularis) 
Compound SST1 SST2 SST3 SST4 SST5 D2S D2L 
BIM-23A387 293 0.1 77.4 ND 1000 22.1* 
BIM-23A760 622 0.03 160 >1000 42 15* 
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are the most commonly used non-human primate models in biomedical research and results 
generated from these models are used to support and launch translational research to humans 
[117-119]. The main reason to use these models is based on the comparative genomic 
analyses, since their molecular phylogeny and the evolutionary process have revealed that the 
separation of this family from Hominidae family happened approximately 25 million years ago, 
which is relatively recent compared with the separation of rodent lineages that happened 65-
85 million years ago [120, 121]. In addition, other evidence that support the use of these 
models is that Macaca mulatta and Macaca fascicularis show genetic identity of 93.54% and 
92.83% with Homo sapiens, respectively [122, 123]. Therefore, all this information makes 
these species suitable models to study the effects of different compounds on normal pituitary 
cell function, which cannot be evaluated in healthy human subjects. 
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4. Aims of the study 
 
The general aim of this study was to extend our cellular, molecular and clinically-relevant 
knowledge on the (patho)physiological regulation of the pituitary gland, and of PitNETs, 
through the identification of novel factors and mechanisms involved in the functional response 
to different pharmacological therapies, including hormone release and the development and 
progression of pituitary tumor pathology.  
To achieve this general aim, we proposed the following specific objectives:  
 
Objective 1: To establish the precise effects of biguanides (metformin, buformin and 
phenformin) on pituitary cell function, by determining the direct in vitro impact of these 
compounds on different functional endpoints (hormone secretion, cell viability, apoptosis, cell 
signaling, etc.) in normal pituitary cells from two non-human primate species and in the most 
representative PitNET subtypes, and to determine the molecular mechanisms underlying those 
effects. 
 
Objective 2: To determine the precise effects of statins, specially simvastatin, on pituitary cell 
function, by determining the direct in vitro impact of these compounds on different functional 
endpoints (cell viability, hormone secretion and cell signaling) in normal pituitary cells from a 
non-human primate species, in the most representative PitNET subtypes and in pituitary cell 
line models (AtT-20 and GH3), and to determine the molecular mechanisms underlying those 
effects. 
 
Objective 3: To determine the therapeutic potential of targeting SST3 in PitNETs, by studying 
the in vivo and/or direct in vitro effects of different SST3-specific agonists/antagonists on key 
functional parameters using primary cell cultures from non-functioning pituitary tumors, and 
that of a selected SST3-specific agonist on tumor-growth in a preclinical mouse-model of 
PitNET.  
 
Objective 4: To study the effects of a novel somatostatin/dopamine chimeric drug, BIM-065, 
on different types of PitNETs, and to compare its actions with those of currently used 
somatostatin analogues (octreotide and pasireotide), by evaluating different functional 
endpoints in cells derived from a well characterized set of PitNETs, and determining the 
molecular mechanisms underlying those effects. 
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Objective 5: To determine and analyze the expression levels of the spliceosome components 
and a selected set of relevant splicing factors in an ample and representative range of PitNETs 
and in normal human pituitary gland samples.  
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5. Results and general discussion 
 
5.1 Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-
dependent and independent mechanisms (Article I)  
 
Metformin (MF), buformin (BF) and phenformin (PF) are antidiabetic drugs that belong to 
the family of biguanides. Currently, only MF is used in the clinical practice to treat type-2 
diabetes mellitus (T2DM) [124]. In addition to its well-known anti-hyperglycemic effect [125], 
it has been suggested that biguanides, specially MF, may reduce the risk of cancer and 
tumorigenesis in different types of neoplasms such as brain, prostate, breast and NETs [126-
131]. However, to date, the direct pharmacological effects of different biguanides on primary 
cell cultures from human PitNETs have been scarcely examined and are not fully elucidated. 
Therefore, we aimed to explore the direct effects of MF, BF and PF on key functional 
parameters (cell viability, apoptosis, hormone secretion/expression and intracellular signaling 
pathways) in primary cell cultures from different human PitNETs subtypes (13 ACTHomas, 13 
GHomas, 13 NFPTs and 3 PRLomas), and two representative, widely use cell line models, the 
mouse corticotrope AtT-20 cells and the rat-derived somatotrope GH3 cells. In addition, we 
evaluated the effects of a combined treatment with MF and SSAs on cell viability and 
hormone secretion. Finally, clinical data of a second cohort of PitNETs were collected to 
explore the role of the pre-treatment with MF in patients with PitNETs. 
In general, treatment with biguanides reduced cell viability in all PitNETs subtypes and 
decreased cell proliferation in the two pituitary cell lines analyzed. In particular, all biguanides 
reduced cell viability in ACTHomas, being PF the most effective compound, which is line with a 
recent report from our group in NETs [131]. Likewise, and consistent with a previous report 
[132], biguanides decreased cell proliferation in AtT-20 cells. In contrast, our results on 
GHomas are not totally in line with a previous report [133], in that we did not observe any 
alteration of cell viability in response to MF, whereas BF and PF clearly decreased cell viability. 
However, in GH3 cells, all biguanides reduced cell proliferation. Nevertheless, although we did 
not observe changes on cell viability in response to MF in GHomas, we detected an increase 
on apoptosis after 24h of incubation, which is consistent with results reported in GH3 cells 
[133]. These results might be viewed as somewhat contradictory; however, several studies 
have shown an imbalance between cell survival and apoptosis under pathological conditions 
[134-136]. In line with that found in GHomas, a similar pattern of response was found in 
PRLomas, where MF did not alter cell viability, while BF and PF decreased this parameter. 
These results could be due to the common developmental lineage of these cells [3], and differ 
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from the growth reduction observed in response to MF in the lactotrophic MMQ cell line 
[137]. In NFPT cultures, all biguanides reduced cell viability in a time-dependent manner.  
SSAs constitute an important tool in the medical arsenal to treat some PitNET types, yet, 
in many cases, these drugs are or become ineffective [138, 139], especially when first-
generation SSAs have been evaluated [140]. Thus, the search for new alternatives to control 
tumor growth and hormone secretion has been intensive over the last years. In this context, 
combination of SSAs with other pharmacological therapies (e.g. dopamine agonists or 
pegvisomant) are frequently used in PitNETs [141, 142]. For this reason, we tested the effects 
of combined administration of MF with SSAs (octreotide or pasireotide) in PitNETs primary 
cell cultures. However, this combined therapy did not enhance the inhibitory effect of MF or 
SSAs alone in ACTHomas and GHomas, which is reminiscent of the results reported using a 
combination of SRIF-14 and AICAR (AMP mimetic compound 5-aminoimidazole-4-
carboxamide ribonucleoside) [143], and activator of AMPK, which is considered the central 
mediator of MF effects [144]. Conversely, the combination therapy displayed a stronger effect 
in reducing cell viability in NFPT cells. Although more experiments are necessary to confirm 
these results and to understand their mechanistic underpinnings, we speculate that this 
additive effect may offer a potential therapeutic avenue for patients with NFPTs and, hence, 
deserves further investigation.  
In addition to cell viability/survival, we also explored the effect of biguanides on hormone 
secretion in PitNETs cells. Our results demonstrate that BF and PF, but not MF, clearly 
reduced GH and PRL secretion, but did not alter ACTH release, after 24h of incubation. These 
results compare nicely with those of a previous report from our group performed in two NET 
cell lines, BON-1 and QGP-1, in which MF did not modify hormone secretion in BON-1 or QGP-
1 cell cultures, but PF decreased hormone secretion in BON-1 [131]. In contrast, all biguanides 
reduced GH secretion in the GH3 cell line after 24h of incubation, supporting the notion that 
the effects of biguanides are highly cell-type dependent. Additionally, we evaluated the 
combination of MF with SSAs on hormone secretion in GHomas. The results showed that the 
combination therapy did not enhance the inhibitory effect of SSAs as monotherapy.  
Furthermore, we analyzed the direct effects of biguanides on mRNA levels of 
pathologically relevant genes in cell cultures from ACTHomas and GHomas. In contrast with 
our recent results in normal pituitary glands from non-human primate species (see section 
3.2. below; [145]), MF and BF did not modify GH, POMC or SSTs mRNA levels. However, PF 
increased GH and SST2 and SST5 mRNA expression levels in a similar way to that seen in 
normal pituitary gland from Papio anubis [145]. These data indicate that the actions of 
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biguanides also include the regulation of the synthesis of key genes involved in the control of 
pituitary pathophysiology.  
Additionally, our study also provides information about the signaling pathways underlying 
the effects of biguanides in PitNETs cells. In particular, our results revealed an inhibition on 
[Ca2+]i levels in response to all biguanides in ACTHomas and NFPTs, but not in GHomas or 
PRLomas, suggesting that calcium kinetics in response to biguanides may be more related 
with their actions on cell viability than with the control of hormone secretion. Moreover, we 
found a regulation of phosphorylation levels of the key mediator of MF [144], AMPK in 
response to BF and PF, but not in response to MF, which is contrast with the results reported 
in GH3 and AtT-20 [132, 133, 146]. In line with this, we found an increase on phosphorylation 
levels of Akt and ERK1/2 in response to BF and PF, but not MF. These results suggest that 
some biguanides would act through AMPK-independent mechanisms in PitNETs cells, in a cell 
type-dependent manner. 
Finally, to assess the clinical context of the potential interplay between PitNETs and 
biguanide treatment, we explore the putative association between treatment with MF and 
clinical outcomes of patients harboring different types of PitNETs. Specifically, we analyzed a 
cohort of 42 ACTHomas, 28 GHomas and 62 NFPTs available at the Reina Sofia University 
Hospital and compared relevant clinical characteristics between patients treated or not with 
metformin (see table 4 attached at the end of this manuscript). As shown, none of the clinical 
parameters evaluated (i.e. BMI, lesion type, tumor size, cephalea, visual alterations, 
extrasellar growth, presence of other treatments, persistence after surgery, etc.) revealed 
significant associations with MF use in this patient cohort. 
In sum, the data presented herein demonstrate that biguanides exert distinct anti-
proliferative and anti-secretory effects in specific PitNETs cell types, which would involve both 
AMPK-dependent ([Ca2+]i kinetics and PI3K-Akt pathway) and -independent (ERK pathway) 
mechanisms. The combination therapy of MF with SSAs did not show relevant additive effects 
in most PitNETs, suggesting overlapping mechanisms of action. Of note, combined therapy 
might represent a potential therapeutic approach for NFPTs. Although MF use was not 
apparently related to any clinical variable in our cohort of patients, the limited number of 
patients treated with MF and the retrospective observational nature of the analysis may limit 
these results. Altogether, these data unveil a clear antitumoral effect of different biguanides 
on PitNETs cells and pave the way to further explore these compounds as a potential new 
option in the treatment of this pathology. 
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5.2 The pituitary gland is a novel major site of action of metformin in non-human 
primates: a potential path to expand and integrate its metabolic actions (Article 
II)  
 
In addition to the well-known antihyperglycemic effect of MF, recent studies have 
reported that MF might exert additional beneficial actions both in the modulation of whole-
body homeostasis and metabolism, by specifically targeting key endocrine/metabolic tissues, 
as well as by exerting other positive effects through alternative mechanisms of action (i.e. 
beneficial use in the treatment of cardiovascular diseases, aging, cancer, immune diseases, 
polycystic ovarian syndrome, etc.) [128, 130, 147-151]. To date, however, no studies have 
explored in detail how biguanides can modulate directly the function of the normal anterior 
pituitary gland in humans or in primate species, and what signaling pathways would be 
involved in those actions. In this sense, it is still under debate if AMPK is the central mediator 
of metformin in all of its metabolic actions, since AMPK-dependent and independent 
mechanisms have been proposed [144, 152, 153]. Therefore, we aimed to determine, for the 
first time, the direct effects of MF and PF on the secretion and gene expression of all anterior 
pituitary hormones in two non-human primate species [Papio anubis (baboons) and Macaca 
fascicularis (macaques)], and to understand the mechanisms behind the actions of these 
biguanides by evaluating the expression of key receptors and transcription factors, and by 
assessing different signaling pathways using standard pharmacological (inhibitory) approaches.  
We first evaluated the direct effects of MF and PF on pituitary hormone release after 
short (4 h) and long (24 h) incubation periods. This revealed that both biguanides inhibited GH, 
ACTH and FSH release, but did not alter PRL, LH or TSH release, and also, that these inhibitory 
effects were more pronounced in a short-term incubation period. We then studied the direct 
interactions between MF and other primary regulators of pituitary function. Interestingly, MF 
was not able to inhibit the stimulatory actions of GHRH on GH release, of ghrelin on GH and 
ACTH release, and that of GnRH on FSH release, which suggest that MF and these regulators 
may operate through shared mechanisms of action, and also reveal that the inhibitory action 
of MF modulates pituitary cell function, but does not seem to overcome the stimulatory action 
of the primary hypothalamic regulators. On the other hand, our results on FSH are apparently 
in contrast with the only previous report indicating that GnRH-stimulated FSH/LH release was 
reduced by MF in rat pituitary cell cultures [154]. However, these discrepancies could be due 
to a number of different factors such as reproductive status of the donor, the time of 
incubation, cell preparation, but also to the fundamental differences in the physiology 
between rat and primate species.  
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In addition, we found that MF regulates not only hormone secretion, but also the 
synthesis of different hormones. Thus, MF treatment reduced GH and POMC mRNA expression 
levels after 24h of incubation, which would reinforce the reduction observed at the hormone 
release level. In contrast, PRL, FSH, LH and TSH expression levels were not altered by MF 
treatment, which also parallels the lack of effect of MF on the release of these hormones, with 
the exception of FSH. Thus, these data indicate that the direct pituitary actions of MF involve 
both hormone synthesis and release in somatotropes and corticotropes, whereas in 
gonadotropes it would only extend to vesicle release. Importantly, the inhibitory effects of MF 
and PF in both non-human primate species were not attributed to an alteration of cell viability 
or to the expression of the transcription factor Pit-1 since these parameters were not modified 
in response to the treatments.  
To better understand these direct actions of MF, we also explored the intracellular 
signaling pathways that could underlie its inhibitory effects in primary pituitary cell cultures. 
Results from these studies, using a standard pharmacological (inhibitory) approach, indicated 
that the effects of MF on GH, ACTH and FSH release were mediated through mTOR, PI3K and 
intracellular Ca2+ mobilization, but did not require activation of adenylate cyclase (AC), 
phospholipase C (PLC) or extracellular Ca2+ mobilization. Additionally, the actions of MF on GH 
secretion also involved the MAPK pathway. Of note, although AMPK is often considered the 
central mediator of MF actions [144], we could not evaluate this pathway using the 
pharmacological approach due to lack of effective, and accepted, specific inhibitors of AMPK. 
Nevertheless, our data suggest that MF acts through AMPK-dependent mechanisms at 
pituitary levels since the signaling pathways that we found to be related to MF effects have 
been described to be upstream or downstream of AMPK signaling pathway [155-158]. 
However, we also observed that, in somatotrope cells, MF also acts through MAPK pathway, 
which is presumably not linked to AMPK, thus suggesting that MF also acts through AMPK-
independent mechanisms in this cell type. The study of the signaling pathways shed some light 
on the possible reasons underlying the inability of MF to counteract the stimulatory actions of 
ghrelin, GHRH or GnRH. In this regard, it has been reported that ghrelin acts through PLC, 
protein kinase C (PKC), intracellular and extracellular Ca2+ mobilization, and MAPK at the 
pituitary level, while GHRH and GnRH act through AC/cAMP/protein kinase A (PKA), 
NOS/guanylate cyclase (GC) and intra-/extracellular Ca2+ dynamics [4]. Consequently, our 
results reveal that MF and those pituitary regulators act through both distinct and common 
(i.e. intracellular Ca2+ and MAPK pathway) signaling pathways, which may explain, at least in 
part, why MF did not influence the actions of these regulators at pituitary level.  
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Finally, our data also revealed that MF increases mRNA expression levels of key receptors 
of pituitary physiology (SST2, SST5, INSR and IGF1R), which probably are associated with 
inhibition of hormone secretion/expression in somatotropes, corticotropes and gonadotropes. 
In summary, our results unveil that MF impacts directly on pituitary somatotrope, 
corticotrope and gonadotrope cells at the secretory, gene expression and signaling levels. 
These actions, if present in vivo, may have translational relevance. Indeed, the decrease on GH 
and ACTH secretion could be a beneficial metabolic action of MF to improve whole body 
homeostasis, inasmuch as several studies have reported that increased circulating levels of GH 
and glucocorticoids can lead to worsening of insulin resistance, glucose intolerance and 
diabetes mellitus [159-162]. Taken together, the results presented herein clearly suggest that 
the pituitary is a primary site for the pharmacological actions of MF, and that this gland would 
represent an additional, key target tissue and a true endocrine sensor contributing, in concert 
with other primary tissues (i.e. liver), to the well-known beneficial metabolic effects of 
biguanides in humans. 
 
5.3 Simvastatin exerts antitumoral actions in pituitary tumor cells (Article III)  
 
Statins are well-stablished drugs commonly used to treat hyperlipidemia, and 
cardiovascular and coronary heart diseases. In addition to the cholesterol-lowering effects, 
statins have been related with a broad range of pleiotropic effects [163, 164]. Among them, 
numerous reports have described anticancer effects of statins in an ample selection of tumor 
types, including neuroendocrine tumor cells [131, 165-168]. However, to the best of our 
knowledge, the precise role of statins in PitNETs cells has not been explored hitherto. 
Therefore, we aimed to ascertain the direct effects of statins, specially simvastatin, on 
important functional parameters (cell viability/proliferation, hormone secretion and 
intracellular signaling pathways) in primary cell cultures from different human PitNETs 
subtypes, including ACTHomas, GHomas and NFPTs, as well as in two representative pituitary 
model cell lines from rodents, the AtT-20 corticotropes and the GH3 somatotropes. Moreover, 
we also analyzed the ability of simvastatin to influence relevant functional parameters 
(hormone secretion, cell viability, gene expression and intracellular signaling pathways) in 
primary cell cultures from normal pituitary of baboons (Papio anubis). 
The first approach of our study was to evaluate the effect of different statins on cell 
proliferation, a parameter tightly linked to tumor growth. In general, all statins were able to 
significantly decrease cell proliferation in AtT-20 cell line, with simvastatin showing slightly 
stronger effects. These results compare favorably with the statin-induced reduction of cell 
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proliferation reported in murine pheochromocytoma cell lines [167] and in human pancreatic 
neuroendocrine tumor cell lines [131]. In the same line, our results showed a clear decrease on 
cell viability at different times of incubation in different PitNETs subtypes. Interestingly, the 
effect of simvastatin was stronger in ACTHomas and NFPTs compared with GHomas, which are 
the most resistant tumor types to the currently available therapeutic options [93, 169]. Most 
importantly, treatment with simvastatin (24h) did not alter cell viability in normal pituitary 
cells. Furthermore, we also explored the effect of simvastatin on hormone secretion in 
different PitNETs subtypes and in normal pituitary cells. Thus, simvastatin treatment (24h) 
reduced ACTH, GH, and chromogranin-A (CgA) secretion in ACTHomas, GHomas, and NFPTs, 
respectively, and ACTH, GH, PRL, FSH and LH secretion in normal pituitary cells. These results 
are also of potential clinical relevance, in that hypersecretion of pituitary hormones causes 
serious comorbidities in patients with PitNETs [3]. Hence, a reduction of hormone secretion 
from tumor cells in response to simvastatin would be clearly beneficial for patients harboring 
these pathologies.  
Regarding the signaling pathways underlying these effects, our results showed that 
inhibitory actions of simvastatin in ACTHomas and NFPTs, but not in GHomas or normal 
pituitary cells, might be slightly mediated through the mobilization of [Ca2+]i levels. Moreover, 
we also found a reduction on the phosphorylation levels of ERK1/2 in response to simvastatin 
after a short-term (4h) and after a long-term (24h) incubation in AtT-20 and GH3 cells, 
respectively. In the same line, we use a standard pharmacological (inhibitory) approach to 
evaluate the signaling pathways involved in simvastatin effect in normal pituitary cells. 
Specifically, we found that the reduction of ACTH, GH, PRL, FSH and LH was mediated through 
mTOR and PI3K pathways, but not through intracellular or extracellular Ca2+ influx. Moreover, 
inhibitory actions on ACTH, GH and PRL secretion also require MAPK, which is in accordance 
with the results observed in AtT-20 cells. Remarkably, simvastatin also evoked a 
downregulation in the expression of key receptors associated to primary stimulation of ACTH, 
GH, PRL, FSH and LH secretion (i.e. GHRHR, GNRHR and KISS1R), which might also be serving to 
enhance the inhibitory effects of simvastatin on hormone release from corticotrpes, 
somatotropes, lactotropes and gonadotropes observed herein.  
On the other hand, taking in account that there are numerous clinical trials, ongoing or 
recently finished [170], using statins as antitumor agents, and that we have reported 
antitumor actions of metformin in NETs and PitNETs [131, 171], we next studied the 
combination therapy of simvastatin and metformin in PitNETs cell lines. In general, combined 
treatment did not modify the effects of simvastatin tested alone (with the exception of an 
additive effect at 24h in GH3 cells that disappeared at 48-/72-h). Likewise, SSAs are also 
 46 
frequently used alone or in combination with other pharmacological options (e.g. dopamine 
agonists, pegvisomant) to control PitNETs symptoms [141, 142]. In our study, the combination 
of simvastatin with SSAs did not produce any additive effect in AtT-20 or GH3 cells. These 
results might suggest that simvastatin, MF, and SSAs are sharing mechanisms of action to exert 
their inhibitory effects in pituitary tumor cells. Indeed, several reports have associated the 
activation of AMP-activated protein kinase (AMPK; considered the central mediator of MF 
actions) by statins in numerous cancer types [165, 172, 173], and also, statins have been linked 
with the dysregulation of several pathways like Ras-MAPK, PI3K-Akt, and AMPK/Akt/mTOR, all 
of them also involved in the effects of SSAs and MF [174, 175].  
Finally, we also explored the putative association between treatment with statins and 
clinical outcomes of patients harboring different PitNETs subtypes. Specifically, we analyzed an 
independent cohort of 42 ACTHomas, 28 GHomas and 62 NFPTs available at the Reina Sofia 
University Hospital. This revealed that patients treated with statins show a trend to have less 
extrasellar growth compared with patients not treated with statins (p=0.07). In contrast, none 
of the other clinical parameters evaluated (i.e. BMI, lesion type, tumor size, cephalea, visual 
alterations, presence of other treatments, persistence after surgery, etc.) revealed significant 
associations with the use of statins in this patient cohort. 
In conclusion, our study provides primary evidence that statins, specially simvastatin, 
exert important antiproliferative and antisecretory effects in different PitNETs subtypes, 
without altering the viability of normal pituitary cells. Furthermore, we present mechanistic 
insights into the plausible signaling pathways underlying the inhibitory actions of simvastatin 
on cell survival and hormone release, which may partially overlap with those employed by MF 
or SSAs, as their combination with simvastatin did not elicit relevant additional antitumor 
effects. Therefore, our data unveil clear antitumoral direct effects of simvastatin on PitNET 
cells, thereby opening the possibility to explore these compounds as a novel tool to enrich the 
limited pharmacological arsenal available to treat patients harboring PitNETs. 
 
5.4 A novel SST3 agonist shows potential antitumor effects in experimental models 
of Nonfunctioning Pituitary Tumors (Article IV)  
 
Currently, the available pharmacological treatment approaches for PitNETs (mainly SSAs 
and dopamine agonists) have shown very limited efficacy in NFPTs [77], and are therefore, 
sparingly applied. In the case of SSAs, it has been proposed that this lack of efficacy may be 
due to the low SST2-SST5 expression levels as compared to those of SST3 [176, 177], given the 
 47 
preferred targeting of first generation SSAs (octreotide, lanreotide) for the former receptor 
subtypes. Importantly, SST3 has been associated with apoptotic/antiproliferative actions in 
several studies using cell lines and, in fact, apoptotic actions of SRIF/SSAs have been 
historically related to SST3 [19, 178]. In this context, pasireotide, which also shows high affinity 
for SST3, has been proposed as a potential therapeutic option in the treatment of NFPTs [177]; 
but, recent results from our group demonstrates that pasireotide does not exert a clear 
inhibitory effect on primary cultures from NFPTs [93]. Based on this information, we 
hypothesized that a compound that selectively or preferentially binds to SST3 might be an 
effective therapeutic option to treat NFPTs. However, it has been very challenging to find 
peptides that selectively activate SST3, and thus, the functional role and pathophysiological 
relevance of this receptors in NFPTs is still poorly understood. Accordingly, the aims of this 
study were to identify specific SST3 agonists through the screening of a peptide library; and to 
determine the in vitro and in vivo therapeutic potential of SST3 agonists. To this end, we first 
studied the direct effect of the identified SST3-specific agonists and antagonists on key 
functional parameters for NFPTs, including cell viability, caspase activity, chromogranin-A 
(CgA) secretion, signaling pathways, and mRNA levels, and also examined the functional 
consequences of SSTR3 silencing on cell viability. Furthermore, we evaluated the effect of a 
selected SST3-specific agonist on tumor-growth in a preclinical mouse-model of PAs. 
We first screened a library of synthetic-peptides produced at IPSEN selecting for 
compounds that bind to SST3 and applying a multidimensional Spotfire analysis to identify 
compounds with the highest selectivity for SST3. Thus, SST3 binding affinities and functional 
cAMP assays revealed that BIM-355 and BIM-071 were the most potent SST3-agonists, and 
BIM-839 was the most potent SST3-antagonist.  
Next, we corroborated that SST3 was overexpressed in our cohort of patients, and 
demonstrated that SST3 (mRNA and protein levels) could discriminate between NFPTs vs 
functioning pituitary tumors (FPTs), but not between normal pituitaries (NPs) and FPTs.  
In addition, we explored the functional role of SST3 using the new peptidic SST3 agonists 
and antagonists in comparison to the previously published non-peptidic L-796,778 SST3 
agonist. Our results revealed a general ability of SST3 agonists to reduce cell viability in NFPT 
cells, being BIM-355 the most potent compound, causing a 23.2% of reduction, which, to our 
knowledge, is the most prominent reduction reached on cell viability through the activation of 
SST3 [178]. We also found an increase on caspase activity in response to SST3 agonists, which is 
in line with previous results in HEK-293 cell line using L-796,778 [178]. These effects on 
caspase activity, as well as those on cell viability, were completely blocked by the antagonist 
BIM-839, thus confirming the specificity of the actions observed. Moreover, supporting these 
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results, we demonstrated, for the first time, that in vivo administration of an SST3-specific 
agonist significantly decreased tumor growth in a preclinical mouse model of PitNET [179].  
Our data also revealed a decreased of CgA secretion in response to SST3 agonists in NFPT 
cells. CgA has been considered as a useful marker of pharmacological effectiveness and has 
been recently proposed as a biomarker of tumorigenesis and invasiveness [180, 181]. 
Interestingly, our in vitro approach unveiled that a subset of NFPTs did not respond to SST3 
agonists in terms of inhibition of cell viability, which is not unexpected since several reports 
have shown a substantial proportion of unresponsive PitNETs upon treatments with different 
compounds [93, 138]. A comparison of the expression profile of SSTs revealed that high SST3 
expression levels are a requisite to elicit a significant response after SST3 agonists 
administration, which is also in line with the finding that ROC-curve analysis demonstrates that 
SST3 is able to discriminate between responsive and unresponsive NFPTs. Moreover, treatment 
with SST3 agonists increased SST3 expression levels in responsive, but not in unresponsive 
NFPTs, thereby suggesting the existence of a positive homologous SST3 (receptor)-SSTR3 
(gene) regulatory circuit in these tumors. 
An additional set of studies was aimed at identifying the signaling pathways underlying 
the ability of SST3 agonists to generate functional responses. Specifically, NFPT cells showed a 
scarce and infrequent response to agonists in terms of [Ca2+]i kinetics. In contrast, in 
responsive NFPTs, BIM-355 produced a striking reduction on the phosphorylation levels of 
relevant protein kinases associated to three important signaling pathways: MAPK, PI3K-
AKT/mTOR and JAK/STAT. Indeed, we found a decrease on ERK1/2 and JNK phosphorylation 
among other proteins of the MAPK pathway in responsive, but not in unresponsive NFPTs. 
These results are in line with previous results on HEK-293 cells treated with L-796,778 [178]. 
Similarly, we also observed a reduction on phosphorylation levels of Akt, GSK-3a/b, Src, 
PRAS40, mTOR and p70-S6 kinase, all of them associated to the PI3K-AKT/mTOR pathway, 
which controls cell cycle progression, protein synthesis and cell proliferation [182]. 
Additionally, we observed a reduction on the phosphorylation levels of some key components 
of the JAK/STAT signaling pathway, such as STAT3, STAT5a/b and STAT6. Although GPCRs have 
not been traditionally related with this signaling pathway, there are several reports describing 
an activation of STAT3 by GPCRs associated with cancer progression [183, 184]. Conversely, of 
note, the phosphorylation status of most of the proteins described above were not altered or 
were increased in unresponsive NFPTs. These results compare favorably with results reporting 
an increase on phosphorylation of Akt levels in a proportion of NFPTs resistant to rapamycin 
[185] and with results in PRLomas showing that a reduced D2S/D2L ratio and an increase on 
MAPK and PI3K/AKT/mTOR pathways might contribute to tumorigenesis and DA resistance 
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[186]. In addition, the comparison of basal phosphorylation levels of responsive and 
unresponsive NFPTs revealed a clear pattern of inhibition in the basal levels of the MAPK, PI3K-
AKT/mTOR and JAK/STAT proteins in unresponsive tumors, which could explain the resistance 
of this population of NFPTs to respond to the SST3 agonist (and possibly to other SSAs). 
Consistent with the existence of two populations of NFPTs, the silencing of SSTR3 gene 
expression by two specific siRNAs (corroborated at mRNA and protein levels) increased cell 
viability by 38% of NFPTs. A potential explanation for this result would be that SST3 bears a 
constitutive inhibitory activity, inasmuch as previous results have demonstrated that various 
SSTs, including SST3, display a relevant degree of ligand-independent constitutive activity in 
different pituitary cell systems [187, 188]. Another possibility would be that these cells release 
SRIF or cortistatin. In this regard, our results revealed negligible levels of SRIF and much higher 
levels of cortistatin, which might suggest the existence of an ultra-short autocrine feedback 
mechanism whereby activation of SST3 by endogenous cortistatin would mediate inhibition of 
cell viability, secretion, etc. Inversely, a reduction in SST3 protein levels (by silencing) could 
lead to the loss of this inhibitory loop and could, ultimately, induce an increase on cell viability. 
Importantly, the fact that BIM-355 did not alter cell viability in s13501-transfected cells (with 
reduced SST3 content), together with the fact that SST3-antagonist BIM-839 completely 
blocked the effects of SST3-agonists, provide compelling evidence that the effects observed in 
response to agonists are completely dependent on and only specific for SST3. 
Altogether, this study represents the first identification and characterization of potent 
and selective SST3 peptidic agonists, which enabled to gain novel experimental results 
supporting that these agonists exert clear antitumor actions on NFPT primary cell cultures. 
Therefore, the present study provides new, compelling evidence demonstrating that SST3 has a 
functional role in the pathophysiology of NFPTs, and invites to suggest that pharmacological 
treatments specifically targeting this receptor could become a promising option to treat 
patients with NFPTs. 
 
5.5 A new generation somatostatin-dopamine analogue exerts potent antitumoral 
actions on pituitary neuroendocrine tumor cells (Article V)  
 
The development of chimeric compounds able to bind simultaneously to SSTs and Ds 
provided a novel, promising therapeutic approach to treat different PitNETs subtypes. 
However, results published regarding BIM-23A760, a chimeric compound able to bind to SST2, 
SST5 and D2, revealed the existence of two PitNET cell populations that oppositely respond to 
the treatment, referred to as an inhibitory- and a stimulatory-population [109], suggesting that 
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this compound might not be a successful therapy in some patients with PitNETs. For this and 
other pharmacologically-related reasons, a new generation of chimeric agonist for 
SST2/SST5/D2 receptors (named BIM-065), with higher potency, efficacy and safety has been 
recently designed and developed by IPSEN that may be used for clinical purposes in the future. 
Therefore, the main aim of this study was to evaluate, for the first time, the direct effects of 
this new compound on relevant functional parameters such as cell viability, apoptosis, 
hormonal secretion and expression and [Ca2+]i kinetics, in primary cell cultures from different 
PitNETs, including ACTHomas, GHomas, NFPTs and PRLomas. 
ACTHomas represent a suitable model to test the effect of BIM-065 since its preferred 
target receptors are highly expressed in these tumors (D2T>D2L>SST5>>SST2). We measured the 
expression of these receptors and also that of the two truncated SST5 variants, SST5TMD4 and 
SST5TMD5, since the presence of these isoforms have been associated to a poor response to 
SSAs [22, 23]. However, the expression levels of these truncated variants were negligible in 
this cohort of PitNET samples. To our knowledge, this is the first time that the effect of a 
chimeric compound is evaluated in detail in ACTHomas. Our results revealed that BIM-065 
induced a comparable reduction of cell viability than octreotide at 10-7 M, but the reduction 
achieved at 10-9 M was higher in response to BIM-065. We also found that BIM-065 increased 
apoptosis and inhibited ACTH secretion after 24h of incubation, without altering mRNA levels 
of key genes (POMC, SST2, SST5, D2, PTTG, CDKN1B or CDK2). Likewise, we observed a 
reduction on [Ca2+]i levels in all ACTHomas tested, which is in line with results observed in 
response to BIM-23A760 [109], although the percentage of responsive cells was higher with 
BIM-065. Additionally, to further test the capacity of BIM-065 to induce functional responses, 
we measured several components of two important signaling pathways (MAPK and PI3K-Akt) 
in corticotrope AtT-20 cells. These pathways are tightly linked to cell growth, proliferation and 
survival in tumor pathologies, including PitNETs [175, 189]. Interestingly, short-term 
incubation with BIM-065 (10 min) clearly increased p-Akt, which was followed by a clear 
reduction of the anti-apoptotic protein Bcl-2. In contrast, long-term incubation with BIM-065 
(24h) numerically up-regulated p-ERK1/2 levels, although this latter effect did not reach 
statistical significance. A similar stimulatory response in ERK1/2 levels has been previously 
reported in PitNET cells after treatment with BIM-23A760 and the dopaminergic agonist BIM-
53097, which was mainly associated to an activation of the dopaminergic signaling through D2 
[107]. Therefore, these results might suggest that BIM-065 modulate ERK1/2 and Akt through 
the preferential activation of the D2/dopaminergic-signaling. Moreover, the decrease in Bcl-2 
levels support the increase of apoptosis observed in response to BIM-065 in PitNETs. 
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Similar to ACTHomas, GHomas express high levels of SSTs and Ds (D2T>D2L>SST5>>SST2). 
Moreover, BIM-065 produced a higher reduction of cell viability and a comparable increase of 
apoptosis compared with our previous results using BIM-23A760 [109]. However, BIM-065 
produced a more striking reduction of GH secretion compared to BIM-23A760 or other 
chimeric compounds [105, 109, 190]. These results are in agreement with a recent report 
showing that BIM-065 can reduce GH and IGF1 levels in healthy male volunteers [191]. 
Comparison of GH reduction between BIM-065 and SSAs did not show any relevant difference. 
Nevertheless, further experiments with a higher number and variety of tumor samples will be 
necessary to unequivocally stablish whether BIM-065 is more potent and efficacious than SSAs 
in GHomas. Additionally, the new dopastatin evoked a clear reduction on [Ca2+]i levels, which 
also agrees with the inhibitory response observed in response to BIM-23A760 [109]. 
In the course of the study, we had the opportunity to test the new chimeric compound on 
two PRLomas. Interestingly, we observed clear differences in the response to BIM-065 and 
cabergoline in terms of cell viability between the two PRLomas analyzed, which could be due 
to their differential receptor expression pattern. Thus, the tumor that was highly responsive 
expressed higher levels of SST5 compared to SST2 and higher levels of both isoforms of D2. 
Furthermore, these data are in line with previous results reporting that dopaminergic 
contribution is more important for the response to chimeric compounds, such as BIM-23A760, 
than the expression of SST2 [192]. Consistent with previous results observed with chimeric 
compounds [109, 190] and with BIM-065 in healthy male volunteers [191], BIM-065 produced 
a decrease on PRL release. Obviously, additional experiments are necessary to confirm and 
extend these results, and to explore the signaling pathways involved in the effects exerted by 
BIM-065 in PRLomas. 
NFPTs expressed high levels of SST2, SST5 and D2 (D2T>D2L>>SST2>SST5) and negligible 
levels of truncated SST5TMD4 and SST5TMD5. However, and in contrast with previous results 
with other dopastatins [108, 109], BIM-065 did not produce any detectable alteration on cell 
viability. On the contrary, BIM-065 induced a clear increase of apoptosis and a decrease in CgA 
in all cases tested. Although the vast majority of observations suggest that the cell 
proliferation and programmed cell death are effectively coupled [193, 194], there are several 
studies showing an imbalance between cell proliferation/survival index and apoptosis in 
pathological conditions [134, 135]. Nevertheless, further experiments are required to 
understand why cell proliferation and apoptosis are apparently uncoupled in response to BIM-
065 in NFPTs cell cultures.  
In sum, our study provides compelling evidence demonstrating that BIM-065 can directly 
alter cell function and behavior in different PitNETs subtypes. Thus, BIM-065 acted mostly by 
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reducing cell viability and hormone secretion and increasing apoptosis. Importantly, in 
contrast to previous data with other dopastatins, treatment with BIM-065 did not evoke any 
stimulatory action in the tumor cells analyzed, while the proportion of responsive tumors/cells 
was higher with this compound than with BIM-23A760, suggesting that this novel dopastatin is 
a more efficacious and specific chimeric compound, an may become an attractive and valuable 
tool in the future treatment of PitNETs. Thence, further studies should be developed to 
confirm and expand the original results provided herein, and to better understand the 
intracellular mechanisms underlying the effects of BIM-065 since this new generation chimeric 
compounds may hopefully help to enhance the currently scarce pharmacological arsenal for 
the treatment of patients harboring PitNETs. 
 
5.6 Splicing machinery is dysregulated in pituitary neuroendocrine tumors and 
associated with aggressiveness features (Article VI)  
 
the primary initiating cause of PitNETs development and possible the existence of general 
and distinctive signatures and molecular elements in this heterogeneous pathology is still 
under debate. In this scenario, an emerging body of evidence indicates that altered alternative 
splicing and its consequent outcome, i.e. the appearance of abnormal patterns of splicing and 
even that of aberrant splicing variants, represents a common feature across most tumor 
pathologies, including PitNETs [23, 25, 55-58]. In addition, the spliceosome system is becoming 
an attractive therapeutic target for tumor pathologies [195]. This is the case for pladienolide-B, 
a natural compound that directly targets and binds a key player in the spliceosome, SF3B1, and 
thereby inhibits spliceosome functions, which in turns appear to mediate the antitumor 
properties of this promising drug [195, 196]. However, the expression pattern and putative 
role of the core splicing machinery components in the development and progression of 
PitNETs, as well as the potential therapeutic effects of pladienolide-B in PitNET cells, has not 
be reported. For these reasons, we aimed to determine and analyze the expression levels of 
the spliceosome core components and a selected set of relevant splicing factors (SFs) in the 
main PitNETs subtypes (GHomas, NFPTs, ACTHomas and PRLomas) as compared to normal 
human pituitary gland samples. Additionally, we evaluated the potential antitumor actions of 
pladienolide-B in PitNET cells by evaluating key functional parameters (i.e. cell 
proliferation/viability and hormone secretion) in human primary PitNETs cell cultures and 
pituitary cell lines (AtT-20 and GH3). 
One of the main observations of this study is the fact that the spliceosome machinery is 
dysregulated in a tumor subtype-dependent manner, where NFPTs, GHomas, ACTHomas and 
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PRLomas exhibit a differentially altered pattern of expression. Specifically, NFPTs showed a 
profound downregulation of three major spliceosome components, two minor spliceosome 
components and 15 SFs compared to normal pituitaries. Bioinformatics analyses [i.e. Variable 
Importance in Projection (VIP) score of Partial Least Squares-Discriminant (PLS-DA)] revealed 
that SRSF9, SND1, U2AF1 and CELF4 were the components with higher capacity to discriminate 
between NFPTs and NPs. Moreover, ROC curve analyses of these four components 
corroborated their capacity to discriminate between NFPTs and NPs showing an AUC of 0.94, 
0.94, 0.93 and 0.89, respectively (p<0.001). Interestingly, a clear alteration of these 
spliceosome components found in our cohort of NFPTs has also been observed in other tumor 
pathologies. Specifically, SRSF9 and SND1 have been found to be overexpressed and 
associated with an increase in cell proliferation, invasion and poor prognosis in several tumor 
pathologies [197-200]. Moreover, CELF proteins have been reported to regulate the splicing of 
neurofibromatosis type 1 (NF1) protein generating a protein with the exon 23a excluded, 
which has 10 times greater ability to regulate Ras signaling, a main component of MAPK 
signaling pathway [201]. In addition, U2AF1 is an important component of the major 
spliceosome that has been found frequently mutated and associated to the generation of 
particular splicing patterns in several pathologies [202, 203]. In this sense, our results might 
suggest that not only the mutation pattern but also the expression pattern of U2AF1 could be 
involved in the malignant behavior of tumor pathologies including NFPTs. 
In GHomas, analysis of a cohort of acromegalic patients from Spain (cohort-1) showed a 
significant overexpression of 6 major spliceosome components, a downregulation of one 
component of the minor spliceosome and 17 significantly altered SFs (16 upregulated and one 
downregulated). In this case, we found that the expression levels of three SFs (RAVER1, RBM3 
and SRSF6) with the highest score in the VIP analysis were able to discriminate between 
GHomas and NPs in two perfect clusters. Moreover, ROC curve analyses of these three SFs 
showed an AUC of 0.99, 1, and 0.98, respectively. Additionally, we confirmed the 
overexpression of RAVER1 and RBM3, but not SRSF6, in another independent cohort of 
GHomas (tumors from Brazil; cohort-2). Interestingly, the dysregulation of RAVER1 and RBM3 
has been recently associated with the development of non-alcoholic fatty liver disease and/or 
with the development of type-2 diabetes in patients with cardiovascular disease [204, 205]. 
Moreover, RBM3 and SRSF6 have been associated with aggressive features and with poor 
prognosis in several tumor pathologies [206-208], and SRSF6 has been postulated as a possible 
therapeutic target to reduce tumorigenesis in colorectal cancer [206-208]. 
In ACTHomas, our data revealed a significantly dysregulation of 11 splicing machinery 
components, two components of major spliceosome and 9 altered SFs. Further analysis 
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revealed that the pattern of two SFs with the highest score in the VIP analysis (MAGOH and 
KHDRSB1) was able to discriminate between ACTHomas and NPs in two perfect clusters, and 
ROC curves analyses of those factors corroborated this capacity with an AUC of 1 and 0.97, 
respectively. These results are in accordance with the overexpression of KHDRSB1 found in 
gastric, epithelial ovarian cancer or sacral chordomas, wherein its presence was associated 
with poor prognosis and aggressive characteristics [209, 210]. Likewise, MAGOH has been 
shown to be differentially expressed in breast cancer, where it served, together with other 
RNA processing factors, to develop a robust stratification of breast cancer subtypes [211]. 
However, the presence and potential role of KHDRSB1 and MAGOH in PitNETs or normal 
pituitary has not been reported hitherto. 
In addition, PRLomas exhibited an overexpression of three major spliceosome 
components, a downregulation of one minor spliceosome component, and an alteration of 14 
SFs (12 upregulated and 2 downregulated) in comparison with NPs. However, the combination 
of the components with higher score in VIP analysis (RNU11, ESRP2, RNU6ATAC, SRSF1 and 
ESRP1) was not sufficient to clearly distinguish between both populations. This might probably 
be associated to the low number of PRLomas analyzed in this study due to the difficulty to 
have access to this type of samples since dopamine agonist’s treatment regimens are highly 
successful in patients with PRLomas. 
Interestingly, we also pinpointed a common downregulation of three minor spliceosome 
components (RNU11, RNU4ATAC and RNU6ATAC) and one SF (SRSF1) in PitNETs, irrespective 
of their origin, which might be patho-physiologically relevant. The fact that these spliceosome 
components are similarly dysregulated in all PitNETs, despite the high heterogeneity of these 
tumors, invite to speculate about the existence of common driver alterations in pituitary 
tumorigenesis, which would pave the way toward the identification of common therapeutic 
targets based on the dysregulations of these key elements. However, further studies should be 
conducted to test this hypothesis. 
Finally, our study also demonstrates that the pharmacological disruption of the splicing 
process using pladienolide-B could have potential antitumor actions in patients with different 
types of PitNETs. Thus, this compound significantly inhibited cell viability/proliferation in all 
PitNETs and cell lines analyzed, and also decreased GH secretion after 24h of incubation in 
GHomas. Our results are in line with the antitumor actions of this compound (i.e. reduction on 
cell viability and colony formation) previously observed in HeLa cells [196]. However, it should 
be mentioned that NFPTs were less sensitive to the effect of pladienolide-B compared to 
GHomas, result that is in line with previous observations in response to other pharmacological 
treatments in NFPTs [93, 169, 171]. 
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Altogether, our data provide compelling evidence to propose that the splicing machinery 
is severely and distinctly dysregulated in the main subtypes of PitNETs compared to NPs, and 
identified unique fingerprints of spliceosome components in each PitNETs subtype that can 
accurately discriminate between normal and tumor pituitary tissues. Furthermore, we also 
found several components, including SFs (SRSF1) and specially three minor spliceosome 
components (RNU11, RNU4ATAC and RNU6ATAC), commonly dysregulated in all PitNET 
subtypes, which could represent novel, common therapeutic targets in these pathologies. 
These discoveries open a new window to investigate the plausible contribution of splicing 
dysregulation and its subsequent outcomes to pituitary tumorigenesis, and to assess the 
potential value of specific splicing machinery components as novel diagnostic/prognostic tools 
in these pathologies. Furthermore, our study unveils splicing, particularly SF3b1, as a novel 
actionable therapeutic point that can be targeted by Pladienolide-B to combat PitNETs. 
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6. General conclusions 
 
1) Biguanides (metformin, buformin and phenformin) reduce cell proliferation and 
hormone secretion in specific PitNETs cell types and these effects seem to involve AMPK-
dependent (Ca2+i signaling and PI3K-Akt pathway) and -independent (MAPK pathway) 
mechanisms. The combined administration of MF and SSAs did not exert additive effects in 
functioning PitNETs, suggesting an overlap of their signaling mechanisms. In contrast, this 
combined therapy exerted stronger effects in reducing cell viability in NFPT cells. Altogether, 
these results pave the way to further explore biguanides as a potential treatment in PitNETs.  
2) Metformin exerts direct regulatory effects on pituitary cells by acting at both hormone 
secretion and gene expression levels in somatotrope, corticotrope and gonadotrope cells, in a 
cell-type specific manner, and through mechanisms involving common and distinct signaling 
pathways. These results suggest that the pituitary gland is a primary site for the 
pharmacological actions of metformin, thereby reinforcing the view that this gland represents 
a true endocrine-metabolic sensor, and would serve as an additional, key target tissue 
contributing, in concert with other primary tissues (i.e. liver), to the well-known beneficial 
metabolic effects of metformin in humans. 
3) Simvastatin exerts antiproliferative and antisecretory effects in different PitNETs 
subtypes mainly through the modulation of MAPK pathway, without altering cell viability of 
normal pituitary cells. Simvastatin also reduces hormone secretion in normal cells through 
MAPK, mTOR and PI3K pathway. Combination of simvastatin with MF or SSAs did not result in 
additive effects in tumor pituitary cell lines. Our findings unveil clear antitumoral effects of 
simvastatin and open the way to also consider these drugs as a potential valuable tool to treat 
patients with PitNETs.  
4) Selective SST3 agonists decrease cell viability and chromogranin-A secretion and 
increase apoptosis in primary cell cultures from NFPTs, by causing a reduction in the 
phosphorylation of key targets associated to MAPK, PI3K-Akt/mTOR and JAK/STAT pathways. 
Moreover, the SST3-specific agonist BIM-355 reduced tumor growth in a preclinical mouse 
model of PitNET. Taken together, these results demonstrate that SST3 plays a relevant 
functional role in the pathophysiology of NFPTs and suggest that pharmacological treatments 
specifically targeting this receptor could become a promising option to treat patients 
harboring NFPTs. 
5) The dopastatin BIM-065, a new chimeric compound targeting SST2/SST5/D2, can 
directly reduce cell viability and hormone secretion and increase apoptosis in different 
subtypes of PitNETs by modulating MAPK and PI3K-Akt pathways, likely through the 
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preferential activation of D2/dopaminergic signaling. In contrast with previous chimeric 
compounds, this dopastatin did not produce any stimulatory action in the tumor cells 
analyzed, and the proportion of responsive tumors/cells observed was higher, which suggest 
that this novel compound may become a valuable tool in the future treatment of PitNETs. 
6) The splicing machinery is clearly dysregulated in all the main PitNETs subtypes as 
compared to NPs. Furthermore, this dysregulation provides specific fingerprints of 
spliceosome components and SFs capable to accurately discriminate between each PitNET 
subtype and NP tissue. Interestingly, this approach identified several components, including 
minor spliceosome components and relevant splicing factors, that are commonly dysregulated 
in all PitNETs analyzed, and could unveil novel and common tumor drivers and potential 
therapeutic targets in these tumors. Actually, our results also indicate that pharmacological 
blockade of the splicing process with pladienolide-B exerts clear antiproliferative and 
antisecretory actions in PitNETs cells. 
 
In conclusion, when viewed together, the results from this thesis indicate that novel 
therapeutic avenues to combat PitNETs can derive from the repurposing of commonly used 
metabolic drugs, such as metformin or simvastatin, which could be a promising tool given 
their antitumoral properties described herein. Moreover, new treatment approaches for 
PitNETs can arise from the development of novel compounds innovatively targeting key 
regulatory receptors for somatostatin and dopamine, such as SST3-specific agonists or novel 
chimeric SST2/SST5/D2 compounds, where the precise knowledge of the quantitative 
expression profile of those receptors might be a key molecular feature to precisely and 
predictively select the most adequate therapeutic option to treat PitNETs in the future. 
Finally, our study provides primary evidence that the splicing machinery is profoundly 
dysregulated in PitNETs, and some its components could be involved in pituitary 
tumorigenesis and may offer new tools to identify original diagnostic and prognostic 
biomarkers and to explore unprecedented therapeutic avenues in PitNETs. Hence, we 
consider that this thesis clearly illustrates the notion that the application of innovational 
molecular, multidisciplinary and collaborative approaches to investigate the biology of the 
pituitary gland and the pathophysiology of PitNETs enable the discovery of valuable 
information on the functioning of this “master gland” and provides new instrumental insights 
to improve our capacity to detect and combat PitNETs. 
 
 
 
 
 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63 
7. References 
 
1. Perez-Castro, C., et al., Cellular and molecular specificity of pituitary gland 
physiology. Physiol Rev, 2012. 92(1): p. 1-38. 
2. Musumeci, G., et al., A journey through the pituitary gland: Development, 
structure and function, with emphasis on embryo-foetal and later development. 
Acta Histochem, 2015. 117(4-5): p. 355-66. 
3. Asa, S.L. and S. Ezzat, The pathogenesis of pituitary tumors. Annu Rev Pathol, 
2009. 4: p. 97-126. 
4. Vazquez-Borrego, M.C., et al., Multiple signaling pathways convey central and 
peripheral signals to regulate pituitary function: Lessons from human and non-
human primate models. Mol Cell Endocrinol, 2018. 463: p. 4-22. 
5. Asa, S.L. and S. Ezzat, The pathogenesis of pituitary tumours. Nat Rev Cancer, 
2002. 2(11): p. 836-49. 
6. Devnath, S. and K. Inoue, An insight to pituitary folliculo-stellate cells. J 
Neuroendocrinol, 2008. 20(6): p. 687-91. 
7. Gan, E. and R. Quinton, Physiological significance of the rhythmic secretion of 
hypothalamic and pituitary hormones. Progress in Brain Research, 2010. 181: p. 
111-126. 
8. Brazeau, P., et al., Hypothalamic polypeptide that inhibits the secretion of 
immunoreactive pituitary growth hormone. Science, 1973. 179(4068): p. 77-9. 
9. Naylor, S.L., et al., Polymorphic human somatostatin gene is located on 
chromosome 3. Proc Natl Acad Sci U S A, 1983. 80(9): p. 2686-9. 
10. Shen, L.P., R.L. Pictet, and W.J. Rutter, Human somatostatin I: sequence of the 
cDNA. Proc Natl Acad Sci U S A, 1982. 79(15): p. 4575-9. 
11. Shen, L.P. and W.J. Rutter, Sequence of the human somatostatin I gene. 
Science, 1984. 224(4645): p. 168-71. 
12. Epelbaum, J., Somatostatin in the central nervous system: physiology and 
pathological modifications. Prog Neurobiol, 1986. 27(1): p. 63-100. 
13. Gunther, T., et al., International Union of Basic and Clinical Pharmacology. CV. 
Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. 
Pharmacol Rev, 2018. 70(4): p. 763-835. 
14. Samson, W.K., et al., Neuronostatin encoded by the somatostatin gene 
regulates neuronal, cardiovascular, and metabolic functions. J Biol Chem, 2008. 
283(46): p. 31949-59. 
15. Bousquet, C., et al., Antiproliferative effect of somatostatin and analogs. 
Chemotherapy, 2001. 47 Suppl 2: p. 30-9. 
16. Lamberts, S.W., The role of somatostatin in the regulation of anterior pituitary 
hormone secretion and the use of its analogs in the treatment of human 
pituitary tumors. Endocr Rev, 1988. 9(4): p. 417-36. 
17. Schettini, G., Brain somatostatin: receptor-coupled transducing mechanisms 
and role in cognitive functions. Pharmacol Res, 1991. 23(3): p. 203-15. 
18. Lamers, C.B., Clinical and pathophysiological aspects of somatostatin and the 
gastrointestinal tract. Acta Endocrinol Suppl (Copenh), 1987. 286: p. 19-25. 
19. Theodoropoulou, M. and G.K. Stalla, Somatostatin receptors: from signaling to 
clinical practice. Front Neuroendocrinol, 2013. 34(3): p. 228-52. 
 64 
20. Fuentes-Fayos, A.C., et al., Molecular determinants of the response to medical 
treatment of growth hormone secreting pituitary neuroendocrine tumors. 
Minerva Endocrinol, 2019. 
21. Durán-Prado, M., et al., Identification and characterization of two novel 
truncated but functional isoforms of the somatostatin receptor subtype 5 
differentially present in pituitary tumors. J Clin Endocrinol Metab, 2009. 94(7): 
p. 2634-43. 
22. Durán-Prado, M., et al., A potential inhibitory role for the new truncated variant 
of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive 
to somatostatin analogs. J Clin Endocrinol Metab, 2010. 95(5): p. 2497-502. 
23. Luque, R.M., et al., Truncated somatostatin receptor variant sst5TMD4 confers 
aggressive features (proliferation, invasion and reduced octreotide response) to 
somatotropinomas. Cancer Lett, 2015. 359(2): p. 299-306. 
24. Sampedro-Nuñez, M., et al., Presence of sst5TMD4, a truncated splice variant of 
the somatostatin receptor subtype 5, is associated to features of increased 
aggressiveness in pancreatic neuroendocrine tumors. Oncotarget, 2016. 7(6): p. 
6593-608. 
25. Hormaechea-Agulla, D., et al., The oncogenic role of the spliced somatostatin 
receptor sst5TMD4 variant in prostate cancer. FASEB J, 2017. 31(11): p. 4682-
4696. 
26. Puig-Domingo, M., et al., The truncated isoform of somatostatin receptor5 
(sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS One, 
2014. 9(1): p. e85527. 
27. Gahete, M.D., et al., The truncated somatostatin receptor sst5TMD4 stimulates 
the angiogenic process and is associated to lymphatic metastasis and disease-
free survival in breast cancer patients. Oncotarget, 2016. 
28. Missale, C., et al., Dopamine receptors: from structure to function. Physiol Rev, 
1998. 78(1): p. 189-225. 
29. Vallone, D., R. Picetti, and E. Borrelli, Structure and function of dopamine 
receptors. Neurosci Biobehav Rev, 2000. 24(1): p. 125-32. 
30. Liu, X., et al., The Mechanism and Pathways of Dopamine and Dopamine 
Agonists in Prolactinomas. Front Endocrinol (Lausanne), 2018. 9: p. 768. 
31. Usiello, A., et al., Distinct functions of the two isoforms of dopamine D2 
receptors. Nature, 2000. 408(6809): p. 199-203. 
32. Rocheville, M., et al., Receptors for dopamine and somatostatin: formation of 
hetero-oligomers with enhanced functional activity. Science, 2000. 288(5463): 
p. 154-7. 
33. Luque, R.M., et al., Examination of the direct effects of metabolic factors on 
somatotrope function in a non-human primate model, Papio anubis. J Mol 
Endocrinol, 2006. 37(1): p. 25-38. 
34. Casanueva, F.F., et al., Acute administration of corticoids: a new and peculiar 
stimulus of growth hormone secretion in man. J Clin Endocrinol Metab, 1990. 
70(1): p. 234-7. 
35. Steger, R.W., A.Y. Silverman, and R.H. Asch, Glucocorticoid suppression of 
pituitary prolactin release in the nonhuman primate. J Clin Endocrinol Metab, 
1981. 53(6): p. 1167-70. 
 65 
36. Shimokaze, T., et al., TSH suppression after intravenous glucocorticosteroid 
administration in preterm infants. J Pediatr Endocrinol Metab, 2012. 25(9-10): 
p. 853-7. 
37. Brabant, G., et al., Circadian and pulsatile thyrotropin secretion in euthyroid 
man under the influence of thyroid hormone and glucocorticoid administration. 
J Clin Endocrinol Metab, 1987. 65(1): p. 83-8. 
38. Mulchahey, J.J., A.M. Di Blasio, and R.B. Jaffe, Effects of growth hormone (GH)-
releasing hormone and somatostatin on GH secretion from individual human 
and monkey fetal anterior pituitary cells: modulation by thyroid hormones and 
glucocorticoids. J Clin Endocrinol Metab, 1988. 66(2): p. 395-401. 
39. Sarmento-Cabral, A., et al., Adipokines (Leptin, Adiponectin, Resistin) 
Differentially Regulate All Hormonal Cell Types in Primary Anterior Pituitary Cell 
Cultures from Two Primate Species. Sci Rep, 2017. 7: p. 43537. 
40. Quabbe, H.J., et al., Plasma glucose and free fatty acids modulate the secretion 
of growth hormone, but not prolactin, in the rhesus and Java monkey. J Clin 
Endocrinol Metab, 1990. 70(4): p. 908-15. 
41. Casanueva, F.F., et al., Free fatty acids block growth hormone (GH) releasing 
hormone-stimulated GH secretion in man directly at the pituitary. J Clin 
Endocrinol Metab, 1987. 65(4): p. 634-42. 
42. Goodyer, C.G., et al., Effect of insulin-like growth factors on human foetal, adult 
normal and tumour pituitary function in tissue culture. Acta Endocrinol 
(Copenh), 1986. 112(1): p. 49-57. 
43. Trainer, P.J., et al., The effect of recombinant IGF-I on anterior pituitary function 
in healthy volunteers. Clin Endocrinol (Oxf), 1994. 41(6): p. 801-7. 
44. Mete, O. and M.B. Lopes, Overview of the 2017 WHO Classification of Pituitary 
Tumors. Endocr Pathol, 2017. 28(3): p. 228-243. 
45. Molitch, M.E., Diagnosis and Treatment of Pituitary Adenomas: A Review. 
JAMA, 2017. 317(5): p. 516-524. 
46. Asa, S.L., et al., From pituitary adenoma to pituitary neuroendocrine tumor 
(PitNET): an International Pituitary Pathology Club proposal. Endocr Relat 
Cancer, 2017. 24(4): p. C5-C8. 
47. Alexander, J.M., et al., Clinically nonfunctioning pituitary tumors are 
monoclonal in origin. J Clin Invest, 1990. 86(1): p. 336-40. 
48. Herman, V., et al., Clonal origin of pituitary adenomas. J Clin Endocrinol Metab, 
1990. 71(6): p. 1427-33. 
49. Melmed, S., Pathogenesis of pituitary tumors. Nat Rev Endocrinol, 2011. 7(5): p. 
257-66. 
50. Barry, S., et al., Tumor microenvironment defines the invasive phenotype of AIP-
mutation-positive pituitary tumors. Oncogene, 2019. 
51. Jacks, T., et al., Effects of an Rb mutation in the mouse. Nature, 1992. 
359(6393): p. 295-300. 
52. Kiyokawa, H., et al., Enhanced growth of mice lacking the cyclin-dependent 
kinase inhibitor function of p27(Kip1). Cell, 1996. 85(5): p. 721-32. 
53. Ewing, I., et al., A mutation and expression analysis of the oncogene BRAF in 
pituitary adenomas. Clin Endocrinol (Oxf), 2007. 66(3): p. 348-52. 
54. Caimari, F. and M. Korbonits, Novel Genetic Causes of Pituitary Adenomas. Clin 
Cancer Res, 2016. 22(20): p. 5030-5042. 
 66 
55. Sveen, A., et al., Aberrant RNA splicing in cancer; expression changes and driver 
mutations of splicing factor genes. Oncogene, 2016. 35(19): p. 2413-27. 
56. Daguenet, E., G. Dujardin, and J. Valcarcel, The pathogenicity of splicing defects: 
mechanistic insights into pre-mRNA processing inform novel therapeutic 
approaches. EMBO Rep, 2015. 16(12): p. 1640-55. 
57. Ibáñez-Costa, A., et al., In1-ghrelin splicing variant is overexpressed in pituitary 
adenomas and increases their aggressive features. Sci Rep, 2015. 5: p. 8714. 
58. Hormaechea-Agulla, D., et al., The oncogenic role of the In1-ghrelin splicing 
variant in prostate cancer aggressiveness. Mol Cancer, 2017. 16(1): p. 146. 
59. Hoskins, A.A. and M.J. Moore, The spliceosome: a flexible, reversible 
macromolecular machine. Trends Biochem Sci, 2012. 37(5): p. 179-88. 
60. Jurica, M.S. and M.J. Moore, Pre-mRNA splicing: awash in a sea of proteins. Mol 
Cell, 2003. 12(1): p. 5-14. 
61. Chen, M. and J.L. Manley, Mechanisms of alternative splicing regulation: 
insights from molecular and genomics approaches. Nat Rev Mol Cell Biol, 2009. 
10(11): p. 741-54. 
62. Kornblihtt, A.R., et al., Alternative splicing: a pivotal step between eukaryotic 
transcription and translation. Nat Rev Mol Cell Biol, 2013. 14(3): p. 153-65. 
63. Kovacs, K., et al., The World Health Organization classification of 
adenohypophysial neoplasms. A proposed five-tier scheme. Cancer, 1996. 78(3): 
p. 502-10. 
64. De Lellis, R.A., et al., eds. World Health Organization Classification of Tumours: 
pathology and genetics of tumours of endocrine organs. 2004, IARC Press: Lyon. 
9-47. 
65. Raverot, G., et al., A prognostic clinicopathologic classification of pituitary 
endocrine tumors. Endocrinol Metab Clin North Am, 2015. 44(1): p. 11-8. 
66. Shaid, M. and M. Korbonits, Genetics of pituitary adenomas. Neurol India, 
2017. 65(3): p. 577-587. 
67. Drummond, J.B., A. Ribeiro-Oliveira, Jr., and B.S. Soares, Non-Functioning 
Pituitary Adenomas, in Endotext, K.R. Feingold, et al., Editors. 2000: South 
Dartmouth (MA). 
68. Mete, O., et al., Silent subtype 3 pituitary adenomas are not always silent and 
represent poorly differentiated monomorphous plurihormonal Pit-1 lineage 
adenomas. Mod Pathol, 2016. 29(2): p. 131-42. 
69. Greenman, Y. and N. Stern, Optimal management of non-functioning pituitary 
adenomas. Endocrine, 2015. 50(1): p. 51-5. 
70. Chaidarun, S.S. and A. Klibanski, Gonadotropinomas. Semin Reprod Med, 2002. 
20(4): p. 339-48. 
71. Olarescu, N., et al., Aggressive and malignant prolactinomas. 
Neuroendocrinology, 2019. 
72. Melmed, S., Acromegaly pathogenesis and treatment. J Clin Invest, 2009. 
119(11): p. 3189-202. 
73. Pivonello, R., et al., Cushing's disease: the burden of illness. Endocrine, 2017. 
56(1): p. 10-18. 
74. Amlashi, F.G. and N.A. Tritos, Thyrotropin-secreting pituitary adenomas: 
epidemiology, diagnosis, and management. Endocrine, 2016. 52(3): p. 427-40. 
 67 
75. Raverot, G., et al., European Society of Endocrinology Clinical Practice 
Guidelines for the management of aggressive pituitary tumours and 
carcinomas. Eur J Endocrinol, 2018. 178(1): p. G1-G24. 
76. Colao, A. and S. Savastano, Medical treatment of prolactinomas. Nat Rev 
Endocrinol, 2011. 7(5): p. 267-78. 
77. Kopczak, A., U. Renner, and G. Karl Stalla, Advances in understanding pituitary 
tumors. F1000Prime Rep, 2014. 6: p. 5. 
78. Li, A., et al., Endoscopic Versus Microscopic Transsphenoidal Surgery in the 
Treatment of Pituitary Adenoma: A Systematic Review and Meta-Analysis. 
World Neurosurg, 2017. 101: p. 236-246. 
79. Taboada, G.F., et al., Quantitative analysis of somatostatin receptor subtype 
(SSTR1-5) gene expression levels in somatotropinomas and non-functioning 
pituitary adenomas. Eur J Endocrinol, 2007. 156(1): p. 65-74. 
80. Neto, L.V., et al., Expression analysis of dopamine receptor subtypes in normal 
human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, 
and the association between dopamine and somatostatin receptors with clinical 
response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab, 2009. 94(6): 
p. 1931-7. 
81. Behling, F., et al., High Expression of Somatostatin Receptors 2A, 3, and 5 in 
Corticotroph Pituitary Adenoma. Int J Endocrinol, 2018. 2018: p. 1763735. 
82. Patel, Y.C. and T. Wheatley, In vivo and in vitro plasma disappearance and 
metabolism of somatostatin-28 and somatostatin-14 in the rat. Endocrinology, 
1983. 112(1): p. 220-5. 
83. Beck-Peccoz, P., et al., Treatment of hyperthyroidism due to inappropriate 
secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin 
Endocrinol Metab, 1989. 68(1): p. 208-14. 
84. Heron, I., et al., Pharmacokinetics and efficacy of a long-acting formulation of 
the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin 
Endocrinol Metab, 1993. 76(3): p. 721-7. 
85. Lamberts, S.W., et al., Long-term treatment of acromegaly with the 
somatostatin analogue SMS 201-995. N Engl J Med, 1985. 313(25): p. 1576-80. 
86. Plewe, G., et al., Long-acting and selective suppression of growth hormone 
secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet, 1984. 
2(8406): p. 782-4. 
87. Colao, A., R.S. Auriemma, and R. Pivonello, The effects of somatostatin 
analogue therapy on pituitary tumor volume in patients with acromegaly. 
Pituitary, 2016. 19(2): p. 210-21. 
88. Mazziotti, G., et al., Somatostatin analogs in the treatment of neuroendocrine 
tumors: current and emerging aspects. Expert Opin Pharmacother, 2017. 
18(16): p. 1679-1689. 
89. Colao, A., et al., Resistance to somatostatin analogs in acromegaly. Endocr Rev, 
2011. 32(2): p. 247-71. 
90. Bruns, C., et al., SOM230: a novel somatostatin peptidomimetic with broad 
somatotropin release inhibiting factor (SRIF) receptor binding and a unique 
antisecretory profile. Eur J Endocrinol, 2002. 146(5): p. 707-16. 
 68 
91. Lesche, S., et al., Differential effects of octreotide and pasireotide on 
somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol 
Metab, 2009. 94(2): p. 654-61. 
92. Gatto, F., et al., Cell specific interaction of pasireotide: review of preclinical 
studies in somatotroph and corticotroph pituitary cells. Pituitary, 2019. 22(1): p. 
89-99. 
93. Ibáñez-Costa, A., et al., Octreotide and pasireotide (dis)similarly inhibit pituitary 
tumor cells in vitro. J Endocrinol, 2016. 231(2): p. 135-145. 
94. Gatto, F., et al., In Vitro Head-to-Head Comparison Between Octreotide and 
Pasireotide in GH-Secreting Pituitary Adenomas. J Clin Endocrinol Metab, 2017. 
102(6): p. 2009-2018. 
95. Colao, A., et al., Managing hyperglycemia in patients with Cushing's disease 
treated with pasireotide: medical expert recommendations. Pituitary, 2014. 
17(2): p. 180-6. 
96. Ferone, D., et al., Somatostatin and dopamine receptor expression in lung 
carcinoma cells and effects of chimeric somatostatin-dopamine molecules on 
cell proliferation. Am J Physiol Endocrinol Metab, 2005. 289(6): p. E1044-50. 
97. de Bruin, C., et al., Somatostatin and dopamine receptors as targets for medical 
treatment of Cushing's Syndrome. Rev Endocr Metab Disord, 2009. 10(2): p. 91-
102. 
98. Cooper, O. and Y. Greenman, Dopamine Agonists for Pituitary Adenomas. Front 
Endocrinol (Lausanne), 2018. 9: p. 469. 
99. Palui, R., et al., Effect of cabergoline monotherapy in Cushing's disease: an 
individual participant data meta-analysis. J Endocrinol Invest, 2018. 41(12): p. 
1445-1455. 
100. Sandret, L., P. Maison, and P. Chanson, Place of cabergoline in acromegaly: a 
meta-analysis. J Clin Endocrinol Metab, 2011. 96(5): p. 1327-35. 
101. Delgado-Lopez, P.D., et al., Recurrent non-functioning pituitary adenomas: a 
review on the new pathological classification, management guidelines and 
treatment options. Clin Transl Oncol, 2018. 20(10): p. 1233-1245. 
102. Baragli, A., et al., Heterooligomerization of human dopamine receptor 2 and 
somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance 
energy transfer analysis. Cell Signal, 2007. 19(11): p. 2304-16. 
103. Durán-Prado, M., et al., Dimerization of G protein-coupled receptors: new 
avenues for somatostatin receptor signalling, control and functioning. Mol Cell 
Endocrinol, 2008. 286(1-2): p. 63-8. 
104. Saveanu, A., et al., Demonstration of enhanced potency of a chimeric 
somatostatin-dopamine molecule, BIM-23A387, in suppressing growth 
hormone and prolactin secretion from human pituitary somatotroph adenoma 
cells. J Clin Endocrinol Metab, 2002. 87(12): p. 5545-52. 
105. Jaquet, P., et al., Efficacy of chimeric molecules directed towards multiple 
somatostatin and dopamine receptors on inhibition of GH and prolactin 
secretion from GH-secreting pituitary adenomas classified as partially 
responsive to somatostatin analog therapy. Eur J Endocrinol, 2005. 153(1): p. 
135-41. 
106. Jaquet, P., et al., BIM-23A760, a chimeric molecule directed towards 
somatostatin and dopamine receptors, vs universal somatostatin receptors 
 69 
ligands in GH-secreting pituitary adenomas partial responders to octreotide. J 
Endocrinol Invest, 2005. 28(11 Suppl International): p. 21-7. 
107. Peverelli, E., et al., The dopamine-somatostatin chimeric compound BIM-
23A760 exerts antiproliferative and cytotoxic effects in human non-functioning 
pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett, 2010. 
288(2): p. 170-6. 
108. Florio, T., et al., Efficacy of a dopamine-somatostatin chimeric molecule, BIM-
23A760, in the control of cell growth from primary cultures of human non-
functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer, 
2008. 15(2): p. 583-96. 
109. Ibáñez-Costa, A., et al., BIM-23A760 influences key functional endpoints in 
pituitary adenomas and normal pituitaries: molecular mechanisms underlying 
the differential response in adenomas. Sci Rep, 2017. 7: p. 42002. 
110. Culler, M.D., Somatostatin-dopamine chimeras: a novel approach to treatment 
of neuroendocrine tumors. Horm Metab Res, 2011. 43(12): p. 854-7. 
111. Fingscheidt, U., et al., Regulation of gonadotrophin secretion by inhibin, 
testosterone and gonadotrophin-releasing hormone in pituitary cell cultures of 
male monkeys. J Endocrinol, 1998. 159(1): p. 103-10. 
112. Norman, R.L., Effects of corticotropin-releasing hormone on luteinizing 
hormone, testosterone, and cortisol secretion in intact male rhesus macaques. 
Biol Reprod, 1993. 49(1): p. 148-53. 
113. Córdoba-Chacón, J., et al., Somatostatin dramatically stimulates growth 
hormone release from primate somatotrophs acting at low doses via 
somatostatin receptor 5 and cyclic AMP. J Neuroendocrinol, 2012. 24(3): p. 
453-63. 
114. Ibanez-Costa, A., et al., Melatonin regulates somatotrope and lactotrope 
function through common and distinct signaling pathways in cultured primary 
pituitary cells from female primates. Endocrinology, 2015. 156(3): p. 1100-10. 
115. Luque, R.M., et al., Obestatin plays an opposite role in the regulation of 
pituitary somatotrope and corticotrope function in female primates and 
male/female mice. Endocrinology, 2014. 155(4): p. 1407-17. 
116. Luque, R.M. and R.D. Kineman, Neuronostatin exerts actions on pituitary that 
are unique from its sibling peptide somatostatin. J Endocrinol, 2018. 237(3): p. 
217-227. 
117. Braundmeier, A.G. and A.T. Fazleabas, The non-human primate model of 
endometriosis: research and implications for fecundity. Mol Hum Reprod, 2009. 
15(10): p. 577-86. 
118. Comuzzie, A.G., et al., The baboon as a nonhuman primate model for the study 
of the genetics of obesity. Obes Res, 2003. 11(1): p. 75-80. 
119. McClure, H.M., Nonhuman primate models for human disease. Adv Vet Sci 
Comp Med, 1984. 28: p. 267-304. 
120. Eizirik, E., W.J. Murphy, and S.J. O'Brien, Molecular dating and biogeography of 
the early placental mammal radiation. J Hered, 2001. 92(2): p. 212-9. 
121. Page, S.L. and M. Goodman, Catarrhine phylogeny: noncoding DNA evidence for 
a diphyletic origin of the mangabeys and for a human-chimpanzee clade. Mol 
Phylogenet Evol, 2001. 18(1): p. 14-25. 
 70 
122. Rhesus Macaque Genome, S., et al., Evolutionary and biomedical insights from 
the rhesus macaque genome. Science, 2007. 316(5822): p. 222-34. 
123. Ebeling, M., et al., Genome-based analysis of the nonhuman primate Macaca 
fascicularis as a model for drug safety assessment. Genome Res, 2011. 21(10): 
p. 1746-56. 
124. Foretz, M., et al., Metformin: from mechanisms of action to therapies. Cell 
metabolism, 2014. 20(6): p. 953-66. 
125. Cho, K., et al., Antihyperglycemic mechanism of metformin occurs via the 
AMPK/LXRalpha/POMC pathway. Sci Rep, 2015. 5: p. 8145. 
126. Vancura, A., et al., Metformin as an Anticancer Agent. Trends Pharmacol Sci, 
2018. 
127. Leidgens, V., et al., Stattic and metformin inhibit brain tumor initiating cells by 
reducing STAT3-phosphorylation. Oncotarget, 2017. 8(5): p. 8250-8263. 
128. Liu, Q., et al., Metformin Inhibits Prostate Cancer Progression by Targeting 
Tumor-Associated Inflammatory Infiltration. Clin Cancer Res, 2018. 
129. Lu, H., et al., Effect of metformin in the prognosis of patients with smallcell lung 
cancer combined with diabetes mellitus. Adv Clin Exp Med, 2018. 
130. Qian, W., et al., Metformin suppresses tumor angiogenesis and enhances the 
chemosensitivity of gemcitabine in a genetically engineered mouse model of 
pancreatic cancer. Life Sci, 2018. 208: p. 253-261. 
131. Herrera-Martinez, A.D., et al., Type 2 diabetes in neuroendocrine tumors: are 
biguanides and statins part of the solution? J Clin Endocrinol Metab, 2018. 
132. Jin, K., et al., Metformin suppresses growth and adrenocorticotrophic hormone 
secretion in mouse pituitary corticotroph tumor AtT20cells. Mol Cell Endocrinol, 
2018. 
133. An, J., et al., Metformin inhibits proliferation and growth hormone secretion of 
GH3 pituitary adenoma cells. Oncotarget, 2017. 8(23): p. 37538-37549. 
134. Hao, X., et al., Imbalance between proliferation and apoptosis in the 
development of colorectal carcinoma. Virchows Arch, 1998. 433(6): p. 523-7. 
135. Liu, S., et al., Measures of cell turnover (proliferation and apoptosis) and their 
association with survival in breast cancer. Clin Cancer Res, 2001. 7(6): p. 1716-
23. 
136. Mattern, J. and M. Volm, Imbalance of cell proliferation and apoptosis during 
progression of lung carcinomas. Anticancer Res, 2004. 24(6): p. 4243-6. 
137. Gao, J., et al., Metformin inhibits growth and prolactin secretion of pituitary 
prolactinoma cells and xenografts. J Cell Mol Med, 2018. 22(12): p. 6368-6379. 
138. Cuevas-Ramos, D. and M. Fleseriu, Somatostatin receptor ligands and 
resistance to treatment in pituitary adenomas. J Mol Endocrinol, 2014. 52(3): p. 
R223-40. 
139. Peverelli, E., et al., Dopamine and Somatostatin Analogues Resistance of 
Pituitary Tumors: Focus on Cytoskeleton Involvement. Front Endocrinol 
(Lausanne), 2015. 6: p. 187. 
140. Losa, M., et al., Effects of octreotide treatment on the proliferation and 
apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab, 
2001. 86(11): p. 5194-200. 
 71 
141. Valea, A., et al., Effects of combination therapy: somatostatin analogues and 
dopamine agonists on GH and IGF1 levels in acromegaly. Clujul Med, 2015. 
88(3): p. 310-3. 
142. Puig-Domingo, M., et al., Use of lanreotide in combination with cabergoline or 
pegvisomant in patients with acromegaly in the clinical practice: The 
ACROCOMB study. Endocrinol Nutr., 2016. 63(8): p. 397-408. 
143. Tulipano, G., et al., Effects of AMPK activation and combined treatment with 
AMPK activators and somatostatin on hormone secretion and cell growth in 
cultured GH-secreting pituitary tumor cells. Mol Cell Endocrinol, 2013. 365(2): 
p. 197-206. 
144. Pryor, R. and F. Cabreiro, Repurposing metformin: an old drug with new tricks in 
its binding pockets. Biochem J, 2015. 471(3): p. 307-22. 
145. Vazquez-Borrego, M.C., et al., The Pituitary Gland is a Novel Major Site of 
Action of Metformin in Non-Human Primates: a Potential Path to Expand and 
Integrate Its Metabolic Actions. Cell Physiol Biochem, 2018. 49(4): p. 1444-
1459. 
146. Faggi, L., A. Giustina, and G. Tulipano, Effects of metformin on cell growth and 
AMPK activity in pituitary adenoma cell cultures, focusing on the interaction 
with adenylyl cyclase activating signals. Mol Cell Endocrinol, 2018. 470: p. 60-
74. 
147. Tahrani, A.A., et al., Management of type 2 diabetes: new and future 
developments in treatment. Lancet, 2011. 378(9786): p. 182-97. 
148. Fung, C.S., et al., Effect of metformin monotherapy on cardiovascular diseases 
and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus 
patients. Cardiovasc Diabetol, 2015. 14: p. 137. 
149. Novelle, M.G., et al., Metformin: A Hopeful Promise in Aging Research. Cold 
Spring Harb Perspect Med, 2016. 6(3): p. a025932. 
150. Billa, E., et al., Metformin administration was associated with a modification of 
LH, prolactin and insulin secretion dynamics in women with polycystic ovarian 
syndrome. Gynecol Endocrinol, 2009. 25(7): p. 427-34. 
151. Oride, A., et al., Effects of metformin administration on plasma gonadotropin 
levels in women with infertility, with an in vitro study of the direct effects on the 
pituitary gonadotrophs. Pituitary, 2010. 13(3): p. 236-41. 
152. Bridges, H.R., et al., Effects of metformin and other biguanides on oxidative 
phosphorylation in mitochondria. Biochem J, 2014. 462(3): p. 475-87. 
153. Owen, M.R., E. Doran, and A.P. Halestrap, Evidence that metformin exerts its 
anti-diabetic effects through inhibition of complex 1 of the mitochondrial 
respiratory chain. Biochem J, 2000. 348 Pt 3: p. 607-14. 
154. Tosca, L., et al., Metformin decreases GnRH- and activin-induced gonadotropin 
secretion in rat pituitary cells: potential involvement of adenosine 5' 
monophosphate-activated protein kinase (PRKA). Biol Reprod, 2011. 84(2): p. 
351-62. 
155. Hawley, S.A., et al., Calmodulin-dependent protein kinase kinase-beta is an 
alternative upstream kinase for AMP-activated protein kinase. Cell Metab, 
2005. 2(1): p. 9-19. 
 72 
156. Wang, Y., et al., Metformin induces autophagy and G0/G1 phase cell cycle 
arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J 
Exp Clin Cancer Res, 2018. 37(1): p. 63. 
157. Han, G., et al., AMPK/mTOR-mediated inhibition of survivin partly contributes to 
metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther, 
2015. 16(1): p. 77-87. 
158. Leclerc, G.M., et al., AMPK-induced activation of Akt by AICAR is mediated by 
IGF-1R dependent and independent mechanisms in acute lymphoblastic 
leukemia. J Mol Signal, 2010. 5: p. 15. 
159. Yuen, K.C., L.E. Chong, and M.C. Riddle, Influence of glucocorticoids and growth 
hormone on insulin sensitivity in humans. Diabet Med, 2013. 30(6): p. 651-63. 
160. Moller, N. and J.O. Jorgensen, Effects of growth hormone on glucose, lipid, and 
protein metabolism in human subjects. Endocr Rev, 2009. 30(2): p. 152-77. 
161. Luque, R.M., et al., Does the pituitary somatotrope play a primary role in 
regulating GH output in metabolic extremes? Ann N Y Acad Sci, 2011. 1220: p. 
82-92. 
162. Kim, S.H. and M.J. Park, Effects of growth hormone on glucose metabolism and 
insulin resistance in human. Ann Pediatr Endocrinol Metab, 2017. 22(3): p. 145-
152. 
163. Gazzerro, P., et al., Pharmacological actions of statins: a critical appraisal in the 
management of cancer. Pharmacol Rev, 2012. 64(1): p. 102-46. 
164. Zhou, Q. and J.K. Liao, Pleiotropic effects of statins. - Basic research and clinical 
perspectives. Circ J, 2010. 74(5): p. 818-26. 
165. Wang, T., et al., Simvastatin-induced breast cancer cell death and deactivation 
of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the 
mevalonate pathway. Oncotarget, 2016. 7(3): p. 2532-44. 
166. Jang, H.J., et al., Statin induces apoptosis of human colon cancer cells and 
downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK 
activation. Oncol Lett, 2016. 12(1): p. 250-256. 
167. Fliedner, S.M., et al., Anti-cancer potential of MAPK pathway inhibition in 
paragangliomas-effect of different statins on mouse pheochromocytoma cells. 
PLoS One, 2014. 9(5): p. e97712. 
168. Hu, H.J., S.H. Zhou, and Q.M. Liu, Treatment of pheochromocytoma blockade of 
MAPK pathway inhibition in the NF-kappaB pathway and bFGF - effect of statins 
on pheochromocytoma patients. Int J Cardiol, 2015. 182: p. 161-2. 
169. Zawada, N.B., et al., An evaluation of the effects of somatostatin analogue 
therapy in non-functioning pituitary adenomas in comparison to acromegaly. 
Endokrynol Pol, 2016. 67(3): p. 292-8. 
170. Iannelli, F., et al., Targeting Mevalonate Pathway in Cancer Treatment: 
Repurposing of Statins. Recent Pat Anticancer Drug Discov, 2018. 13(2): p. 184-
200. 
171. Vázquez-Borrego, M.C., et al., Biguanides exert antitumoral actions in pituitary 
tumor cells through AMPK-dependent and -independent mechanisms. J Clin 
Endocrinol Metab, 2019. 104(5): p. 1-13. 
172. Misirkic, M., et al., Inhibition of AMPK-dependent autophagy enhances in vitro 
antiglioma effect of simvastatin. Pharmacol Res, 2012. 65(1): p. 111-9. 
 73 
173. Wang, J.C., et al., Activation of AMPK by simvastatin inhibited breast tumor 
angiogenesis via impeding HIF-1alpha-induced pro-angiogenic factor. Cancer 
Sci, 2018. 109(5): p. 1627-1637. 
174. Cakir, M. and A.B. Grossman, Targeting MAPK (Ras/ERK) and PI3K/Akt 
pathways in pituitary tumorigenesis. Expert Opin Ther Targets, 2009. 13(9): p. 
1121-34. 
175. Roof, A.K. and A. Gutierrez-Hartmann, Consider the context: Ras/ERK and 
PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific. Mol Cell 
Endocrinol, 2018. 463: p. 87-96. 
176. Hofland, L.J., et al., Pituitary tumours: the sst/D2 receptors as molecular 
targets. Mol Cell Endocrinol, 2010. 326(1-2): p. 89-98. 
177. Lee, M., et al., SSTR3 is a putative target for the medical treatment of 
gonadotroph adenomas of the pituitary. Endocr Relat Cancer, 2015. 22(1): p. 
111-9. 
178. War, S.A., R.K. Somvanshi, and U. Kumar, Somatostatin receptor-3 mediated 
intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. 
Biochim Biophys Acta, 2011. 1813(3): p. 390-402. 
179. Karpac, J., et al., Proopiomelanocortin heterozygous and homozygous null 
mutant mice develop pituitary adenomas. Cell Mol Biol (Noisy-le-grand), 2006. 
52(2): p. 47-52. 
180. Zatelli, M.C., et al., Evidence for differential effects of selective somatostatin 
receptor subtype agonists on alpha-subunit and chromogranin a secretion and 
on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin 
Endocrinol Metab, 2004. 89(10): p. 5181-8. 
181. Yu, S.Y., et al., Integrative proteomics and transcriptomics identify novel 
invasive-related biomarkers of non-functioning pituitary adenomas. Tumour 
Biol, 2016. 37(7): p. 8923-30. 
182. Theodoropoulou, M., et al., Octreotide, a somatostatin analogue, mediates its 
antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 
3-kinase signaling and inducing Zac1 expression. Cancer Res, 2006. 66(3): p. 
1576-82. 
183. Yu, H., et al., Revisiting STAT3 signalling in cancer: new and unexpected 
biological functions. Nat Rev Cancer, 2014. 14(11): p. 736-46. 
184. Lee, H., et al., STAT3-induced S1PR1 expression is crucial for persistent STAT3 
activation in tumors. Nat Med, 2010. 16(12): p. 1421-8. 
185. Cerovac, V., et al., The somatostatin analogue octreotide confers sensitivity to 
rapamycin treatment on pituitary tumor cells. Cancer Res, 2010. 70(2): p. 666-
74. 
186. Roof, A.K., et al., The Balance of PI3K and ERK Signaling Is Dysregulated in 
Prolactinoma and Modulated by Dopamine. Endocrinology, 2018. 159(6): p. 
2421-2434. 
187. Eigler, T., et al., Constitutive somatostatin receptor subtype-3 signaling 
suppresses growth hormone synthesis. Mol Endocrinol, 2014. 28(4): p. 554-64. 
188. Ben-Shlomo, A., et al., Selective regulation of somatostatin receptor subtype 
signaling: evidence for constitutive receptor activation. Mol Endocrinol, 2007. 
21(10): p. 2565-78. 
 74 
189. Lee, M., et al., Targeting PI3K/mTOR Signaling Displays Potent Antitumor 
Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res, 2015. 
21(14): p. 3204-15. 
190. Gruszka, A., M.D. Culler, and S. Melmed, Somatostatin analogs and chimeric 
somatostatin-dopamine molecules differentially regulate human growth 
hormone and prolactin gene expression and secretion in vitro. Mol Cell 
Endocrinol, 2012. 362(1-2): p. 104-9. 
191. de Boon, W.M.I., et al., A Novel Somatostatin-Dopamine Chimera (BIM23B065) 
Reduced GH Secretion in a First-in-Human Clinical Trial. J Clin Endocrinol Metab, 
2019. 104(3): p. 883-891. 
192. Cuny, T., et al., Somatostatin receptor sst2 gene transfer in human 
prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and 
dopastatin, in the control of prolactin secretion. Mol Cell Endocrinol, 2012. 
355(1): p. 106-13. 
193. Pucci, B., M. Kasten, and A. Giordano, Cell cycle and apoptosis. Neoplasia, 2000. 
2(4): p. 291-9. 
194. Evan, G.I. and K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer. 
Nature, 2001. 411(6835): p. 342-8. 
195. van Alphen, R.J., et al., The spliceosome as target for anticancer treatment. Br J 
Cancer, 2009. 100(2): p. 228-32. 
196. Zhang, Q., et al., Inhibition of SF3b1 by pladienolide B evokes cycle arrest, 
apoptosis induction and p73 splicing in human cervical carcinoma cells. Artif 
Cells Nanomed Biotechnol, 2019. 47(1): p. 1273-1280. 
197. Fu, Y., et al., SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-
mediated tumorigenesis by enhancing beta-catenin biosynthesis. EMBO Mol 
Med, 2013. 5(5): p. 737-50. 
198. Yoshino, H., et al., Tumor suppressive microRNA-1 mediated novel apoptosis 
pathways through direct inhibition of splicing factor serine/arginine-rich 9 
(SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun, 2012. 
417(1): p. 588-93. 
199. Gu, X., et al., SND1 expression in breast cancer tumors is associated with poor 
prognosis. Ann N Y Acad Sci, 2018. 1433(1): p. 53-60. 
200. Cui, X., et al., SND1 acts as an anti-apoptotic factor via regulating the 
expression of lncRNA UCA1 in hepatocellular carcinoma. RNA Biol, 2018. 15(10): 
p. 1364-1375. 
201. Barron, V.A., et al., The neurofibromatosis type I pre-mRNA is a novel target of 
CELF protein-mediated splicing regulation. Nucleic Acids Res, 2010. 38(1): p. 
253-64. 
202. Kim, S., et al., Integrative Profiling of Alternative Splicing Induced by U2AF1 
S34F Mutation in Lung Adenocarcinoma Reveals a Mechanistic Link to Mitotic 
Stress. Mol Cells, 2018. 41(8): p. 733-741. 
203. Smith, M.A., et al., U2AF1 mutations induce oncogenic IRAK4 isoforms and 
activate innate immune pathways in myeloid malignancies. Nat Cell Biol, 2019. 
21(5): p. 640-650. 
204. Del Rio-Moreno, M., et al., Dysregulation of the splicing machinery is associated 
to the development of non-alcoholic fatty liver disease. J Clin Endocrinol Metab, 
2019. 
 75 
205. Gahete, M.D., et al., Changes in Splicing Machinery Components Influence, 
Precede, and Early Predict the Development of Type 2 Diabetes: From the 
CORDIOPREV Study. EBioMedicine, 2018. 
206. Melling, N., et al., Prevalence and clinical significance of RBM3 immunostaining 
in non-small cell lung cancers. J Cancer Res Clin Oncol, 2019. 145(4): p. 873-879. 
207. Grupp, K., et al., Reduced RBM3 expression is associated with aggressive tumor 
features in esophageal cancer but not significantly linked to patient outcome. 
BMC Cancer, 2018. 18(1): p. 1106. 
208. Wan, L., et al., SRSF6-regulated alternative splicing that promotes tumour 
progression offers a therapy target for colorectal cancer. Gut, 2019. 68(1): p. 
118-129. 
209. Xiao, J., et al., Clinical significance and effect of Sam68 expression in gastric 
cancer. Oncol Lett, 2018. 15(4): p. 4745-4752. 
210. Dong, L., et al., Sam68 is Overexpressed in Epithelial Ovarian Cancer and 
Promotes Tumor Cell Proliferation. Med Sci Monit, 2016. 22: p. 3248-56. 
211. Stricker, T.P., et al., Robust stratification of breast cancer subtypes using 
differential patterns of transcript isoform expression. PLoS Genet, 2017. 13(3): 
p. e1006589. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
8. Articles 
 
This Thesis is based on the research articles and review listed below. 
 
Article I. Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-
dependent and -independent mechanisms. 
 
Article II. The pituitary gland is a novel major site of action of metformin in non-human 
primates: a potential path to expand and integrate its metabolic actions.  
 
Article III. The pituitary gland is a major site of actions of statins: Potential antitumor effects of 
simvastatin in pituitary neuroendocrine tumor cells. 
 
Article IV. A novel SST3 agonist shows potential antitumor effects in experimental models of 
non-functioning pituitary tumors. 
 
Article V. A new generation somatostatin-dopamine analogue exerts potent antitumoral 
actions on pituitary neuroendocrine tumor cells. 
 
Article VI. Splicing machinery is dysregulated in pituitary neuroendocrine tumors and 
associated with aggressiveness features.  
 
Article VII.  Multiple signaling pathways convey central and peripheral signals to regulate 
pituitary function: Lessons from human and non-human primate models (Review). 
 
  
Biguanides exert antitumoral actions in pituitary tumor cells through 
AMPK-dependent and -independent mechanisms. 
 
Mari C. Vázquez-Borrego, Antonio C. Fuentes-Fayos, Aura D. Herrera Martínez, Fernando 
L-López, Alejandro Ibáñez-Costa, Paloma Moreno Moreno, María R. Alhambra-Expósito, 
Ana Barrera-Martín, Cristóbal Blanco-Acevedo, Elena Dios, Eva Venegas-Moreno, Juan 
Solivera, Manuel D. Gahete, Alfonso Soto-Moreno, María A. Gálvez-Moreno, Justo P. 
Castaño, Raúl M. Luque. 
 
The Journal of Clinical Endocrinology & Metabolism 
Endocrine Society 
 
Submitted: January 09, 2019 
Accepted: March 06, 2019 
First Online: March 12, 2019 
 
Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but 
not yet copyedited. The manuscripts are published online as soon as possible after acceptance and 
before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by 
the authors at the modification stage), and do not reflect editorial changes. No 
corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be 
differences between the Advance Article manuscripts and the final, typeset articles. The 
manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. 
At that point, the manuscripts are removed from the Advance Article page. 
 
DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express 
or particular purpose, or non-infringement. Changes will be made to these manuscripts before 
publication. Review and/or use or reliance on these materials is at the discretion and risk of the 
reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising 
references to, products or publications do not imply endorsement of that product or publication. 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00056/5372730 by Q
ueen M
ary U
niversity of London user on 23 April 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00056 
 
 
1
Direct effects of biguanides on pituitary tumors. 
Biguanides exert antitumoral actions in pituitary tumor cells through 
AMPK-dependent and -independent mechanisms. 
Mari C. Vázquez-Borrego1,2,3,4, Antonio C. Fuentes-Fayos1,2,3,4, Aura D. Herrera 
Martínez1,3,5, Fernando L-López1,2,3,4, Alejandro Ibáñez-Costa1,2,3,4, Paloma Moreno 
Moreno1,3,5, María R. Alhambra-Expósito1,3,5, Ana Barrera-Martín1,3,5, Cristóbal Blanco-
Acevedo1,3,6, Elena Dios7, Eva Venegas-Moreno7, Juan Solivera1,3,6, Manuel D. Gahete1,2,3,4, 
Alfonso Soto-Moreno7, María A. Gálvez-Moreno1,3,5, Justo P. Castaño1,2,3,4, Raúl M. 
Luque1,2,3,4.  
1Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain; 2Department of 
Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain; 3Reina Sofia 
University Hospital (HURS), 14004 Cordoba, Spain; 4CIBER Physiopathology of Obesity and Nutrition 
(CIBERobn), 14004 Cordoba, Spain; 5Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, 
Spain. 6Service of Neurosurgery, HURS, 14004 Cordoba, Spain. 7Metabolism and Nutrition Unit, Hospital 
Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), 41013 Sevilla, Spain.  
ORCiD numbers: 
0000-0002-7585-1913 
Luque 
Raul M 
Received 09 January 2019. Accepted 06 March 2019. 
Context: Pituitary neuroendocrine tumors (PitNETs) comprise a commonly underestimated 
pathology in terms of incidence and associated morbimortality. Currently, an appreciable 
subset of patients is resistant or poorly responsive to the main current medical treatments [i.e. 
somatostatin-analogues (SSAs)/dopamine-agonists]. Thus, development/optimization of 
novel/available medical therapies is necessary. Biguanides (metformin/buformin/phenformin) 
are antidiabetic drugs that exert antitumoral actions in several tumor types, but their 
pharmacological effects on PitNETs are poorly known. 
Objective: We aimed to explore the direct effects of biguanides on key functions (cell-
viability/hormone-release/apoptosis/signaling-pathways) in primary cell-cultures from human 
PitNETs and cell-lines. dditionally, we evaluated the combination of metformin with SSAs 
on cell-viability and hormone secretion.  
Design: A total of 13 corticotropinomas, 13 somatotropinomas, 13 non-functioning PitNETs, 
3 prolactinomas and two tumoral pituitary cell-lines (AtT-20 and GH3) were used to evaluate 
the direct effects of biguanides on cell-viability, hormone-release, apoptosis and signaling-
pathways.  
Results: Biguanides reduced cell-viability in all PitNETs and cell-lines (being phenformin 
the most effective biguanide), and increased apoptosis in somatotropinomas. Moreover, 
buformin and phenformin, but not metformin, reduced hormone secretion in a cell-type 
specific manner. Combination metformin-SSAs therapy did not enhance SSAs monotherapy 
effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMPK-
dependent ([Ca2+]i, PI3K/Akt) and independent (MAPK) mechanisms.  
Conclusion: Altogether, our data unveil clear antitumoral effects of biguanides on PitNET 
cells, opening new avenues to explore their potential as drugs to treat these pathologies.  
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Biguanides reduced aggressiveness features (proliferation, apoptosis,  etc.) in pituitary 
neuroendocrine tumors, opening new avenues to  explore their potential as drugs to treat these 
pathologies. 
INTRODUCTION 
Pituitary neuroendocrine tumors (PitNETs) are mostly benign neuroendocrine tumors that 
comprise a commonly underestimated pathology in terms of incidence and associated 
morbimortality. Specifically, PitNETs constitute approximately 15% of all intracranial 
neoplasms and appear in approximately 16.9% of the population (1-3). The genesis of 
PitNETs resides in an excessive and uncontrolled cell proliferation produced by the 
expansion of precursor cells. PitNETs are often accompanied by serious comorbidities related 
to mass effects and inappropriate secretion of pituitary hormones (1, 4-6). Transsphenoidal 
surgery is the first-line therapy in these patients, but approximately a 30% show tumor 
regrowth after surgery (7). The pharmacological arsenal currently available to treat PitNETs 
is mainly limited to synthetic somatostatin analogues (SSAs) and dopamine agonists (8), 
which exert their effects through the binding to their corresponding G-protein coupled 
receptor families, both encoded by 5 genes (SSTR1-5 and DRD1-5, respectively) (9, 10). 
These drugs have a demonstrated efficacy in decreasing hormone hypersecretion and 
inducing tumor shrinkage/stabilization in functioning PitNETs (8, 11). However, some 
patients are (o become) unresponsive to these drugs (9, 12). For these reasons, the search for 
new therapies to control tumor growth and/or hormone secretion is crucial.  
Metformin (MF), buformin (BF) and phenformin (PF) are antidiabetic drugs belonging to 
the biguanide family. Currently, only MF is used to treat type-2 diabetes mellitus (T2DM) 
(13). In addition to its well-known anti-hyperglycemic effect (14), it has been suggested that 
MF may reduce the risk of cancer and tumorigenesis in different types of neoplasms such as 
brain, prostate, breast and neuroendocrine tumors (15-20). Based on this, clinical trials using 
MF in non-diabetic cancer patients have been performed. Unfortunately, some results are 
contradictory, especially in terms of reduction of Ki-67 expression, but other findings seem to 
be promising, including the reduction of the prostate specific antigen in prostate cancer 
patients (15). The precise molecular mechanisms underlying the antitumoral effects of MF 
are still controversial. Specifically, MF activates the AMP-activated protein kinase (AMPK), 
which has been associated to the modulation of cell proliferation, hormone secretion and 
apoptosis in endocrine-related cancers and in PitNET cells (21, 22). Additionally, MF has 
been also suggested to exert some of its actions through AMPK-independent mechanisms 
(23). 
Recent results from our group have revealed that biguanides reduce viability and 
secretory activity in two neuroendocrine tumor model cell lines (20). Moreover, we have also 
reported recently that both MF and PF exert notable direct effects in the modulation of 
hormonal secretion in normal pituitary cells from two primate species (24). In line with our 
observations, some recent reports have provided evidence that MF has a direct effect altering 
certain functional parameters in somatotrope GH3 and corticotrope AtT-20 pituitary cell lines 
(25-27). However, to date, the pharmacological effects of different biguanides on human 
primary PitNET cell cultures are not fully elucidated. Therefore, we aimed to explore the 
direct effects of MF, BF and PF on key functional parameters (cell viability, apoptosis, 
hormonal secretion/expression and intracellular signaling pathways) in primary cell cultures 
from different human PitNETs subtypes, including adrenocorticotropin and growth hormone 
secreting adenomas (ACTHomas, GHomas, respectively), non-functioning pituitary 
adenomas (NFPAs) and prolactinomas (PRLomas).  
MATERIALS AND METHODS 
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Drugs and reagents 
All reagents and drugs used in this study were purchased from Sigma-Aldrich unless 
otherwise specified. Buformin was purchased from Santa Cruz Biotechnology (Heidelberg, 
Germany). Octreotide was obtained from GP-Pharm (Barcelona, Spain) and pasireotide was 
generously provided by Novartis (Barcelona, Spain). Metformin was used at 10 mM, 
buformin and phenformin at 5 mM, and SSAs at 100 nM. All doses were selected based on 
previous studies (20, 24, 28, 29) or based on in vitro dose-response experiments (see Figure 
1). 
Patients, samples and primary cell cultures 
This study was carried out within a project approved by our Hospital Research Ethics 
Committee and was conducted in accordance with ethical standards of the Helsinki 
Declaration of the World Medical Association. Written informed consent was obtained from 
each patient. Human pituitary samples were collected during transsphenoidal surgery from 42 
patients (13 corticotropinomas, 13 somatotropinomas, 13 NFPAs and 3 prolactinomas). 
General characteristics of the patients are summarized in Table 1. In all cases, specimens 
were placed in sterile cold medium (S-MEM, Gibco, Madrid, Spain; supplemented with 0.1% 
BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2,5% HEPES) and 
dispersed into single cells following the methods previously described (29-32). The type of 
tumor was confirmed by 2 separate methods: examination by anatomo-pathologists and 
molecular screening by quantitative real-time PCR (qPCR), as previously described (29-32). 
Cell lines and culturing  
The two pituitary cell line models most widely used in cell biology research were used in the 
present study: the mouse corticotrope pituitary derived cell line AtT-20/D16v-F2 (ATCC® 
CRL-1795™) and the rat somatotrope pituitary derived cell line GH3 (ATCC® CCL-
82.1™). Both were cultured and maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) complemented with 10% FBS, 100 U/ml penicillin/streptomycin, 0.024 M of 2-
(4(2-hydroxyethyl)-1-piperazine)-ethane sulfonic acid (HEPES), and maintained at 37ºC and 
5% CO2, under sterile conditions. Additionally, both cell lines were checked for mycoplasma 
contamination by PCR (33).  
Analysis of cell viability 
As previously reported (30, 32), Alamar-blue reagent (Invitrogen, Madrid, Spain) was used to 
assess the effect of different biguanides alone, or the combination of MF with SSAs 
(octreotide or pasireotide) every 24h until 72h on cell viability. 10,000 cells/well (human 
pituitary cultures) or 6,000 cells/well (AtT-20 and GH3 cell cultures) were plated in a 96-well 
plate. Treatments were daily refreshed after each measurement and cell viability was 
evaluated using FlexStation III system (Molecular Devices, Sunnyvale, CA, USA). 
Measurement of hormone release  
To analyze the effect of different biguanides alone, or the combination of MF with SSAs 
(octreotide or pasireotide) on pituitary hormone release from different primary PitNET cells 
and/or cell lines, 150,000-200,000 cells/well were plated onto 24-well plates in serum-
containing media. Media were collected after 24h of incubation and hormone secretion was 
measured using human [reference numbers: ACTH: EIA-3647; GH: EIA-3552; PRL: EIA-
1291 (DRG, Mountainside, NJ, USA)], and rat [reference number: GH: EZRMGH-45K 
(Merck Millipore, Darmstadt, Germany)] commercial ELISAs, following the manufacturer´s 
instructions.  
Analysis of apoptotic rate in somatotrope cells 
Caspase-Glo 3/7 assay (Promega, Madrid, Spain) was used to analyze the effect of MF on 
apoptotic rate by measuring caspase 3/7 activity according to manufacturer’s instructions. 
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Thus, 25,000 cells/well were plated in 96-well white microplate and maintained for 24h at 
37ºC and 5% CO2. Then, cells were treated with MF and vehicle and incubated for another 
24h. After this period, 100 µl of Caspase-Glo 3/7 reagent was added to each well and 
luminescence was measured at room temperature using FlexStation III system for 3h. 
RNA isolation, reverse transcription and qPCR of human and primate transcripts 
Details of RNA extraction, quantification, reverse-transcription (RT) and qPCR using a 
specific set of primers included in this study have been previously reported elsewhere by our 
group (31, 32). New primer sequences were used in the present study to amplify rHprt1 
(sense, AGCTTGCTGGTGAAAAGGAC and antisense, TCCACTTTCGCTGATGACAC; 
accession number, NC_005120.4; product size, 153pb), rPpia (sense, 
CGTCTGCTTCGAGCTGTTT and antisense, GGAACCCTTATAGCCAAATCCT; 
accession number, NC_005113.4; product size, 97 pb), rSst1 (sense, 
TGCCCTTTCTGGTCACTTCC and antisense, AGCGGTCCACACTAAGCACA; accession 
number, NC_005105.4; product size, 135 pb), rSst2 (sense, CCCATCCTGTACGCCTTCTT 
and antisense, GTCTCATTCAGCCGGGATTT ; accession number, NC_005109.4; product 
size, 134 pb), rSst5 (sense, TCATTGTGGTCAAGGTGAAGG and antisense, 
AAGAAATAGAGGCCGGCAGA; accession number, NC_005109.4; product size, 199 pb), 
rAmpk (sense, CTGTAAACACGGGAGGGTTG and antisense, 
ACGTTCTCTGGCTTCAGGTC; accession number, NC_000070.6; product size, 120 pb), 
mAmpk (sense, TCGGCTGGTTGTAGTGAATG and antisense, 
TCTCCTTCTGTTTGGCACCT; accession number, NC_000071.6; product size, 106 pb) and 
hAMPK (sense, AGATTGTATGCAGGCCCAGA and antisense, 
TGGTCATCATCAAATGGAAGG; accession number, NC_000005.10; product size, 92 pb). 
To control for variations in the amount of RNA used in the RT reaction and the efficiency of 
the RT reaction, the expression level (copy-number) of each transcript was adjusted using a 
normalization factor (NF) calculated from beta actin (ACTB), hypoxanthine-guanine 
phosphoribosyltransferase 1 (HPRT1) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) expression levels in PitNETs and calculated from Actb, Hprt and Ppia 
(peptidylprolyl isomerase A) expression levels in cell lines.  
Measurement of free cytosolic calcium ([Ca2+]i) kinetics 
Kinetics of free cytosolic calcium ([Ca2+]i) were measured in response to different biguanides 
alone in human pituitary primary cell cultures, as previously described (30-32). Thus, 50,000 
cells/coverslip were plated and changes in [Ca2+]i in single cells were measured using fura-
2AM (Molecular Probes, Eugene, OR, USA). 
Measurement of signaling pathways by western blotting 
In short, 500,000 cells/well were cultured in 12-well plates and incubated for 8 min with 
different biguanides alone and vehicle-treated controls. Proteins were extracted, separated by 
SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Darmstadt, Germany), as 
previously reported (31). Then, blocked membranes were incubated with the primary 
antibodies [anti-phosphoAMPKα (SC-33524) and anti-ERK1/2 (SC-154) from Santa Cruz 
(CA, USA) and anti-AMPKα (2532S), anti-phosphoERK1/2 (4370S), anti-Akt (9272S) and 
anti-phosphoAkt (4060S) from Cell Signaling (Danvers, MA, USA)] and appropriate 
secondary antibody (anti-rabbit antibody from Cell Signaling, Danvers, MA, USA). Proteins 
were developed using an enhanced chemiluminescence detection system (GE Healthcare, 
Madrid, Spain) with dyed molecular weight markers. A densitometric analysis of the bands 
was carried out with ImageJ software. Relative phosphorylation was estimated from 
normalization of p-AMPK, p-ERK1/2 or p-Akt against the total AMPK, ERK1/2 or Akt, 
respectively. 
Statistical analysis 
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Statistical differences were evaluated by paired parametric t-test or two-way ANOVA 
followed by Tukey’s test for multiple comparison (according to normality evaluated by 
Kolmogorov-Smirnov test). All data are expressed as mean ± SEM. As previously reported 
(30), to normalize values within each treatment and minimize intragroup variations in the 
different in vitro experiments (i.e. different age of the tissue donor or metabolic 
environment), the values obtained were compared with vehicle-treated controls (set at 100%). 
All experiments were performed in a minimum of three independent primary pituitary 
cultures from different patients (3-4 replicates/treatment per experiment), unless otherwise 
indicated. P-values ≤0.05 were considered statistically significant. A trend for significance 
was indicated when p-values ranged between >0.05 and <0.1. All statistical analyses were 
performed using GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA). 
RESULTS  
Biguanides reduce cell viability in PitNET cells 
In general, administration of biguanides produced a reduction of cell viability in all types of 
PitNET cell cultures and a decrease in cell proliferation in the pituitary cell lines tested (Fig-
2). In particular, MF (10 mM) significantly reduced cell viability after 72h of incubation in 
ACTHomas cells (Fig-2A), and BF and PF (5 mM) also decreased cell viability in 
ACTHomas after 24, 48 and/or 72h of incubation, being PF the most effective compound 
(Fig-2A). Moreover, MF (the only type of biguanides currently used in the clinical practice) 
was also evaluated in combination with SSAs (octreotide or pasireotide) in primary 
ACTHoma cultures (Fig-2B). Thus, MF alone significantly reduced cell viability by 49.7% 
after 72h of incubation. In contrast, although treatment with octreotide and pasireotide alone 
apparently reduced cell viability at 72h (35.1% and 18.4% reduction, respectively), this 
reduction did not reach statistical significance in any case (Fig-2B). Co-incubation of MF 
with both SSAs did not significant alter the inhibitory actions of MF (Fig-2B). In the same 
line, MF significantly reduced cell proliferation after 72h of incubation in AtT-20 cells (Fig-
2A). BF and PF (5 mM) also decreased cell proliferation in AtT-20 cells after 24, 48 and 72h 
of incubation (Fig-2A), being PF the most effective compound (Fig-2A). In this point, it 
should be clarified that Fig. 2B only shows the ACTHoma samples that were treated with 
metformin, SSAs and the combination of them (n=3 experiments), whereas Fig. 2A shows 
the results of all the ACTHoma samples treated with metformin (n=10 cell cultures), 
including the tumors that appeared in Fig. 2B. Therefore, although the final results and 
conclusion are similar in both graphics (i.e. metformin treatment significantly decreased cell 
viability in primary cell cultures from ACTH-producing tumors), direct comparisons between 
figures 2A and 2B should be done with caution, as the number of tumors included in each 
figure differs considerably. 
 In primary GH-secreting PitNET cell cultures, administration of MF did not alter cell 
viability at any of the incubation times tested; whereas, in contrast, BF, but specially PF, 
clearly decreased cell viability after 24-72h of incubation (Fig-2C). In the GH3 cell line, all 
biguanides significantly decreased cell proliferation (Fig-2C). Co-administration of MF with 
SSAs was also evaluated in primary GH-secreting PitNET cells (Fig-2C). As previously 
observed, MF did not alter cell viability in GHoma cell cultures; however, octreotide and 
pasireotide alone decreased cell viability by 35.8% and 33.2% at 72h of incubation, 
respectively. The combination therapy of MF with octreotide or pasireotide did not alter the 
inhibitory effect of both SSAs (Fig-2D).  
In primary NFPA cell cultures, treatment with MF and BF significantly decreased cell 
viability after 48-72h of incubation and PF decreased this parameter after 24-72h of 
incubation in a time dependent-manner (Fig-2E). Interestingly, although cell viability was not 
reduced in response to octreotide and pasireotide in NFPA cell cultures, combination therapy 
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of MF with both SSAs seemed to produce a higher decrease on cell viability as compared to 
the different treatments alone (Fig-2F); however, this reduction did not reach statistical 
significance probably due to the fact that we could only test this combination therapy in two 
primary NFPA cell cultures. Finally, PF, but not MF and BF, significantly decreased cell 
viability in primary PRLoma cell cultures (Fig-2G).  
Metformin increases apoptotic rate in GHoma cells.  
Due to the limited number of cells obtained after dispersions, the effect of MF on apoptosis 
was only evaluated in primary GH-secreting adenomas. Specifically, MF (10 mM) 
significantly increased caspase 3/7 activity, a robust indicator of apoptosis, as compared to 
vehicle-treated controls after 24h of incubation (Fig-2H).  
Effect of biguanides on hormone secretion in PitNET cells. 
MF, BF and PF did not alter ACTH secretion after 24h of incubation in ACTHoma cell 
cultures (Fig-3A). In GHoma cell cultures, BF and PF, but not MF, reduced GH secretion 
(Fig-3B). In line with the cell viability results previously observed, the three biguanides 
significantly reduced GH secretion in the GH3 cell line after 24h of incubation (Fig-3E). 
Additionally, we had the opportunity to measure the effect of MF alone or in combination 
with SSAs (octreotide and pasireotide) in cell cultures from GHomas (Fig-3C). The results 
showed that treatment with SSAs alone tended to decrease GH release and, that the 
combination therapy of SSAs with MF did not modify the inhibitory action of both SSAs 
when tested alone (Fig-3C). Finally, BF and PF, but not MF, treatment tended to decrease 
PRL secretion in cell cultures from PRLomas as compared to vehicle treated-controls after 
24h of incubation (Fig-3D).  
Effect of biguanides on mRNA expression of relevant genes in PitNETs. 
We evaluated the direct effect of the treatment with different biguanides alone on mRNA 
levels of pathologically relevant genes in cell cultures of corticotropinomas (primary 
ACTHoma cells and AtT-20 cells) and somatotropinomas (primary GHoma cells and GH3 
cells). MF and BF did not modify the mRNA expression levels of POMC (ACTH-precursor) 
in ACTHoma or AtT-20 cell cultures (Fig-4A); in contrast, PF significantly reduced Pomc 
expression levels in AtT-20, but not ACTHomas, cell cultures (Fig-4A). Interestingly, PF, but 
not MF or BF treatment tended to increase the expression levels of somatostatin receptors 
(SST1, SST2 and SST5) in ACTHoma cell cultures (Fig-4B; left-panel). Similar results were 
observed in AtT-20 cell cultures wherein PF significantly increased Sst2 expression levels 
(both isoforms identified in rodents) but not Sst5 [Fig-4B; right-panel; Sst1 was not expressed 
in AtT-20 cell line (data not shown)].  
Administration of PF, but not MF or BF, increased GH mRNA levels after 24h of 
incubation in GHoma and GH3 cell cultures (Fig-4C). Interestingly, treatment with PF, but 
not MF and BF, increased SST2 and SST5, but not SST1 expression levels in GHoma cell 
cultures (Fig-4D; left-panel). In GH3, Sst2 expression seemed to be up-regulated in response 
to the treatment with all biguanides, although this increase was only statistically significant in 
response to MF. Moreover, PF increased Sst5 and reduced Sst1 expression levels (Fig-4D; 
right-panel). 
To further explore the mechanisms involved in biguanide actions, we measured the 
effects of MF, BF and PF on the expression of AMPK, since this enzyme has been typically 
considered the central mediator of MF effects (34). Results revealed that administration of 
MF and BF did not modify AMPK expression in ACTHoma or GHoma cell cultures (i.e. 
primary ACTHoma and GHoma cell cultures and AtT-20 cells, but with the exception of 
GH3 wherein MF increase Ampk expression levels). By contrast, PF treatment significantly 
increased AMPK expression levels in all the cellular model of ACTHoma or GHoma tested 
(Fig-4E and -4F, respectively).  
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Effect of biguanides on intracellular signaling pathways in PitNET cells.  
To test the ability of biguanides to modulate intracellular signaling pathways in PitNETs, we 
first evaluated the dynamics of free cytosolic calcium concentration ([Ca2+]i) in single cells 
derived from ACTHomas, GHomas, NFPAs and PRLomas in response to the treatment with 
MF, BF and PF (Table 2). Specifically, all biguanides elicited a calcium response in more 
than 50% of ACTHomas analysed, evoking a similar reduction in [Ca2+]i that ranged between 
23.34 and 27.11%. However, differences were found regarding the percentage of responsive 
cells. Thus, BF was the most effective compound since 46.80% of ACTH-secreting cells 
responded compared to 30.25% or 9.8% of responsive cells to PF and MF, respectively.  In 
contrast, treatment with biguanides did not elicit any [Ca2+]i response in the GHomas 
analyzed. In NFPAs, MF reduced [Ca2+]i by 30.62% in 50% of the samples, BF decreased it 
by 20.6% in 66.7% of NFPAs and PF was the most effective compound reducing [Ca2+]i by 
44.7% in 32.4% of responsive cells of the 66.7% NFPAs analyzed. Finally, in PRLomas, BF 
and PF did not alter [Ca2+]i dynamics and MF reduced by 18.4% in one of the two tested 
PRLomas.  
Furthermore, we could analyze the combination therapy with octreotide in 2 ACTHomas 
and 2 GHomas cell cultures available (Table 3).  In ACTHoma cells, combined incubation 
with MF and octreotide did not significantly impact the [Ca2+]i  reduction elicited by MF or 
octreotide alone (28.9% vs. 20% or 23.9%, respectively). In GH-secreting cells, MF did not 
elicit changes in calcium dynamics as mentioned above and octreotide slightly reduced 
calcium levels in 10% of the cells analyzed. Interestingly, the co-administration of MF and 
octreotide produced a higher reduction of [Ca2+]i (37.6% vs. 0% or 21.6%) and an increase of 
responsive cells compared to MF or octreotide administered alone (27.9% vs. 0% or 10%).  
To better understand the effects observed in response to biguanides, we explored several 
signaling pathways in GHomas (Fig-5). Our results show that a short-term incubation with 
BF and PF numerically increase phosphorylation levels of AMPKα as compared to vehicle-
treated controls, although this difference did not reach statistical significance. In contrast, MF 
did not alter the phosphorylation levels of AMPKα, which is in accordance with the results 
obtained at mRNA levels in GHomas. We also measured other signaling pathways intimately 
related with proliferation and survival in tumor pathologies, including PitNETs (35, 36). 
Thus, we observed an increase in phosphorylation levels of Akt and ERK1/2 in response to 
BF and PF, being this increase only significant in ERK1/2 in response to BF. On the other 
hand, MF did not alter phosphorylation levels of Akt or ERK1/2 (Fig-5).  
DISCUSSION 
PitNETs are commonly considered benign tumors due to their frequent slow growth and 
moderate proliferative capacity (37). However, the incidence of PitNETs is increasing, also 
owing to the enhanced diagnostic capacity of novel imaging techniques and improved 
diagnostic technologies, which have increased the sensitivity to detect pituitary neoplasms 
(38). Likewise, the severe morbimortality associated to PitNETs is nowadays clearly 
established, thereby reinforcing the necessity to develop novel therapeutic options, especially 
for invasive, recurrent and/or functioning tumors. In this context, there is an emerging interest 
in biguanides, particularly in MF, by their potential as antitumoral compounds, related to 
their beneficial effects in increasing insulin sensitivity and decreasing oxidative 
phosphorylation (39). In line with this, we recently described that different biguanides exert 
direct actions in the pituitary cells of two non-human primate species suggesting that the 
well-known metabolic effects of biguanides might be, at least in part, influenced by their 
actions at the pituitary level (24). However, the antitumoral actions of these compounds on 
different human PitNETs are poorly understood. Thus, we evaluated the direct antitumoral 
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effects of different biguanides on primary cultures of functioning and non-functioning 
PitNETs and explored their possible underlying mechanisms.  
The antiproliferative capacity of MF has been described previously in different 
endocrine-cancer settings, including neuroendocrine tumor cells (20, 40-42), and in various 
animal models (42), and is currently being tested as adjuvant therapy in several clinical trials 
(43). However, MF does not alter epithelial proliferation in Barrett’s esophagus (44), 
suggesting that this drug might exert cell-and tissue-type dependent antiproliferative effects. 
In our study, ACTHoma cells were more sensitive to MF compared to GHoma and NFPA 
cells. Moreover, PF was the most effective compound in reducing cell viability in all cases, 
which is in accordance with a recent report from our group in neuroendocrine tumors (20). 
Additionally, results reporting a marked reduction of cell viability in response to MF in AtT-
20 (27) and GH3 cells (26) are consistent with our results in these cell lines. However, our 
present findings in GHomas are not totally in line with previous reports, where MF reduced 
cell viability in 7 out of 8 somatotropinomas (26). These differences could be due to 
disparities in the experimental design, or in the basal characteristics of the GHomas analyzed. 
Nevertheless, although we did not observe significant changes on cell viability, there was a 
significant increase of apoptotic rate in response to MF in GHomas after 24h of incubation, 
which is consistent with results reported in GH3 cells (26). These results might be seen 
contradictory since the vast majority of reports seem to associate cell proliferation with 
apoptosis through the modulation of common and/or distinct proteins (45, 46). However, 
several studies have showed an imbalance between cell survival and apoptosis in pathological 
conditions such as breast or lung cancer (47-49). In line with the results observed in GHomas, 
a similar pattern of response to biguanides in terms of cell viability was found in PRLomas, 
which could be due to the common developmental lineage of these cells (4). However, these 
results differ from the growth reduction observed in response to MF in the lactotrophic MMQ 
cell line (50), supporting again the idea that the effect of biguanides is highly cell-type 
dependent. 
As previously mentioned, SSAs represent important tools in the medical treatment of 
some PitNET types, especially in GH-secreting tumors, in relapsed or persistent disease (51); 
however, these treatments are in many cases ineffective (52, 53), and in vitro data suggests a 
mild effect on cell proliferation, especially when first-generation SSAs have been evaluated 
(54). For these reasons, the search for new pharmacological alternatives to control tumor 
growth and/or hormone secretion has been crucial over the last years. In this context, 
treatment with SSAs combined with other pharmacological therapies, such as dopamine 
agonists or pegvisomant, are frequently  used to control hormone-related and/or other 
symptoms in PitNETs (55, 56). Here, we tested the combined therapy of MF with SSAs but 
found that this combination did not alter the inhibitory effect of MF or SSAs alone in 
functioning PitNETs (GH-/ACTH-omas). Similar results have been reported using AICAR 
(AMP mimetic compound 5-aminoimidazole-4-carboxamide ribonucleoside; AMPK 
activator) and somatostatin-14, where only 1 out of 8 GHomas showed an additive effect of 
both compounds (22). Of note, however, our study indicate that the combination therapy of 
MF and SSAs seems to have a stronger effect in reducing cell viability in NFPA cell cultures, 
a tumor type where SSAs have shown poor efficacy (57). Although more experiments are 
necessary to confirm and understand this interesting observation, we might speculate that this 
additive effect of MF and SSAs could represent a potential therapeutic combination for 
patients with NFPAs since these tumors are the most resistant PitNETs to the therapeutic 
options currently available (29, 58). 
With regard to hormone secretion, previous reports have described a time- and dose-
dependent effect of MF on ACTH and GH secretion in AtT-20 and GH3 cell line (26, 27). In 
our study, BF and PF, but not MF treatment clearly reduced GH and PRL secretion without 
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altering ACTH release. These results are in part comparable to a previous recent report from 
our group performed in neuroendocrine tumor cells, in which MF had no effect on hormone 
secretion in BON-1 or QGP-1 cell cultures, whereas PF decreased hormone secretion in 
BON-1, but not in QGP-1 cell cultures (20). However, we found that all biguanides 
significantly reduced GH secretion in the GH3 cell line, supporting again the notion of a cell-
type specific effect of different biguanides on pituitary cells. In line with the results observed 
in cell viability, the combination therapy with SSAs did not increase the effectiveness of the 
SSA in monotherapy at the level of hormone secretion. Indeed, the fact that MF did not 
impact on SSAs effect at both, cell viability and hormone secretion, levels might suggest 
shared mechanisms of action between MF and SSAs in pituitary tumor cells.  
In contrast with the results published recently by our group in normal pituitary glands 
from non-human primate species (24), MF and BF did not modify GH, POMC or SSTs at 
mRNA expression levels. On the contrary, PF significantly increased GH expression levels, 
which could occur as a feedback loop mechanism in order to compensate the striking 
reduction of GH secretion observed in GHomas and GH3 cell line in response to this 
compound. PF also increased SST2 and SST5 expression levels in ACTH- and GH-secreting 
cells, which is in line with the similar increase observed in normal pituitary gland in Papio 
anubis (24). These data indicate that the actions of different biguanide types in PitNET cells 
are not only confined to the regulation of cell viability and/or hormonal secretions, but also 
included the regulation of the synthesis of key genes involved in the regulation of pituitary 
pathophysiology (i.e. pituitary hormones and SSTs). Although additional experimental work 
is necessary to confirm, understand and achieve a definitive interpretation of the biological 
meaning of these results, our data adds compelling evidence on the direct effects that 
biguanides exert on the expression profile of relevant pituitary genes, which might pave the 
way towards the identification and validation of additional biomarkers and/or therapeutic 
targets in these pathologies. 
Our report also provides information about the signaling pathways underlying the effects 
of biguanides in PitNET cells. Calcium is a relevant second messenger for pituitary cell 
physiology which has been classically associated to pituitary hormone secretion (59). In this 
sense, our results showed an inhibitory action on [Ca2+]i levels predominantly in ACTHomas 
and NFPAs, and not in GHomas or PRLomas. Intriguingly, the calcium dynamics observed in 
our study do not seem to be associated to hormone secretion, since biguanides did not modify 
ACTH secretion from corticotropinoma cells. Therefore, our results suggest that calcium 
kinetics in response to biguanides could be more related with another functional parameter 
such as cell viability (60, 61). Additionally, combination therapy of MF with SSAs did not 
alter the effect of MF as monotherapy in ACTHomas, but seemed to increase the effect of 
octreotide in GHomas, although this increase was not enough to associate it to any functional 
endpoint. Furthermore, as expected, we also found a regulation on the phosphorylation levels 
of AMPK (considered the central mediator of MF effects in different tissues/organs (34) in 
response to BF and PF (which is in line with our results at mRNA expression levels). 
However, this increase in AMPK phosphorylation levels was not observed in response to MF, 
which is in contrast with the increase reported in GH3 and AtT-20 cell lines (25-27). In the 
same line, in this study we found an overall increase on phosphorylation levels of Akt and 
ERK1/2 in response of BF and PF, but not MF. It should be mentioned that an increase in the 
phosphorylation levels of these two pathways has been related in several reports with a 
reduction of cell proliferation in response to short-period of incubations with SSAs or 
dopamine analogues in PitNETs (62, 63). Therefore, our findings demonstrate that some 
biguanides act through signaling pathways that has not been linked to AMPK, suggesting that 
some actions of these compounds could be exerted though AMPK-independent mechanisms 
in PitNET cells. 
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In conclusion, our study provides primary evidence that biguanides exert important anti-
proliferative and anti-secretory effects in some PitNET cell types through the modulation of 
AMPK-dependent ([Ca2+]i dynamics, PI3K-Akt pathway) and independent (ERK pathway) 
mechanisms. Moreover, combination of MF and SSAs treatment did not exert additional 
antitumoral effects in functioning PitNETs, which suggest shared mechanisms of actions. Of 
note, combined therapy with MF and SSAs might represent a potential new therapeutic 
approach for patients with NFPAs. Taken together, our results unveil a clear overall 
antitumoral effect of different biguanides on PitNET cells and pave the way to consider these 
compounds as a potential new option in the treatment of these severe pathologies.  
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Figure 1: Dose-response experiment of cell viability in response to metformin (5 and 10 
mM) in primary ACTHoma (n=7), GHoma (n=3) and NFPA (n=7) cell cultures, 
measured by Alamar-blue reduction. Data are expressed as percent of vehicle-treated 
controls (set at 100%) within experiment. Values represent the mean ± SEM. Asterisks (* 
p<0.05) indicate statistically significant differences. 
Figure 2: Measurement of cell viability (24-72 h) and apoptosis in response to different 
biguanides alone or in response to the combination of metformin with somatostatin 
analogues (octreotide or pasireotide) in primary PitNET cell cultures and pituitary cell 
lines. (A) Effect of metformin (MF; 10 mM), buformin (BF; 5 mM) and phenformin (PF; 5 
mM) on cell viability in primary ACTHoma cell cultures (MF: n=10; BF: n=6; PF: n=5) and 
in the corticotropinoma AtT-20 cell line (MF: n=9; BF: n=6; PF: n=7), measured by Alamar-
blue reduction. (B) Effect of MF alone or in combination with octreotide or pasireotide on 
cell viability in ACTHomas (n=3). (C) Effect of MF, BF and PF in primary GHoma cell 
cultures (MF: n=9; BF and PF: n=4) and in the somatotropinoma GH3 cell line (n=4). (D) 
Effect of MF alone or in combination with octreotide or pasireotide on cell viability in 
GHomas (n=5). (E) Effect of biguanides in primary NFPA cell cultures (MF: n=11; BF: n=7; 
PF: n=8). (F) Effect of MF alone or in combination with octreotide or pasireotide on cell 
viability in NFPAs (n=2). (G) Effect of biguanides in primary PRLoma cell cultures (n=3). 
(H) Effect of MF on apoptosis (24h treatment) in primary GHoma cell cultures measured by 
Caspase-Glo 3/7 assay. Data are expressed as percent of vehicle-treated controls (set at 
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100%) within experiment. Values represent the mean ± SEM. Asterisks (* p<0.05; ** 
p<0.01; *** p<0.001) indicate statistically significant differences. In cases where less than 
three experiments were performed, no significance tests were performed.  
Figure 3: Hormone secretion in response to different biguanides alone or to metformin 
in combination with octreotide or pasireotide in human PitNET cell cultures and cell 
lines. (A) Effect of metformin (MF; 10 mM). buformin (BF; 5 mM) and phenformin (PF; 5 
mM) on ACTH secretion in primary ACTHoma cell cultures (24h treatment; MF: n=6; BF 
and PF: n=3), determined by commercial ELISA kit. (B) Effect of MF, BF and PF on GH 
secretion in primary GHoma cell cultures (MF: n=8; BF: n=4; PF: n=3). (C) Effect of MF 
alone or in combination with octreotide or pasireotide on GH secretion in primary GHoma 
cell cultures (n=4). (D) Effect of biguanides on PRL secretion in primary PRLoma cell 
cultures (n=2). (E) Effect of MF on GH secretion in GH3 cell line (n=5), determined by 
commercial ELISA kit. Data are expressed as percent of vehicle-treated controls (set at 
100%) within experiment. Values represent the mean ± SEM. Asterisks (* p<0.05; ** 
p<0.01; *** p<0.001) indicate statistically significant differences. In cases where less than 
three experiments were performed, no significance tests were performed. 
Figure 4: Measurement of mRNA expression levels of key genes in response to different 
biguanides in human PitNET cell cultures and cell lines. (A-B, E) Effect of metformin 
(MF; 10 mM). buformin (BF; 5 mM) and phenformin (PF; 5 mM) on the expression levels of 
different genes in primary ACTHoma cell cultures (MF: n=3; BF and PF: n=2) and in the 
corticotropinoma AtT-20 cell line (n=4). (C-D, F) Effect of MF, BF and PF on expression 
levels in primary GHoma cell cultures (n=4) and in the somatotropinoma GH3 cell line (n=4). 
Expression levels were measured by quantitative-PCR and adjusted by normalization factor 
(NF). Data are expressed as percent of vehicle-treated controls (set at 100%) within 
experiment. Values represent the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) 
indicate statistically significant differences. In cases where less than three experiments were 
performed, no significance tests were performed. 
Figure 5: Measurement of phosphorylation levels of AMPK, Akt and ERK1/2 in 
response to different biguanides in primary GHoma cell cultures. Representative Western 
Blots and quantification of levels of p-AMPK/total AMPK (n=3), p-Akt/total Akt (n=2) and 
p-ERK1/2/ total ERK1/2 (n=3) in response to MF (10 mM), BF (5 mM) and PF (5 mM) in 
GHomas. Data are expressed as percent of vehicle-treated controls (set at 100%) within 
experiment. Values represent the mean ± SEM. Asterisks (* p<0.05) indicate statistically 
significant differences. In cases where less than three experiments were performed, no 
significance tests were performed. 
Table 1: Demographic data of patients included in the study. 
Tumor type N Sex (% of women) Age (min-max) 
Corticotropinomas 13 92%  56 (18-79) 
Somatotropinomas 13 54% 50 (29-64) 
Prolactinomas 3 33% 25 (20-34) 
Non-functioning pituitary adenomas 13 62% 49 (24-75) 
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Table 2: Results from free cytosolic calcium dynamic assays in PitNET cells in response to 
biguanides. 
Treatment # samples Cells analyzed % PRC % PRM ± SEM Time (s) ± SEM 
ACTHomas 
Metformin 3/5 236 9.80% 23.34 ± 1.77 49.38 ± 2.67 
Buformin 3/4 154 46.80% 25.5 ± 1.64 61.55 ± 3.10 
Phenformin 2/3 119 30.25% 27.11 ± 2.14 65.98 ± 2.78 
GHomas 
Metformin 0/3 150 0 - - 
Buformin 0/3 79 0 - - 
Phenformin 0/3 81 0 - - 
NFPAs 
Metformin 2/4 144 16.00% 30.62 ± 2.62 54.7 ± 5.67 
Buformin 2/3 106 18.90% 20.6 ± 3.2 54.7 ± 3.46 
Phenformin 2/3 105 32.40% 44.7 ± 4.92 62.2 ± 2.2 
PRLomas 
Metformin 1/2 60 6.70% 18.4 ± 0.92 61.25 ± 2.07 
Buformin 0/2 49 0 - - 
Phenformin 0/2 58 0 - - 
# samples: number of responsive samples of the total of samples analyzed. 
Cells analyzed: total of individual cells analyzed. 
% PRC: percentage of responsive cells in responsive samples. 
Time: time of response to biguanides administration. 
Table 3: Results from free cytosolic calcium dynamic assays in PitNET cells in response to 
metformin alone or in combination with octreotide. 
Treatment # samples Cells analyzed % PRC % PRM ± SEM Time (s) ± SEM 
ACTHomas 
Metformin 1/2 58 12.1% 20 ± 1.77 51.43 ± 1.95 
Octreotide 1/2 67 4.5% 23.9 ± 3.62 110 ± 0 
MF + Octreotide 1/2 66 4.5% 28.9 ± 5.44 45 ± 4.08 
GHomas 
Metformin 0/2 70 0 - - 
Octreotide 2/2 70 10% 21.6 ± 0.8 89.4 ± 3.71 
MF + Octreotide 1/2 68 27.9% 37.6 ± 3.89 85 ± 0 
# samples: number of responsive samples of the total of samples analyzed. 
Cells analyzed: total of individual cells analyzed. 
% PRC: percentage of responsive cells in responsive samples. 
Time: time of response to biguanides administration. A
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Abstract
Background/Aims: Biguanides are anti-hyperglycaemic agents used to treat diabetes by acting 
primarily on the liver, inhibiting hepatic gluconeogenesis. However, biguanides may target 
other key metabolic tissues to exert beneficial actions. As the “master endocrine gland”, the 
pituitary is a true homeostatic sensor that controls whole body homeostasis and metabolism 
by integrating central and peripheral signals. However, whether the pituitary is a primary site of 
biguanides action in normal adult humans/primates remains unknown. Therefore, we aimed to 
elucidate the direct effects of two biguanides (metformin/phenformin) on the expression and 
secretion of all anterior pituitary hormones in two non-human primate species (Papio anubis 
and Macaca fascicularis), and the molecular/signalling-mechanisms behind these actions. 
Methods: Primary pituitary cell cultures from baboons and macaques were used to determine 
the direct impact of metformin/phenformin (alone and combined with primary regulators) on 
the functioning of all pituitary cell-types (i.e. expression/secretion/signaling-pathways, etc). 
Results: Metformin/phenformin inhibited basal, but not GHRH/ghrelin-stimulated GH/ACTH/
FSH-secretion and GH/POMC-expression, without altering secretion or expression of other 
pituitary hormones (PRL/LH/TSH), FSH-expression or cell viability in both primate models. 
These biguanide actions are likely mediated through modulation of: 1) common (mTOR/
PI3K/intracellular-Ca2+mobilization) and distinct (MAPK) signaling pathways; and 2) gene 
expression of key receptors regulating somatotrope/corticotrope/gonadotrope function (i.e. 
upregulation of SSTR2/SSTR5/INSR/IGF1R/LEPR). Conclusion: The pituitary gland is a primary 
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target of biguanide actions wherein they modulate somatotrope/corticotrope/gonadotrope-
function through multiple molecular/signaling pathways in non-human primate-models. 
This suggests that the well-known metabolic effects of biguanides might be, at least in part, 
influenced by their actions at the pituitary level.
IntroductionBiguanides are a synthetic class of antidiabetic (anti-hyperglycaemic) agents constituted by two N-linked guanidine rings (i.e. metformin and phenformin), whose origin derives from galegine (isoamylene guanidine), a natural compound found in Galega officinalis [1]. Metformin has been the most frequently prescribed drug used to treat type-2 diabetes (T2D) 
for many years, and has been found to be safe and efficacious both as monotherapy and in combination with other oral antidiabetic agents. However, the sites and mechanisms of actions of metformin have been only partially explored and remain somewhat controversial. 
Specifically, the liver is presumed to be the primary site of metformin function, as the antihyperglycemic effect of metformin is mainly due to the inhibition of hepatic gluconeogenesis, wherein AMP-activated protein kinase (AMPK), a protein kinase that plays a key role in maintaining energy homeostasis, is assumed to be the prime hepatic target of metformin [2, 3]. However, recent studies have revealed that metformin, besides its glucose-lowering action, might exert additional, promising actions for the modulation of whole 
body homeostasis and metabolism, by specifically targeting other key endocrine/metabolic tissues, as well as by exerting other positive effects through additional mechanisms of actions 
(i.e. beneficial use in the treatment of cancer, cardiovascular diseases, aging, immunity and polycystic ovarian syndrome, etc.); although, these and other effects and mechanism of actions of metformin require further investigation [4-12]. Actually, it is still unclear if AMPK is the central mediator of metformin effects in all metabolic tissues and, therefore, the existence of both AMPK-dependent and independent mechanisms has been proposed [2, 13, 14].In this context, the pituitary gland, classically known as the “master endocrine gland”, is currently considered also a true metabolic sensor for whole body function, and one of the most important players in the control of body homeostasis, integrating central and peripheral 
signals [15]. Specifically, the five hormone-producing cells of the adenohypophysis (i.e. GH-producing somatotropes, PRL-producing lactotropes, ACTH-producing corticotropes, TSH-
producing thyrotropes, and FSH/LH-producing gonadotropes) receive multiple central and peripheral signals and, the integration of these signals results in the modulation of the corresponding hormonal secretions, which, in turn, control key peripheral organs and tissues related with essential metabolic functions such as growth, lactation, stress responses, appetite, reproduction, whole-body metabolism and puberty [16]. Inasmuch as metformin is involved in the modulation of a wide variety of metabolic processes in humans, it seems 
reasonable to think that this agent could exert some of these effects by directly influencing pituitary gland function. Indeed, some observations suggest that metformin is able to modify pituitary hormone levels in some pathological conditions (i.e. patients with pituitary adenomas, hypothyroidism or polycystic ovary syndrome (PCOS) [17, 18]), although these results are scattered, inconsistent and controversial.To the best of our knowledge, no studies have explored hitherto, on suitable models, how metformin or other biguanides agents can modulate directly the function of all the anterior pituitary cell types in normal adult humans or in primate species, and what intracellular signaling pathways would be involved in these putative actions. Accordingly, in 
the present study, we aimed at determining, for the first time, the direct effects of metformin and phenformin on the expression and secretion of all anterior pituitary hormones in two primate model species that closely resemble human physiology: Papio anubis (baboons) and 
Macaca fascicularis [19-21]. In addition, we also used primary pituitary cell cultures from baboons to better understand the mechanisms behind these actions, by evaluating the effects of these biguanides on the expression of selected key receptors and transcriptional factors involved in the normal functioning of the pituitary cell types, and by assessing the precise contribution of different signaling pathways in the actions of metformin using standard pharmacological (inhibitory) approaches.
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Materials and Methods
ReagentsAll reagents and inhibitors of intracellular signaling pathways used in this study were purchased 
from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. Ghrelin was purchased from Phoenix Pharmaceuticals (Burlingame, CA). a-MEM, HEPES, horse serum, and penicillin-streptomycin were obtained 
from Invitrogen (Grand Island, NY), and U73122 was purchased from Cayman Chemical (Ann Arbor, MI).
Animals and tissue collectionPituitary glands were obtained from randomly cyclic female baboons (Olive Baboon; Papio anubis; n=6; 7–12 years of age) and macaques (Macaca fascicularis; n=3; 7 years of age) within 15 min after sodium pentobarbital overdose as previously reported [22, 23]. The animals represent control animals from a 
breeding colony at the University of Illinois at Chicago (UIC). All procedures were approved and conducted 
under the Institutional Animal Care and Use Committee at the UIC (Chicago, IL), and all methods were carried out in accordance with relevant guidelines and regulations. Right after the animals were euthanized, pituitaries were excised, placed in sterile cold (4 °C) basic media (a-MEM with: 0.15% BSA, 6nM HEPES, 
10-IU/mL penicillin, and 10-mg/mL streptomycin) and immediately transported to the laboratory in sterile conditions.
Primary pituitary cell cultures
Pars distalis of the pituitary was isolated, washed twice in fresh media, and cut into small pieces (~20 – 40 mg) with surgical blades; then, fragments were incubated in 30 mL S-MEM medium complemented with 
0.3% trypsin (Beckton, Dickinson and Company, Sparks, MD, USA) in a spinner flask (Bellco Glass, Vineland, 
NJ, USA) for 2 h at 37 °C under gentle shaking to obtain dispersed single cells for culture, as previously 
reported [22-25]. To avoid fibroblast contamination, suspensions of dispersed pituitary cells were filtered 
through a nylon gauze of 130 µM-mesh and cultured in media with D-Valine (replaced for L-valine) to 
selectively inhibit fibroblast proliferation/overgrowth. In addition, visual inspection of primary cell cultures 
at the time of experimental assays showed no sign of cells displaying the typical fibroblast-like morphology.
Single cells (50.000-200.000 cells/ well) were plated onto 48- or 24-well plates in media containing 10% fetal horse serum. After 36h incubation (37°C, 5% CO2), media was removed and cells pre-incubated for 1h with fresh, warm (37 oC) serum-free medium to stabilize basal hormone secretion. After this pre-incubation period, cells were incubated with serum-free medium alone (controls) or serum-free media containing the following treatments: 1) metformin or phenformin alone (10-7 to 5x10-3 M; dose-response 
experiment; 4h incubation; doses selected based on previous studies [12, 26, 27]); 2) metformin or phenformin alone (5x10-3 M) for 4h and 24h (time-course experiment); 3) metformin or phenformin alone (5x10-3 M) or in combination with GH-releasing hormone (GHRH; 10 nM), acylated-ghrelin (10 nM) 
or gonadotropin-releasing hormone (GnRH, 10 nM) for 4h. Cells from different pituitaries (i.e. n=6 from baboons and n=3 from macaques) were not pooled. It should be noted that, given the limited source of macaque cell preparations (n=3), and the amount of cells obtained after dispersion of the pituitary glands, we were not able to reproduce the total amount of experiments included herein in both primate species.To study the intracellular signaling pathways involved in the metformin-mediated actions on baboon pituitary hormone release, after the 1h pre-incubation period with serum-free media, cells were incubated for an additional 90-minute period in serum-free media containing the following inhibitors of selected intracellular signaling pathways: mammalian target of rapamycin (mTOR; rapamycin; 10 µM), phosphatidylinositol 3-kinase activity (PI3K; wortmannin; 1 µM), mitogen-activated protein kinase activity 
(MAPK; PD-98, 059; 10μM), extracellular Ca2+ L-type channels (nifedipine; 1µM), intracellular Ca2+ channels 
(thapsigargin; 10µM), adenylyl cyclase (AC; MDL-12, 330A; 10µM), and phospholipase-C (PLC; U73122; 
50µM). Thereafter, the media were replaced with media with the specific inhibitor alone (vehicle) or media with the inhibitor containing metformin (5x10-3 M), and cells were incubated for an additional 4h. Additional controls consisted of serum-free media alone or media with metformin (in all cases without 
inhibitors). Doses for GHRH, acylated-ghrelin, GnRH or inhibitors of intracellular signaling pathways were selected based on previous studies [22-25, 28, 29]. At the end of the corresponding incubation periods with the different treatments, media were collected for hormone analysis using commercial ELISAs (see section below) and, in selected cases, cells were processed for total RNA recovery and assessment of mRNA levels by quantitative real-time PCR (qPCR; see section below).
Hormone release analysis.
GH, PRL, ACTH, LH, FSH and TSH hormone concentrations in the culture media were measured using 
human commercial ELISAs [Human: GH, PRL, ACTH, FSH, LH and TSH (reference numbers: EIA-1787, EIA-
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1291, EIA-3647, EIA-1288, EIA-1289 and EIA-1790, respectively; DRG, Mountainside, NJ)], as previously described [22, 24]. All the assays were performed following the manufacturer’s instructions where the 
information regarding specificity, detectability and reproducibility for each of the assays can be accessed at the websites of the indicated company.
RNA isolation, reverse transcription and qPCR of primate transcriptsPrimary pituitary cell cultures from baboons were processed for recovery of total RNA and the 
subsequent quantification of the amount of RNA recovered using kits and methods previously described 
[23, 29]. Briefly, total RNA was extracted using the Absolutely RNA RT-PCR Miniprep Kit (Stratagene, La Jolla, 
CA) with deoxyribonuclease treatment. The amount of RNA recovered was quantified by the Ribogreen RNA 
quantification kit (Molecular Probes, Eugene, OR) and reverse transcribed in a 20ml volume using random-hexamer primers and the cDNA First Strand Synthesis kit (MRI Fermentas, Hanover, MD). cDNAs were 
treated with ribonuclease H (1 U; MRI Fermentas) and amplified by qPCR using a Stratagene Mx3000p 
real-time PCR machine and the Brilliant III Ultra-Fast SYBR® QPCR Master Mix (Stratagene, La Jolla, CA, 
USA). To estimate mRNA copy number, samples were run against specific synthetic standards (1-106 copies of synthetic cDNA template for each transcript of interest) run on the same plate. Details regarding the 
development, validation, and application of a qPCR as well as the specific sets of primers sequences to measure expression levels of primates transcripts included in this study, including cyclophilin A (PPIA; used as a reference, housekeeping gene), have been reported previously [22-24, 29, 30]. New baboon primer sequences were used in the present study to amplify GNRHR, (sense, TGCCTCTTCATCATCCCTCTT 
and antisense AGTCTTCAGCCGTGCTCTTG; accession number, NM000406; product size, 144 pb) and LEPR 
(sense, GGAAGGAGTGGGAAAACCAAAG and antisense, CCAAGCAATAAGATGGAAGAGG; accession number, XM_009210050.2; product size, 126 pb). To control for variations in the amount of RNA used in the RT 
reaction and the efficiency of the RT reaction, mRNA copy numbers of the baboon transcripts analyzed were 
adjusted by cyclophilin-A expression, where baboon cyclophilin-A mRNA levels did not significantly vary between experimental groups (data not shown).
Cell viabilityIn order to determine if metformin or phenformin altered cell viability, trypan blue (Sigma, St. Louis, 
MO) assay was used as previously reported [22], following the manufacturer’s instructions. Specifically, macaque and baboon primary pituitary cell cultures were plated onto 48-well tissue culture plates (100, 
000 cells/well: 3 wells/treatment) in basic medium containing 10% horse serum. After 24h of incubation (37oC, 5% CO2), medium was removed, and cells were preincubated for 4h in fresh, warm (37oC) serum-free medium to induce cells synchronization. Then, cells were washed 3 times with serum-free medium and incubated 24h with serum-free medium alone (controls) or containing metformin or phenformin (5x10-3 
M). After that, cell viability was evaluated using trypan blue reagent (counting a minimum of 300 cells/
well/treatment).
Statistical analysisSamples from all groups within an experiment were processed at the same time. Results are expressed as mean ± SEM and were obtained from at least three separate, independent experiments carried out on 
different days, and with different cell preparations (3-4 replicate culture wells/treatment/experiment). To normalize values within each treatment and minimize intragroup variations in the different experiments (i.e. different age of the donor, metabolic environment, stage of the estrus cycle, etc.), the values obtained were compared with the corresponding vehicle-treated controls (set at 100%), where this style of data presentation does not alter the relative differences between the different biguanides-treated and vehicle-
treated groups. Differences between experimental groups were assessed by one-way ANOVA [or two-way 
ANOVA when the intracellular signaling pathways, with treatments with and without (controls) specific inhibitors, were studied] followed by Fisher’s test for multiple comparisons. P<0.05 was considered 
significant difference. All statistical analyses were performed using GB-STAT software package (Dynamic Microsystems, Inc., Silver Spring, MD).
Results
Direct effects of metformin and phenformin on primate pituitary hormone release.Incubation of cultured baboon and macaque pituitary cells with increasing doses of metformin (from 10-7 to 5x10-3 M) for 4h revealed significant inhibitory effects on GH, ACTH and FSH release in a concentration-dependent manner (at doses equal to or above 
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10−5 M for GH/ACTH and 5x10-3 M for FSH; Fig. 1A-B; n=3-4). Conversely, metformin failed to alter basal PRL, LH or TSH release at all the doses tested (Fig. 1A-B). Treatment with phenformin exerted the same effects than metformin on the secretion of all the pituitary hormones [Fig. 1B; macaque-model (n=3), and a single pilot experiment performed in the baboon-model (Fig. 1A)]. Based on these results, the dose of metformin and phenformin that 
caused a maximal or significant decrease of GH, ACTH and TSH release, 5x10-3 M, was chosen to further analyze the action of these agents on primate pituitary function.
Direct effects of metformin and phenformin after a short vs. long incubation period on 
primate pituitary hormone releaseIn a separate experiment, treatment with 5x10-3 M metformin and phenformin, for 
different incubation times, i.e. short- (4h) and long-term (24h), confirmed an inhibitory effect 
Fig. 1. Dose-response (4h) of metformin and phenformin (5mM, 10-5M and 10-7M) on the secretion of GH, PRL, ACTH, FSH, LH and TSH in primary pituitary cell cultures from baboons (A: metformin, n=4; phenformin, n=1) and macaques (B; n=3). Data are expressed as percent of control (set at 100%) and represent the mean 
± SEM (n=3-4 wells/experiments). Values that do not share a common letter (a, b and c) are statistically different.
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of both biguanides on GH, ACTH and FSH release [Fig. 2A-B (n=3-4); and Fig. 2A (phenformin; n=1)], but not on PRL, LH or FSH release (data not shown), mostly conserved between 4h and 24h. However, it should be noted that these inhibitory effects were apparently more pronounced after a short-term compared to a long-term incubation-period, being this 
inhibitory effect not statistically significant for baboon/macaque FSH-release (Fig. 2A-B) and macaque ACTH-release (Fig. 2B) after metformin treatment at 24h.
Direct effects of metformin on primate pituitary hormone expression.Metformin treatment (5x10-3M) clearly reduced the expression levels of GH and proopiomelanocortin (POMC, the ACTH precursor) at 24h, but not at 4h in baboon primary pituitary cells (Fig. 3). In contrast, it did not alter FSHB expression levels (Fig. 3), or those of other pituitary hormones (PRL, LHB or TSHB) at 4- or 24-h (Fig. 3).
Interaction of metformin with key regulators of GH, ACTH and FSH secretion: GHRH, 
ghrelin and GnRH in primate modelsWe next tested the direct effects of 4h of incubation with metformin alone or in combination with primary stimulatory factors of somatotrope, corticotrope or gonadotrope 
function, i.e. GHRH, ghrelin and GnRH; [22, 24, 29] (Fig. 4). This first revealed that, as 
expected, treatment with metformin alone inhibited GH, ACTH and FSH release, whereas 
GHRH, ghrelin or GnRH alone stimulated GH, ACTH and/or FSH release in primary pituitary cell cultures from baboons and macaques (Fig. 4). Interestingly, co-administration with 
Fig. 2. Time response (4h and 24h) of metformin and phenformin (5 mM) on GH, ACTH and FSH secretion in primary pituitary cell cultures from baboons (A: metformin, n=3-4; phenformin, n=1) and macaques (B; 
n=3). Data are expressed as percent of control (set at 100%) and represent the mean ± SEM (n=3-4 wells/
experiments). Asterisks (*p<0.05, **p<0.01) indicate values that significantly differ from their respective control values.
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metformin did not impact the stimulatory actions of GHRH-stimulated GH release, ghrelin-
stimulated GH or ACTH release, or GnRH-stimulated FSH release (Fig. 4).
Direct effects of metformin on primate pituitary cell viabilityTreatment with metformin and phenformin did not alter cell viability in macaque primary pituitary cell cultures (Fig. 5). Similarly, pilot results from a single experiment performed in baboon primary pituitary cell cultures also indicated that metformin and phenformin treatment did not impact cell viability (data not shown). Moreover, as an indirect measurement of the maintenance of cell number after the treatments with metformin or phenformin in baboon and macaque primary pituitary cell cultures, we analyzed and observed that the recovery of total RNA in the vehicle-treated samples and in the biguanide-treated samples across experiments were markedly constant [RNA concentrations measure 
using the Ribogreen RNA quantification kit and also a NanoDrop Lite (Thermo Fisher 
Scientific, Wilmington, DE 19810, USA)], which indirectly confirmed that the treatment with these biguanides did not affect cell viability in normal primary pituitary cell cultures (data not shown).
Intracellular signaling pathways involved in the metformin-induced reductions in GH, 
ACTH and FSH release in the baboon model
The use of pharmacological inhibitors revealed that metformin inhibits GH, ACTH and FSH release through highly similar, if not identical signaling pathways (Fig. 6A-C, respectively). 
Specifically, our results indicate that the inhibitory effect of metformin on GH, ACTH and FSH release is likely mediated through mTOR, PI3K and intracellular Ca2+ influx, because 
incubation with specific blockers of these routes, but not with extracellular Ca2+influx, AC or 
PLC inhibitors, completely blocked the inhibitory effect of metformin on GH, ACTH and FSH secretion (Fig. 6; metformin-columns). Interestingly, blockade of MAPK activity completely 
abolished the inhibitory effect of metformin on GH, but not ACTH or FSH, secretion (Fig. 6). 
Importantly, administration of these inhibitors alone did not modify basal GH, ACTH or FSH release (Fig. 6; control-columns). It should be noted that given the limited source of baboon cell preparations, we were able to study only some signaling routes, which were selected based on their importance on the functioning of multiple pituitary cell types [15]. Moreover, 
we were not able to study AMPK signaling using a similar approach since no specific and reliable pharmacological inhibitor is available to examine its function.
Fig. 3. Direct effect of metformin (5 mM) on mRNA expression of GH1, POMC, FSHB, PRL, LHB and TSHB in baboons. Data are expressed as percent of control (set at 100%) and represent the mean ± SEM (n=3 
individual experiments, n=3-4 wells/experiments). Asterisks (*p<0.05) indicate values that significantly differ from their respective control values.
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Fig. 4.  Effect of 4h treatment of GHRH, ghrelin or GnRH (10 nM) in absence or presence of metformin (5 
mM) on GH, ACTH and FSH secretion in primary pituitary cell cultures from baboons (A, C, E) and macaques (B, D, F). Data are expressed as percent of control (set at 100%) and represent the mean ± SEM (n=3-4 
individual experiments, n=3-4 wells/experiments). Values that do not share a common letter (a, b and c) are statistically different.
Fig. 5. Effect of metformin (5 mM) on cell viability (24h) of primary pituitary cell cultures from macaques assessed by trypan-blue assay. Results are expressed as percent of control (set at 100%) and represent the mean ± SEM (n=3 individual experiments, n=3-
4 wells/experiments).
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Direct effects of metformin on the expression of key receptors and a transcriptional factor 
involved in somatotrope, corticotrope and gonadotrope function.Next, we studied the direct effect of metformin (24h of incubation) on the mRNA expression of a basic transcription factor for somatotropes, the pituitary transcription factor-1 (POU1F1) (Fig. 7A), and of selected key receptors controlling pituitary physiology (Fig. 7B). Metformin caused clear increases in the expression of key receptors associated to primary regulation of somatotrope, corticoptrope and gonadotrope function, including somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5; the two main pituitary receptor 
Fig. 6. Intracellular signaling pathways of metformin-regulated baboon GH (A), ACTH (B) and FSH (C). Effect of inhibition of mTOR (rapamycin; 1 µM), PI3K (wortmannin; 1µM), MAPK (PD-98,059; 10µM), extracellular Ca2+ channels (nifepidine; 1µM), intracellular Ca2+ channels (thapsigargin; 10µM), AC (MDL-12,330A; 10µM), 
and PLC (U73122; 50µM) on metformin-stimulated hormone release in primary pituitary cell cultures from 
baboons. Values are expressed as percent of vehicle-treated control without inhibitor (set at 100% within 
each experiment) and represent the mean ± SEM (n=3-4 individual experiments, n=3-4 wells/experiments). 
Values that do not share a common letter (a, b and c) are statistically different.
Figure-6 
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Fig. 7. Direct effect of metformin (n=3; 5 mM) and phenformin (n=1; 5 mM) on mRNA expression of (A, 
C) the pituitary transcription factor-1 (POU1F1); and (B, D) key receptors involved in the functioning of 
different pituitary cell-types (SSTR1, SSTR2, SSTR5, DRD2, GHRHR, GNRHR, CRHR, GHSR, KISS1R, LEPR, 
INSR and IGF1R) in primary pituitary cell cultures from baboons. Data are expressed as percent of control 
(set at 100%) and represent the mean ± SEM (n=3-4 wells/experiments). Asterisks (*p<0.05, **p<0.01) 
indicate values that significantly differ from their respective control values.of the somatostatin system), and the receptors for leptin (LEPR), insulin (INSR) and IGF1 (IGF1R)] (Fig. 7B). Conversely, metformin did not alter the expression of POU1F1 (Fig. 7A) or those of other receptors tested (somatostatin receptor subtype 1 (SSTR1), dopamine receptor subtype-2 (DRD2), GHRH-receptor (GHRHR), corticotropin-releasing hormone-receptor (CRHR), ghrelin-receptor (GHSR) or kisspeptin-receptor (KISSR). Moreover, results from a pilot, single experiment revealed that phenformin treatment exerted comparable effects to those observed with metformin on the expression of these receptor and POU1F1 (Fig. 7C-D).
DiscussionBiguanides are synthetic drugs widely known by their antidiabetic properties, which seem to be primarily mediated by the inhibition of hepatic gluconeogenesis and the increase of glucose uptake in peripheral tissues, such as muscle or fat [2, 3]. However, biguanides 
are also being thoroughly studied due to their beneficial actions in the modulation of other critical (patho)physiological conditions such as the development of metabolic syndrome, cardiovascular disease or different types of cancer [4-10]. This pleiotropic nature of biguanides has also suggested the existence of additional sites of action (tissue targets) for these compounds. In this context, the “master endocrine gland”, i.e. the pituitary gland, could also serve as a suitable target and mediator for the actions of biguanides, owing to its emerging role as a true sensor of alterations in whole body homeostasis and metabolism, by receiving, integrating and processing the information originating from central and peripheral signals, and appropriately conveying it to various key target endocrine and non-endocrine organs (i.e. liver, fat, muscle, etc) [15]. However, the information available about the effects that biguanides exert at the pituitary level is scarce, partially contradictory and 
somewhat controversial. Specifically, most of the data available mainly derives from early studies conducted in patients with different pathological conditions [i.e. polycystic ovary syndrome (PCOS), hypothyroidism, hyperprolactinaemia, or obesity], which have shown 
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that metformin could exert inhibitory actions on LH (but not FSH) TSH, PRL or GH levels, respectively [11, 12, 17, 18, 31-34]. But, our understanding of the effects of metformin, or other biguanides, in healthy humans remains a subject of intense debate since the available 
studies are quite limited and indicate that metformin does not seem to significantly impact 
plasma GH, LH or FSH levels [11, 12]; however, a caveat should be introduced at this point, 
because, although these early data undoubtedly have great value for the scientific community, most of this information was generated from studies using metformin for prolonged periods of time. Moreover, to the best of our knowledge, the direct, in vitro, effects of metformin at the pituitary level have been only reported in two studies showing that LH or FSH secretion levels were not altered in response to different doses of metformin after 48h of incubation 
in normal rat primary pituitary cells [26], whereas GH release was significantly reduced by 
metformin in tumoral GH3 cells and in cultured human GH-producing adenomas [35].Thus, the question remains: can biguanides directly regulate pituitary function (basal and stimulated hormone release and hormone gene expression) under normal, non-pathological conditions in humans or non-human primates? To address this question, in the current study, 
we examined whether metformin and phenformin could directly impact hormone release/expression in primary pituitary cell cultures from normal baboons and macaques. These two primate species are of great interest for translational biomedical research, since they closely model human physiology, and have been frequently used to test a variety of hypotheses that cannot be directly tested in human subjects [19, 20]. Indeed, this approach provided here the 
first compelling evidence that metformin and phenformin inhibit somatotrope, corticotrope 
and gonadotrope function. Specifically, we showed that these biguanides act selectively to 
suppress basal GH, ACTH and FSH release and that this inhibitory action could be held over 
time. In fact, the maximal hormone release inhibition was already achieved (for GH, ACTH and FSH) after 4h of incubation, and although the inhibitory effect was still observed after 
long-term (24h) incubation for GH and ACTH, but not FSH, secretion, no further quantitative reduction was appreciable above the initial inhibition observed at 4h.
In addition, to our knowledge, this is the first report studying, in a cell culture system, the direct interaction between metformin with other primary regulators of somatotrope 
and corticotrope function. Specifically, we found that metformin treatment did not impact 
the stimulatory actions of GHRH-stimulated GH release, ghrelin-stimulated GH or ACTH 
release or GnRH-stimulated FSH release, which might suggest common mechanisms of action between those pituitary hormones-modulators and metformin (as will be further discussed below). It should be mentioned that this latter result is in contrast with the 
only previous report published to date indicating that GnRH-stimulated FSH and LH was reduced by metformin in rat primary pituitary cell cultures [26]. These discrepancies on 
the modulation of gonadotropes may be due, in part, to the age, sex and/or reproductive status of the donor, to the time of incubation (short vs. long periods), cell preparation and culture conditions, etc., but also, most likely, to fundamental differences in the physiology of gonadotropes from rat vs. primate species. Nevertheless, although the mechanisms and physiologic relevance behind the actions of metformin and phenformin observed in the present study remain unknown, our results are novel and demonstrate that one of the 
primary actions of these biguanides are confined to the regulation of basal, non-stimulated, 
GH, ACTH and FSH release. Moreover, these results demonstrate that these effects of both biguanides are conserved across the two primate models analyzed in this study, two species that closely model human genetics and physiology; thence, it is tempting to speculate that these biguanides may exert similar effects in anterior pituitary cells of humans, which set the stage for future investigations. In any case, our current data further extend previous observations, suggesting that the physiological actions of biguanides include a pituitary site of action as well.Additionally, our data also indicated that the primary actions of metformin in the pituitary 
of baboons were not confined to the regulation of hormonal secretions, but also included regulation of the synthesis of different hormones. No previous studies have described the direct actions of metformin in the synthesis of all the anterior pituitary hormones in humans 
or non-human primates. Specifically, our data indicated that the observed inhibitory effects of 
metformin on baboon GH and ACTH secretion would be directly associated to and reinforced by a decrease in the expression of these hormones (i.e. GH1 and POMC). Moreover, we also found that metformin did not alter PRL, FSHB, LHB and TSHB expression, which closely parallels the lack of effect observed at 24h of incubation in the release of these hormones. 
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Consequently, these data indicate that, whereas the pituitary actions of metformin extend to both hormonal synthesis and release in somatotrope and corticotropes, its effects on gonadotropes only seem to modulate secretory vesicle release, but not FSH expression. Importantly, our results indicate that the inhibitory actions of metformin and phenformin on pituitary cells cannot be attributed to an effect on cell viability or in the expression of the transcription factor Pit-1 since 24h-incubation with these biguanides did not alter cell viability or POU1F1 expression in primate primary pituitary cell cultures.
Our report also provides the first analysis of the different intracellular signaling pathways that underlie the direct effects evoked by metformin on multiple anterior pituitary hormone 
secretions (i.e. GH, ACTH and FSH release). Specifically, the use of a standard pharmacological 
(inhibitory) approach revealed that the actions of metformin on GH, ACTH and FSH secretion are mediated by mTOR, PI3K and intracellular Ca2+ mobilization, but not by AC, PLC or extracellular Ca2+ influx. Of note, we also found that the inhibitory actions of metformin on GH, but not ACTH or FSH, secretion also require MAPK. At this point, it is important to mention that AMPK has been classically considered to be a central mediator of metformin effects in 
different tissues/organs 2; however, this contention remains controversial since numerous reports have also demonstrated AMPK-independent mechanism of actions for metformin [13, 14]. Indeed, although we were not able to determine the implication of AMPK using 
this pharmacological approach due to the lack of effective, and accepted, specific inhibitors of AMPK, our data further support the notion that metformin can act through AMPK-
dependent and –independent pathways. Specifically, we found that three of the signaling pathways that are essential to mediated the actions of metformin at the pituitary (i.e. mTOR, PI3K and intracellular Ca2+ mobilization), have been previously described to be upstream or downstream of AMPK signaling pathway [36-40], which might suggests that metformin might act through these pathways in a AMPK-associated manner at the pituitary level. 
Additionally, we have also observed that metformin exerts inhibitory effects on GH secretion through pathways not linked with AMPK, such as MAPK signaling, which also demonstrate the existence of AMPK-independent mechanisms in somatotrope cells. Furthermore, the analysis of the different intracellular signaling pathways help to explain the reason why 
metformin treatment did not impact the stimulatory actions of ghrelin/GHRH /GnRH, as the actions of metformin are associated to the activation of similar and divergent signaling 
pathways to those evoked by these peptides. Specifically, ghrelin has been associated with the activation of multiple signaling cascades at the pituitary level in non-human primates, including PLC, protein kinase C (PKC), intracellular and extracellular Ca2+ and MAPK [15, 
41]; while the signaling pathways associated to GHRH and GnRH include AC/cAMP/ protein 
kinase A (PKA), NOS/guanylate cyclase (GC) and intra-/extracellular Ca2+ [15]. Therefore, 
this report reveals that metformin, ghrelin, GHRH and GnRH exert their pituitary actions through distinct, but also common (i.e. intracellular Ca2+ and MAPK pathways), signaling 
pathways, which could explain, in part, why metformin treatment might not influence the stimulatory actions of these peptides at the pituitary level.Our data indicated that the actions of metformin in the baboon pituitary also include regulation of the sensitivity of somatotropes, corticotropes and gonadotropes to some of 
their well-known regulatory factors (i.e. insulin, IGF1, leptin and somatostatin), some of which are tightly related with metabolic homeostasis [15, 29, 42-45]. In particular, metformin 
treatment provoked a significant increase in the expression of key receptors associated to 
primary inhibition of GH, ACTH and/or FSH secretion (e.g. SSTR2, SSTR5, INSR and IGF1R), which, in conjunction, might also be serving to enhance the inhibitory effects of metformin on the hormone expression and release of somatotropes, corticotropes and gonadotropes observed in these primate models.
ConclusionOverall, the results of this report unveil the existence of various regulatory layers for metformin at the secretory, gene expression and signaling levels in the somatotrope, corticotrope and gonadotrope axes; however, there is a temporal dissociation between them. 
Specifically, signaling and secretory actions are rapid (4h) and can be sustained over time (24h), whereas gene expression effects (GH1, POMC and key regulatory receptors) necessarily require longer periods to be effective [24h, but not at 4h], and might represent an additional 
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regulatory mechanism to enhance the responsiveness of these pituitary cells to metformin. 
In this sense, the increase in the expression levels of insulin and IGF-1 receptors observed after 24h of incubation with metformin might represent a critical molecular, sensory element at the pituitary level associated to the anti-hyperglycemic and pro-metabolic character 
of biguanides, wherein metformin would increase the sensitivity to insulin and IGF-1 in different endocrine tissues, including the pituitary, to induce an increment in the uptake of glucose by the cells [46-49].
At the same time, the decrease in the secretion of GH and ACTH could be also one of 
the primary, beneficial, metabolic actions exerted by metformin to improve whole body homeostasis and metabolism since clinical and experimental studies have established that 
increased circulating levels of GH and glucocorticoids (secreted in response to pituitary ACTH) can lead to worsening of insulin resistance, glucose intolerance, overt diabetes 
mellitus [50]. In fact, given that GH is an important regulator of cellular and whole-body 
metabolism as well as body composition, and that elevation of circulating GH levels causes 
hyperinsulinemia and insulin resistance [50-55], a reduction in GH levels in response to metformin might be primary mechanism associated with the improved insulin sensitivity observed in response to metformin treatment. Therefore, overall, the results generated in the present study using two non-human primate models reinforce the contention that the pituitary is a primary site for the physiological actions of metformin, and that this gland would represent an additional, key target tissue and a true endocrine sensor contributing, in 
concert with other primary tissues (i.e. liver), to the well-known beneficial metabolic effects of biguanides in humans.
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ABSTRACT 34 
Pituitary neuroendocrine tumors (PitNETs) are the most abundant of all intracranial tumors 35 
(approx. 15%) and are associated with severe comorbidities. Transsphenoidal surgery is 36 
commonly the first-line therapy, but subsequent post-operative pharmacological therapy is often 37 
necessary to control disease symptoms. Unfortunately, a substantial proportion of patients are 38 
unresponsive or become resistant to available pharmacological therapies [somatostatin-39 
analogues (SSAs)/dopamine-agonists], emphasizing the urgent need to identify new therapeutic 40 
options. Statins are well-known drugs commonly prescribed to treat 41 
hyperlipidemia/cardiovascular-diseases, but have also been related with other beneficial effects, 42 
including antitumor properties. The direct effects of statins on normal human pituitary or 43 
PitNETs are poorly know. Thus, here we aimed to explore the direct effects of statins, 44 
especially simvastatin, on key functional parameters (hormone-secretion/proliferation/cell-45 
viability/signaling-pathways, etc.) in normal and tumoral primary pituitary cell-cultures from a 46 
primate model (Papio anubis) and different human PitNET-types 47 
[corticotropinomas/somatotropinomas/non-functioning pituitary-tumors (NFPTs)], respectively, 48 
and in rodent PitNET cell-lines (AtT20/GH3-cells). Additionally, combined effects of 49 
simvastatin with metformin (MF) or SSAs on AtT20/GH3 cell proliferation were also 50 
evaluated. All statins decreased proliferation in AtT20-cells, with simvastatin showing stronger 51 
effects. Indeed, simvastatin reduced cell-viability and/or hormone-secretion in all PitNETs-52 
subtypes and cell-lines tested, and ACTH/GH/PRL/FSH/LH-secretion, but not TSH-secretion or 53 
ACTH/GH/PRL/FSH/LH/TSH-expression, in primate cell-cultures, likely through modulation 54 
of MAPK/PI3K/mTOR signaling pathways and expression of key receptors regulating 55 
corticotrope/somatotrope/lactotrope/gonadotrope function (i.e. down-regulation of GHRH-56 
R/ghrelin-R/Kiss1-R). Addition of MF or SSAs did not enhance simvastatin antitumor effects. 57 
Interestingly, analysis of a second cohort of PitNETs patients revealed that pre-surgical statins 58 
treatment tended to be associated with less extrasellar-growth (p=0.07). Altogether, our data 59 
reveal a clear direct antitumor effect of simvastatin on PitNET-cells, thus paving the way to 60 
explore these compounds as a possible tool to treat PitNETs.   61 
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INTRODUCTION 62 
Pituitary neuroendocrine tumors (PitNETs) represent approximately 15% of all brain tumors 63 
with a prevalence ranging from 1 in 865 to 1 in 2,688 people [1, 2]. Despite being often 64 
considered benign due to their extremely low metastatic capacity, PitNETs are accompanied by 65 
inadequate hormone secretion and mass effects, which cause severe comorbidities, from 66 
infertility and sexual dysfunctions, to growth abnormalities, hypogonadism, or hypopituitarism, 67 
and also increase mortality [3]. With the exception of prolactinomas, where dopamine agonists 68 
are the treatment of choice [4], transsphenoidal surgery is the first-line therapeutic option in 69 
patients harboring functioning PitNETs or non-functioning PitNETs presenting with 70 
compressive symptoms. In functioning tumors, surgical success is higher in patients with 71 
microadenomas (<10 mm), but in many cases there is an inadequate disease control, and 72 
subsequent pharmacological therapy and/or radiotherapy is necessary. To date, somatostatin 73 
analogues (SSAs) and dopamine agonists constitute the main pharmacological options to treat 74 
PitNETs patients [5]. Although these drugs have demonstrated great efficacy in reducing 75 
hormone hypersecretion and also inducing tumor shrinkage [5, 6], many studies have shown 76 
that some patients are (or become) unresponsive to these treatments [7, 8]. Accordingly, the 77 
search for new therapeutic options to enrich the pharmacological arsenal to treat PitNETs 78 
patients is urgently necessary.  79 
Statins are well-established drugs, commonly prescribed in the clinical practice to treat 80 
hyperlipidemia and in cardiovascular or coronary heart diseases [9]. However, besides their 81 
cholesterol-lowering effects, statins have been related with an ample range of pleiotropic effects 82 
including immunomodulatory effects triggering the major histocompatibility complex, 83 
improvement of endothelial function and vasculoprotective effects, alteration of bone 84 
metabolism, etc. [9, 10], which confer to statins the ability to affect numerous tissue functions 85 
acting through cholesterol-dependent and -independent mechanisms [10]. Importantly, some 86 
studies have also related the use of statins with antitumor properties in different endocrine- and 87 
non-endocrine-related tumors [11-16]. Indeed, a meta-analysis analyzing several types of cancer 88 
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revealed that the use of statins seems to be beneficial for overall survival and cancer-specific 89 
survival [17]. For these reasons, there are several phase 1 and 2 clinical trials ongoing or 90 
finished using statins in different tumor pathologies including breast, prostate or lung cancer. 91 
Actually, although certain studies have related the use of statins with a potential risk of cancer 92 
[18], in vitro studies support the former, onco-protective contention, demonstrating that statins 93 
exert direct antitumor effects, including antiproliferative effects, inhibition of migration and 94 
invasion, pro-apoptotic actions and cancer-stem cells inhibition. These antitumor effects have 95 
been described in several tumor types including, among others, breast cancer, melanoma, and 96 
colon cancer [11, 12, 19]. Moreover, statins have been also related with an increase on apoptosis 97 
and a reduction on cell proliferation in pheochromocytoma and paraganglioma cells [14, 15], 98 
and results recently reported from our group have demonstrated a clear antitumor effect of 99 
statins in two neuroendocrine tumors-cell models (BON1 and QGP1 cells) [16]. However, to 100 
the best of our knowledge, the potential antitumoral actions of statins on PitNETs have not been 101 
reported to date. Likewise, although statins are known to modulate a wide variety of metabolic 102 
processes in humans, no studies have explored hitherto how statins can modulate directly the 103 
function of the normal anterior pituitary cell types in humans or in a close, primate species 104 
model. 105 
Based on the above, this study was devised to explore the direct effects of statins, specially 106 
simvastatin, on key functional parameters (cell viability/proliferation, hormone secretion, and 107 
intracellular signaling pathways) in primary cell cultures from different human PitNET 108 
subtypes, including corticotropinomas (ACTHomas), somatotropinomas (GHomas) and non-109 
functioning pituitary tumors (NFPTs), as well as in two rodent pituitary cell line models (AtT-110 
20 and GH3). In addition, we also analyzed the ability of simvastatin to influence relevant 111 
functional parameters (hormone secretion, cell viability, and modulation of expression of key 112 
genes and intracellular signaling pathways) in primary cell cultures from normal pituitary of 113 
baboons (Papio anubis), a species that closely resemble human physiology [20, 21]. Moreover, 114 
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we aimed to assess the putative association between pre-surgical statin treatment and clinical 115 
and tumor parameters in an ample cohort of PitNET patients. 116 
  117 
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MATERIALS AND METHODS 118 
Drugs and reagents 119 
All reagents, inhibitors of intracellular signaling pathways and drugs, including all statin 120 
types, used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless 121 
otherwise specified. Octreotide was obtained from GP-Pharm (Barcelona, Spain) and 122 
pasireotide was generously provided by Novartis (Barcelona, Spain). Metformin (MF) was used 123 
at 10 mM and SSAs at 100 nM. All doses were selected based on previous studies [16, 22-24]. 124 
Patients, tumor samples and primary cell cultures 125 
This study was carried out within a project approved by our Hospital Research Ethics 126 
Committees, was conducted in accordance with ethical standards of the Helsinki Declaration of 127 
the World Medical Association, and written informed consent was obtained from each patient. 128 
Human PitNETs samples for in vitro (primary cell cultures) studies were collected during 129 
transsphenoidal surgery from 19 patients (7 ACTHomas [mean age: 46 (21-79); 86% women], 8 130 
GHomas [mean age: 49 (36-66); 63% women] and 4 NFPTs [mean age: 58 (41-71); 75% 131 
women]. Each pituitary sample subtype was evaluated by an expert anatomo-pathologist and 132 
confirmed by immunohistochemistry. Additionally a molecular confirmation screening of 133 
relevant genes using quantitative real-time PCR (qPCR) was performed, as previously described 134 
[24-27]. In all cases, samples were placed in sterile cold medium ( supplemented S-MEM, 135 
Gibco, Madrid, Spain) and dispersed into single cells following the methods and reagents 136 
previously described [24, 26]. Cells (10.000-150.000 cells/well) were plated onto 96-, 24- or 12-137 
well plates and incubated with serum-free medium alone (controls) or serum-free media 138 
containing simvastatin (1nM-10µM) using the material and reagents previously described [24, 139 
26]. 140 
Additionally, clinical data from a second cohort of PitNET patients (n=132; 42 141 
ACTHomas, 28 GHomas and 62 NFPTs) were collected to explore the putative association 142 
between treatment with statins and clinical outcomes of patients harboring different PitNETs 143 
subtypes (Table 1).  144 
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 145 
Pituitary tumor cell lines  146 
Two commonly used rodent pituitary tumor cell lines, the mouse pituitary corticotrope-147 
derived cell line AtT-20/D16v-F2 (ATCC® CRL-1795™) and the rat pituitary somatotrope-148 
derived cell line GH3 (ATCC® CCL-82.1™), were used. Both cell lines were cultured in 149 
Dulbecco’s Modified Eagle’s Medium (DMEM) complemented with 10% FBS, 100 U/ml 150 
penicillin/streptomycin, 0.024 M of HEPES, and maintained at 37ºC and 5% CO2, under sterile 151 
conditions. Both cell lines were checked for mycoplasma contamination by PCR [28].  152 
 153 
Animals, pituitary collection and primary cell cultures 154 
Primate (Olive Baboon, Papio anubis; n=4, 8-10 years of age) pituitaries were obtained 155 
from females within 15 min after sodium pentobarbital overdose as previously reported [29]. 156 
These baboons represent control animals from a breeding colony, all under Institutional Animal 157 
Care and Use Committee approved studies conducted by other University of Illinois at Chicago 158 
investigators. All experimental protocols were approved by University of Illinois at Chicago 159 
institutional committees. Right after the animals were euthanized, pituitaries were excised, 160 
placed in sterile cold (4 °C) basic media (-MEM with 0.15% BSA, 6-nM HEPES, 10-IU/mL 161 
penicillin, and 10-µg/mL streptomycin) and immediately transported to the laboratory in sterile 162 
conditions. Then, distal pituitary was isolated, washed twice in fresh media, cut into small 163 
pieces with surgical blades and dispersed into single cells, as previously reported [30]. Cells 164 
(25.000-100.000 cells/ well) were plated onto 48- or 24-well plates and incubated with serum-165 
free medium alone (controls) or serum-free media containing simvastatin (1nM-10µM) using 166 
the material and reagents previously described [22]. 167 
To avoid fibroblast contamination, suspensions of dispersed human PitNETs cells or 168 
baboon pituitary cells were filtered and cultured in media with D-Valine (replaced for L-valine) 169 
to selectively inhibit fibroblast proliferation/overgrowth. In addition, visual inspection of 170 
primary cell cultures at the time of experimental assays showed no sign of cells displaying the 171 
typical fibroblast-like morphology. 172 
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 173 
Analysis of cell proliferation/viability 174 
Cell viability of PitNETs cell cultures (10,000 cells/well in 96-well plates: 3 175 
wells/treatment) was evaluated every 24h until 72h in response to different statins using 176 
Alamar-blue reagent (Invitrogen, Madrid, Spain). Similarly, proliferation rate was evaluated in 177 
GH3 or AtT-20 cell lines (6,000 cells/well were seeded in 96-well plates) in response to 178 
simvastatin, MF, SSAs (octreotide and pasireotide) or in response to the combination of 179 
simvastatin with MF or SSAs. Treatments were daily refreshed after each measure. Reduction 180 
of Alamar-blue was quantified using a FlexStation III system (Molecular Devices, Sunnyvale, 181 
CA), as previously reported [25, 27, 31]. Moreover, in order to determine if simvastatin altered 182 
cell viability in baboon primary pituitary cell cultures (25,000 cells/well in 48-well plates: 3 183 
wells/treatment), trypan blue assay (Sigma, St. Louis, MO) was used as previously reported 184 
[22], following the manufacturer’s instructions. 185 
 186 
Measurement of hormone release  187 
Human primary PitNET cell cultures (150,000 cells/well) or baboon primary pituitary cell 188 
cultures (100,000 cells/well) were incubated with media alone (controls) or simvastatin (10M) 189 
for 24h. After this time, media were collected and hormone secretion was measured using 190 
human commercial ELISAs [ACTH, GH, PRL, FSH, LH, TSH or Chromogranin A; reference 191 
numbers: EIA-3647; EIA-1787, EIA-1291, EIA-1288, EIA-1289, EIA-1790 and EIA-4937, 192 
respectively (DRG, Mountainside, NJ)]. All the assays were performed following the 193 
manufacturer’s instructions where the information regarding specificity, detectability and 194 
reproducibility for each of the assays can be accessed at the websites of the indicated company. 195 
 196 
RNA isolation, reverse-transcription and qrtPCR of baboon transcripts 197 
Primary pituitary cell cultures from baboons were processed for recovery of total RNA, 198 
subsequent quantification of RNA amount, reverse-transcription (RT) and application of a 199 
quantitative real-time PCR using kits, primers and methods previously described [30]. Samples 200 
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were run against synthetic standards (1-106 copies) for each transcript of interest [somatostatin-201 
receptor subtype (SST1, SST2, SST3 and SST5), GH-releasing hormone receptor (GHRHR), 202 
ghrelin-receptor (GHSR), corticotropin-releasing hormone receptor (CRHR), gonadotropin-203 
releasing hormone receptor (GNRHR) and kisspeptin-receptor (KISS1R)] to estimate mRNA 204 
copy number, and a No-RT sample was used as a negative control. As previously reported [22, 205 
30, 32], to control for variations in the amount of RNA used in the RT reaction and the 206 
efficiency of the RT reaction, mRNA copy numbers of the baboon transcripts analyzed were 207 
adjusted by PPIA (cyclophilin-A; used as housekeeping gene) expression, where baboon 208 
cyclophilin-A mRNA levels did not significantly vary between experimental groups (data not 209 
shown). 210 
 211 
Measurement of signaling pathways  212 
Due to the limited number of primary PitNET cells obtained after dispersions, AtT-20 and 213 
GH3 cell lines were used to further explore the signaling pathways involved in the response to 214 
simvastatin in pituitary tumor cells. Thus, 500,000 cells/well were plated in 12-well plates and 215 
incubated 10 min, 4h and 24h with simvastatin or vehicle-treated controls. Proteins were 216 
extracted, separated by SDS-PAGE and transferred to nitrocellulose membranes (Millipore, 217 
Darmstadt, Germany), as previously reported [27]. Then, blocked membranes were incubated 218 
with different primary antibodies [phospho-ERK1/2 (Ref. CS4370), ERK1/2 (Ref. SC-154), 219 
phospho-Akt (Ref. CS9271S) and Akt (Ref. CS9272)] and the appropriate secondary antibody 220 
(anti-rabbit antibody from Cell Signaling, Danvers, MA, USA). Proteins were developed using 221 
an enhanced chemiluminescence detection system (GE Healthcare, Madrid, Spain) with dyed 222 
molecular weight markers. A densitometry analysis of the bands was carried out with ImageJ 223 
software. Relative phosphorylation was estimated from normalization of p-ERK1/2 or p-Akt 224 
against the total ERK1/2 or Akt, respectively. It should be mentioned that, as previously 225 
observed, p-Akt could not be detected in GH3 cells using this antibody. 226 
Additionally, in order to study the intracellular signaling pathways involved in the 227 
simvastatin-mediated pituitary actions in baboon cells, we used inhibitors of different 228 
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intracellular signaling pathways [mTOR (rapamycin; 10 nM) and PI3K (wortmannin; 1 μM), 229 
MAPK (PD-98,059; 10 μM), extracellular Ca2+ L-type channels (nifedipine; 1 µM) and 230 
intracellular Ca2+ channels (thapsigargin; 10 µM); 100,000 cells/well in 24-well plates: 3 231 
wells/treatment; 24h incubation] using the material, reagents and the doses of inhibitors 232 
previously described [22, 30, 32]. 233 
 234 
Statistical analysis 235 
Samples from all groups within an experiment were processed at the same time. All data 236 
are expressed as mean ± SEM. Statistical differences were assessed by paired parametric t-test 237 
or one-way ANOVA [or two way ANOVA when the intracellular signaling pathways, with 238 
treatments with and without (controls) specific inhibitors, were studied] followed by Dunnett´s 239 
test for multiple comparison (according to normality evaluated by Kolmogorov-Smirnov test). 240 
The values obtained were compared with vehicle-treated controls (set at 100%) to normalize 241 
values within each treatment and minimize intragroup variations in the in vitro experiments (i.e. 242 
different age of the tissue donor, stage of the estrus cycle and/or to the metabolic environment, 243 
etc.). All experiments were done in a minimum of three independent primary cultures from 244 
different patients, baboons or three independent passages of cell lines (3-4 replicates/treatment 245 
per experiment), unless otherwise indicated. P-values ≤0.05 were considered statistically 246 
significant. A trend for significance was indicated when P values ranged between >0.05 and 247 
<0.1. All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software; La 248 
Jolla, CA, USA) or GB-STAT software package (Dynamic Microsystems, Silver Spring, MD). 249 
  250 
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RESULTS 251 
Direct effects of statins on proliferation, cell viability and hormone secretion in PitNETs 252 
cells and cell lines 253 
Concentration-response experiments carried out with different statins (simvastatin, 254 
atorvastatin, lovastatin, or rosuvastatin) in corticotrope AtT-20 cells demonstrated statin- and 255 
dose-dependent effects on cell proliferation. Specifically, nM doses (1nM or 100nM) of 256 
different statins (simvastatin, atorvastatin, lovastatin and rosuvastatin) did not alter proliferation 257 
in AtT-20 cells at any of the incubation times tested (24-72h; Figure-1). In contrast, 10M of 258 
simvastatin, lovastatin and rosuvastatin clearly reduced cell proliferation at 24, 48, and 72h of 259 
incubation, while the same dose of atorvastatin reduced proliferation only at 72h. In general, 260 
simvastatin was the most effective statin reducing cell-proliferation at 72h (64.5% of reduction 261 
compared to 28.6%, 40%, and 40.5% for atorvastatin, lovastatin, and rosuvastatin, respectively; 262 
Figure-1). These results, coupled to the fact that simvastatin was the statin most related to 263 
antitumor properties in pre-clinical and clinical studies [11, 33-35], prompted us to select the 264 
10M dose of simvastatin for further experiments.  265 
We next tested the antitumor effects of simvastatin (10M) in primary cell cultures 266 
from different PitNETs subtypes. Remarkably, simvastatin clearly reduced cell viability at 24, 267 
48 and 72h of incubation in ACTHomas and NFPTs, and also at 72h in GHomas (Figure-2A). 268 
Similarly, simvastatin (24h) also decreased ACTH and GH secretion in ACTHomas and 269 
GHomas, although this reduction only reached statistical significance in ACTHomas (n=4 and 270 
2; 18.6 % and 20.5 % of reduction, respectively; Figure-2B). Moreover, simvastatin decreased 271 
chromogranin-A secretion by 50 % in NFPTs cell culture (Figure-2B). 272 
 273 
Direct effects of simvastatin on primate pituitary hormone expression/release and cell 274 
viability 275 
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Increasing doses of simvastatin (1 nM-10 M) for 24h in cultured baboon pituitary cells 276 
decreased the spontaneous secretion of ACTH, GH, PRL, FSH and LH, but not TSH, in a dose-277 
dependent manner (i.e. at 10 M in all cases, and also at 1M in the case of GH and PRL 278 
release; Figure-3A). Therefore, the dose of simvastatin that caused a maximal decrease of 279 
ACTH, GH, PRL, FSH and LH release, 10 M, was chosen to further analyze the action of the 280 
peptide on primate pituitary function. Interestingly, treatment with simvastatin did not alter the 281 
gene expression of any of the primate pituitary hormones [pro-opiomelanocortin (POMC, the 282 
precursor of ACTH), GH, PRL, FSH, LH or TSH; (Figure-3B)] and did not influence cell 283 
viability of cultured primate primary pituitary cells (Figure-3C). 284 
 285 
Effect of simvastatin on intracellular signaling pathways in tumor and normal pituitary 286 
cells 287 
Due to the limited number of cells obtained after cellular dispersion of PitNET tissues, 288 
we initially used AtT-20 and GH3 cells to assess the signaling pathways modulated by 289 
simvastatin pituitary tumor cells. First, we confirmed that simvastatin (10 M) significantly 290 
reduced cell proliferation at 24, 48, and 72h in corticotrope AtT-20 cells (Figure-4A, left-panel; 291 
which includes a higher number of experiments than those presented in Figure-1) and in 292 
somatotrope GH3 cells (Figure-4A, right-panel), being these effects comparable in both 293 
pituitary cell lines (Figure-4). Then, we measured selected signaling pathways closely 294 
associated with proliferation in tumor pathologies, including PitNETs [36-38]. Our results show 295 
that simvastatin significantly decreased the phosphorylation levels of ERK1/2 in AtT-20 and 296 
GH3 after short-time (4h) and long-time (24h) incubation periods, respectively. In contrast, 297 
simvastatin did not alter phosphorylation levels of Akt in AtT-20 cells (Figure 4B).  298 
As shown in table 2, simvastatin was also able to modulate the dynamics of free 299 
cytosolic calcium concentration ([Ca2+]i) in single cells derived from PitNETs. Specifically, 300 
simvastatin modestly suppressed Ca2+i levels in a small number of cells in ACTHomas (11%), 301 
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and NFPTs (9%) cells (evoking a reduction in [Ca2+]i of 25% and 20%, respectively), with no 302 
effect in GHomas. 303 
To better understand the effects observed in response to simvastatin in normal primary 304 
pituitary cell cultures from primates, we explored the underlying signaling pathways using 305 
pharmacological inhibitors (Figure-5A). However, given the limited source of baboon cell 306 
preparations, we were able to study only some key selected signaling routes. This approach 307 
revealed that blockade of PI3K and mTOR activity completely abolished the inhibitory effect of 308 
simvastatin on ACTH, GH, PRL, FSH and LH release (Figure-5A). Interestingly, our results 309 
also indicate that the inhibitory effect of simvastatin on ACTH, GH and PRL release, but not 310 
FSH and LH secretion, is also mediated through MAPK in normal primary pituitary cell 311 
cultures (Figure-5A). Finally, we could also test, in two baboon cell cultures experiments, the 312 
role played by Ca2+ signaling in simvastatin-mediated actions of pituitary hormone secretion. 313 
These results revealed that the inhibitory effects of simvastatin on ACTH, GH, PRL, FSH and 314 
LH release were not mediated through extra-/intra-cellular Ca2+ influx because incubation with 315 
specific blockers of these routes did not alter the inhibitory effect of simvastatin on the secretion 316 
of these hormones (data not shown), consistent with the minor effect of simvastatin on 317 
Ca2+signaling in PitNETs cells (Table-2).  318 
 319 
Effects of simvastatin on the expression of key receptors in corticotrope, somatotrope, 320 
lactotrope and gonadotrope function 321 
Next, we studied the direct effect of simvastatin (24h of incubation) on the mRNA 322 
expression of selected receptors controlling pituitary physiology (Figure-5B). Simvastatin 323 
significantly reduced the expression of key receptors associated to primary regulation of 324 
corticoptrope, somatotrope, lactotrope and gonadotrope function, including GHRH-receptor 325 
(GHRHR), ghrelin-receptor (GHSR) and kisspeptin-receptor (KISSR). Conversely, simvastatin 326 
did not alter the expression of the receptors of the somatostatin system, SST1, SST2, SST3 and 327 
SST5, or those for CRH (CRHR) and GnRH (GNRHR) (Figure-5B). 328 
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 329 
Combined effect of simvastatin with metformin (MF) or SSAs in pituitary cell lines. 330 
We also employed AtT-20 and GH3 cells to evaluate the potential antiproliferative effects 331 
of the combined administration of simvastatin with MF, an antidiabetic drug commonly used to 332 
treat type-2 diabetes mellitus, which we recently demonstrated to exert antitumor actions in 333 
PitNETs [38], as well as with first-generation SSAs (octreotide and pasireotide). This revealed 334 
that MF clearly reduced cell proliferation after 24, 48, and 72h of incubation in GH3 cells 335 
(Figure-6A, right-panel). Whereas, in AtT-20 cells, in spite of the numerical reduction observed, 336 
the inhibitory action of MF did not reach statistical significance (Figure-6A, left-panel). In line 337 
with this, the combination therapy of simvastatin and MF did not modify the inhibitory actions 338 
of simvastatin tested alone in AtT-20 cells (Figure-6A, right-panel). In contrast, the effect of 339 
this combination therapy was markedly higher in GH3 cells after short-term incubation (24h) 340 
compared with simvastatin or MF in monotherapy, but this effect was not observed after longer 341 
incubation periods (48 or 72h; Figure-6A, left-panel). Furthermore, the combination of 342 
simvastatin with octreotide or pasireotide did not significantly impact the reduction elicited by 343 
simvastatin in AtT-20 and GH3 cells (figure-6B). 344 
 345 
Clinical relevance of treatment with statins in patients with PitNETs. 346 
To assess the clinical context of the potential interplay between statins treatment and 347 
PitNETs, we explored the putative association between pre-surgery treatment with statins and 348 
clinical outcomes of patients harboring different types of PitNETs. Clinical characteristics were 349 
compared between patients with PitNETs treated or not with statins (Table 1). These 350 
comparisons revealed that patients with NFPTs and treated with statins (n=12) showed a trend 351 
to have less extrasellar growth compared with patients not treated (n=36, p=0.07). Conversely, 352 
none of the other clinical parameters evaluated (i.e. BMI, lesion type, tumor size, symptoms 353 
including cephalea or visual alterations, use of other treatments, disease persistence after 354 
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surgery, etc.) revealed significant associations with statins treatment in this pilot, exploratory 355 
patient cohort. 356 
357 
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DISCUSSION 358 
Evidence gathered over the last years has prompted an emerging interest in exploring the 359 
putative role of statins in the development and progression of different endocrine- and non-360 
endocrine-related tumors [11-16], particularly in view of recent meta-analysis analyzing several 361 
types of cancer, which revealed that the use of statins improve overall survival and cancer-362 
specific survival [17]. However, to date, the possible antitumoral actions of these compounds on 363 
PitNETs, as well as the direct effects of statins in normal pituitary cells, had not been reported. 364 
In this study, we demonstrate for the first time that statins, especially simvastatin, exerts 365 
relevant antitumor actions (i.e. reduction in cell viability/proliferation and hormone secretion) in 366 
cell cultures from different human PitNET types (ACTHomas, GHomas and NFPTs) and 367 
representative pituitary cell lines (ACTH- and GH-producing cells) mainly through the 368 
modulation of MAPK (i.e. ERK1/2) pathway. Moreover, we found that simvastatin also 369 
decreases pituitary hormone secretion, but not gene expression, or cell viability, in primary 370 
normal pituitary cell cultures from baboons through the modulation of PI3K, mTOR and 371 
MAPK. Therefore, these results suggest that the medical use of simvastatin could be beneficial 372 
to improve key clinical/pathological aggressiveness parameters in patients with PitNETs, in that 373 
this drug might reduce cell viability/proliferation of ACTHomas, GHomas and NFPTs, but not 374 
normal pituitary cells, as well as decrease hormone secretion in normal and tumor pituitary 375 
cells. 376 
Our first set of studies revealed that different statins, specially simvastatin, can reduce cell 377 
proliferation in AtT-20 and GH3 cell lines, as well as cell viability in human PitNET cells, 378 
while they did not alter survival of normal pituitary cells from primates. In line with this, an 379 
antiproliferative capacity of statins has been described in different tumor pathologies, including 380 
neuroendocrine tumor cells [14, 16, 34, 35]. In our study, all statins tested were able to 381 
significantly decrease proliferation in AtT20 cells, with simvastatin showing slightly stronger 382 
effects. These results are in agreement with the reduction of cell proliferation previously 383 
observed in murine pheochromocytoma cell lines [14], and with a recent study from our group 384 
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in human pancreatic NET cell lines [16], wherein simvastatin was the most efficient statin in 385 
decreasing this parameter. Interestingly, compared with GHomas, the effects of simvastatin 386 
were more evident in ACTHomas and NFPTs, which are the most resistant tumor types to the 387 
currently available therapeutic options [24, 39]. Thus, our results unveil a previously unknown 388 
antitumoral potential of statins, particularly simvastatin, in PitNETs. 389 
Furthermore, exploration of the effect of simvastatin on hormone secretion in different 390 
PitNETs subtypes and in normal pituitary cells demonstrated that simvastatin can reduce 391 
ACTH, GH and chromogranin-A secretion in ACTHomas, GHomas and NFPTs, respectively, 392 
as well as ACTH, GH, PRL, FSH and LH secretion in normal pituitary cells from primates. 393 
These results are also of potential clinical relevance, in that hypersecretion of pituitary 394 
hormones causes serious comorbidities in patients with PitNETs [3]. Hence, a reduction of 395 
hormone secretion from tumor cells in response to simvastatin would be clearly beneficial for 396 
patients harboring these pathologies. On the other hand, the nearly general inhibitory action of 397 
statins on pituitary hormone secretion from normal primary cells from a primate species closely 398 
resembling human physiology is intriguing, and it unveils an unpredicted potential endocrine 399 
action of long-term statin use in patients in vivo that certainly deserves further examination in 400 
the future.  401 
Mechanistic assays provided further insights into the signaling pathways underlying the 402 
effects of simvastatin in normal pituitary and PitNET cells. Specifically, functional assays 403 
showed that the inhibitory action of simvastatin in ACTHoma and NFPT cells may not be 404 
mainly mediated through Ca2+i signaling, in that only ~10% of the cells displayed changes in 405 
their [Ca2+]i in response to simvastatin, and also, that this pathway would not be involved in the 406 
actions of simvastatin in GHomas. On the contrary, our results strongly indicate that the 407 
antitumoral actions of simvastatin in ACTHomas and GHomas are mediated through the 408 
modulation of the MAPK signaling pathway, according to the reduction on the phosphorylation 409 
levels of ERK1/2 observed in AtT-20 and GH3 cells in response to simvastatin. The relevance 410 
of this signaling pathway on simvastatin-mediated effects in PitNET cells compares nicely with 411 
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previous studies in different tumor pathologies, where the MAPK pathway is also essential for 412 
the actions of statins [11, 14, 16]. Interestingly, a decrease in the phosphorylation levels of this 413 
pathway has been commonly associated to a reduction of cell proliferation in different PitNET 414 
subtypes [37].  415 
In the same line, the present report also provides the first analysis of the different 416 
intracellular signaling pathways that underlie the direct inhibitory effects evoked by simvastatin 417 
on the secretion of multiple anterior pituitary hormones from a primate model (i.e. ACTH, GH, 418 
PRL, FSH and LH). Specifically, the use of a standard pharmacological (inhibitory) approach 419 
revealed that the actions of simvastatin on ACTH, GH, PRL, FSH and LH secretion are 420 
mediated by mTOR and PI3K, but do not appear to involve intracellular Ca2+ mobilization or 421 
extracellular Ca2+ influx. Interestingly, we also found that the inhibitory actions of simvastatin 422 
on ACTH, GH or PRL secretion also require MAPK, which is in accordance with the results 423 
previously observed with the modulation of ERK1/2 in ACTHoma and GHomas cells. In 424 
addition, our data revealed that simvastatin actions in primate pituitary would also include 425 
regulation of the sensitivity of pituitary cells to some of their well-known regulatory factors (i.e. 426 
GHRH, ghrelin and kisspeptin). Thus, simvastatin treatment evoked a significant 427 
downregulation in the expression of key receptors associated to the stimulation of ACTH, GH, 428 
PRL, FSH and LH secretion (e.g. GHRHR, GHSR and KISS1R) [29, 30, 40, 41], which, in 429 
conjunction, might also be serving to enhance the inhibitory effects of simvastatin on hormone 430 
release from corticotropes, somatotropes, lactotropes and gonadotropes observed herein. 431 
Finally, taking into account that: 1) our group has recently reported the antitumor actions of 432 
MF in cells from NETs and different PitNETs subtypes [38]; 2) there are numerous ongoing or 433 
finished clinical trials with simvastatin as monotherapy or in combination with other agents 434 
[42]; and, 3) simvastatin and MF are commonly used in clinical practice, and both drugs have 435 
demonstrated antitumor properties, we sought to ascertain the potential antitumor effects of the 436 
combination therapy of simvastatin and MF in PitNET cell lines. Our results revealed that, in 437 
general, the addition of MF did not modify the effects of simvastatin in different pituitary tumor 438 
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cells (with the exception of an additive effect at 24h in GH3 cells that disappeared at 48-72h). 439 
Along the same lines, SSAs are also frequently used alone or in combination with other 440 
pharmacological options (dopamine agonists or pegvisomant) to control PitNETs symptoms 441 
[43, 44]. In our study, the combination of simvastatin and SSAs did not result in any additive 442 
effect in AtT-20 or GH3 cells. All these evidences might suggest that simvastatin, MF, and 443 
SSAs are sharing mechanisms of action in pituitary tumor cells. Indeed, several reports have 444 
linked the statins with the activation of AMP-activated protein kinase (AMPK; considered the 445 
central mediator of MF actions) in numerous cancer types [45-47]. Likewise, the antitumor 446 
effects of simvastatin observed in this and other studies have been associated to the 447 
dysregulation of several signaling pathways including Ras-MAPK, PI3K-Akt, and 448 
AMPK/Akt/mTOR pathways, all of them also involved in the effects of SSAs and MF [22, 37, 449 
38, 48].  450 
Finally, a pilot, exploratory analysis of the potential clinical context of statins use in PitNET 451 
patients did not reveal major associations between use of statins and clinical variables in our 452 
cohort of patients, except for a non-significant trend to lower extrasellar growth in NFPTs. 453 
However, the limited number of patients treated with statins and the retrospective observational 454 
nature of the analysis likely limit these results, and this issue certainly warrants further 455 
investigation. 456 
In conclusion, our study provides primary evidence that statins, especially simvastatin, exert 457 
effective antiproliferative and antisecretory effects in different PitNET subtypes, without 458 
altering the viability of normal pituitary cells. Furthermore, we present mechanistic insights into 459 
the plausible signaling pathways underlying the inhibitory actions of simvastatin on cell 460 
survival and hormone release, which may partially overlap with those employed by MF or 461 
SSAs, as their combination with simvastatin did not elicit relevant additional antitumor effects. 462 
Therefore, our data unveil clear antitumoral direct effects of simvastatin on PitNET cells, 463 
thereby opening the possibility to explore these compounds as a novel tool to enrich the limited 464 
pharmacological arsenal available to treat patients harboring PitNETs.  465 
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FIGURE CAPTIONS. 601 
Figure 1: Dose-response experiment of cell proliferation in response to different statins 602 
(simvastatin, atorvastatin, lovastatin and rosuvastatin) at 1 nM, 100 nM and 10 M in AtT20 603 
cells (n=4), measured by Alamar-blue reduction. Data are expressed as percent of vehicle-604 
treated controls (set at 100%) within experiment. Values represent the mean ± SEM. Asterisks 605 
(* p<0.05; ** p<0.01) indicate statistically significant differences. 606 
Figure 2: Functional assays in response to simvastatin in PitNETs primary cell cultures. (A) 607 
Effect of simvastatin (10 M) on cell viability (24-72h) in primary ACTHomas (n=5), GHomas 608 
(n=6), and NFPTs (n=4), measured by Alamar-blue reduction. (B) Effect of simvastatin (24h 609 
treatment) on ACTH, GH, and chromogranin A secretion in ACTHomas (n=5), GHomas (n=2) 610 
and NFPTs (n=1), respectively, determined by commercial ELISA kit. Data are expressed as 611 
percent of vehicle-treated controls (set at 100%) within experiment. Values represent the mean 612 
± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 613 
differences. In cases where less than three experiments were performed, no significance tests 614 
were performed.  615 
Figure 3: Functional assays in response to simvastatin in normal pituitary cells. (A) Dose-616 
response (24h) of simvastatin on the secretion of ACTH, GH, PRL, FSH, LH and TSH in 617 
primary pituitary cell cultures from baboons (n=4). (B) Effect of simvastatin (10 M) on mRNA 618 
expression of POMC, GH, PRL, FSH, LH and TSH (n=3). (C) Effect of simvastatin (10 M) on 619 
cell viability (24h) of primary pituitary cell cultures from baboons assessed by trypan-blue 620 
assay (n=4). Data are expressed as percent of control (set at 100%) and represent the mean ± 621 
SEM. Values that do not share a common letter (a, b and c) are statistically different. 622 
Figure 4: Measurement of cell proliferation and signaling pathways in pituitary cell lines. (A) 623 
Effect of simvastatin (10 M) on cell proliferation (24-72h) in corticotropinoma AtT-20 (n=6) 624 
and somatotropinoma GH3 (n=8) cell lines, measured by Alamar-blue reduction. (B) 625 
Representative Western Blots and quantification of levels of pERK1/2/ total ERK1/2 and p-Akt/ 626 
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total Akt in response to simvastatin in AtT-20 and GH3 cells (10 M; n=3). Data are expressed 627 
as percent of vehicle-treated controls (set at 100%) within experiment. Values represent the 628 
mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 629 
differences. 630 
Figure 5: Direct effect of simvastatin (10 M) on intracellular signaling pathways and mRNA 631 
expression levels of key genes. (A) Effect of inhibition of mTOR (rapamycin; 1 μM), PI3K 632 
(wortmannin; 1μM) and MAPK (PD-98,059; 10μM) on simvastatin-stimulated hormone release 633 
in primary pituitary cell cultures from baboons (n=3). (B) Effect of simvastatin on mRNA 634 
expression of key receptors involved in the functioning of different pituitary cell types in 635 
primary pituitary cell cultures from baboons (n=3). Values are expressed as percent of vehicle-636 
treated control without inhibitor (set at 100% within each experiment) and represent the mean ± 637 
SEM. Values that do not share a common letter (a, b and c) are statistically different. Asterisks 638 
(*p<0.05, **p<0.01) indicate values that significantly differ from their respective control 639 
values. 640 
Figure 6: Measurement of cell proliferation/viability (24-72 h) in response to simvastatin alone 641 
or in combination with metformin (10 mM) or SSAs (octreotide and pasireotide; 100 nM) in 642 
pituitary cell lines, measured by Alamar-blue reduction. (A) Effect of simvastatin alone or in 643 
combination with metformin in AtT-20 (n=8) and GH3 (n= 4) cells. (B) Effect of simvastatin 644 
alone or in combination with SSAs in AtT-20 and GH3 (n=4) cells. Data are expressed as 645 
percent of vehicle-treated controls (set at 100%) within experiment. Values represent the mean 646 
± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 647 
differences. 648 
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Table 2: Results from free cytosolic calcium dynamic assays in PitNET cells in response to 
simvastatin. 
 
Tumor type # samples Cells analyzed % PRC % PRM ± SEM Time (s) ± SEM 
ACTHomas 3/4 147 11 % 25 ± 2.9 16 ± 3.2 
GHomas 0/5 155 0 % - - 
NFPTs 2/3 93 9 % 20 ± 0.34 6.25 ± 0.89 
# samples: number of responsive samples of the total of samples analyzed. 
Cells analyzed: total of individual cells analyzed. 
% PRC: percentage of responsive cells in responsive samples. 
% PRM: percentage of maximum calcium reduction in response to simvastatin 
Time: time of response to simvastatin administration. 
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ABSTRACT  32 
Somatostatin-analogs (SSAs) are efficacious and safe treatments for a variety of neuroendocrine 33 
tumors, especially pituitary neuroendocrine tumors (PitNETs). Their therapeutic effects are mainly mediated by 34 
somatostatin receptors SST2 and SST5. Most peptidic SSAs, such as Octreotide/Lanreotide/Pasireotide, are 35 
either nonselective or activate mainly SST2. However, non-functioning pituitary tumors (NFPTs), the most 36 
common PitNET type, mainly express SST3 and finding peptides that activate this particular somatostatin 37 
receptor has been very challenging. Therefore, the main objective of this study was to identify SST3-agonists 38 
and characterize their effects on experimental NFPT models. Binding to SSTs and cAMP level determinations 39 
were used to screen a peptide library and identify SST3-agonists. Key functional parameters (cell viability, 40 
caspase activity, chromogranin A secretion, mRNA expression and intracellular signaling pathways) were 41 
assessed on NFPT primary cell cultures in response to SST3-agonists. Tumor growth was assessed in a 42 
preclinical PitNET mouse model treated with a SST3-agonist. Thus, we successfully identified the first SST3-43 
agonist peptides. SST3-agonists lowered cell viability and chromogranin A secretion, increased apoptosis in 44 
vitro, and reduced tumor growth in a preclinical PitNET model. As expected, inhibition of cell viability in 45 
response to SST3-agonists defined two NFPTs populations: responsive and unresponsive, wherein responsive 46 
NFPTs expressed more SST3 than unresponsive NFPTs and exhibited a profound reduction of MAPK, PI3K-47 
AKT/mTOR and JAK/STAT signaling-pathways upon SST3-agonist treatments. Concurrently, SSTR3-silencing 48 
increased cell viability in a subset of NFPTs. In conclusion, this study demonstrates that SST3-agonists activate 49 
signaling mechanisms that reduce NFPT cell viability and inhibit pituitary tumor growth in experimental models 50 
that expresses SST3, suggesting that targeting this receptor could be an efficacious treatment for NFPTs. 51 
 52 
KEYWORDS: SST3 / non-functioning pituitary tumors / agonists / antagonist / primary cultures. 53 
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INTRODUCTION 61 
Somatostatin receptors (SST1-5) comprise a family of seven transmembrane G-protein coupled 62 
receptors able to bind and be activated by somatostatin [41,3]. SSTs activation has been widely associated to 63 
multiple effects, most of them inhibitory actions on hormone secretion and cellular processes such as 64 
proliferation in normal and tumor tissues [41]. Thus, SSTs are considered as an attractive therapeutic target to 65 
treat different tumor pathologies [41,43]. Clinically available somatostatin-analogs 66 
(Octreotide/Lanreotide/Pasireotide) are used to treat neuroendocrine tumors (NETs), including pituitary 67 
neuroendocrine tumors (PitNETs), where they reduce/normalize hormonal levels, shrink tumors, and improve 68 
clinical symptoms [41,31]. Most of their therapeutic actions are assumed to be mediated through SST2 and SST5 69 
activation [41]. Although SSAs are able to bind other SSTs, such as SST3, this binding capacity is significantly 70 
lower in comparison to SST2/SST5 [41]. Remarkably, some NETs types express SST3 at higher or similar levels 71 
than SST2 or SST5. This is the case for some gastroenteropancreatic NETs [15], pheochromocytomas [9] and 72 
specially non-functioning pituitary tumors (NFPTs), which represent a heterogeneous group of tumors that 73 
constitute 30% of all PitNETs [19,16,25,2].  74 
Most NFPTs are silent gonadotropinomas characterized by lack of hormone hypersecretion, which 75 
usually determines a delay in diagnosis [2] and, therefore, are mostly detected as macroadenomas with 76 
consequently associated severe comorbidities related to mass effect (i.e. headaches/visual 77 
defects/hypopituitarism) [12,11]. Transsphenoidal surgery is the first-line therapy and the only current curative 78 
approach of NFPTs; however, is often not definitive due to the invasion of surrounding structures 79 
(sphenoidal/cavernous sinuses) and tumor relapses are frequent even when resection seems total (20-30% of 80 
relapses at 10 years after the first surgery) [32,6]. Radiotherapy has been largely used to prevent tumor relapses 81 
but long-term side effects have been reported [20,34]. To date, the pharmacological treatment options for 82 
NFPTs are insufficient. Unfortunately, drugs currently available for functional PitNETs, such as dopamine 83 
agonists (DAs) or SSAs, have shown poor efficacy in NFPTs [22,34]. Moreover, in vitro treatment of NFPT 84 
primary cell cultures with octreotide may not decrease cell viability [19], which could be explained by the low 85 
SST2/SST5 expression levels [16,25], as mentioned above.  86 
In this scenario, the importance of SST3 relies on the fact that SST3 has been associated with 87 
apoptotic/antiproliferative actions in various studies using cell lines [41,45,40]. Indeed, the apoptotic actions of 88 
somatostatin/SSAs have been historically related to SST3 [41,45,40]. Naturally, pasireotide has been suggested 89 
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as a potential therapeutic option due to its ability to bind to SST3 with higher affinity than octreotide/lanreotide 90 
[41,25]. However, recent results from our group demonstrate that it does not have a clear inhibitory effect on 91 
NFPT primary cultures, being even less potent than octreotide [19], thus reinforcing the notion that 92 
identification and validation of novel therapeutic approaches is necessary to manage NFPTs. Hence, based on all 93 
this information, we hypothesized that a compound that preferentially binds to SST3 might be an effective 94 
therapeutic option to treat NFPTs. However, it has been very challenging to find peptides that selectively 95 
activate SST3, and its functional role and pathophysiological relevance in NFPTs still need further 96 
demonstration. Therefore, the aims of this study were to: 1) identify specific SST3-agonists through the 97 
screening of a peptide library; and 2) determine the in vitro/in vivo therapeutic potential of SST3 by studying: 98 
2A) the direct effect of the identified SST3-specific agonists/antagonists on key functional parameters for 99 
NFPTs (i.e. cell viability/caspase activity/chromogranin A secretion/signaling pathways/mRNA expression) and 100 
the functional consequences of SSTR3 silencing on cell viability; and, 2B) the effect of a selected SST3-specific 101 
agonist on tumor growth in a preclinical mouse model of PitNETs. 102 
 103 
MATERIALS AND METHODS 104 
Reagents 105 
All reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless 106 
otherwise specified. Subtype selective SST3 agonists (L-796,778/BIM-355/BIM-071) and antagonists (BIM-107 
839/BIM-152, previously known as BN81658), were generously provided by Merck & Co., Inc. (L-796,778; 108 
Whitehouse Station, NJ, USA) or IPSEN Bioscience, Inc. (BIM-compounds; Cambridge, MA, USA). 109 
Specificity of the MERCK human-agonist was previously reported [36]. Detailed information of the affinity 110 
profile [expressed as Ki (nM)] and structure of the human SST3 agonists/antagonists is described in 111 
Supplementary Table-S1 and Fig-1. 112 
Library screening 113 
The identification of compounds that act as selective SST3-agonists was based on the examination of 114 
IPSEN’s extensive collection of synthetic peptides: see supplemental information for details. 115 
Radioligand binding assays 116 
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The affinities of the compounds of interest for the different human and mouse SSTs were determined 117 
by radioligand binding assays in HEK293 cells (ATCC) stably transfected with each receptor. Single clones 118 
were selected based on their mRNA expression measured by qPCR, further selected by their membrane 119 
expression of each SST, and by their response to lanreotide in cAMP assays. Membranes were isolated from 120 
these cells, mixed with trace concentrations of each specific radioligand and a range of concentrations of the 121 
compounds of interest, and then incubated at room temperature for 30-60 minutes. Unbound radioligands were 122 
removed by filtration through GF/C filters and membrane-bound radioactivity was measured using a gamma 123 
counter. Nonspecific binding was defined in the presence of 1 µM lanreotide. The inhibition constants (Ki) were 124 
calculated from the following equation: Ki = IC50/(1+L/Kd) where L is the radioligand concentration and Kd the 125 
equilibrium dissociation constant of the radioligand for each receptor subtype. Radioligands were: [125I-Tyr11]-126 
lanreotide for SST3, [125I-Tyr]-seglitide for SST2 and [125I-Tyr]-BIM-23015 for SST5.  127 
Cyclic AMP accumulation assay 128 
The functional agonist activities of the compounds of interest in inhibiting intracellular cAMP 129 
production (stimulated by forskolin) were determined in the same cell lines used for radioligand binding cells 130 
(HEK293 cells stably expressing different human and mouse SSTs). Cells were plated in 384-well plates and 131 
cultured for 16-24 hours at 37C. Compounds of interest at a range of concentrations were incubated with the 132 
cells in the presence of forskolin for 30 minutes. Cell homogenates were incubated with fluorescence-labelled 133 
cAMP and anti-cAMP antibodies for 1 hour, using the cAMP Dynamic 2 kit (Cisbio Bioassays), before reading 134 
the homogeneous time resolved fluorescence. 135 
Patients, samples and primary cell cultures 136 
Three different types of pituitary samples have been included in the present study: Cohort 1) Fresh 137 
samples from 80 NFPTs (mean age: 57 [18-80] years; 42% women) and 80 functioning PitNETs [63 GHomas 138 
(mean age: 43 [12-73] years; 48% women) and 17 ACTHomas (mean age: 38 [20-67] years; 94% women)] 139 
obtained during transsphenoidal surgery in different hospitals from Spain [formalin–fixed paraffin-embedded 140 
(FFPE) pieces were also available for n=29 NFPT samples]; Cohort 2) 35 FFPE NFPTs [n=25 tumors from 141 
France (Hospices Civils de Lyon, Lyon) and n=10 from Spain (Hospital Universitario Virgen del Rocío, 142 
Seville)] (mean age: 63 [25-82] years; 46% women); and Cohort 3) 12 normal pituitary (NP) samples (mean 143 
age: 61 [44-85; 50% women] obtained during autopsies. All techniques carried out in this study were conducted 144 
in accordance with the ethical standards of the Helsinki Declaration, of the World Medical Association and with 145 
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the approval of the University of Cordoba/IMIBIC and Ethics Committees from all the Hospitals involved in the 146 
study. Informed consent from each patient or relative, in case of autopsy, was obtained. See supplemental 147 
information for details. 148 
RNA isolation, reverse transcription and analysis of gene expression levels by qPCR 149 
Information about RNA extraction, quantification, reverse-transcription (RT) and qPCR using specific 150 
primers included in this study has been previously reported elsewhere by our group [18,1]. See supplemental 151 
information for more details. 152 
Immunohistochemical analysis (IHC) for SST3 in NFPTs 153 
IHC staining for SST3 was performed using an automated immunostainer (Benchmark XT, Ventana 154 
Medical Systems, Tucson, AZ) to corroborate the presence of SST3 in a set of 35 FFPE NFPTs [Cohort 2: n=25 155 
tumors from France (Hospices Civils de Lyon, Lyon) and n=10 from Spain (Hospital Universitario Virgen del 156 
Rocío, Seville)] and to evaluate the presence of SST3 in SST3-agonist responsive (n=17) and unresponsive 157 
(n=12) NFPTs (Available FFPE samples from Cohort 1). See supplemental information for details. 158 
Measurement of cell viability in primary pituitary tumor cell cultures 159 
Viability of primary pituitary tumor cells was evaluated every 24h (10,000 cells/well in 96-well plates) 160 
in response to SST3-agonists and antagonists (treatments were daily refreshed after each measure) using 161 
Alamar-blue reagent (Invitrogen, Madrid, Spain) and a FlexStation III system (Molecular Devices, Sunnyvale, 162 
CA), as previously reported [18].  163 
Measurement of caspase activity of primary pituitary tumor cell cultures 164 
As a surrogate marker of apoptosis induction capacity, we measured caspase 3/7 activity in response to 165 
different SST3-agonists and BIM-839 antagonist using the Caspase-Glo 3/7 assay (Promega, Madrid, Spain) 166 
according to manufacturer´s instructions. See supplemental information for details.  167 
Measurement of chromogranin A release in primary pituitary tumor cell cultures 168 
To evaluate the effects of SST3-agonists on chromogranin-A (CgA) release, 150,000-200,000 cells/well 169 
were used. Media were recollected after 24h of treatment and CgA concentration was evaluated using a 170 
commercial ELISA (EIA-4937; DRG, Mountainside, NJ, USA).  171 
Measurement of free cytosolic calcium concentration ([Ca2+]i) kinetics 172 
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To assess the effects of different SST3-agonists on free cytosolic calcium kinetics, 50,000 173 
cells/coverslip were plated and changes in [Ca2+]i in single cells were measured using fura-2AM (Molecular 174 
Probes, Eugene, OR), as described previously [29,18].  175 
Analysis of signaling pathways by human phospho-kinase array. 176 
To test the signaling pathways altered in responsive and unresponsive NFPTs treated with a selected 177 
SST3-agonist, 500,000 cells/well were cultured in 12-well plates and incubated for 8 minutes with vehicle and 178 
BIM-355. See supplemental information for details. 179 
Preclinical mouse model 180 
A preclinical mouse model of non-secreting PitNET (the POMC-knockout generated through 181 
homologous gene targeting in embryonic stem cells) was used as previously reported [21,47]. Four-weeks after 182 
birth, mice were treated with vehicle or a selected SST3-agonist by subcutaneous implantation of 7-day mini-183 
pumps (ALZET) for eight weeks. Three groups were established: vehicle (n=16), low BIM-355 dose (2.2 184 
mg/kg/day; n=8) and high BIM-355 dose (7.4 mg/kg/day; n=6). Tumor volume was measured weekly by MRI-185 
imaging. After euthanasia, pituitary glands were carefully removed, fixed and embedded in paraffin. IHC for 186 
SST3 and Ki67 were performed in the mouse pituitary samples. All experimental procedures were carried out 187 
following the European Regulations for Animal Care, in accordance with guidelines and regulations, and under 188 
the approval of the University/Regional's Government Research Ethics Committees. 189 
 190 
Silencing of SSTR3 gene with specific siRNAs 191 
To perform silencing experiments, 500,000 cells/well were plated and transfected with two specific 192 
SSTR3 siRNAs at 100nM (s13501 and s224690 Silencer Select Pre-designed siRNAs; Ambion, Wilmington, 193 
NC) and a commercial negative control (Scramble: Silencer Select Negative Control 1 siRNA; Ambion) using 194 
Lipofectamine RNAiMAX (Life Technologies). See supplemental information for details. 195 
Statistical analysis and receiver operating characteristic (ROC) curves 196 
All data are expressed as mean ± SEM. Statistical differences between the expression levels of NFPT 197 
and NPs were assessed by unpaired nonparametric Mann-Whitney tests (according to normality evaluated by 198 
Kolmogorov-Smirnov test). Differences between SSTs mRNA levels within NFPTs or, comparison of SST3 199 
levels between NFPT, functioning PitNETs and NPs were assessed by Kruskal-Wallis test followed by Dunn’s 200 
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test for multiple comparisons. As previously reported [29], to normalize values within each treatment and 201 
minimize intragroup variations in the different in vitro experiments (i.e. different age of the tissue donor or 202 
metabolic environment), the values obtained were compared with vehicle-treated controls (set at 100%). All 203 
experiments were performed in a minimum of three independent primary pituitary cultures from different 204 
patients (3-4 replicates/treatment per experiment), unless otherwise indicated. p<0.05 was considered 205 
significant. Regarding the preclinical model, a generalized linear mixed model to account for repeated measures 206 
was used to evaluate tumor volume across time (baseline to week 8) adjusted by baseline tumor volume, time, 207 
treatment group, interaction between time and treatment group, and interaction between baseline tumor volume 208 
and time. The log-normal distribution analysed by SAS 9.4 was found to be the best fit. The results were 209 
expressed as geometric least square (LS) means for tumor volume across time from baseline to week 8 for the 210 
different treatment groups. In addition, geometric LS adjusted for baseline tumor volume was analysed for each 211 
treatment group by time and was adjusted by Tukey-Kram. 212 
As previously reported [33,30], ROC-curves were used as a tool to measure how well the expression of 213 
SST3 could discriminate between different diagnostic groups. Statistical analysis of ROC curves was performed 214 
by calculating the Area Under the Curve (AUC) of each receptor and comparing them with the AUC of the 215 
reference line using Student’s t-test. All statistical analyses were performed using GraphPad Prism 6 (GraphPad 216 
Software; La Jolla, CA, USA). 217 
For more details of methods see Supplementary information. 218 
 219 
RESULTS 220 
Identification of SST3 peptide agonists 221 
We screened a library of synthetic peptides produced at IPSEN, first selecting for compounds that bind 222 
to SST3 and then applying a multidimensional Spotfire analysis designed to identify compounds with the 223 
highest selectivity for SST3 versus SST2 and SST5. This tool was customized to display the selectivity of every 224 
compound for each of the three SSTs tested along three different axes. The SST3 selective compounds showed a 225 
clearly different localization in this three-dimensional space clustering together on the SST3 axis. The peptides 226 
obtained in the Sporfire analysis (i.e. BIM-23A185), while being active in receptor assays, were only hit 227 
compounds and did not have optimal drug-like properties. For example, their solubility and stability were 228 
suboptimal in standard quality control measurements. For this reason, small structural changes were introduced 229 
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into the structure of BIM-23A185 to obtain derivates with more drug-like characteristics. These changes yielded 230 
several peptides (i.e. BIM-355, BIM-071, BIM-839 among others) that preserved the general similarity with 231 
BIM-23A185 and had improved solubility, stability, reproducible binding, and pharmacological activity. Several 232 
batches of these compounds were synthesized independently and tested to confirm their structures and activities. 233 
High-throughput synthesis of these peptides allowed the characterization of their binding, selectivity, and 234 
functional activity on different SSTs (Table-S1), being BIM-23A185 discarded for further analyses due to the 235 
low level of robustness of the results generated (data not shown). The most potent peptides (BIM-355, BIM-071, 236 
BIM-839) bind to SST3 with affinities in the low nanomolar range while the binding to SST2 and SST5 is orders 237 
of magnitude weaker than Octreotide/Lanreotide/Pasireotide [3]. Functional cAMP assays confirmed that the 238 
newly identified peptides (BIM-355, BIM-071) activate SST3, while BIM-839 showed SST3-antagonist activity. 239 
Based on these results, we selected BIM-355, BIM-071, and BIM-839 as the most selective and potent 240 
compounds for further characterization. Binding-assays using human/rat/mouse SST3 showed that BIM-071 241 
does not activate rodent receptors. Based on all these results we selected these peptides to perform experiments 242 
in human NFPT primary cultures and in vivo in mice with PitNETs. 243 
SST3-agonists modulate key functional parameters in NFPT primary cell cultures 244 
SST3 was the highest expressed receptor in our cohort of NFPTs followed by SST2, SST1, SST5 and the 245 
two SST5 splicing-variants (SST5TMD4/SST5TMD5) (Fig-S1A-C). We also found a clear differential SST3 246 
expression pattern between functioning PitNETs (GHomas/ACTHomas) and NFPTs, being this expression 247 
significantly lower in GHomas/ACTHomas vs. NFPTs (Fig-S2A-D). Moreover, SST3 IHC-staining was present 248 
in approximately 50% of samples, showing in all cases similar membrane and cytoplasmic localizations (Fig-249 
S1D), as previously reported [25,28]. We next explored the functional role of SST3 using the new peptidic 250 
SST3-agonists/antagonists in comparison to the previously published non-peptidic L-796,778 SST3-agonist. All 251 
SST3-agonists induced a clear concentration-dependent reduction of cell viability, being 10-7M, the lowest 252 
concentration that caused a maximal effect, selected for further experiments (Fig-S3A). The antagonists BIM-253 
839 and BIM-152 did not elicit changes on cell viability at any of the concentration tested (10-5 to 10-11M and 254 
10-6 to 10-11, respectively; Fig-S3B). 255 
When comparing the effects of all SST3-agonists (at 10-7M), we observed a comparable significant 256 
decrease of cell viability after 48-72h of incubation (23.2%, 18.3% and 17.9% of reduction at 72h with BIM-257 
355, BIM-071 and L-796,778, respectively), although BIM-355 seemed to be the agonist exerting a stronger 258 
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reduction (Fig-2A). To demonstrate the specificity of these effects, we blocked them with two antagonists. Co-259 
administration of BIM-839 (10-5M) or BIM-152 (10-9M) with each agonist (10-7M) fully counteracted the 260 
agonist´s effect, confirming the functional role of SST3 in these effects (Fig-2B). Remarkably, at the selected 261 
concentrations, BIM-839 did not alter cell viability (Fig-2B) but BIM-152 reduced cell viability at high 262 
concentrations in some tumors, which prompted us not to use this compound in subsequent experiments. 263 
Additionally, administration of BIM-355, BIM-071 or L-796,778 increased caspase 3/7 activity (indicator of an 264 
increase on apoptotic rate), BIM-355 appearing as the most potent compound. Of note, these effects were also 265 
completely blocked in the presence of BIM-839 (Fig-2C).  266 
Furthermore, BIM-355, BIM-071 and L-796,778 clearly reduced CgA-secretion (considered as a 267 
valuable marker of NFPTs [14,50]) after 24h incubation (Fig-2D). Finally, we analyzed whether SST3-agonists 268 
may regulate the expression of key genes related with the pathogenesis of PitNETs [13] (Fig. 2E). Incubation of 269 
BIM-355, but not BIM-071, reduced gonadotropin-hormones expression (FSHB and LHB), whereas BIM-071 270 
significantly reduced the common α-subunit (CGA) mRNA levels. However, incubation with L-796,778 did not 271 
alter CGA, FSHB or LHB levels. Moreover, PTTG1, and MYC levels were not altered in response to the 272 
different agonists but TP53 was significantly decreased in response to BIM-355 (Fig-2E). 273 
Although these data demonstrate important roles of SST3 in NFPT cells, it should be noted that a 274 
proportion of the NFPTs analyzed did not respond to SST3-agonists. This conclusion is mainly based on the 275 
study of cell viability, which was evaluated in all the available NFPT cell cultures. Indeed, 16 out of the 42 276 
NFPT cultures tested (38%) did not show a reduction of cell viability in response to any of the SST3-agonists 277 
tested (at least two SST3-agonists were tested per NFPT culture). The functional assays performed in each 278 
individual responsive and unresponsive NFPT and the responsiveness to each SST3-agonist is shown on Table 279 
S2 and S3. 280 
Differential SST3 expression in responsive vs. unresponsive NFPTs  281 
To understand the differential response to SST3-agonists observed in cell viability assays, we compared 282 
the SSTs expression levels between responsive and unresponsive tumors. Interestingly, we found higher SST3 283 
mRNA and protein levels (statistically significant changes: p=0.029 and 0.039, respectively) in responsive vs. 284 
unresponsive tumors (Fig-3A-C). However, no significant changes were found in the expression of other SST-285 
subtypes between the two NFPT-populations at mRNA (Fig-3A). Moreover, while 286 
SST1/SST2/SST5/SST5TMD4/SST5TMD5 mRNA levels were unable to distinguish between both groups, SST3 287 
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expression levels significantly discriminated between responsive and unresponsive tumors (mRNA levels: 288 
AUC=0.71; p=0.03; Fig-3A and Fig-S4; and protein levels: AUC=0.69; p=0.098; Fig-3B). We also evaluated if 289 
any clinical parameter (extrasellar growth, cavernous sinus invasion, cure rate, etc) could be different, and able 290 
to discriminate, between responsive and unresponsive tumors. However, Chi-square tests did not reveal any 291 
significant result (Table S4), suggesting that only the SST3 expression pattern is able to discriminate between 292 
responsive vs. unresponsive NFPTs. Taking into account the differential SST3 expression pattern, we further 293 
investigated the capacity of different SST3-agonists to modulate this receptor expression profile in both 294 
responsive and unresponsive tumors. This revealed that BIM-355 and L-796,778 clearly increased SST3 mRNA 295 
levels (24h-incubation) in responsive primary NFPT-cultures, whereas SST3 expression was reduced in 296 
unresponsive NFPTs in response to BIM-071, but unaltered in response to BIM-355 and L-796,778 (Fig-3D). 297 
Signaling pathways modulated in response to SST3-agonists 298 
We next identified the signaling pathways underlying the ability of SST3-agonists to generate 299 
functional responses. Specifically, NFPT cells showed little response to SST3-agonists in terms of [Ca2+]i 300 
kinetics (12.4, 10 and 7% of responsive cells to BIM-355, BIM-071 and L-796,778, respectively) with modest 301 
[Ca2+]i reductions, ranging between 25.6 and 27.4% (Fig-S5A). Conversely, BIM-355 treated cells from 302 
responsive NFPTs showed a decrease in phosphorylated proteins levels involved in three major signaling-303 
pathways: MAPK (HSP27/PLCG1/ERK1-2/RSK1-2-3/CREB/JNK1-2-3/c-Jun), PI3K-AKT/mTOR (Akt,/GSK-304 
3a/b/Src/FAK/p53/PRAS40/TOR/p70 S6-kinase) and JAK/STAT (STAT3/STAT5a-b/STAT6), when compared 305 
to vehicle-treated controls (Fig-4A). In contrast, BIM-355 treatment of unresponsive NFPTs did not evoke 306 
similar reductions, and even elicited an increase of phosphorylated levels of several proteins belonging to the 307 
same pathways, such as MSK1-2/c-Jun/Src/FAK/TOR/STAT2/STAT5a-b/STAT5b/STAT6 (Fig-4B). 308 
Interestingly, we observed clearly reduced basal phosphorylation levels in most of these proteins in responsive 309 
NFPTs compared to unresponsive tumors (Fig-S5B).  310 
Effect of SSTR3 gene silencing on cell viability 311 
SSTR3 gene silencing was achieved at the mRNA levels using two specific siRNAs (Fig-5A). 312 
Additionally, we could test the silencing at protein level in 2 independent NFPTs at 48- or 72h after transfection, 313 
respectively. This approach revealed a SST3 content reduction of 70% (48h after transfection with s13501) and 314 
20-40% (72h after transfection with s13501 and s224690 siRNA, respectively) compared to scramble-315 
transfected cells in the two NFPTs analyzed (Fig-S6A-B). Particularly, s13501 did not alter cell viability, but 316 
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s224690 significantly increased cell viability 48-72h after transfection in 38% of NFPTs analyzed (those named 317 
responsive to silencing) compared to scramble-transfected cells (Fig-5B). This differential response to s224690 318 
was not associated to the initial SST3 levels (Fig-5C), to the percentage of reduction in the level of SST3 (Fig-319 
5D) or to the presence of the endogenous ligands of SST3, somatostatin or cortistatin. Indeed, this analysis 320 
revealed low levels of somatostatin (average of 0.0066 mRNA copies adjusted by HPRT) and much higher 321 
levels of cortistatin (average of 0.98 mRNA copies adjusted by HPRT), with no significant differences between 322 
responders and non-responders to SSTR3-silencing (data not shown).  On the other hand, and as expected, the 323 
treatment with BIM-355 induced a reduction on cell viability in scramble-transfected cells; however, this effect 324 
was completely blunted in s13501-transfected cells where the SST3 content was clearly reduced (Fig-S6C). This 325 
approach was implemented in cells from a single NFPT and suggests that the effect of BIM-355 is mediated by 326 
SST3. 327 
SST3-agonist reduced tumor growth in an in vivo preclinical model 328 
To demonstrate the ability of SST3 to mediate a reduction in tumor growth in vivo, we used the POMC-329 
KO mice, a mouse model of PitNETs. Mice were treated with two doses of BIM-355 (group-1: 2.2mg/kg/day 330 
and group-2: 7.4mg/kg/day). Treatment with BIM-355 reduced tumor-size after 8-weeks of treatment in a dose-331 
dependent manner. This reduction was statistically significant only at the higher dose (Fig-6C/D; it should be 332 
noted that although 6 animals started in the higher dose group, 3 of them were removed after three weeks due to 333 
an irritation at the minipump site. This can be clearly seen in Fig-S7. Additionally, IHC analysis of the tumors 334 
formed confirmed the presence of SST3-staining (Fig-6A), and a strong presence of Ki67-staining in the tumor 335 
area in contrast to the normal/adjacent mice pituitary gland (Fig-6B).  336 
 337 
DISCUSSION 338 
In this study, we identified for the first time two selective peptidic SST3-agonists and used them to 339 
explore the functional relevance of SST3 in NFPTs using a battery of experimental and analytical techniques. 340 
Our first objective was to identify specific SST3-agonists that could activate SST3 through the screening of a 341 
peptide library. From all tested peptides, SST3 binding affinities and functional cAMP assays revealed that BIM-342 
355 and BIM-071 were the most potent and specific SST3-agonists, while BIM-839 was the most potent SST3-343 
antagonist.  344 
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To determine whether SST3 could play a significant pathophysiological role in NFPT cells, we first 345 
corroborated that SST3 was the highest overexpressed receptor in our NFPT cohort, and demonstrated that SST3 346 
mRNA levels could discriminate between NFPTs vs. functioning PitNETs, but not between NPs vs. functioning 347 
PitNETs. Moreover, use of IHC also validated the presence of SST3 protein in approximately 50% of NFPTs 348 
analyzed, using two different cohorts of patients, which presented both a membrane and cytoplasmic 349 
localization, as previously described [25]. To further explore the functional relevance of this receptor in NFPTs, 350 
we compared the effects of the two peptidic agonists identified herein with those exerted by the previously 351 
published non-peptidic agonist L-796,778 [36]. The first approach was to assess the effect of SST3-agonists 352 
treatment on cell viability, a parameter tightly linked to tumor growth, the main clinical problem associated to 353 
NFPTs. Our data revealed a general ability of SST3-agonists to reduce cell viability in NFPT cells cultured in 354 
vitro, wherein BIM-355 was the most potent agonist (i.e. 23.2% of reduction), which, to our knowledge, is the 355 
most prominent reduction reached to date in a cell culture model on cell viability through the activation of SST3 356 
[e.g. treatment with the SST3-agonist (L-796,778) exerted a 19% inhibition on cell proliferation in HEK-293 357 
cells in previous studies [45]]. At this point, it is important to note that pituitary tumor cells, and specially NFPT 358 
cells, are not as markedly responsive to pharmacological treatments as cells from other tumor types [19,18]. 359 
Most importantly, we also observed a clear increase of caspase activity, which is likely translated into an 360 
increase of apoptosis, in response to treatment with different SST3-agonists. These effects on caspase activity, as 361 
well as those on cell viability, were completely blocked by the antagonist BIM-839, thus confirming the 362 
specificity of the actions observed. These results are in line with the previous results mentioned above, which 363 
indicated that treatment with L-796,778 increased the apoptotic index or related markers in the HEK-293 cell 364 
line [45]. Moreover, similar effects were reported in SST3-overexpressing breast cancer cells [44], further 365 
suggesting a clear, robust antiproliferative and proapoptotic role of this receptor. Of note, in support of the anti-366 
proliferative and proapoptotic role of SST3 in NFPTs observed in the present study, we demonstrated, for the 367 
first time, that in vivo administration of an SST3-specific agonist significantly decreased tumor growth in a 368 
preclinical mouse model of PitNET [47,21]. It has to be also noted that the differential response observed in the 369 
functional assays depending on the SST3-agonist used may be due to the highly complex activation of G protein-370 
coupled receptors (GPCRs), including the presence of multiple ligand-binding sites that can influence signal 371 
transduction in a distinct manner [23]. 372 
Our data also revealed a significant decrease of CgA secretion/expression in NFPT cells cultured in 373 
vitro in response to SST3-agonists. In addition to CGA, a reduction of FSH/LH mRNA was found in response to 374 
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BIM-355 (the most effective compound), which is not rare since we have previously observed a reduction of 375 
CGA and other hormones at mRNA levels in response to other treatments in PitNETs [18]. Moreover, CgA has 376 
been detected in secretory granules of NFPT cells, its secretion has been employed as a useful marker of 377 
pharmacological effectiveness, and has been recently proposed as a biomarker of tumorigenesis and 378 
invasiveness since it was altered in invasive NFPTs [49,50,35], again supporting SST3 as an attractive 379 
therapeutic target in NFPTs. In this sense, it is important to note that the development of the non-peptidic SST3 380 
agonist L-796,778 has been stopped and, therefore, the new peptides described in this work open a new avenue 381 
for the future development and use of SST3-agonists to treat these tumors. 382 
Interestingly, we found that a subset of NFPTs did not respond to SST3-agonists in terms of inhibition 383 
of cell viability. This is not surprising, in that previous studies have shown a percentage of unresponsive NFPTs 384 
and functioning PitNETs, or even total absence of effect, upon treatment with different antitumor compounds 385 
[19,10,7]. A comparison of the expression profile of SSTs revealed higher SST3 expression levels in responsive 386 
vs. unresponsive tumors, while no other significant changes were found between the two populations. Moreover, 387 
this result was corroborated at protein levels (higher SST3 in responsive vs. unresponsive tumors), thus 388 
suggesting that high SST3 levels are a requisite to elicit a significant response after SST3-agonists 389 
administration. This notion is further supported by ROC-curve analysis demonstrating that only SST3 levels, but 390 
not that of the other SST-subtypes, were able to discriminate between responsive and unresponsive NFPTs. 391 
SST3-agonists were able to increase SST3 expression levels in responsive, but not in unresponsive NFPTs (the 392 
latter showing even a reduction of SST3 expression), thereby suggesting that a positive feedback, and thus a 393 
functionally unique SST3(receptor)-SSTR3(gene) regulatory circuit might operate in these tumors. Remarkably, 394 
this is neither the sole nor the first time that an up-regulation of SSTs expression levels has been reported in 395 
response to different agonists. Thus, we have previously reported an increase of SST2 and SST5 expression 396 
levels in response to the chimeric compound BIM-23A760 in pituitary cells [18]. On the contrary, the reduction 397 
observed in unresponsive NFPTs could be due to an internalization/degradation of SST3 in response to the 398 
agonist since it has been demonstrated in CHO-K1 cells overexpressing SST3 that this receptor can undergo a 399 
rapid internalization (within minutes) in an agonist-dependent manner [17]. Nevertheless, the specific reasons 400 
why SST3 reduction only occurs in unresponsive NFPTs need to be further explored. 401 
To interrogate the mechanisms underlying the response to treatment with SST3-agonists, we explored 402 
an ample range of signaling pathways. In contrast with the scarce association (if any) observed between [Ca2+]i 403 
dynamics and response to SST3-agonists, our data revealed, for the first time, a striking reduction on the 404 
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phosphorylation levels of relevant protein kinases associated to three important signaling pathways (i.e. MAPK, 405 
PI3K-AKT/mTOR and JAK/STAT). Specifically, we observed a decrease on ERK1/2 and JNK 406 
phosphorylation, as well as in other proteins of the MAPK pathway such as RSK1/2/3, CREB and c-Jun in 407 
response to BIM-355 in responsive NFPTs, but not in unresponsive NFPTs. In fact, these pathways have been 408 
commonly associated with cell growth, proliferation and cell survival in tumor pathologies, including NFPTs 409 
[39,46,37]. Moreover, our results demonstrating the importance of the MAPK pathway in the response to SST3-410 
agonists in NFPTs are in line with previous results on HEK-293 cells treated with L-796,778 [45]. Similarly, we 411 
also found a decreased phosphorylated status in Akt, GSK-3a/b, Src, PRAS40, mTOR and p70-S6 kinase, all of 412 
them associated to the PI3K/AKT/mTOR pathway, which controls cell cycle progression, protein synthesis and 413 
cell proliferation [37]. Indeed, it has been demonstrated that SSAs, such as octreotide, elicit their 414 
antiproliferative actions through inhibition of PI3K/AKT pathway [42], and also that specific inhibitors of 415 
mTOR pathway exhibit a potent antitumor efficacy in NFPTs [26]. Remarkably, all the changes in 416 
phosphorylation levels are consistent with reduced PI3K/AKT/mTOR signaling, except for p53, an important 417 
tumor suppressor, whose phosphorylation is involved in apoptosis. In fact, our results show a reduction on TP53 418 
mRNA expression and phosphorylated-p53 levels, which is in line with the reduction observed in C6 glioma 419 
cell in response to Acetaminophen [27]. It is well established that p53 is regulated by complex mechanisms. 420 
Nevertheless, the reduced levels of p53 remain to be confirmed. In any case, the caspase-mediated apoptotic 421 
effects observed in response to SST3-agonists could be explained by the reduction in phosphorylated-CREB 422 
levels, which can reduce Bcl-2, an important anti-apoptotic protein, generating an increase on apoptosis [46]. 423 
Additionally, we observed a reduction on the phosphorylation levels of some components of JAK/STAT 424 
signaling pathway such as STAT3, STAT5a/b and STAT6. Although GPCRs have not been traditionally related 425 
with this signaling pathway, there are several reports describing an activation of STAT3 by GPCRs associated 426 
with cancer progression [48,24]. In marked contrast with responsive tumors, in unresponsive NFPTs, the 427 
phosphorylation status of most of the proteins described above were not altered upon BIM-355 treatment, or 428 
were increased. This situation is in accordance with results showing an increase on phosphorylation of Akt 429 
levels in a proportion of NFPTs resistant to rapamycin [5] and recent results published in prolactinomas 430 
showing that a reduced D2S/D2L expression ratio and an increase on MAPK and PI3K/AKT/mTOR pathways 431 
might contribute to tumorigenesis and DA resistance [38]. Moreover, comparing the basal phosphorylation 432 
levels of vehicle-treated controls from responsive and unresponsive NFPTs revealed a clear pattern of inhibition 433 
in the basal phosphorylation levels of the MAPK, PI3K-AKT/mT4OR and JAK/STAT proteins in unresponsive 434 
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tumors, which could explain the resistance of this population of NFPTs to respond to SST3-agonists (and 435 
possibly to other SSAs). 436 
Consistent with the existence of two populations of NFPTs (at least in terms of reduction of cell 437 
viability and signaling capacity in response to SST3-agonists), the experimental silencing of SSTR3 gene 438 
expression by specific siRNAs increased cell viability in 38% of NFPTs analyzed. A potential explanation for 439 
this observation would be that SST3 bears a constitutive inhibitory activity, as previous results have 440 
demonstrated that various SSTs, including SST3, display a relevant degree of ligand-independent constitutive 441 
activity in different pituitary cell systems [8,4]. Another possibility would be the endogenous release of 442 
somatostatin or its relative peptide cortistatin. In this sense, our results revealed almost negligible expression 443 
levels of somatostatin and much higher levels of cortistatin, which might suggest the existence of an ultra-short 444 
autocrine feedback mechanism whereby activation of SST3 by endogenous cortistatin would mediate inhibition 445 
of cell viability, secretion, etc. Inversely, a reduction in SST3 protein levels (by silencing) could lead to the loss 446 
of this inhibitory loop and could, ultimately, induce an increase on cell viability. However, the levels of 447 
somatostatin and cortistatin were not different between SSTR3-silencing responsive and unresponsive tumours 448 
and this hypothesis should be further explored. Importantly, the fact that BIM-355 did not alter cell viability in 449 
s13501-transfected cells (with reduced SST3 content), together with the fact that SST3-antagonist BIM-839 450 
completely blocked the effects of SST3-agonists, provide compelling evidence that, although cAMP IC50 for 451 
BIM-355 for SST3 and SST5 are very similar, the effects observed in response to agonists are completely and 452 
only specific of SST3. These observations unveiled new conceptual and functional avenues in NFPTs, with 453 
potential therapeutic implications, which are worth exploring in future studies. 454 
Taken together, this study represents the first identification and characterization of SST3-peptidic 455 
agonists, which enabled to gain novel experimental results supporting that these agonists exert clear antitumor 456 
actions on NFPT primary cell cultures. Moreover, our data reveal a role of SST3 in key pathophysiological 457 
processes of NFPT cells such as cell viability, apoptosis, and CgA secretion when SST3 is targeted with specific 458 
agonists. These actions are likely mediated through the modulation of three important signaling pathways 459 
(MAPK, PI3K-AKT/mTOR and JAK/STAT). We also found two populations of NFPTs with a differential 460 
expression of SST3 (statistically significant at the mRNA and protein level) and different capacity to respond to 461 
SST3-agonists in terms of activation of signaling pathways and functional parameters. Therefore, the present 462 
study provides new compelling evidence, demonstrating that SST3 has a functional role in the pathophysiology 463 
of NFPTs, and invites to suggest that pharmacological treatments specifically targeting this receptor could 464 
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become a promising option to treat patients with NFPTs, providing a relevant clinical conclusion, which should 465 
be soon tested for their use in humans. 466 
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FIGURE CAPTIONS 626 
Figure 1. Chemical structures of selected SST3-agonists and antagonist compounds. These compounds are 627 
representative of the families of peptides that showed the highest activity and selectivity for SST3. 628 
Figure 2. Functional assays in response to SST3-agonists and antagonists in NFPTs primary cell cultures. 629 
(A) Effect of three agonists [10-7 M: BIM-355 (n=16), BIM-071 (n=13) and L-796,778 (n=18) on cell viability 630 
in responsive tumors (24-72 h treatment), measured by Alamar-blue reduction. (B) Effect of BIM-355 (n=4), 631 
BIM-071 (n=3) and L-796,778 (n=9) alone or in combination with antagonists (BIM-839 and BIM-152) on cell 632 
viability. (C) Effect of agonists (BIM-355 [n=5], BIM-071 and L-796,778 [n=3]) on caspase activity (24h 633 
treatment), measured by Caspase-Glo 3/7 assay. (D) Effect of agonists (BIM-355 [n=4], BIM-071 [n=3] and L-634 
796,778 [n=8]) on chromogranin A secretion (24h treatment), determined by commercial ELISA kit. (E) mRNA 635 
expression levels of key genes in response to SST3-agonists were measured by qPCR and adjusted by 636 
normalization factor (NF) (n=7). Data are expressed as percent of vehicle-treated controls (set at 100%) within 637 
experiment. Values represent the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate 638 
statistically significant differences.  639 
Figure 3. Differential expression profile of key genes according to responsive or unresponsive NFPTs in 640 
terms of cell viability. (A) Expression profile of somatostatin receptors in responsive (RP, black bars; n=26) 641 
compared with unresponsive tumors (URP, grey bars; n=16) and ROC-curve analyses to determine the accuracy 642 
of SST3 expression as diagnostic test to discriminate between RP and URP NFPTs. Data represent median ± 643 
interquartile range of absolute expression levels (copy number) of each transcript adjusted by the expression 644 
level of a control gene (HPRT). (B) SST3 protein levels in both responsive (RP; n=17) and unresponsive (URP; 645 
n=12) NFPTs evaluated by IHC and ROC-curve analyses of SST3 expression. Data represent median ± 646 
interquartile range. Asterisk (* p<0.05) indicate statistically significant differences. (C) Representative 647 
immunohistochemical staining (400X magnification; scale bar: 20µm) for SST3 measured in RP and URP 648 
NFPTs. (D) Expression profile of SST3 in both RP and URP tumors in response to treatment with SST3-agonists 649 
(10-7 M) [RP (n=3) and URP (n=4): BIM-355, BIM-071 and L-796,778]. Data are expressed as percent of 650 
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vehicle-treated controls (set at 100%) within experiment. Values represent the mean ± SEM. Asterisks (* 651 
p<0.05; ** p<0.01) indicate statistically significant differences. 652 
Figure 4. Measurement of intracellular signaling pathways in response to BIM-355 in NFPTs. Direct 653 
effects of BIM-355 on the phosphorylation levels of 43 kinase phosphorylation sites, measured by phospho-654 
kinase array. Array images are shown for responsive and unresponsive tumors treated with BIM-355 or vehicle. 655 
Graphs represent spot intensities of indicated proteins by quantifying the mean spot pixel densities. Values 656 
represent the mean ± SEM of duplicate spots from a pool of three NFPT cultures. Asterisks (* p <0.05; ** p 657 
<0.01; *** p <0.001) indicate statistically significant differences. 658 
Figure 5. Cell viability in response to SSTR3 gene silencing in NFPTs primary cell cultures. (A) Validation 659 
by qPCR of SSTR3 gene silencing with two specific siRNAs (s13501 [n=9] and s224690 [n=6]). (B) Effect of 660 
24-, 48- and 72-h silencing of SST3 expression levels (non-responsive (n=5) and responsive (n=4) to silencing) 661 
on cell viability, determined by Alamar-blue reduction. (C) Basal SST3 expression levels in responsive (RP, 662 
n=3) compared with non-responsive tumors (URP, n=5), before to perform the SSTR3 gene silencing. (D) SST3 663 
expression levels in responsive (RP, n=3) compared with non-responsive tumors (URP, n=5). Data are 664 
expressed as percent of control random siRNA (Scramble; set at 100%) within experiment. Values represent the 665 
mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate data that significantly differ from scramble 666 
controls. 667 
Figure 6. Direct effect of BIM-355 on tumor growth in a preclinical PA mouse model. (A) Representative 668 
IHC of SST3 in tumors generated in this model compared with SST3 protein expression on human NFPTs (200X 669 
magnification; scale bar: 20µm). (B) Representative IHC of Ki67 in normal adjacent pituitary gland and tumors 670 
formed in this model (200X magnification; scale bar: 20µm). (C) Effect of BIM-355 [2.2 mg/kg/day (n=8) and 671 
7.4 mg/kg/day (n=3)] on tumor volume growth during 8 weeks, measured by MRI. The asterisks represent 672 
statistical significance evaluated time-by-time by geometric least square values adjusted for baseline tumor 673 
volume. (D) Final tumor volume after 8 weeks of treatment. The bars represent geometric least square mean 674 
values corresponding to the complete curves from baseline to week 8, as described in Statistical Methods.  675 
 
BIM-355: c(Cys-bAla-Phe-Phe-DTrp-Lys-Thr-Phe-Cys)-NH2
BIM-071: Pro-Phe-c(DCys-DTrp-Lys-DCys)-Thr-Phe-NH2
BIM-839: hPro-Phe-c(DCys-DTrp-Lys-DCys)-Val-NH2
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Methods 
Library screening 
The identification of compounds that act as selective SST3-agonists was based on the 
examination of IPSEN’s extensive collection of synthetic peptides. First, we measured the affinity of all 
the peptides to SST2, SST3, and SST5 as previously described 1. Then, peptides that showed binding to 
SST3 regardless of their potency were included in a multidimensional Spotfire® analysis designed to 
elucidate compounds with the highest selectivity for SST3. Particular focus was paid to compounds that 
had simultaneous selectivity against SST2 and SST5. Structural analysis of the most selective compounds 
allowed them to be classified into 3 main families with 6, 4 and 2 members respectively. The most 
representative structures are BIM-355, BIM-071 and BIM-23A185. High throughput synthesis of family 
members from each group allowed the confirmation of their SST3 binding, selectivity, and cellular 
activity. The activation of SSTs was performed by measuring cAMP as previously described 1.  
 
Patients, samples and primary cell cultures 
The appropriate classification of each pituitary sample collected (NP or tumor type) was 
confirmed by two different methods: examination by expert anatomo-pathologists and by the molecular 
screening using quantitative real-time PCR (qPCR) as previously described 2-4.  
For in vitro assays, fresh tumor samples were placed in sterile cold media and dispersed into 
single cells by mechanical and enzymatic disruption and cultured onto different tissue culture plates 
following the methods and reagents previously reported 2,4. 
 
RNA isolation, reverse transcription and analysis of gene expression levels by qPCR 
We have evaluated the stability of the expression of three reference genes ACTB, HPRT and 
GAPDH in all samples using RefFinder, a comprehensive tool that integrates the currently available 
major computational programmes 5, and found HPRT to be the most stable. Taking this into account, the 
expression values of the genes of interest were normalized to HPRT mRNA levels.  
 
Immunohistochemical analysis (IHC) for SST3 in NFPTs 
The presence of antigen was revealed with the UltraView Universal DAB Detection Kit 
(Ventana). SST3 antibody was diluted 1/1000 (UMB-5, Abcam, Burlingame, CA). An immunoreactive 
 
 
score (IRS) was established for each section. This score was calculated (ranging from 0 to 12) as the 
product of the percentage of positive cells (0-4: 0, ≤10, 11-50, 51-79 and ≥80%, respectively) and the 
staining intensity (0-3: no staining, mild, moderate and strong, respectively). The slides were semi-
quantitatively scored by two independent, experienced pathologists by a double-blind method and similar 
results were obtained. 
 
Measurement of caspase activity of primary pituitary tumor cell cultures 
For this purpose, 25,000 cells/well were plated in a 96-well white microplate and cultured for 
24h at 37°C in an atmosphere containing 5% CO2. Then, cells were incubated for another 24h with 
different SST3-agonists, BIM-839 antagonist and vehicle. After the incubation period, 100µl of Caspase-
Glo 3/7 reagent was added to each well and luminescence was measured at room temperature using 
FlexStation III system for 3h. 
 
Analysis of signaling pathways by human phospho-kinase array. 
Three different NFPTs of each condition (vehicle/treatment; responsive/unresponsive NFPTs) 
were pooled and 600µg of cell lysates were loaded in the array membranes to detect relative 
phosphorylation levels of 43 relevant kinase phosphorylation sites, following the manufacturer´s protocol 
(Proteome Profiler™; R&D Systems). The average signal of the pair of duplicate spots, representing each 
phosphorylated site, was calculated after subtraction of background values (pixel density) from negative 
control spots and normalization to average values from positive control spots using HLImage++ sofware 
(Version 22.0.0a; R&D Systems). 
 
Silencing of SSTR3 gene with specific siRNAs 
The validation of silencing conditions was carried out using the BON-1 cell line, which displays 
a high SST3 expression (data not shown). After 24h of transfection, cells were detached and used for 
validation of the transfection efficiency (determined by qPCR) and for cell viability measurements as 
described above. 
 
 
 
 
 
Validation of SST3 silencing by western blotting. 
 To assess the SST3 protein reduction in response to the silencing, 300,000-500,000 transfected 
cells (scramble and s13501) were washed and lysed in SDS-DTT buffer after 48h of transfection. Proteins 
were separated by SDS-PAGE and transferred to nitrocellulose membranes (EMD Millipore, Billerica, 
MA, USA). Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline with 0,05% Tween 
20 and incubated overnight a 4ºC with primary antibodies [anti-SST3: UMB5, ab137026 (Abcam, 
Cambridge, UK); anti--tubulin: 2128S (Cell Signaling, Danvers, MA, USA)]. Secondary horseradish 
peroxidase-conjugated anti-rabbit were purchased from Cell Signaling (Danvers, MA, USA). Proteins 
were developed by using ECL detection system (GE Healthcare, UK) with dyed molecular weight 
markers. A densitometric analysis of the bands was carried out with ImageJ software (National Institutes 
of Health, Bethesda, MD, USA).  
 
 
  
 
 
Fig S1. mRNA and protein expression pattern of key somatostatin receptors in non-functioning 
pituitary tumors (NFPTs) and normal pituitaries (NPs). (A) The expression profile of somatostatin 
receptors was determined by qPCR in a battery of 80 NFPTs and 12 NPs. (B) Comparative expression 
profile of somatostatin system in 80 NFPTs. Data represent median ± interquartile range of absolute 
expression levels (copy number) of each transcript adjusted by the expression level of a control gene 
(HPRT). Asterisks (* p<0.05; ** p<0.01; *** p<0.001) and values that do not share a common letter 
indicate statistically significant differences. (C) ROC-curve analyses to determine the accuracy of SSTs 
expression levels to discriminate between patients with NFPTs and normal tissue (NPs). (D) 
Immunohistochemical staining (400X magnification; scale bar: 20µm) and immunoreactive score (IRS) 
for SST3 measured in two different cohorts of NFPTs (n=35). 
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Fig. S2. mRNA expression levels of SST3 in different pituitary neuroendocrine tumors (PitNETs) 
and NPs. (A) Comparative expression profile of SST3 between NFPTs (n=80), functioning PitNETs 
[GHomas (n=63) and ACTHomas (n=17)] and NPs (n=12). (B-D) ROC-curve analyses to determine the 
accuracy of SST3 expression to discriminate between (B) patients with NFPTs and functioning PitNETs, 
(C) between NPs and GHomas or ACTHomas and (D) between GHomas or ACTHomas. (E) Association 
between SST3 mRNA expression levels and LHB mRNA expression and clinical parameters. Data 
represent median ± interquartile range of absolute expression levels (copy number) of each transcript 
adjusted by the expression level of a control gene (HPRT). Values that do not share a common letter 
indicate statistically significant differences.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3. Cell viability in response to SST3-agonists and antagonists in NFPTs primary cell cultures, 
measured by Alamar-blue reduction. (A) Concentration-dependent response experiments of SST3-
agonists [BIM-355 (n=4), BIM-071 (n=4), and L-796,778 (n=5)]. (B) Concentration-dependent response 
experiments of two SST3-antagonists (BIM-839 [n=3] and BIM-152 [n=9]). Data are expressed as percent 
of vehicle-treated controls (set at 100%) within experiment. Values represent the mean ± SEM. Asterisks 
(** p<0.01; *** p<0.001) indicate statistically significant differences. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. S4. ROC-curve analyses to determine the accuracy of SSTs expression levels to discriminate 
between responsive and unresponsive NFPTs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. S5. Intracellular signaling involved in the effects observed in response to SST3-agonists. (A) 
Summarized table and representative profile of [Ca2+]i kinetics assay in response to different agonists 
(BIM-355 [n=4], BIM-071 and L-796,778 [n=11]). n stands for “responsive samples/total samples 
analyzed”; PRC, proportion of responsive cells showing changes in [Ca2+]i in response to agonists; PMR, 
percentage of maximum response; and time, time of response to agonists administration. (B) Comparison 
of the basal phosphorylation levels of vehicle-treated controls from responsive and unresponsive NFPTs, 
measured by phospho-kinase array. Graphs represent spot intensities of indicated proteins by quantifying 
the mean spot pixel densities. Values represent the mean ± SEM of duplicate spots from a pool of three 
NFPT cultures. Asterisks (* p <0.05; ** p <0.01; *** p <0.001) indicate statistically significant 
differences. 
 
 
 
 
 
  
 
 
Fig. S6. Cell viability in response to BIM-355 and SSTR3 gene silencing in NFPT primary cell 
cultures. (A) Validation by western blotting of SST3 silencing after 48h of transfection using s13501 
(n=1). (B) Validation by western blotting of SST3 silencing after 72h of transfection using s13501 and 
s224690 siRNA (n=1). (C) Effect of 24-, 48- and 72-h silencing of SST3 protein alone or in combination 
with BIM-355 treatment on cell viability (n=1), determined by Alamar-blue reduction. Data are expressed 
as percent of vehicle-treated controls (set at 100%). Values represent the mean ± SEM. Asterisks (** 
p<0.01) indicate statistically significant differences between a given treatment vs. vehicle-treated control 
using the replicates (n=4) within each treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S7. Direct effect of BIM-355 at different doses on tumor growth in POMC-KO mice model. 
Graphs are representing the tumor volume measured by MRI in individual mice.  
 
 
 
 
 
 
 
 
 
Table S1. Pharmacological characterization of SST3-selective compounds 
Compound Type 
Molecular 
weight 
(g/mol) 
Ki (nM) 
hSST3 
cAMP assay IC50 (nM) 
hSST2 hSST3 hSST5 mSST3 mSST5 
BIM-355 Peptidic agonist 1269,5 1.98 ± 0.1 224 ± 73 4 ± 0.8 5.7 ± 1 19 ± 6.3 229 ± 36 
BIM-071 Peptidic agonist 1028,3 3.55 ± 0.5 62.7 ± 12.8 1.8 ± 0.5 >1000 >1000 ND 
L-796,778 Non-peptidic agonist 585,7 ND ND 18 8  ND ND ND 
BIM-839 Peptidic antagonist 1121,2 11.92 ± 7.0 >1000 2 ± 0.5 >500 ND ND 
ND: Not determined 
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Table S2. Relation of functional experiments performed in responsive (RP) and unresponsive (URP) 
NFPTs.  
Sample 
Type of 
response 
mRNA expression at 
basal levels (from tissue) 
 
IHC Cell viability  
Caspase 3/7 
activity 
Chromogranin A 
secretion 
mRNA expression  
NFPT-1 RP X X X - - - 
NFPT-2 RP X X X - X X 
NFPT-3 RP X X X - X X 
NFPT-4 RP X X X - - - 
NFPT-5 RP X X X - - - 
NFPT-6 RP X X X - X - 
NFPT-7 RP X X X - - - 
NFPT-8 RP X X X - - - 
NFPT-9 RP X  X - X X 
NFPT-10 RP X X X - - - 
NFPT-11 RP X  X - X X 
NFPT-12 RP X  X - X X 
NFPT-13 RP X  X - - - 
NFPT-14 RP X  X - - - 
NFPT-15 RP X  X - - - 
NFPT-16 RP X  X - - - 
NFPT-17 RP X  X - - - 
NFPT-18 RP X X X - - - 
NFPT-19 RP X X X X X X 
NFPT-20 RP X X X X - - 
NFPT-21 RP X X X X - - 
NFPT-22 RP X  X X X X 
NFPT-23 RP X X X X - - 
NFPT-24 RP X X X - - - 
NFPT-25 RP X X X - - - 
NFPT-26 RP X X X - - - 
NFPT-27 URP X X X - - - 
NFPT-28 URP X  X - - - 
NFPT-29 URP X X X - - - 
NFPT-30 URP X X X - X X 
NFPT-31 URP X X X - X X 
NFPT-32 URP X  X - X X 
NFPT-33 URP X X X - - X 
NFPT-34 URP X X X - - - 
 
 
 
 
Table S3. Percentage of responsive and unresponsive NFPTs regarding SST3-specific agonists in terms of 
cell viability. 
 BIM-355 BIM-071 L-796,778 
Responsive tumors 70% (n=16) 59% (n=13) 55% (n=18) 
Unresponsive tumors 30% (n=7) 41% (n=9) 45% (n=15) 
Total number of samples N=23 N=22 N=33 
 
 
Table S4. Results from Chi-square test of clinical parameters between responsive and unresponsive 
NFPTs. 
Clinical parameter Chi-squared test p-value 
Cephalea 0.178 1.000 
Visual alterations 0.009 1.000 
Extrasellar growth 0.197 1.000 
Cavernous sinus invasion 0,433 0.707 
Chiasmatic compression 0.423 0.601 
Clinical symptoms derived from 
hormonal deficit 
0.134 1 
Pre-surgery treatment 0.029 1.000 
Knosp Grade 0.008 1.000 
Ki67 (<2% or 2%) 0.117 1.000 
Cure rate 3.463 0.135 
 
 
 
NFPT-35 URP X X X - - - 
NFPT-36 URP X X X - - - 
NFPT-37 URP X X X - - - 
NFPT-38 URP X X X - - - 
NFPT-39 URP X X X - - - 
NFPT-40 URP X  X - - - 
NFPT-41 URP X X X - - - 
NFPT-42 URP X  X - - - 
 
 
Table S5. Clinical data and SST3 mRNA expression levels of individual NFPTs. 
Nº Gender Age Cephalea 
Visual 
Alterations 
Extrasellar 
growth 
Cavernous 
sinus 
invasion 
Knosp 
Grade 
Cure rate Ki67 (%) 
1 F 53 Yes No Yes No 2 Yes <2% 
2 F 71 Yes Yes Yes No 0 No <2% 
3 M 73 No Yes Yes No 0 Yes <2% 
4 F 52 No No Yes No 0 No <2% 
5 M 67 Yes No Yes No 0 No <2% 
6 F 51 No Yes Yes No 0 No <2% 
7 F 67 Yes No Yes Yes 3 Yes <2% 
8 M 41 Yes Yes Yes Yes 3 No = or >2% 
9 F 57 Yes ND Yes Yes 4 No <2% 
10 M 73 Yes Yes Yes No 0 No <2% 
11 M 54 No No Yes Yes 3 ND <2% 
12 M 39 Yes No Yes No 2 Yes <2% 
13 F 43 No Yes Yes No 0 Yes <2% 
14 M 74 Yes Yes Yes No 2 Yes <2% 
15 F 50 No No Yes No 1 No = or >2% 
16 F 71 Yes Yes Yes No 2 No <2% 
17 M 64 No No Yes Yes 4 No <2% 
18 M 43 No Yes Yes No 0 Yes <2% 
19 M 56 No Yes Yes No 2 No <2% 
20 F 42 No Yes Yes No 1 Yes <2% 
21 F 71 ND Yes Yes Yes 3 No = or >2% 
22 F 57 No Yes Yes No 0 No = or >2% 
23 M 51 No Yes Yes No 2 Yes <2% 
24 M 55 No No No No 2 Yes <2% 
25 M 44 Yes No Yes Yes 3 Yes ND 
26 M 37 No No Yes Yes 3 Yes <2% 
27 F 47 No Yes Yes No 0 Yes <2% 
28 M 75 No Yes Yes Yes 3 No <2% 
29 F 51 No Yes Yes No 0 No = or >2% 
30 M 40 No Yes Yes ND ND Yes <2% 
31 M 40 No Yes Yes No 0 Yes <2% 
32 M 65 No Yes Yes No 2 No = or >2% 
33 M 68 No No Yes No 2 Yes <2% 
34 F 73 No Yes Yes No ND No ND 
35 M 57 No No Yes Yes 4 No <2% 
36 M 51 Yes No Yes No 2 No ND 
37 M 58 No No No No 1 No ND 
38 M 63 No No Yes Yes 0 Yes = or >2% 
39 M 43 No No No No 3 No <2% 
40 F 65 No No Yes Yes 4 No <2% 
41 F 52 No Yes Yes Yes 1 No <2% 
42 F 66 No No Yes No 1 Yes = or >2% 
43 M 67 Yes No Yes Yes 1 No <2% 
44 M 75 No No Yes Yes 4 No <2% 
45 F 32 No Yes Yes No 4 No = or >2% 
46 M 16 Yes Yes Yes No ND Yes = or >2% 
47 M 44 Yes Yes Yes No 1 No <2% 
48 M 58 No Yes ND ND ND No ND 
49 F 48 Yes Yes Yes Yes ND No = or >2% 
50 F 79 No Yes Yes Yes 1 No = or >2% 
51 M 59 Yes Yes Yes Yes 2 Yes <2% 
52 F 65 No Yes Yes Yes 3 Yes <2% 
 
 
NA: Not available; ND: Not determined 
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1. Abstract 
Background: Pituitary neuroendocrine tumors (PitNETs) represent approximately 15% of all 
intracranial tumors and usually are associated with severe comorbidities. Unfortunately, a relevant 
number of patients do not respond to currently available pharmacological treatments, i.e. 
somatostatin-analogues (SSAs) or dopamine-agonists (DA). Thus, novel, chimeric 
somatostatin/dopamine compounds (dopastatins) that could improve medical treatment of PitNETs 
have been designed.  
Objective: This study aims to determine the direct therapeutic effects of a new-generation 
dopastatin, BIM-065, on primary cell cultures from different PitNETs subtypes.  
Methods: 31 PitNET-derived cell-cultures [9 corticotropinomas, 9 somatotropinomas, 11 non-
functioning pituitary adenomas (NFPAs) and 2 prolactinomas], were treated with BIM-065, and key 
functional endpoints were assessed (cell viability, apoptosis, hormone secretion, expression levels of 
key genes, free cytosolic [Ca2+]i dynamics, etc.). AtT-20 cell line was used to evaluate signaling 
pathways in response to BIM-065.  
Results: This chimeric compound decreased cell viability in all corticotropinomas and 
somatotropinomas tested, but not in NFPAs. BIM-065 reduced ACTH, GH, chromogranin-A and PRL 
secretion, and increased apoptosis in corticotropinomas, somatotropinomas and NFPAs. These 
effects were possibly mediated through modulation of pivotal signaling cascades like [Ca2+]i 
mobilization and Akt- or ERK1/2-phosphorylation.  
Conclusions: Our results unveil a robust antitumoral effect in vitro of the novel chimeric compound 
BIM-065 on the main PitNET-subtypes, inform on the mechanisms involved, and suggest that BIM-
065 could be an efficacious therapeutic option to be considered in the treatment of PitNETs.   
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2. Introduction 
Pituitary neuroendocrine tumors (PitNETs) are mostly benign neuroendocrine neoplasms confined to 
the sella turcica that constitute approximately 15% of all intracranial tumors [1, 2]. These tumors are 
usually monoclonal, derived from the expansion of single precursor cells, and are associated with 
severe comorbidities related to hormonal hypersecretion and/or mass effects, such as 
hypopituitarism, visual defects, amenorrhea, galactorrhea, sexual dysfunctions and growth 
abnormalities [3-5]. The expression of somatostatin and dopamine receptors (SST1-5 and D1-5, 
respectively) has been largely studied in the different PitNETs subtypes, wherein high levels of 
certain SSTs/Ds, especially SST2, SST5 and D2, have been described [6-10]. For this reason, 
somatostatin analogues (SSAs: i.e. octreotide, pasireotide and lanreotide) and dopamine agonists 
(i.e. cabergoline and bromocriptine) have been widely used as pharmacological treatments to 
manage this and other endocrine-related pathologies due to their multiple antiproliferative and 
antisecretory actions [6, 11, 12]. Nevertheless, numerous reports have demonstrated that a high 
proportion of patients are unable to respond to these treatments, or that the responses show a high 
variability or decline over time [12-14]. Inasmuch as PitNETs often express, simultaneously, high 
levels of various SSTs and Ds, and both families of receptors have the capacity of heterodimerize 
resulting in altered pharmacological properties [15, 16], new chimeric somatostatin (SRIF)/ 
Dopamine (DA) compounds were developed in order to increase their efficacy and improve the 
control of the disease compared with individual SSA and/or DA [17].  
In this context, BIM-23A760, a chimeric compound able to bind SST2, SST5 and D2 with high affinity, 
was considered a promising therapeutic option to treat different PitNETs subtypes. In fact, the direct 
effects of this chimeric compound have been tested in different normal and tumoral pituitary cell 
models [8, 18-24]. Recently, our group has demonstrated that treatment with BIM-23A760 reduce 
hormone secretion and/or expression in a set of somatotropinomas (GHomas), prolactinomas 
(PRLomas) and corticotropinomas (ACTHomas) [8]. However, these results also showed the existence 
of two PitNET cell populations that oppositely responded to the treatment of BIM-23A760, an 
inhibitory- and stimulatory-population [8], suggesting that this compound might not be a successful 
therapeutic option in some patients with PAs. Moreover, BIM-23A760 has been finally withdrawn 
from clinical development after discovering a dopaminergic metabolite that accumulates and 
interferes with the activity of the parent compound in vivo [17].  
For all these reasons, a new generation of chimeric agonist for SST2/SST5/D2 receptors (named BIM-
065), with higher potency, efficacy and safety has been recently designed and developed by IPSEN 
that may be used for clinical purposes in the future [25, 26]. Therefore, the main aim of this study 
was to evaluate, for the first time, the direct effects of this new compound on relevant functional 
parameters (cell viability, apoptosis, hormonal secretion/expression and [Ca2+]i kinetics) in primary 
cell cultures from different PitNETs, including ACTHomas, GHomas, non-functioning pituitary 
adenomas (NFPAs) and PRLomas. 
3. Materials and Methods 
3.1 Reagents 
All reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise specified. BIM-065 and cabergoline were kindly provided by IPSEN Bioscience (Cambridge, 
MA, USA) and prepared following the instructions of the company. Octreotide was obtained from GP-
Pharm (Barcelona, Spain) and pasireotide was generously provided by Novartis. All compounds were 
used at 100nM based on previous studies [8, 27, 28]. 
3.2 Patients, samples and primary cell cultures 
Human PitNETs were obtained during trans-sphenoidal surgery from a total of 31 patients: 9 
ACTHomas (mean age: 51 [29 – 79] years; 67% women), 9 GHomas (mean age: 48 [29 – 63] years; 
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44% women), 2 PRLomas (mean age: 25 [20 – 30] years; 50% women) and 11 NFPAs (mean age: 56 
[41 – 75] years; 45% women). The appropriate classification of each pituitary sample collected was 
confirmed by two different methods: examination by expert anatomo-pathologists and by the 
molecular screening using quantitative real-time PCR (qPCR) as previously described [8, 28-30]. All 
techniques carried out in this study were conducted in accordance with the ethical standards of the 
Helsinki Declaration, of the World Medical Association and with the approval of the University of 
Cordoba/IMIBIC and Ethics Committees from all the Hospitals involved in the study. Informed 
consent from each patient was obtained. 
All human samples were placed in sterile cold medium (S-MEM, Gibco, Madrid, Spain) supplemented 
with 0.1% BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2,5% 2-(4(2-
hydroxyethyl)-1-piperazine)-ethane sulfonic acid (HEPES). The samples were rapidly moved to our 
laboratory and dispersed into single cells by mechanical and enzymatic disruption and cultured onto 
different tissue culture plates following the methods and reagents previously described [28, 29].  
3.3 Cell line and culturing. 
The mouse corticotroph pituitary derived cell line AtT-20/D16v-F2 (ATCC® CRL-1795) was cultured 
and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) complemented with 10% FBS, 100 
U/ml penicillin/streptomycin, 0.024 M of HEPES, and maintained at 37ºC and 5% CO2, under sterile 
conditions, as previously reported [29]. The passage numbers used for the experiments were ranged 
between 20 and 25. Additionally, both cell lines were checked for mycoplasma contamination by PCR 
[31].  
3.4 Measurement of cell viability 
Cell viability of PitNET cell cultures (10,000 cells/well in 96-well plates) was evaluated every 24h until 
72h in response to BIM-065, octreotide, pasireotide or cabergoline using Alamar-blue reagent 
(Invitrogen, Madrid, Spain). In experiments using AtT-20 cell line, 6,000 cells/well were seeded in 96-
well plates. The treatment was daily refreshed after each measure. Reduction of Alamar-blue was 
quantified using a FlexStation III system (Molecular Devices, Sunnyvale, CA), as previously reported 
[8, 30, 32].  
3.5 Measurement of apoptotic rate 
Apoptotic rate was determined by measuring caspase 3/7 activity in response to BIM-065 using the 
Caspase-Glo 3/7 assay (Promega, Madrid, Spain) according to manufacturer’s instructions. Briefly, 
25,000 cells/well were plated in a 96-well white microplate and cultured for 24h at 37°C in an 
atmosphere containing 5% CO2. Then, cells were incubated for another 24h with BIM-065 and 
vehicle. After the incubation period, 100µl of Caspase-Glo 3/7 reagent was added to each well and 
luminescence was measured at room temperature using FlexStation III system (Molecular Devices, 
Sunnyvale, CA) for 3h. 
3.6 Measurement of pituitary hormone release 
To evaluate the effect of BIM-065 on pituitary hormone secretion, 150,000 – 200,000 cells/well were 
used. Media were recollected after 24h of treatment and ACTH, GH, chromogranin-A (CgA) and PRL 
were evaluated using commercial ELISA kits (reference numbers: EIA-3647, EIA-3552, EIA-4937 and 
EIA-1291, respectively; DRG, Mountainside, NJ, USA) following the manufacturer’s instructions. All 
the information regarding specificity, detectability, and reproducibility for each of the assays can be 
accessed at the website of the company.  
3.7 Measurement of dynamics of free cytosolic calcium concentration ([Ca2+]i). 
To assess the direct effect of BIM-065 on free cytosolic calcium mobilization, 50,000 cells/coverslip 
were plated and changes in [Ca2+]i in single cells of all types of PitNETs were measured using fura-
2AM (Molecular Probes, Eugene, OR), as previously described [8, 29, 30].  
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3.8 Measurement of MAPK and PI3K-Akt signaling pathways by western blotting 
The mouse corticotroph PitNET derived cell line AtT-20/D16v-F2 (ATCC® CRL-1795) was used to 
further explore the signaling pathways modulated in response to BIM-065 due to the limited number 
of primary PitNET cells available for the culture experiments. 500,000 cells were cultured in 6-well 
plates and incubated for 24h with BIM-065 and vehicle-treated controls, as described previously [30]. 
Extracted protein samples were incubated with the primary antibodies [p-AKT (Ser47; Ref. CS9271S), 
Akt (Ref. CS9272), Bcl-2 (Ref. CS3498), p-ERK1/2 (Ref. CS4370), ERK1/2 (Ref. CS154), from Cell 
Signaling (Danvers, MA, USA)] and the appropriate secondary antibodies (secondary anti-rabbit 
antibody from Cell Signaling, Danvers, MA, USA), and developed using an enhanced 
chemiluminescence detection system (GE Healthcare, UK) with dyed molecular weight markers. A 
densitometric analysis of the bands was carried out with ImageJ software [33]. Relative 
phosphorylation of ERK1/2 and Akt was obtained from normalization of p-ERK1/2 or p-Akt against 
the total ERK1/2 or p-Akt, respectively. Bcl-2 was normalized by using total protein loading (ponceau 
staining).  
3.9 RNA isolation, reverse transcription and analysis of gene expression levels by qPCR. 
Details of RNA extraction, quantification, reverse-transcription (RT) and qPCR using specific primers 
included in this study have been previously reported elsewhere by our group [8, 30, 34, 35]. It should 
be mentioned that since it is not possible to design a specific set of primers for qPCR that only 
amplified the short isoform of D2, a set of primers that amplify both, the long and short, isoforms 
(D2T) and a set of primers that only amplify the long isoform (D2L) were used in this study, as 
previously reported [36]. In addition, new primer sequences were used in the present study to 
amplify CDKN1B (sense, ATAAGGAAGCGACCTGCAAC and antisense, TTGGGGAACCGTCTGAAA; 
accession number, NC_000012.12; product size, 88 pb) and CDK2 (sense, GCTCTCACTGGCATTCCTCTT 
and antisense, GAGGTTTAAGGTCTCGGTGGA; accession number, NC_000012.12; product size, 109 
pb). It should be noted that, as previously reported and based on the stringent criteria to maximize 
specificity and efficiency, the qPCR technique, as applied, can be used to accurately quantify copy 
numbers for all human transcripts included in this study [36]. A no RT sample was used to ascertain 
that no detectable genomic DNA was present in the total RNA preparation. Moreover, to control for 
variations in the amount of RNA used in the RT reaction and the efficiency of the RT reaction, the 
expression level (copy-number) of each transcript was adjusted using a normalization factor (NF) 
calculated from beta actin (ACTB), hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression levels.  
3.10 Statistical analysis 
All data are expressed as mean ± SEM. Statistical differences were assessed by paired parametric t-
test or one-way ANOVA followed by Dunnett´s test for multiple comparison (according to normality 
evaluated by Kolmogorov-Smirnov test). As previously reported [29], to normalize values within each 
treatment and minimize intragroup variations in the different in vitro experiments (i.e. different age 
of the tissue donor and metabolic environment), the values obtained were compared with vehicle-
treated controls (set at 100%). All experiments were performed in a minimum of three independent 
primary pituitary cultures from different patients (3 – 4 replicates/treatment per experiment), unless 
otherwise indicated. p-values ≤0.05 were considered statistically significant and a trend for 
significance was indicated when p-values ranged between >0.05 and <0.1. All statistical analyses 
were performed using GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA). 
 
4. Results 
4.1 Expression profile of SST2, SST5 and D2 and effects of BIM-065 on ACTHomas 
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SST2, SST5 and D2, the target receptors for BIM-065, were highly expressed in human ACTHomas, with 
relative order of D2T>D2L>SST5>>SST2 (Fig-1A), suggesting that corticotropinomas represent an 
appropriate model to test the effect of the new dopastatin compound. We also measured the 
expression of the two truncated SST5 variants, SST5TMD4 and SST5TMD5, since the presence of these 
isoforms have been associated to a poor response to SSAs [7, 37]; however, the expression levels of 
these truncated SST5 variants were negligible (less than 10 copies) in this cohort of samples. 
Incubation of cultured ACTHoma cells with different doses of BIM-065 (10-9 to 10-6 M) revealed clear 
inhibitory effects on cell viability (Fig-1B). Interestingly, the four doses employed reduced cell 
viability at similar levels after 48-72h of incubation. It should be noted that, due to the limited 
number of cells available for the culture experiments, we could not test a wider range of doses; 
however, we had the opportunity to expand the doses employed in one ACTHoma cell preparation, 
in which a clear dose-response reduction on cell viability was observed at lower concentrations of 
BIM-065 (10-13 to 10-9 M; Supplementary Figure 1A). Specifically, BIM-065 does not seem to 
significantly alter cell viability at 10-13 or 10-11 M, whereas, as previously observed (Fig-1B), it clearly 
reduced this parameter at 10-9 M after 72h of incubation (Supplementary Figure 1A). Based on these 
results and, in order to compare the effects of BIM-065 with previously selected, efficacious doses of 
SSAs (i.e. octreotide and pasireotide) and BIM-23A760 (the first generation dopastatin compound) in 
PA cell cultures [8, 28], we selected the 10-7 M dose in further experiments.  
Our results indicated that BIM-065 and octreotide produced a comparable significant reduction on 
cell viability in ACTHoma cell cultures (31.1% vs. 26.1%); however, pasireotide did not significantly 
alter cell viability (Fig-1C). Interestingly, we could also compare the effects of BIM-065 and octreotide 
at a lower dose (10-9 M) in an ACTHoma cell preparation, and the results clearly indicated that BIM-
065 seems to be more effective than octreotide in reducing cell-viability after 72h of incubation (41% 
vs. 10%, respectively; Supplementary Figure 1B). In addition, we observed that incubation with BIM-
065 (10-7 M) increased apoptosis after 24h compared with vehicle-treated controls (Fig-1D). 
Moreover, BIM-065 also appeared to decrease ACTH release in all ACTHomas analyzed, although this 
difference did not reach statistical significance probably due to the limited number of samples 
(p=0.07; Fig-1E); whereas, it did not alter mRNA expression levels of POMC (ACTH-precursor), 
somatostatin and dopamine receptors (SST2, SST5, D2T, D2L; Fig-1F) or tumor markers commonly 
associated with progression and aggressiveness of PitNETs such as PTTG1, CDKN1B and CDK2 [38-40] 
(Supplementary Figure 5A).  
We also analyzed the direct effects of BIM-065 on [Ca2+]i dynamics in single cells, since this is a key 
second messenger involved in the regulation of pituitary cell physiology and is closely related to 
hormone secretion through the modulation of secretory vesicle release [30, 41, 42]. This showed that 
BIM-065 treatment evoked a rapid inhibitory effect in the kinetics of [Ca2+]i in all ACTHomas cases 
analyzed (3/3), exhibiting an averaged 26.4% of reduction in 44% of responsive corticotropinoma 
cells (Fig-1G). Finally, to further test the capacity of BIM-065 to induce functional responses in 
pituitary tumor cells, we measured the levels of phosphorylation of several components of two 
important signaling pathways (MAPK and PI3K-Akt) in the PitNET derived cell line AtT-20 (Fig-2). As 
previously observed in primary ACTHoma cell cultures, treatment with BIM-065 (10-7 M) markedly 
reduced cell proliferation in cultured AtT-20 cells as compared to vehicle-treated controls (Fig-2A). 
Interestingly, short-term incubation with BIM-065 (10 min) clearly increased p-Akt (p=0.004), which 
was followed by a clear reduction of the anti-apoptotic protein Bcl-2 (Fig-2B). In contrast, long-term 
incubation with BIM-065 (24h) up-regulated p-ERK1/2 levels, although this latter effect did not reach 
statistical significance (p=0.1; Fig-2B). 
4.2 Expression profile of SST2, SST5 and D2 and effects of BIM-065 on GHomas 
Similar to ACTHomas, SST2, SST5 and D2 were highly expressed in human GHomas, with relative order 
of D2T>D2L>SST5>>SST2 (Fig-3A). This expression profile is consistent with previous results evaluating 
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and comparing the mRNA levels and protein content [43, 44], therefore supporting that 
somatotropinomas also represent an appropriate model to test the effect of BIM-065. It should be 
mentioned that the expression levels of the truncated SST5 variants were also negligible in this set of 
samples. 
Specifically, treatment with BIM-065 (10-7 M) significantly decreased cell viability in GHoma cell 
cultures after 72h of incubation. Our data also revealed that the efficacy of BIM-065, octreotide and 
pasireotide to reduce cell viability was comparable in GHoma cell cultures (35.6%, 24.7%, 41.8%, 
respectively; Fig-3B) with respect to vehicle-treated control. BIM-065 also increased apoptosis (Fig-
3C), and strongly reduced GH secretion after 24h of incubation (Fig-3D). In line with this, we also had 
the opportunity to compare the effects of BIM-065 vs. octreotide/pasireotide (10-7M) in two 
independent GHoma cell cultures and found that all the compounds inhibited GH release 
(Supplementary Figure 2).  
Treatment with BIM-065 did not alter the mRNA expression levels of GH or other genes of interest 
mentioned above [SST2, SST5, D2T, D2L (Fig-3E); PTTG1, CDKN1B and (Supplementary Figure 5B)], 
except for CDK2, whose expression increased in response to BIM-065 compared to vehicle treated-
control (Supplementary Figure 5B). Finally, BIM-065 treatment clearly reduced [Ca2+]i levels (32.74% 
of reduction) in 2 out of the 3 GHomas analyzed, affecting the 30% of cells (Fig-3F).  
4.3 Expression profile of SST2, SST5 and D2 and effects of BIM-065 on NFPAs  
NFPAs expressed high levels of SST2, SST5 and D2, and negligible levels of truncated SST5TMD4 and 
SST5TMD5, with relative order of D2T>D2L>>SST2>SST5 (Fig-4A). Remarkably, in contrast to that found 
with ACTHomas and GHomas, none of the NFPAs analyzed in this study responded to BIM-065 in 
terms of cell viability (Fig-4B; Supplementary Figure 3). Conversely, similar to ACTHomas and 
GHomas, NFPA cells were clearly responsive to BIM-065 in terms of increase in apoptosis (Fig-4C) and 
reduce of CgA-secretion (Fig-4D) after 24h of incubation. Moreover, as we observed with ACTHomas 
and GHomas, treatment with BIM-065 did not produce any significant alteration in the mRNA 
expression levels of gonadotropin pituitary hormones (FSHB, LHB or CGA), SST2, SST5, D2T, D2L (Fig-
4E) or of the tumor markers PTTG1 or CDK2, while CDKN1B expression slightly decreased in response 
to BIM-065 compared to vehicle treated-control (Supplementary Figure 5C). Finally, BIM-065 
treatment also reduced [Ca2+]i levels (30.18% of reduction) in 2/3 NFPAs analyzed but only in a 
limited percentage of NFPA cells (27%) as compared to ACTHoma and GHoma cells (43.50% or 
30.43%, respectively; Fig-4F). 
4.4 Expression profile of SST2, SST5 and D2 and effects of BIM-065 on PRLomas 
 We also had the opportunity to analyze the expression levels of SST2, SST5, D2s and truncated SST5 
variants in two available PRLoma samples and to test the response to BIM-065. Specifically, PRLoma 
cells expressed high levels of D2 compared with SST2 and SST5 (and negligible levels of truncated SST5 
variants), with relative order of D2T>D2L>>>>SST5 in PRLoma-1 and D2T>D2L>>>>SST2> in PRLoma-2 
(Supplementary Figure 4A). BIM-065 decreased cell viability at all the doses tested after 72h of 
incubation (Supplementary Figure 4B) and this reduction was seemingly more pronounced than the 
effect of cabergoline (34.92% vs 15.4%, respectively; Supplementary Figure 4C). A decrease of PRL 
secretion was also observed in response to BIM-065 compared with vehicle-treated control after 24h 
of incubation (Supplementary Figure 4D). Similar to than previously observed in other cultured 
PitNET cell types, the expression levels of PRL, SST2, SST5, D2T and D2L were not significantly altered in 
response to BIM-065 (Supplementary Figure 4F). Moreover, BIM-065 treatment did not alter [Ca2+]i 
kinetics in the PRLoma analyzed (Supplementary Figure 4E).  
 
5. Discussion/Conclusion 
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In the present study, we have tested, for the first time and in a representative set of distinct PitNETs 
subtypes, the actions of a new peptidic chimeric compound, called BIM-065. BIM-065 has been 
designed with the same affinity to bind SST2, higher affinity to bind SST5 and slightly smaller affinity 
to bind D2 compared to the previous chimeric compound known as BIM-23A760 (binding affinity of 
BIM-065 in nM: 0.03 for SST2; 0.5 for SST5 and 27.2 for D2 [17, 25, 26]). Moreover, this second-
generation dopastatin molecule has been designed with an improved chemical structure to avoid the 
generation of metabolites with potent dopaminergic activity as the one found to accumulate in 
patients enrolled in Phase IIb study in response to BIM-23A760 [17], and also, to avoid the 
paradoxical stimulatory responses found in a small but relevant proportion of pituitary tumor cell 
populations after treatment with this latter compound [8].  
Of particular novelty are the results showing that BIM-065 decreases cell viability, increases 
apoptosis and inhibits ACTH secretion in corticotropinomas, without significantly altering mRNA 
expression levels of the genes of interest at the times evaluated. To our knowledge, this is the first 
time that the effect of a chimeric compound is evaluated in detail in ACTH-secreting PitNETs. 
Although BIM-065 induced a comparable reduction of cell viability than octreotide at 10-7 M, the 
results achieved at 10-9 M revealed a higher reduction of cell viability in response to BIM-065. 
Nevertheless, this observation should be taken with caution, as this comparison could only be tested 
in one ACTHoma. In contrast, pasireotide did not exert an inhibitory effect on cell proliferation 
despite the high expression levels of SST5 and also SST2, which might suggest that additional 
mechanisms distinct from the mere presence of a given receptor are required to exert an anti-
proliferative effect. Indeed, several reports have described that the expression levels of other 
proteins such as filamin A, -arrestins or E-cadherin might be important for SSAs to exert their 
antitumor actions in pituitary tumors [45-49]. Interestingly, results of a previous study from our 
group demonstrated a decrease on ACTH secretion in response to BIM-23A760 in one ACTHoma 
analyzed [8], which is in accordance with the results of this report. In the same line, we observed a 
reduction on [Ca2+]i  levels in all ACTHomas tested in response to BIM-065, which is also in 
accordance with the [Ca2+]i  response observed in the previous study. Indeed, the reduction of [Ca2+]i  
levels was similar in both studies (26.4% of decrease in response to BIM-065 vs 27% of decrease 
observed in response to BIM-23A760) but the percentage of responsive cells was higher with BIM-
065 than with BIM-23A760 (43.50% vs 24.0%, respectively) [8]. Of note, in contrast with the previous 
study, we did not observe any stimulatory effect in response to BIM-065 in the ACTHomas tested. In 
addition, we also demonstrate that treatment with BIM-065 increased p-Akt and p-ERK1/2 levels and 
decreased Bcl-2 in AtT-20 cells. These two pathways are tightly linked to cell growth, proliferation 
and survival in tumor pathologies, including PitNETs [50, 51], albeit they displayed a distinct temporal 
course: p-Akt increased acutely, at 10 min, while p-ERK1/2 levels raised after long-term, 24h-
incubation. A similar stimulatory response in ERK1/2 levels has been previously reported in PitNET 
cells after treatment with BIM-23A760 and the dopaminergic agonist BIM-53097, which was mainly 
associated to an activation of the dopaminergic signaling through D2 that contributed to the 
antiproliferative effects of the two compounds in NFPA cell cultures [22]. Therefore, our results 
might suggest that the effects of BIM-065 on p-ERK1/2 and p-Akt proteins might be associated to a 
preferential activation of the D2/dopaminergic-signaling. Moreover, the decrease in Bcl-2 levels 
support the increase of apoptosis observed in response to BIM-065 in PitNETs. Therefore, the data 
presented provide novel evidence regarding how this new compound regulates some key 
intracellular signaling pathways in PitNETs cells. It should be noted that although a side-by-side study 
comparing BIM-065 and BIM-23A760 might have been interesting to make direct comparisons 
between both dopastatin compounds, the limitation of PitNET samples and the fact that BIM-23A760 
was withdrawn from clinical development, prompted us to disregard this option and to implement 
the direct, side-by-side comparison of BIM-065 with treatments currently used in medical practice 
(octreotide and pasireotide). 
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Results on GH-secreting PitNETs revealed that BIM-065 also induced profound direct actions on this 
tumor type, where we observed a higher reduction of cell viability and a comparable increase of 
apoptosis compared with our previous results with BIM-23A760 in somatotropinomas [8]. In the case 
of GH secretion, we observed a 53.2% of reduction of GH release, which is more striking than the 
decrease produced in response to BIM-23A760 or other chimeric compounds (SST2-SST5 or SST2-D2) in 
somatotropinomas or GH3 pituitary cell line [8, 18, 24, 52]. These results are in agreement with a 
very recent report showing that BIM-065 can reduce GH and IGF1 levels in healthy male volunteers 
with a safety and tolerability profile only limited by orthostatic hypotension [53]. On the other hand, 
treatment with BIM-065 was not accompanied by decreased GH mRNA levels after long-term 
exposition (24h) in human GH-secreting PitNETs, which is in contrast to our previous results with 
BIM-23A760 [8], but compares well with the results reported by Gruszka et al. in response to BIM-
23A760 and BIM-23A761 [24]. Comparison of GH reduction between BIM-065 and SSAs did not show 
any relevant difference in the cases analyzed. Nevertheless, further experiments testing different 
BIM-065 doses and in additional tumor preparations will be necessary to unequivocally establish 
whether BIM-065 is more potent and efficacious than SSAs in somatotropinomas. An initial analysis 
of the possible mechanisms involved in the functional response observed in these tumors revealed 
that the new dopastatin evoked a clear reduction on [Ca2+]i  levels, which also agrees with the 
predominant inhibitory responses observed by our group in the face of BIM-23A760 [8]; yet, in clear 
discrepancy with that observed previously for BIM-23A760 in somatotropinomas [8], but in line with 
our present results in ACTHomas, we did not detect herein any stimulatory response from 
somatotropinoma cells.  
It is currently rare to have access to PRLoma samples for in vitro testing, given, fortunately, to the 
frequent success of dopamine agonists treatment regimens to control or even cure this type of 
tumors. However, in the course of this study we had the opportunity to test this compound on two 
PRL-secreting PitNETs. Interestingly, we observed clear differences in the response to BIM-065 and 
cabergoline in terms of cell viability between the two PRLomas analyzed, which could be due to their 
differential receptor expression pattern. Thus, the tumor that was highly responsive to BIM-065 
expressed higher levels of SST5 compared to SST2 and higher levels (and similar between them) of 
both isoforms of D2, which is a comparable expression pattern to that found in the rest of functioning 
PitNETs analyzed. Furthermore, these data are in line with previous results reporting that 
dopaminergic contribution is more important for the response to chimeric compounds, such as BIM-
23A760, than the expression of SST2 [54]. Consistent with previous results observed with chimeric 
compounds [8, 24], a profound decrease on PRL release was detected in response to BIM-065; 
whereas, in contrast with the data reported so far in human PRLomas, rat pituitary cell cultures and 
MMQ cell line [8, 24, 52], no changes were found on PRL mRNA levels. Nonetheless, our results 
showing that BIM-065 is able to decrease PRL release compare favorably with a very recent report 
showing that this compound inhibited PRL levels in healthy male volunteers [53].  Obviously, 
additional experiments are necessary to confirm/complement the results obtained herein, and to 
explore the signaling pathways involved, particularly given the unexpected observation that the 
effects observed in PRLomas did not seem to be accompanied by parallel changes in [Ca2+]i  dynamics.  
In contrast to previous results from our group and others with other dopastatins [8, 21], NFPA 
primary cell cultures did not show relevant alterations in terms of cell viability in response to BIM-
065. Yet, surprisingly, the treatment with BIM-065 did induce a clear increase on apoptotic rate and a 
significant decrease in CgA in all cases tested. Although the vast majority of observations suggest that 
the cell proliferation and programmed cell death are effectively coupled [55, 56], there are several 
studies showing an imbalance between cell proliferation/survival index and apoptosis in pathological 
conditions such as breast, lung or colorectal cancer [57-59].  Nevertheless, this observation is both, 
clinically relevant for this difficult-to-treat type of tumor, and biologically intriguing, and therefore 
further studies are warranted to explore the reasons why cell proliferation and apoptosis are 
apparently uncoupled in response to BIM-065 in NFPA primary cell cultures.  
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In summary, our data provide compelling evidence demonstrating that BIM-065 can directly and 
profoundly alter cell function and behavior in the most relevant subtypes of PitNETs. While not 
universal for all tumor types, BIM-065 acted reducing cell viability, likely by increasing apoptosis, and 
inhibiting hormone secretion, mostly by reducing [Ca2+]i levels. Importantly, in contrast to previous 
dopastatin, treatment with BIM-065 did not evoke any stimulatory action in the tumor cells analyzed, 
while the proportion of responsive tumors/cells was higher with this compound than with BIM-
23A760, suggesting that this novel dopastatin is a more efficacious and specific chimeric compound 
that could become a useful tool in the future treatment of PitNETs. Indeed, this compound could be 
used to treat patients harboring NFPAs without a clear indication of surgical resection, patients with 
a tumor residue or with hormone hypersecretion persistence after transsphenoidal surgery or to 
control hormone hypersecretion and reduce tumor growth before surgery. In any case, further 
studies should be implemented to confirm and expand the original results provided herein, and a 
randomized clinical trial comparing BIM-065 with the pharmacological options currently available 
should be performed. Thus, this new generation chimeric compound may hopefully help to enhance 
the currently scarce pharmacological arsenal for the treatment of patients harboring PitNETs. 
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10. Figure Legends 
Figure 1: ACTH-secreting adenomas. (A) Expression profile of SST2, SST5, D2 (total and long isoforms), 
SST5TMD4 and SST5TMD5 (n=5). (B) Dose-response experiment of cell viability in response to BIM-
065 (10-9 to 10-6 M; n=3). (C) Effect of BIM-065, octreotide and pasireotide on cell viability (10-7 M; 
n=3-6; 24 – 72h treatment). (D) Effect of BIM-065 (n=3) on apoptosis (24h treatment). (E) 
Measurement of ACTH secretion (24h treatment; n=3). (F) mRNA expression levels of key genes in 
response to BIM-065 measured by qPCR and adjusted by normalization factor (NF) (n=4). (G) 
Summarized table and representative profile of [Ca2+]i kinetics assay in response to BIM-065 (n=3). 
PRC, proportion of responsive cells showing changes in [Ca2+]i in response to the treatment; PMR, 
percentage of maximum response; and time, time of response to treatment administration. Data are 
expressed as percent of vehicle-treated controls (set at 100%) within experiment. Values represent 
the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 
differences.  
Figure 2: AtT-20 corticotrope cell line. (A) Effect of BIM-065 (10-7 M; n=5) of cell proliferation (24 – 
72h treatment), measured by Alamar-blue reduction. (B) Representative Western Blots and 
quantification of levels of p-Akt/total Akt, Bcl-2/ponceau and p-ERK1/2/ total ERK1/2 in response to 
BIM-065 (10-7 M; n=3). Data are expressed as percent of vehicle-treated controls (set at 100%) within 
experiment. Values represent the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate 
statistically significant differences.  
Figure 3: GH-secreting adenomas. (A) Expression profile of SST2, SST5, D2 (total and long isoforms), 
SST5TMD4 and SST5TMD5 (n=4). (B) Effect of BIM-065, octreotide and pasireotide on cell viability (10-
7 M; n=4; 24 – 72h treatment). (C) Effect of BIM-065 (n=3) on apoptosis (24h treatment). (D) 
Measurement of GH secretion (24h treatment; n=4). (E) mRNA expression levels of key genes in 
response to BIM-065 were measured by qPCR and adjusted by normalization factor (NF) (n=3). (F) 
Summarized table and representative profile of [Ca2+]i kinetics assay in response to BIM-065 (n=3). 
PRC, proportion of responsive cells showing changes in [Ca2+]i in response to the treatment; PMR, 
percentage of maximum response; and time, time of response to treatment administration. Data are 
expressed as percent of vehicle-treated controls (set at 100%) within experiment. Values represent 
the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 
differences. 
Figure 4: Non-functioning pituitary adenomas. (A) Expression profile of SST2, SST5, D2 (total and long 
isoforms), SST5TMD4 and SST5TMD5 (n=3). (B) Effect of BIM-065 on cell viability (10-7 M; n=8; 24 – 
72h treatment), measured by Alamar-blue reduction. (C) Effect of BIM-065 (n=3) on apoptosis (24h 
treatment), measured by Caspase-Glo 3/7 assay. (D) Measurement of Chromogranin A secretion (24h 
treatment) (n=3), determined by commercial ELISA kit. (E) mRNA expression levels of key genes in 
response to BIM-065 were measured by qPCR and adjusted by normalization factor (NF) (n=3). (E) 
Summarized table and representative profile of [Ca2+]i kinetics assay in response to BIM-065 (n=3). 
PRC, proportion of responsive cells showing changes in [Ca2+]i in response to the treatment; PMR, 
percentage of maximum response; and time, time of response to treatment administration. Data are 
expressed as percent of vehicle-treated controls (set at 100%) within experiment. Values represent 
the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate statistically significant 
differences. 
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Supplementary Figure 1: ACTH-secreting adenomas. (A) Dose-response experiment of cell viability in 
response to BIM-065 (10-13 to 10-9 M; n=1), measured by Alamar-blue reduction. (B) Comparison of dose-
response experiment between BIM-065 and octreotide on cell viability (10-11 to 10-7 M; n=1), measured 
by Alamar-blue reduction. Data are expressed as percent of vehicle-treated controls (set at 100%) within 
experiment. In cases where less than three experiment were carried out, no significance tests were 
performed.  
 
Supplementary Figure 2: GH-secreting adenomas. Direct effect of BIM-065, octreotide and pasireotide 
on GH secretion (24h treatment; n=2), determined by commercial ELISA kit. Data are expressed as percent 
of vehicle-treated controls (set at 100%) within experiment. Values represent the mean ± SEM. In cases 
where less than three experiment were carried out, no significance tests were performed.  
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Supplementary Figure 3: Non-functioning pituitary adenomas. Dose-response experiment of cell viability 
in response to BIM-065 (10-9 to 10-6 M; n=3), measured by Alamar-blue reduction. Data are expressed as 
percent of vehicle-treated controls (set at 100%) within experiment. Values represent the mean ± SEM. 
 
Supplementary Figure 4: PRL-secreting adenomas. (A) Expression profile of SST2, SST5, D2 (total and long 
isoforms), SST5TMD4 and SST5TMD5 of two different PRLomas. (B) Dose-response experiment of cell 
viability in response to BIM-065 (10-9 to 10-6 M; n=1), measured by Alamar-blue reduction. (C) Effect of 
BIM-065 and cabergoline on cell viability (10-7 M; 24 – 72h treatment) in two different PRLomas, measured 
by Alamar-blue reduction. (D) Measurement of PRL secretion (24h treatment) (n=1), determined by 
commercial ELISA kit. (E) mRNA expression levels of key genes in response to BIM-065 were measured by 
qPCR and adjusted by normalization factor (NF) (n=1). (F) Representative profile of [Ca2+]i kinetics assay 
in response to BIM-065 (n=1). Data are expressed as percent of vehicle-treated controls (set at 100%) 
within experiment. Values represent the mean ± SEM. In cases where less than three experiment were 
carried out, no significance tests were performed. 
 
 
Supplementary Figure 5: Expression profile of tumor markers (PTTG1, CDKN1B and CDK2) in response to 
BIM-065 in different pituitary adenomas, measured by qPCR and adjusted by normalization factor (NF). 
(A) ACTH-secreting PitNETs (n=4); (B) GH-secreting PitNETs (n=3); (C) Non-functioning pituitary adenomas 
(n=3) (D) PRL-secreting PitNETs (n=1). Data are expressed as percent of vehicle-treated controls (set at 
100%) within experiment. Values represent the mean ± SEM. Asterisks (* p<0.05) indicate statistically 
significant differences. In cases where less than three experiment were carried out, no significance tests 
were performed. 
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ABSTRACT 34 
Pituitary neuroendocrine tumors (PitNETs) comprise approximately 15% of all brain 35 
tumors and the majority of them have a sporadic origin. Although some studies have explored 36 
the mutational landscape of PitNETs, there is evidence that additional mechanisms would have 37 
to contribute relevantly to the development and behavior of these tumors. Recent studies 38 
suggest that altered alternative splicing and, consequently, appearance of an abnormal pattern of 39 
splicing and even of aberrant splicing variants, represent a common molecular feature of most 40 
tumor pathologies. Moreover, the spliceosome machinery is emerging as an attractive 41 
therapeutic target to treat tumor pathologies, and, for instance, inhibition of SF3b1 using 42 
pladienolide-B has been shown to exert promising antitumor properties. Therefore, we aimed to 43 
analyze the expression levels of selected splicing machinery components in 261 PitNETs [138 44 
GHomas/90 non-functioning PitNETS (NFPTs)/24 ACTHomas/9 PRLomas]. Additionally, we 45 
evaluated the direct effects of pladienolide-B in cell-proliferation/viability and hormone 46 
secretion in human PitNETs cell cultures and pituitary model cell-lines (AtT-20 and GH3). 47 
Results revealed a severe dysregulation of the expression levels of splicing machinery 48 
components in all the PitNET-subtypes compared to normal pituitaries, which provided unique 49 
fingerprints of splicing components that accurately discriminate between normal and tumor 50 
tissue in each of the PitNET-subtypes analyzed. Results also identified several components 51 
commonly dysregulated in all PitNET-subtypes. Functional assays demonstrated that 52 
pladienolide-B markedly reduced cell-proliferation/viability and GH secretion in PitNET cell-53 
cultures and cell-lines. Altogether, the present results provide novel, compelling evidence to 54 
propose that the splicing machinery is severely and distinctly dysregulated in the main PitNET-55 
subtypes. This discovery opens a new window to investigate the plausible contribution of 56 
splicing dysregulation and its subsequent outcomes to pituitary tumorigenesis, and to assess the 57 
potential value of specific splicing machinery components as novel diagnostic/prognostic tools 58 
in these pathologies. Furthermore, our study unveils splicing, particularly SF3b1, as a novel 59 
actionable therapeutic point that can be targeted by Pladenolide-B to combat PitNETs. 60 
61 
 4 
INTRODUCTION 62 
Pituitary neuroendocrine tumors (PitNETs), formerly referred to as pituitary adenomas, are 63 
more abundant than often thought, for they represent approximately 15% of all brain tumors and 64 
have an estimated prevalence that ranges from 1 in 865-2,688 people [1, 2]. Likewise, PitNETs 65 
have been classically considered as a benign pathology because they rarely metastatize, thus the 66 
term adenomas. However, the great variety of clinical behaviors accompanying these 67 
pathologies, coupled to their diverse and severe associated comorbidities and increased 68 
mortality led the “International Pituitary Pathology Club” to propose, in a recent consensus, a 69 
reclassification of pituitary tumors and to establish the nomenclature of “pituitary 70 
neuroendocrine tumors (PitNETs)” instead of “pituitary adenomas” [3].  71 
Interestingly, the vast majority of PitNETs have a sporadic origin, whereas only a small 72 
percentage (5%) is due to familial tumor syndromes [4, 5]. Moreover, recent studies exploring 73 
the genomic landscape of PitNETs confirmed and extended earlier studies by reporting that all 74 
major tumor subtypes studied present a relatively low number of somatic mutations per tumor, 75 
and that there are scarce recurrent mutations, none of which is commonly found across PitNET 76 
subtypes [6, 7]. Overall, these genomic analyses, albeit highly informative and valuable, support 77 
the contention that mutations and purely genetic alterations alone would not fully explain 78 
PitNET tumorigenesis, and therefore, that alternative oncogenic events, including epigenetic 79 
alterations [8] or miRNAs [9, 10], should be explored further to understand their actual 80 
contribution in this regard. Indeed, the primary initiating cause of PitNETs development and 81 
possible the existence of general and distinctive signatures and molecular elements in this 82 
heterogeneous pathology is still under debate [4, 5, 11-14].  83 
In this scenario, an emerging body of evidence indicates that altered alternative splicing and 84 
its consequent outcome, i.e. the appearance of abnormal patterns of splicing and even that of 85 
aberrant splicing variants, represents a common feature across most tumor pathologies, 86 
including PitNETs [15-22]. Alternative RNA splicing is a common post-transcriptional (i.e. 87 
epigenetic) mechanism that provides a valuable source of biological versatility under 88 
physiological circumstances for most eukaryotic genes (>95%) [23]. The intracellular 89 
 5 
machinery that catalyzes and thereby controls the process of alternative splicing is the 90 
spliceosome, a ribonucleoproteic complex that recognizes specific sequences that determine the 91 
precise localization of the exon-intron junctions [24]. This complex machinery, organized into 92 
two systems, the major and the minor spliceosome, is comprised by structural proteins, splicing 93 
factors (SFs), RNA-dependent ATPase/helicases, and other regulatory proteins [25, 26]. All 94 
these elements cooperate in a highly dynamic fashion to finely regulate the splicing process 95 
[27].  96 
Alterations of spliceosome function can compromise the normal splicing process of an 97 
ample range of genes, thus originating the appearance of multiple, often aberrant splicing 98 
variants, which could be directly associated with the development/progression of tumor 99 
pathologies [17, 18, 21, 22, 28]. Indeed, results from our group have demonstrated that 100 
oncogenic splicing variants from somatostatin and ghrelin systems (SST5TMD4/5 and In1-101 
ghrelin) are poorly expressed in normal tissue but highly expressed in neuroendocrine tumors 102 
(NETs), including PitNETs [17-20, 29, 30], where they increase aggressiveness features. Based 103 
on the above, the spliceosome system is becoming an attractive therapeutic target for tumor 104 
pathologies [31]. This is the case for pladienolide-B, a natural compound that directly targets 105 
and binds a key player in the spliceosome, SF3B1, and thereby inhibits spliceosome functions, 106 
which in turns appear to mediate the antitumor properties of this promising drug [31, 32].  107 
To date, the expression pattern and putative role of the core splicing machinery components 108 
in the development and progression of PitNETs, as well as the potential therapeutic effects of 109 
pladienolide-B in PitNET cells, has not been reported. Accordingly, we aimed to determine and 110 
analyze the expression levels of the spliceosome core components and a selected set of relevant 111 
SFs in the main PitNETs subtypes, i.e. somatotropinomas (GHomas), non-functioning pituitary 112 
tumors (NFPTs), corticotropinomas (ACTHomas) and prolactinomas (PRLomas), as compared 113 
to normal human pituitary gland samples. Additionally, we evaluated the potential antitumor 114 
actions of pladienolide-B in PitNET cells by evaluating key functional parameters (i.e. cell 115 
proliferation/viability and hormone secretion) in human primary PitNETs cell cultures and two 116 
pituitary model cell lines (AtT-20 and GH3). 117 
 6 
MATERIALS AND METHODS 118 
 119 
Drugs and reagents 120 
All reagents and drugs used in this study were purchased from Sigma-Aldrich (Madrid, 121 
Spain) or Fluidigm (San Francisco, CA, USA) unless otherwise specified. Pladienolide-B was 122 
obtained from Santa Cruz Biotechnology (Heidelberg, Germany).  123 
 124 
Patients, samples and primary cell cultures 125 
Human PitNETs samples were collected during transsphenoidal surgery from 171 patients 126 
from Spain (90 NFPTs [mean age: 58 (20-83); 39% women], 48 GHomas [mean age: 43 (21-127 
64); 60 % women; Cohort 1; C1], 24 ACTHomas [mean age: 40 (18-61); 78% women], and 9 128 
PRLomas [mean age: 47 (28-74); 38% women]. Moreover, a second cohort of 90 GHomas from 129 
Brazil (Cohort 2; C2) was obtained. Additionally, 11 normal pituitary glands (NP) [mean age: 130 
61 (44-85); 50% women] were obtained during autopsies. Each pituitary sample subtype was 131 
confirmed by expert anatomo-pathologists and by the molecular screening using quantitative 132 
real-time PCR (qPCR), as previously described [17, 33-35]. In all cases, samples were 133 
immediately placed in sterile cold medium (S-MEM, Gibco, Madrid, Spain; supplemented with 134 
0.1% BSA, 0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2,5% HEPES) after 135 
surgery and rapidly frozen and stored at -80 ºC until extraction for total RNA. In a second set of 136 
experiments, PitNETs samples placed in sterile cold medium after surgery were dispersed into 137 
single cells following the methods and reagents previously described [33, 35]. This study was 138 
carried out within a project approved by our Hospital Research Ethics Committee, was 139 
conducted in accordance with ethical standards of the Helsinki Declaration of the World 140 
Medical Association, and written informed consent was obtained from each patient. 141 
 142 
Cell lines and culturing  143 
The mouse corticotrope pituitary derived cell line AtT-20/D16v-F2 (ATCC® CRL-1795™) 144 
and the rat somatotrope pituitary derived cell line GH3 (ATCC® CCL-82.1™) were used in the 145 
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present study. Both cell lines were checked for mycoplasma contamination by PCR [36], 146 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) complemented with 10% FBS, 100 147 
U/ml penicillin/streptomycin, 0.024 M of HEPES, and maintained at 37ºC and 5% CO2, under 148 
sterile conditions.  149 
 150 
RNA extraction, quantification and reverse transcription 151 
Total RNA from fresh tissue samples was isolated using AllPrep DNA/RNA/Protein Mini 152 
Kit followed by DNase treatment using RNase-Free DNase Set (Qiagen; Limburg, 153 
Netherlands). Total RNA concentration and purity was assessed using Nanodrop 2000 154 
spectrophotometer (Thermo Fisher; Waltham, MA, Estados Unidos), and retro-transcribed using 155 
random hexamer primers with the First Strand Synthesis Kit (Thermo Fisher).  156 
 157 
Analysis of splicing machinery components by a customized qPCR dynamic array 158 
As previously described [37, 38], a 48.48 Dynamic Array based on microfluidic technology 159 
(Fluidigim) was used to determine the expression levels of 48 transcripts in 48 PitNETs 160 
samples, simultaneously. The specific set of primers used in this study has been previously 161 
reported by our group [37, 38], and include components of the major (n=13) and minor (n=4) 162 
spliceosome, associated SFs (n=28) and three reference genes (ACTB, HPRT1 and GAPDH, 163 
used for the normalization of gene expression levels).  164 
We performed a preamplification, exonuclease treatment and the qPCR dynamic array 165 
following the manufacturer’s instructions. Thus, 12.5ng of cDNA of each sample were pre-166 
amplified using 1μL of PreAmp Master Mix (Fluidigm) and 0.5μL of all primers mix (500nM) 167 
in a T100 Thermal-cycler (BioRad, Hercules, CA, USA), using the following program: 1) 2 min 168 
at 95 ºC; 2) 15 sec at 94 ºC and 4 min at 60 ºC (14 cycles). Then, samples were treated with 2μL 169 
of 4U/μL Exonuclease I solution (New England BioLabs, Ipswich, MA, USA) following 170 
manufacturer’s instructions. Samples were diluted with 18μL of TE Buffer (Thermo Scientific), 171 
and 2.7μL were mixed with 3μL of EvaGreen Supermix (Bio-Rad) and 0.3μL of DNA Binding 172 
Dye Sample Loading Reagent (Fluidigm). Primers were diluted to 5μM with 2X Assay Loading 173 
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Reagent (Fluidigm). Control line fluid was charged in the chip and Prime script program was 174 
run into the IFC controller MX (Fluidigm). Finally, 5μL of each primer and 5μL of each sample 175 
were pipetted into their respective inlets on the chip and the Load Mix script in the IFC 176 
controller software was run. After this program, the qPCR was run using Biomark System 177 
(Fluidigm) with the following thermal profile: 1) 1 min at 95 ºC; 2) 35 cycles of denaturing (5 178 
sec at 95 ºC) and annealing/extension (20 sec at 60 ºC); and 3) a last cycle where final products 179 
were subjected to graded-temperature-dependent dissociation (60 ºC to 95 ºC, increasing 1ºC/3 180 
sec). Results were processed with Real-Time PCR Analysis Software 3.0 (Fluidigm).  181 
 182 
Measurement of cell proliferation/viability 183 
As previously reported [17, 33, 34], 10,000 cells per well (for PitNET cells) and 6,000 cells 184 
per well (for cell lines) were plated in 96-well plates to measure cell proliferation/viability every 185 
24h until 72h using Alamar-blue reagent (Invitrogen, Madrid, Spain). Pladienolide-B was daily 186 
refreshed after each measurement, and cell proliferation/viability was evaluated using Flex-187 
Station III System (Molecular Devices, Sunnyvale, CA, USA). 188 
 189 
Measurement of hormone secretion 190 
We plated 150,000-200,000 cells per well in 24-well plates in serum-containing media. GH-191 
secreting PitNETs cells were used to analyze the effect of pladienolide-B on GH secretion after 192 
24h of incubation in serum-free media. GH was measured using human commercial ELISA kit 193 
(reference number: EIA-3552; DRG, Mountainside, NJ), according to the manufacturer’s 194 
instructions.  195 
 196 
Statistical analysis 197 
All data were evaluated for heterogeneity of variance using the Kolmogorov-Smirnov test. 198 
Statistical differences from qPCR dynamic array results were evaluated by unpaired 199 
nonparametric Mann Whitney test and data were expressed as mean  interquartile range. As 200 
previously reported [18, 30], ROC curves were used as a tool to measure how well the 201 
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expression of splicing machinery components could discriminate between different diagnostic 202 
groups. Statistical analysis of ROC curves was performed by calculating the Area Under the 203 
Curve (AUC) of each component and comparing them with the AUC of the reference line using 204 
Student’s t-test. Heatmaps and clustering analysis were performed using MetaboAnalyst 3.0 205 
[39]. Statistical analyses from functional assays were assessed by paired parametric t-test or 206 
one-way ANOVA test followed by Dunnett’s test for multiple comparisons, and data were 207 
expressed as mean  SEM. As previously reported, to normalize values within each treatment 208 
and minimize intragroup variations in the different in vitro experiments (i.e., different age of the 209 
tissue donor or metabolic environment), the values obtained were compared with vehicle-treated 210 
controls (set at 100%). All experiments were performed in a minimum of three different primary 211 
pituitary cultures from different patients (three or four replicates per treatment per experiment), 212 
unless otherwise specified. P values  0.05 were considered statistically significant. A trend for 213 
significance was indicated when P values ranged between >0.05 and <0.1. All statistical 214 
analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).  215 
216 
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RESULTS 217 
 218 
Dysregulation of splicing machinery in NFPTs 219 
Results from a dynamic qPCR microfluidic custom-made array revealed a marked 220 
dysregulation of the expression levels of several components of the splicing machinery in 221 
NFPTs compared to NPs, wherein most elements were clearly downregulated (20 out of 44) or 222 
exhibited a trend to be downregulated in NFPTs (Figure-1A; Supplemental Figure-S1). 223 
Specifically, NFPTs showed a significant downregulation of 3 major spliceosome components 224 
(RNU6, U2AF1 and U2AF2), 2 minor spliceosome components (RNU11 and RNU6ATAC), 225 
and 15 SFs (CELF4, CELF1, ESRP1, SRRM4, PTBP1, RBM17, RBM45, SND1, SRSF1, 226 
SRSF10, SRSF3, SRSF5, SRSF9, TRA2A, and TRA2B) (Figure-1A and Supplemental Figure-227 
S1). Moreover, although non-supervised hierarchical analysis based on the expression pattern of 228 
all spliceosome components and SFs analyzed was not able to appropriately separate NFPTs 229 
from NPs (Figure-1B), Partial Least Squares-Discriminant (PLS-DA) analysis suggested the 230 
possibility of discriminating between NFPTs and NPs using the expression pattern of 231 
spliceosome components and SFs (Figure-1C). Indeed, Variable Importance in Projection (VIP) 232 
score of PLS-DA analysis indicated that SRSF9, SND1, U2AF1 and CELF4 were the 233 
components with higher capacity to discriminate between both populations (Figure-1D). In fact, 234 
although the heatmap generated with the expression of these four components did not produce a 235 
complete clustering of NFPTs and NPs, it was able to cluster together all NP-samples 236 
independently of NFPT samples. Moreover, ROC curve analyses of these 4 components 237 
corroborated their capacity to discriminate between NFPTs and NPs showing an AUC of 0.94, 238 
0.94, 0.93 and 0.89, respectively (p<0.001; Figure-1F).  239 
 240 
Dysregulation of splicing machinery in GHomas 241 
In GH-secreting PitNETs, a clear dysregulation of splicing machinery components was also 242 
found compared to NPs (expression of 24 out of 44 elements were significantly altered; Figure-243 
2A and supplemental Figure-S2). Specifically, analysis of cohort-1 of GHomas (tumors from 244 
 11 
Spain) showed an overexpression of 6 major spliceosome components (SNRNP200, U2AF1, 245 
U2AF2, TCERG1, PRPF8 and RBM22), a downregulation of one component of the minor 246 
spliceosome (RNU11), and 17 significantly altered SFs [16 upregulated (CELF4, CELF1, 247 
MAGOH, SRRM4, SPFQ, PTBP1, RAVER1, RBM17, RBM3, KHDRSB1, SRSF2, SND1, 248 
SRRM1, SRSF3, SRSF5, SRSF6, SRSF9, TIA1 and TRA2B) and one downregulated (ESRP2)] 249 
(Figure-2A and supplemental Figure-S2). A non-supervised hierarchical analysis with the 250 
expression levels of all the splicing machinery components was able to cluster together all NP-251 
samples independently of GHoma samples, but did not generate a complete clustering of 252 
GHomas and NPs (Figure-2B). However, PLS-DA analysis showed a clear segregation between 253 
GHomas and NPs (Figure-2C) and further analysis revealed that the pattern of three SFs with 254 
the highest score in the VIP analysis (RAVER1, RBM3 and SRSF6; Figure-2D) was able to 255 
discriminate between GHomas and NPs in two perfect clusters (Figure-2E). Moreover, ROC 256 
curve analyses of these three SFs (RAVER1, RBM3, and SRSF6) showed an AUC of 0.99, 1, 257 
and 0.98, respectively (Figure-2F). Additionally, we had the opportunity to corroborate these 258 
results in another cohort of GHomas from Brazil (cohort-2; C2). In this case, we confirmed the 259 
overexpression of RAVER1 and RBM3, but not SRSF6, in this cohort of GHomas compared to 260 
NPs. Moreover, ROC curves analyses of RAVER1 and RBM3, but not of SRSF6, confirmed 261 
their capacity to discriminate between NPs and the validation cohort (C2; Figure-2F) with an 262 
AUC of 0.77, 0.93, and 0.59, respectively. 263 
 264 
Dysregulation of splicing machinery in ACTHomas 265 
In ACTH-secreting PitNETs, qPCR array revealed a significantly dysregulation of 11 266 
splicing machinery components, two components of major spliceosome (upregulation of U2 and 267 
downregulation of U2AF2) and 9 altered SFs (upregulation of CELF4, MAGOH, NOVA1, 268 
SPFQ, KHDRSB1, SRSF2, SNW1 and TRA2B, and downregulation of ESRP1) (Figure-3A and 269 
supplemental Figure-S3). Non-supervised hierarchical analysis of all splicing machinery 270 
components analyzed did not generate a clustering able to discriminate between ACTHomas 271 
and NPs (Figure-3B) but PLS-DA analysis showed a clear separation between ACTHomas and 272 
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NPs (Figure-3C). Further analysis revealed that the pattern of two SFs with the highest score in 273 
the VIP analysis (MAGOH and KHDRSB1; Figure-3D) was able to discriminate between 274 
ACTHomas and NPs in two perfect clusters (Figure-3E). Moreover, ROC curve analyses of 275 
MAGOH and KHDRSB1 corroborated their capacity to discriminate between ACTHomas and 276 
NPs with an AUC of 1 and 0.97, respectively (Figure-3F). 277 
 278 
Dysregulation of splicing machinery in PRLomas 279 
PRLomas also exhibited a clearly dysregulated expression pattern of spliceosomal 280 
components (18 out of 44) compared to NPs (Figure-4A and supplemental Figure-S4), with a 281 
significant overexpression of 3 major spliceosome components (PRPF40A, PRPF8, and 282 
RBM22), a downregulation of one minor spliceosome components (RNU11), and an alteration 283 
of 14 SFs [12 upregulated (CELF1, MAGOH, SRRM4, PTBP1, RAVER1, RBM3, KHDRSB1, 284 
SRSF2, SNW1, SRSF3, SRSF6, and TIA1) and 2 downregulated (ESRP2 and SRSF1)] (Figure-285 
4A and supplemental Figure-S4). Although the non-supervised hierarchical analysis did not 286 
identify a perfect clustering between PRLomas and NPs, both populations were visually well 287 
differentiated in the heatmap (Figure-4B). However, although PLS-DA analysis suggested a 288 
different expression pattern between PRLomas and NPs (Figure-4C) and VIP analysis revealed 289 
several components with high capacity to discriminate between both populations (Figure-4D), 290 
any combination of these high-scored factors was able to improve the clustering to discriminate 291 
between PRLomas and NPs (Figure-4E). The best combination included minor spliceosome 292 
components and SFs (RNU11, ESRP2, RNU6ATAC, SRSF1, and ESRP1) with an AUC of 293 
0.96, 0.91, 0.73, 0.76, and 0.74, respectively (Figure-4F). 294 
 295 
Similar dysregulation of specific splicing machinery components in all PitNET subtypes.  296 
A fold-change representation of the splicing machinery alterations in all PitNETs subtypes 297 
analyzed revealed a common fingerprint between all of them (Supplemental Figure-S5A). 298 
Specifically, we found a common downregulation of three minor spliceosome components 299 
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(RNU11, RNU4ATAC and RNU6ATAC) and one SF (SRSF1). However, these changes did 300 
not reach statistically significance in all of them (Supplemental Figure-S5B). 301 
 302 
Effect of Pladienolide-B treatment in PitNETs cells.  303 
Dose-response experiments using pladienolide-B in pituitary cell lines, corticotrope AtT-20 304 
and somatotrope GH3, at different times of incubation showed that lower doses of pladienolide-305 
B (10-9 and 10-11 M) did not alter cell proliferation at any of the times tested (Figure-5A). In 306 
contrast, 10-7M pladienolide-B markedly decreased cell proliferation at 24, 48 and 72h in both 307 
cell lines (Figure-5A). Based on these results, the 10-7M dose of pladienolide-B was used in 308 
NFPT, GHoma and ACTHoma cell cultures, which revealed that cell viability was clearly 309 
reduced after 72h of incubation in NFPTs, and after 48 and 72h of incubation in GHomas cell 310 
cultures. In ACTHomas, results revealed a clear numerical decrease of cell viability after 72h of 311 
incubation, but these results could not be analyzed statistically, due to the limited number of 312 
samples available to be tested with this PitNET subtype (n=2). Finally, treatment with 313 
pladienolide-B significantly reduced GH secretion after 24h of incubation in GHomas.  314 
315 
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DISCUSSION 316 
Evidence gathered over the last years indicates that tumor pathologies, including NETs 317 
share as a common feature the altered expression of functionally and pathologically relevant 318 
splicing variants of diverse molecules, from membrane receptors to key signaling enzymes 319 
(DLK1, GHRHR, IGF1R, EGFR, CSH2 or PTEN) [40-44]. Actually, results from our group led 320 
to the identification of previously unrecognized aberrant splicing variants from somatostatin and 321 
ghrelin systems (SST5TMD4/5 and In1-ghrelin), and demonstrated that these variants are 322 
overexpressed in tumors and can contribute to their oncogenesis, increasing aggressiveness and 323 
malignant features in different tumor types, including PitNETs [17-22, 30, 45, 46]. To ascertain 324 
the potential mechanisms underlying the genesis of these tumor-related abnormal splicing 325 
events, we hypothesized that they could be linked to alterations in the machinery responsible for 326 
this process, i.e. the spliceosome core and its associated SFs. In line with this notion, mutations 327 
and other functional defects in certain spliceosome components have been reported to cause 328 
diverse pathologies, including cancer [47]. Accordingly, the present study was devised to 329 
determine the pattern of expression of the splicing machinery in the main types of PitNETs and 330 
to assess the potential existence of specific alterations in spliceosome components and SFs 331 
associated to each type of tumor, which may serve as future tools to guide the 332 
diagnostic/prognostic of these tumors, and could  provide novel actionable therapeutic targets. 333 
Indeed, results from this study demonstrate, for first time, that the splicing machinery 334 
(spliceosome and SFs) is distinctly dysregulated in PitNETs compared to NP glands, and that its 335 
modulation with a specific drug targeting SF3b1, a key player in the spliceosome function, 336 
decreases aggressiveness features in PitNET cell cultures. 337 
One of the main findings of this study is the discovery that the spliceosome machinery is 338 
dysregulated in a tumor subtype-dependent manner, where NFPTs, GHomas, ACTHomas and 339 
PRLomas exhibit a differentially altered pattern of expression. Of particular interest are the 340 
results found in NFPTs, which displayed a profound downregulation of most of the components 341 
analyzed, in striking contrast with the alterations observed in functioning PitNETs (GHomas, 342 
ACTHomas and PRLomas). In line with this, previous results have demonstrated that NFPTs 343 
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have a dissimilar behavior and different expression pattern of relevant components involved in 344 
pituitary cell function, such as somatostatin receptors, in comparison with functioning PitNETs 345 
and normal tissue [33, 48-50]. Interestingly, our results showed that the expression levels of 346 
SRSF9, SND1, U2AF1 and CELF4 were able to discriminate, although not perfectly, between 347 
NFPTs and NP tissues. The absence of a perfect discrimination between both populations could 348 
be due to the intrinsic heterogeneous nature of NFPTs [51]. Nonetheless, a clear alteration of 349 
these spliceosome components found in our cohort of NFPTs has also been observed in other 350 
tumor pathologies. Specifically, SRSF9 and SND1 have been found overexpressed in several 351 
tumor pathologies such as breast cancer, bladder cancer, glioblastoma, melanoma or 352 
hepatocellular carcinoma, where they have been related with an increase in cell proliferation, 353 
invasion and poor prognosis [52-56]. Moreover, CELF proteins have been reported to target and 354 
regulate the splicing of neurofibromatosis type 1 (NF1) protein generating a protein with the 355 
exon 23a excluded, which has 10 times greater ability to regulate Ras signaling, a main 356 
component of MAPK signaling pathway [57]. In addition, U2AF1 is an important component of 357 
the major spliceosome that has been found frequently mutated and associated to the generation 358 
of particular splicing patterns in several pathologies, including the production of oncogenic 359 
splicing variants in cancer [58, 59]. In this sense, our data showed a clear downregulation of 360 
U2AF1 in NFPTs compared to NPs, which might suggest that not only the mutation pattern but 361 
also the expression pattern could be involved in the malignant behavior of tumor pathologies 362 
including NFPTs.  363 
In a first cohort of GHomas, we found a profound overexpression of three SFs, RAVER1, 364 
RBM3 and SRSF6, whose expression pattern clearly discriminated between GHomas and NPs. 365 
Importantly, the altered expression pattern of RAVER1 and RBM3 was corroborated in a 366 
second, independent cohort of GHomas. Interestingly, previous results from our group have 367 
revealed that the alteration of these spliceosome components could be associated to the 368 
development of different pathological conditions. Indeed, the dysregulation of RAVER1 and 369 
RBM3 has been related with the development of non-alcoholic fatty liver disease [38], while 370 
RAVER1 has been found to be dysregulated in patients with cardiovascular disease at higher 371 
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risk of type-2 diabetes development [37]. But most importantly, additional evidence suggests 372 
that alterations in the expression level of RBM3 could be associated with advanced pathological 373 
tumor stages in lung carcinoma or with aggressive features in esophageal, colorectal or breast 374 
cancer [60-63], which reinforces the crucial role of this factor in tumor pathologies. Moreover, 375 
our results with SRSF6 in the first cohort analyzed are also in accordance with the changes 376 
reported in colorectal cancer, where SRSF6 was associated with poor prognosis and was 377 
postulated as a possible therapeutic target to reduce tumorigenesis [64].  378 
In ACTHomas, our results demonstrated that only the altered expression of two SFs, 379 
MAGOH and KHDRSB1, was sufficient to clearly discriminate between ACTHomas and NPs. 380 
These SFs were significantly upregulated in ACTHomas, which is in accordance with the 381 
increased expression of KHDRSB1 found in gastric cancer, epithelial ovarian cancer or sacral 382 
chordomas, wherein its presence was associated with poor prognosis and aggressive 383 
characteristics [65, 66]. Likewise, MAGOH has been shown to be differentially expressed in 384 
breast cancer, where it served, together with other RNA processing factors, to develop a robust 385 
stratification of breast cancer subtypes [67]. However, the presence and potential role of 386 
KHDRSB1 and MAGOH in PitNETs or normal pituitary has not been reported hitherto. 387 
Our data in PRLomas revealed that only the combination of all spliceosome components 388 
was able to distinguish, although not in a perfect manner, between PRLomas and NPs. 389 
Conversely, the combination of the components with higher score in VIP analysis was not 390 
sufficient to distinguish between both populations. This might probably be associated to the low 391 
number of PRLomas analyzed in this study, owing to the difficulty to have access to this type of 392 
samples since dopamine agonists treatment are highly successful in patients with PRLomas.  393 
Together with the identification of clearly distinct, tumor type-dependent dysregulations of 394 
the components of the splicing machinery, it is worth noting that we also pinpointed a common 395 
downregulation of three minor spliceosome components (RNU11, RNU4ATAC and 396 
RNU6ATAC) and one SF (SRSF1) in most PitNETs, irrespective of their subtype, an 397 
observation which might be patho-physiologically relevant. In particular, SRSF1 has been 398 
described to interact with many different proteins to regulate several cellular functions, 399 
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including of course splicing, and has been found overexpressed in several types of cancer 400 
(breast and lung cancer), where it is considered a proto-oncogene [68]. The fact that these 401 
spliceosome components are similarly dysregulated in all PitNETs, despite the high 402 
heterogeneity of these tumors, invite to speculate about the existence of common driver 403 
alterations in pituitary tumorigenesis, which would pave the way toward the identification of 404 
common therapeutic targets based on the dysregulations of these key elements. However, 405 
further studies should be conducted to test this hypothesis. 406 
Finally, our study also provides an initial unprecedented proof-of-concept on the suitability 407 
of splicing dysregulation as a novel potential target for PitNET treatment, by demonstrating that 408 
the pharmacological disruption of the splicing process with specific drugs may have antitumor 409 
effects in these neoplasms. In particular, we tested the direct effect of pladienolide-B in 410 
different PitNETs subtypes and pituitary cell lines. This compound is able to directly target a 411 
key component involved in the assembly of the spliceosome SF3B1 [69], leading to the 412 
reduction of its activity [70]. Several reports have associated pladienolide-B with antitumor 413 
properties in different cancer types [32, 71-73], but its role in PitNETs was still unknown. Our 414 
results demonstrate for the first time that treatment with pladienolide-B inhibits cell viability/ 415 
proliferation in all PitNETs subtypes tested and in AtT-20 and GH3 cell lines, which is in line 416 
with the reduction on cell viability and colony formation observed in HeLa cells [32]. NFPTs 417 
were less sensitive to the effect of pladienolide-B compared to GHomas or ACTHomas, which 418 
is in line with previous observations in response to other treatments in NFPTs [33, 48, 74]. 419 
Notably, pladienolide-B was also able to reduce GH secretion after 24h of incubation, a relevant 420 
result since tumor hypersecretion is linked to most of the symptoms caused by GHomas. 421 
In summary, the present results provide novel, compelling evidence to propose that the 422 
splicing machinery is severely and distinctly dysregulated in the main subtypes of PitNETs 423 
compared to NPs, and identified unique fingerprints of spliceosome components in each 424 
PitNETs subtype that can accurately discriminate between normal and tumor pituitary tissues. 425 
Furthermore, we also found several components, including SFs (SRSF1) and specially three 426 
minor spliceosome components (RNU11, RNU4ATAC and RNU6ATAC), commonly 427 
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dysregulated in all PitNET subtypes, which could represent novel, common therapeutic targets 428 
in these pathologies. These discoveries open a new window to investigate the plausible 429 
contribution of splicing dysregulation and its subsequent outcomes to pituitary tumorigenesis, 430 
and to assess the potential value of specific splicing machinery components as novel 431 
diagnostic/prognostic tools in these pathologies. Furthermore, our study unveils splicing, 432 
particularly SF3b1, as a novel actionable therapeutic point that can be targeted by Pladienolide-433 
B to combat PitNETs. 434 
435 
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FIGURE CAPTIONS 636 
 637 
Figure 1: Non-functioning pituitary tumors (NFPTs). (A) Heatmap of the mRNA expression 638 
levels of all spliceosome components measured in the qPCR array in NFPTs (n=90; green color) 639 
compared to NPs (n=11; red color). (B) Individual Fold-Change of each spliceosome 640 
component expression levels in NFPTs compared to NPs. (C) Principal Components Analysis 641 
(PCA) of the mRNA expression levels of the spliceosome components analyzed in the same set 642 
of samples. (D) Vip Scores top-feature of Partial Least Squares Discriminant Analysis (PLS-643 
DA). (E) Heatmap of the spliceosome components with higher vip score in the same set of 644 
samples. (F) mRNA expression levels of spliceosome components with higher vip score in 645 
NFPTs compared to NPs and ROC curves analyses showing the accuracy of the selected 646 
spliceosome components to discriminate between NFPTs and NPs. Data represent median ± 647 
interquartile range of absolute expression levels (copy number) of each transcript adjusted by a 648 
normalization factor. Asterisks (*** p<0.001) indicate statistically significant differences 649 
between groups. 650 
 651 
Figure 2: GH-secreting PitNETs (A) (A) Heatmap of the mRNA expression levels of all 652 
spliceosome components measured in the qPCR array in GHomas (n=48; green color) compared 653 
to NPs (n=11; red color). (B) Individual Fold-Change of each spliceosome component 654 
expression levels in GHomas compared to NPs. (C) Principal Components Analysis (PCA) of 655 
the mRNA expression levels of the spliceosome components analyzed in the same set of 656 
samples. (D) Vip Scores top-feature of Partial Least Squares Discriminant Analysis (PLS-DA). 657 
(E) Heatmap of the spliceosome components with higher vip score in the same set of samples. 658 
(F) mRNA expression levels of spliceosome components with higher vip score in GHomas from 659 
cohorts 1 (C1; n=48) and 2 (C2; n=96) compared to NPs (n=11) and ROC curves analyses 660 
showing the accuracy of the selected spliceosome components to discriminate between both 661 
cohorts of GHomas and NPs. Data represent median ± interquartile range of absolute expression 662 
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levels (copy number) of each transcript adjusted by a normalization factor. Asterisks (** 663 
p<0.01, *** p<0.001) indicate statistically significant differences between groups. 664 
 665 
Figure 3: ACTH-secreting PitNETs. (A) Heatmap of the mRNA expression levels of all 666 
spliceosome components measured in the qPCR array in ACTHomas (n=24; green color) 667 
compared to NPs (n=10; red color). (B) Individual Fold-Change of each spliceosome 668 
component expression levels in ACTHomas compared to NPs. (C) Principal Components 669 
Analysis (PCA) of the mRNA expression levels of the spliceosome components analyzed in the 670 
same set of samples. (D) Vip Scores top-feature of Partial Least Squares Discriminant Analysis 671 
(PLS-DA). (E) Heatmap of the spliceosome components with higher vip score in the same set of 672 
samples. (F) mRNA expression levels of spliceosome components with higher vip score in 673 
ACTHomas compared to NPs and ROC curves analyses showing the accuracy of the selected 674 
spliceosome components to discriminate between ACTHomas and NPs. Data represent median 675 
± interquartile range of absolute expression levels (copy number) of each transcript adjusted by 676 
a normalization factor. Asterisks (*** p<0.001) indicate statistically significant differences 677 
between groups. 678 
 679 
Figure 4: PRL-secreting PitNETs. (A) Heatmap of the mRNA expression levels of all 680 
spliceosome components measured in the qPCR array in PRLomas (n=9; green color) compared 681 
to NPs (n=11; red color). (B) Individual Fold-Change of each spliceosome component 682 
expression levels in PRLomas compared to NPs. (C) Principal Components Analysis (PCA) of 683 
the mRNA expression levels of the spliceosome components analyzed in the same set of 684 
samples. (D) Vip Scores top-feature of Partial Least Squares Discriminant Analysis (PLS-DA). 685 
(E) Heatmap of the spliceosome components with higher vip score in the same set of samples. 686 
(F) mRNA expression levels of spliceosome components with higher vip score in PRLomas 687 
compared to NPs and ROC curves analyses showing the accuracy of the selected spliceosome 688 
components to discriminate between PRLomas and NPs. Data represent median ± interquartile 689 
range of absolute expression levels (copy number) of each transcript adjusted by a 690 
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normalization factor. Asterisks (* p<0.05; *** p<0.001) indicate statistically significant 691 
differences between groups. 692 
 693 
Figure 5: Functional assays in response to pladienolide-B in pituitary cell lines and PitNETs 694 
primary cell cultures. (A) Dose-response experiments of cell proliferation in response to 695 
pladienolide-B at 10-7, 10-9, and 10-11 M in GH3 and AtT20 cells (n=4), measured by Alamar-696 
blue reduction. (B) Dose-response experiments of cell viability in response to pladienolide-B in 697 
NFPTs (n=5), GHomas (n=3), and ACTHomas (n=2), measured by Alamar-blue reduction. (C) 698 
Effect of pladienolide-B in GH secretion in GHomas (n=2), determined by commercial ELISA 699 
kit. Data are expressed as percent of vehicle-treated controls (set at 100%) within experiment. 700 
Values represent the mean ± SEM. Asterisks (* p<0.05; ** p<0.01; *** p<0.001) indicate 701 
statistically significant differences. 702 
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The anterior pituitary gland is a key organ involved in the control of multiple physiological functions
including growth, reproduction, metabolism and stress. These functions are controlled by ﬁve distinct
hormone-producing pituitary cell types that produce growth hormone (somatotropes), prolactin (lac-
totropes), adrenocorticotropin (corticotropes), thyrotropin (thyrotropes) and follicle stimulating hor-
mone/luteinizing hormone (gonadotropes). Classically, the synthesis and release of pituitary hormones
was thought to be primarily regulated by central (neuroendocrine) signals. However, it is now becoming
apparent that factors produced by pituitary hormone targets (endocrine and non-endocrine organs) can
feedback directly to the pituitary to adjust pituitary hormone synthesis and release. Therefore, pituitary
cells serve as sensors to integrate central and peripheral signals in order to ﬁne-tune whole-body ho-
meostasis, although it is clear that pituitary cell regulation is species-, age- and sex-dependent. The
purpose of this review is to provide a comprehensive, general overview of our current knowledge of both
central and peripheral regulators of pituitary cell function and associated intracellular mechanisms,
focusing on human and non-human primates.
© 2017 Elsevier B.V. All rights reserved.Contents
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the pituitary gland
The pituitary gland, also known as the “master gland”, is a
fundamental regulator of a plethora of relevant physiological
functions such as growth, puberty, reproduction, lactation, meta-
bolism and stress. To exert its function, the pituitary receives and
processes the information originating from central and peripheral
signals (as illustrated in Fig. 1) and appropriately conveys it to
several, key target endocrine and non-endocrine organs
(Musumeci et al., 2015). Thus, to achieve their goal, these complex
networks of multiple regulatory signals must be integrated
together to ﬁnely modulate the synthesis and release of various
pituitary hormones, which, in turn, will be responsible to control
the function of various organs involved in the vital processes
mentioned above (Musumeci et al., 2015).
The pituitary gland is located at the sella turcica, a depression in
the sphenoid bone, at the base of the brain (Lechan et al., 2000) and
is comprised of the adenohypophysis [consisting of the anterior
(subject of this review) and intermediate lobes] and the neurohy-
pophysis (or posterior lobe), which are two distinct structures from
the morphological and functional point of view, which display a
strong developmental and functional interplay (Asa De Grootet al,
2000). The adenohypophysis develops from an upward invagina-
tion of the oral ectoderm, named the Rathke's pouch (Kelberman
et al., 2009), which contains undifferentiated proliferative pro-
genitors that differentiate into ﬁve hormone-producing cell types:
growth hormone (GH)-producing or somatotrope cells, prolactin-
producing or lactotrope cells, adrenocorticotropin (ACTH)-pro-
ducing or corticotrope cells, thyrotropin (TSH)-producing or thy-
rotrope cells, and follicle stimulating hormone (FSH)/luteinizing
hormone (LH)-producing or gonadotrope cells (Musumeci et al.,
2015). Remarkably, the synthesis and release of these pituitary
hormones (GH, PRL, ACTH, TSH, FSH and LH) and the subsequent
fundamental actions on the numerous physiological processes cited
above are ﬁnely tuned by an intricate interplay among manyprimary regulators (Fig. 1). Speciﬁcally, the actions of multiple
central (mainly hypothalamic) and peripheral signals, with their
speciﬁc receptors located at the pituitary cells, are directly
orchestrated and integrated at the intracellular signal transduction
level to subsequently regulate pituitary hormone secretion.
Classically, the primary control of pituitary hormone secretion
was thought to reside in the hypothalamus. The hypothalamic
hormones involved in pituitary cell regulation have changed during
vertebrate evolution. For example, for somatotropes, somatostatin
(SST), GH-releasing factor (GHRH), and PACAP are considered the
main regulators in teleosts, amphibians and reptiles. In contrast,
PACAP does not have an obvious role in birds and mammals,
wherein GHRH and SST regulate GH secretion through a tight
interplay (for review, see (Gahete et al., 2008a)). There are many
other examples of evolutionary differences in the number and
nature of regulatory molecules implicated in the control of species-
dependent pituitary hormone synthesis and release. Although a
plethora of data has been generated using non-primate models
(rats, mice, etc.), more limited information has been generated in
humans due to the obvious intrinsic research limitations to explore
pituitary physiology; however, non-human primates have emerged
as suitable tools to model human pituitary function. Therefore, the
present review provides a comprehensive overview of the different
central and peripheral regulators of pituitary function and their
associated intracellular mechanisms, primarily focusing on studies
performed in humans and non-human primates.2. Non-human primates as suitable model for the study of
human physiology
The vast majority of the knowledge gathered to date about the
regulation of human pituitary cell function has been generated
through the use of laboratory rodents and human (patho)physio-
logical samples (such as fetal and tumoral cell cultures). However,
despite the signiﬁcant information generated using these ap-
proaches, there are still a number of aspects of the regulation of
Fig. 1. Representative model summarizing central and peripheral regulators involved in the modulation of the function of different cell types comprising the anterior
pituitary gland.
This model is based on the studies performed in human and non-human primates. Question marks (?) indicate regulators whose action have not been fully deﬁned. Those factors
shown in bold are primarily considered neuroendocrine factors, while those shown in standard type are considered coming from systemic sources. Those factors demarcated by
asterisks (*) can be produced by central and systemic tissues.
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Therefore, our laboratory and others have used pituitary cells ob-
tained from non-human primates. Speciﬁcally, baboons (Papio sp)
and rhesus monkeys (Macaca mulatta and Macaca fascicularis),
three species belonging to the Cercopithecoidea family (the Old
World monkeys) (Perelman et al., 2011), are the most commonly
used non-human primates in biomedical research. Indeed, results
obtained from non-human primate models are used for trans-
lational research to humans (Braundmeier and Fazleabas, 2009;
Comuzzie et al., 2003; McClure, 1984). Comparative genomic ana-
lyses exploring their molecular phylogeny and their evolutionary
process have revealed that the separation of this family from the
Hominoidea family occurred approximately 25 million years ago,
which is relatively recent compared to the separation of rodent
lineages with eutherian mammals that happened between 65 and85 million years ago (Eizirik et al., 2001; Page and Goodman, 2001).
Indeed, Macaca mulatta and Macaca fascicularis show a genetic
identity of 93,54% and 92,83% with Homo sapiens, respectively
(Gibbs et al., 2007; Ebeling et al., 2011). Additionally, the fact that
olive baboon (Papio anubis) also shares a high ﬁdelity at genomic,
proteomic and physiological levels, together with the in vivo and
in vitro conservation of the pituitary regulatory systems (as dis-
cussed below), makes these species suitable models to study the
effects of different peptides/hormones on pituitary cell function,
which cannot be evaluated in healthy human subjects. Hence,
current evidence supports the notion that non-humanprimates can
be considered as valuable and useful models to study normal, non-
pathological, human physiology (Braundmeier and Fazleabas,
2009; Guardado-Mendoza et al., 2009; Kineman and Luque,
2007; Luque et al., 2006, 2014; Iba~nez-Costa et al., 2015).
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3.1. Hypothalamic modulators of pituitary cell function
In 1965, it was shown for the ﬁrst time that hypothalamic ex-
tracts induced GH release (Müller and Pecile, 1965). Since that time,
the understanding of the neuroendocrine control of the somato-
trope, as well as other pituitary cell types has led to the identiﬁ-
cation of a plethora of central factors that regulate pituitary
function. Below is an overview of these central factors, shown in
bold in Fig. 1.
3.1.1. GH-releasing hormone (GHRH)
GHRH is a 44-amino acid peptide hormone originally isolated
and identiﬁed from a pancreatic tumour causing acromegaly
(Guillemin et al., 1982; Rivier et al., 1982) and subsequently shown
to be produced by neurons located in the arcuate nucleus (ARC) of
the human hypothalamus (Ling et al., 1984). GHRH has been un-
equivocally accepted as themain hypophysiotropic neuropeptide in
the generation and maintenance of pulsatile/episodic GH secretion
in humans (Gahete et al., 2009; Murray et al., 2015), as well as in
female rhesus monkey (Nakamura et al., 2003). Speciﬁcally, either
GHRH antagonism or ARC nucleus ablation results in an impair-
ment of GH pulsatility or complete loss of GH secretion, respec-
tively (Murray et al., 2015; Goldenberg and Barkan, 2007). In
addition, administration of synthetic GHRH reliably increases GH
release in humans (Goldenberg and Barkan, 2007), as well as in
female baboon pituitary cultures (Papio anubis) (Cordoba-Chacon
et al., 2012). Previous studies have shown that GHRH speciﬁcally
couples to GHRH receptor in somatotrope cells to activate multiple
intracellular signaling mechanisms. Thus, in several species,
including humans and baboons, it has been described that GHRH/
GHRH-R coupling signiﬁcantly stimulates GH release by activating
adenylate cyclase (AC), increasing cAMP production, which in turn
leads to an increase in protein kinase A (PKA) activity (Kineman and
Luque, 2007; Cordoba-Chacon et al., 2012; Mayo et al., 2000).
Additionally, it has been described that GHRH also requires other
signaling pathways such as intracellular and extracellular Ca2þ,
NOS/NO/GC/cGMP and/or PKC/PLC pathways to stimulate GH
release in other species including non-human primates (Kineman
and Luque, 2007; Gracia-Navarro et al., 2002).
3.1.2. Somatostatin (SST)
SST or somatotropin-release inhibitory factor (SRIF) is derived
from a 116 precursor that produces two different cyclic forms by
alternative post-translational processing: somatostatin-14 and
somatostatin-28. SST biological actions are mediated by its speciﬁc
interaction with at least 5 receptor subtypes (SST1-5 receptors),
which exhibit the structure of typical G-protein-coupled receptors
(GPCRs) with seven transmembrane domains. Similar expression
proﬁle for all ﬁve receptor subtypes has been reported in human
and baboon pituitary extracts and pituitary cell cultures, where
subtypes 2 and 5 are the predominant subtypes (Neto et al., 2009;
Cordoba-Chacon et al., 2011; Iba~nez-Costa et al., 2017a). Speciﬁc
SST binding elicits the recruitment of several downstream trans-
duction pathways including AC, protein phosphatases, cGMP
dependent protein kinases, and calcium and other ion channels
(Lim et al., 2000; Chang et al., 2012; Eigler and Ben-Shlomo, 2014).
Overall, SST exhibits inhibitory actions on virtually all (neuro)
endocrine secretions. At the anterior pituitary, SST is the main
inhibitory signal for somatotrope function by directly inhibiting GH
release as well as antagonizing the GH stimulatory effect elicited by
either GHRH or ghrelin (Gahete et al., 2009; Lim et al., 2000).
Interestingly, in non-human primates, it has been shown that SST
can exert both negative and positive effects on GH release(Cordoba-Chacon et al., 2011). Speciﬁcally, it has been documented
that high doses of SST do not alter basal GH secretion but block both
GHRH- and ghrelin-induced GH release (Cordoba-Chacon et al.,
2011). In contrast, low doses of SST signiﬁcantly stimulate GH
release, to a similar extent to that elicited by GHRH or ghrelin, in
primary pituitary cultures from female adult baboons (Papio
anubis) (Cordoba-Chacon et al., 2011). In this experimental model,
SST inhibitory actions were shown to be mediated through acti-
vation of SST1 and SST2 receptors, which involved AC and MAPK
signaling. In contrast, SST5 receptor signaling through AC/cAMP/
PKA and intracellular calcium pathways mediated the stimulatory
action of low doses of SST on GH release. In addition, it has been
reported that the main regulators of the hypothalamic-GH axis
(GHRH, ghrelin and SST) in baboons can also regulate the expres-
sion of their receptors by both homologous and heterologous
mechanisms (Cordoba-Chacon et al., 2012).
Besides the well described SST role on somatotrope function, it
has also been documented that SST regulates other anterior pitui-
tary cell types in several animal models, as well as humans
(Theodoropoulou and Stalla, 2013). Speciﬁcally, in human fetal pi-
tuitary cultures, SST has been reported to exert an inhibitory effect
on TSH, PRL and ACTH release, which mainly involves the differ-
ential participation of SST2 and SST5 receptors (Theodoropoulou
and Stalla, 2013; Shimon et al., 1997). SST-mediated inhibition of
PRL, ACTH, TSH, LH or FSH has also been described in healthy
humans (Weeke et al., 1975; Faure et al., 1977; Hadjidakis et al.,
1986; Yang et al., 1996; Bratusch-Marrain and Waldh€ausl, 1979;
Uberti et al., 1985). However, contradictory results have been
published showing no signiﬁcant effects of SST on spontaneous PRL
or ACTH secretion (Gottero et al., 2004).
3.1.3. Ghrelin
Ghrelin is a 28-amino acid peptide hormone originally isolated
from the stomach of humans and rats (Kojima et al., 1999) based on
its strong GH-releasing ability, which is mediated through the acti-
vation of the GH-secretagogue receptor 1a (GHSR1a), ﬁrst identiﬁed
as an orphan GPCR and later identiﬁed as the receptor for synthetic
GH-secretagogues. Soonafter its discoveryand isolation, ghrelinwas
also found tobepresent inmultiple organs and tissues. At the level of
the central nervous system, ghrelin expression has been detected in
the pituitary and hypothalamus (Ueberberg et al., 2009; Iba~nez-
Costa, 2015). Ghrelin circulates in two main forms, octanoylated
(acylated) and deoctanoylated (deacylated). Acyl-ghrelin was the
ﬁrst form to be identiﬁed, based on its ability to stimulateGH release
upon GHSR1a activation. In contrast, unacylated-ghrelin lacks the
GH stimulatory action elicited by acyl-ghrelin on somatotrope cells.
Although acylated ghrelin stimulatesGH secretion directly acting on
human (Tong et al., 2012) and monkey pituitaries (Kineman and
Luque, 2007), an indirect hypothalamic-mediated mechanism
involving an increase in GHRHand aweak inhibition of SST neurons,
has also been documented (Kineman and Luque, 2007; Baragli et al.,
2011; Lorenzi et al., 2009; Motta et al., 2016). In terms of signal
transduction, ghrelin/GHSR1a interaction at the pituitary level has
been shown to activate multiple signaling cascades, including
phospholipase C (PLC), protein kinase C (PKC), PKA (Kojima and
Kangawa, 2005), intracellular and extracellular Ca2þ or mitogen-
activated protein kinases (Lorenzi et al., 2009; Mousseaux et al.,
2006; Cami~na et al., 2007). Interestingly, besides its action on
somatotrope function, studies in humans and non-human primate
models have revealed that ghrelin also regulates anterior pituitary
function by inhibiting LH and FSH secretion and consequently
modulating reproductive function (Motta et al., 2016; Lanfranco
et al., 2008; Kluge et al., 2009), as well as stimulating PRL and
ACTH release (Motta et al., 2016; Takaya et al., 2000; van der Lely
et al., 2004; Coiro et al., 2005; Lengyel, 2006; Messini et al., 2011).
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PACAP is a C-terminally amidated peptide with two forms of 38
and 27 residues, which belongs to the VIP/secretin/glucagon su-
perfamily of peptides. It was ﬁrst isolated from ovine hypothalamic
extracts based on its ability to stimulate AC activity in rat pituitary
cells. In mammals, contradictory ﬁndings about the role of PACAP
on GH secretion have been documented. Some studies report a
stimulatory action while others, show no effect on GH release
(Gahete et al., 2009). In human somatotrope tumour cells, PACAP
was able to increase both cAMP production and GH release simi-
larly to that previously reported for GHRH although in a less potent
manner (Adams et al., 1994). This stimulatory action was shown to
involve the activation of voltage-operated/gated Ca2þchannels via
AC/PKA pathway (Gahete et al., 2009; Murakami et al., 2001).
Conversely, in healthy human volunteers, intravenous PACAP
administrationwas unable to induce GH and gonadotropins release
(Chiodera et al., 1996). However, it has been described that intra-
venous PACAP administration can regulate ACTH and PRL secretion
in different mammalian species including humans (Chiodera et al.,
1996; Thomas et al., 2012; Halvorson, 2014). PACAP elicits its bio-
logical action by coupling to different G-protein-coupled receptors
classiﬁed into three groups based on their differential afﬁnity for
PACAP or VIP. Thus, PACAP type 1 receptors (PAC1R) are more
speciﬁc for PACAP while VPAC1 and VPAC2 receptors present
similar afﬁnity for either PACAP isoforms or VIP. Additionally,
PAC1R alternative splicing generates at least ﬁve different PAC1R
subtypes that seem to trigger different signaling pathways as well
as their relative afﬁnity for PACAP isoforms (Halvorson, 2014;
Kanasaki et al., 2016). All these receptors are widely distributed
throughout the brain, including hypothalamus and pituitary, as
well as in peripheral organs (Halvorson, 2014; Kanasaki et al.,
2016).3.1.5. Gonadotropin releasing hormone (GnRH)
GnRH is a hypothalamic decapeptide released in a pulsatile
manner that is essential in the maintenance of reproductive func-
tion throughout the episodic secretion of gonadotropic pituitary
hormones (Krsmanovic et al., 2009). Indeed, the direct effect of
GnRH on LH and FSH release in healthy subjects is ﬁrmly estab-
lished (Jayasena et al., 2015). In line with this, a stimulation of LH
secretion in response to exogenous GnRH has been also reported in
macaques (Weinbauer et al., 1992). Additionally, a signiﬁcant in-
crease on LH secretion after GnRH treatment has been observed in
primary pituitary cell cultures from baboons. In most vertebrates,
including humans, at least two GnRH receptor (GnRH-R) isoforms
have been described, type I and type II GnRH-R. Both isoforms are
expressed at the pituitary and non-pituitary level, including
reproductive and non-reproductive tissues. Type I GnRH-R is the
functional receptor isoform that belongs to the G-protein-coupled
receptor superfamily with seven transmembrane domains, a hy-
drophilic extracellular domain and a hydrophobic cytosolic tail.
This GnRH-R differs fromothers GPCRs in its short cytosolic tail that
slows receptor internalization and prevents rapid desensitation
(Choi et al., 2012). Human type II GnRH-R is a non-functional iso-
form due to the presence of a frameshift and a premature stop
codon in its sequence (Choi et al., 2012; Limonta et al., 2012). The
signaling pathways involved in the GnRH actions cited above were
NOS/NO/GC/cGMP pathway and extracellular Ca2þmobilization but
not AC pathway (Luque et al., 2011). On the other hand, in higher
vertebrates, including humans and non-human primates, no data
have been documented on the effect of GnRH on GH release under
normal conditions, while several studies documented amodulatory
effect of GnRH on GH release under different pathological disorders
(Skinner et al., 2009).3.1.6. Kisspeptins
Kisspeptin (KISS1) is an amidated neurohormone ﬁrst identiﬁed
as a key regulator involved in GnRH control at the level of the hy-
pothalamus. KISS1 gene encodes a 145-amino acids precursor
protein that can originate four possible derivate peptides with 54-,
14-, 13- or 10-amino acids (Kotani et al., 2001; Muir et al., 2001;
Ohtaki et al., 2001; Stafford et al., 2002). All these peptides have
the same efﬁcacy and afﬁnity for their receptor, GPR54, being
kisspeptin-10 the most commonly used in biomedical research
(Ramaswamy et al., 2009; Smith et al., 2008). In addition to its
central effects, KISS1 and its receptor (GPR54, KISS1R or AXOR12)
are widely distributed in different tissues including pituitary gland,
suggesting that this neurohormone system could play an important
role in the control of hypophyseal hormone release (Kotani et al.,
2001; Muir et al., 2001; Ramaswamy et al., 2009; Clarkson et al.,
2009; Pinilla et al., 2012; Roa et al., 2011). Speciﬁcally, in non-
human primates (Macaca mulatta), kisspeptin-positive cells have
been described to be present in intermediate lobe co-localizing
with a-MSH, in neural lobe with GnRH axons, and, only in 50%
with ACTH-positive cells in the periphery of anterior lobe of pitu-
itary (Ramaswamy et al., 2009; Gahete et al., 2016). In humans,
kisspeptin-54 and kisspeptin-10 were able to similarly induce LH
and FSH levels. However, both kisspeptins were less potent in
stimulating gonadotropins levels than GnRH (Jayasena et al., 2015;
Narayanaswamy et al., 2016). Furthermore, intravenous adminis-
tration of kisspeptin-10 in Macaca mulatta increased LH levels, an
effect apparently mediated by hypothalamic actions (GnRH-
induced), while other hypophyseal hormones were not altered
(Ramaswamy et al., 2009). In addition, results from studies on
women did not conﬁrm a role of kisspeptin on GH, TSH and PRL
release after acute or chronic administration (Jayasena et al., 2014).
However, kisspeptins seem to exert a direct effect on primary pi-
tuitary cell cultures from baboons. Speciﬁcally, kisspeptin-10
stimulated GH and LH secretion and mRNA levels after short- and
long-term exposure (4e48 h), at a broad range of doses (1014 to
106) (Luque et al., 2011). In contrast, kisspeptin-10 did not alter
FSH, PRL, ACTH or TSH secretion/expression. The signaling path-
ways involved in the regulation of GH and LH pituitary hormones
by kisspeptins were phospholipase C, protein kinase C, MAPK, and
intracellular Ca2þ mobilization. Interestingly, LH, but not GH,
release also involved mammalian target of rapamycin (mTOR) and
PI3K (Luque et al., 2011). Taken together, in vitro and in vivo evi-
dences suggest that kisspeptins could play a relevant role, at least,
on LH regulation and seems to exert the effects not only through
hypothalamic actions but also directly on the pituitary gland.
3.1.7. Gonadotropin-inhibitory hormone (GnIH)
Gonadotropin-inhibitory hormone (GnIH) was initially discov-
ered in the quail hypothalamus, wherein its inhibitory action on
gonadotropin secretion from cultured anterior pituitary cells was
documented (Tsutsui et al., 2000, 2017). Subsequent studies
described that avian GnIH was well conserved across various
mammals and primates including humans, in which an inhibitory
action on reproductive function was also reported for these GnIH
orthologs (Tsutsui et al., 2000, 2017). In particular, the functional
human GnIH ortolog, RFRP-3, as well as other GnIH peptides are
called RF-related peptides (RFRPs) in that they share a common
structural feature with kisspeptins: the presence of a C-terminal
Arg-Phe-NH2 (RFamide) motif, thus belongings to the RFamide
peptide family members. In humans and non-human primates,
GnIH/RFRP neural cell bodies are located at the dorsomedial region
and intermediate periventricular nucleus of the hypothalamus,
respectively. In addition, human GnIH/RFRP expression in cell
bodies was also documented in other areas of the brain and in
neuronal ﬁbres projected to the median eminence (Ubuka et al.,
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Parkington, 2014). GPR147 (NPFF1, OT7T022) has been identiﬁed
as the cognate receptor that mediates GnIH/RFRPs inhibitory ac-
tions. In this sense, it has been reported in a rodent ovarian cell line
that RFRPs action reduces intracellular cAMP levels, suggesting that
GPR147 couples to Gi protein (Hinuma et al., 2000). Additionally, in
a mouse gonadotrope cell line, it has been reported that the
inhibitory action of RFRPs on gonadotropin secretion is mediated
by the inhibition of AC/cAMP/PKA/ERK pathway (Son et al., 2012).
Moreover, human RFRP-3 is able to inhibit, in vivo and in vitro,
GnRH-induced gonadotropin release in sheep through inhibition of
intracellular calcium mobilization (Clarke and Parkington, 2014).
3.1.8. Corticotropin-releasing hormone (CRH)
CRH is a 41-amino acid peptide hormone produced by neuro-
endocrine cells of the paraventricular nucleus of the hypothalamus.
At the anterior pituitary, CRH induces ACTH secretion, which, in
turn, stimulates the secretion of glucocorticoid hormones (mainly
cortisol in humans) from the adrenal cortex. CRH exerts its bio-
logical actions by coupling to speciﬁc receptors that recruit several
intracellular effectors such as cAMP and protein kinases
(Grammatopoulos, 2012). In addition, a role for CRH on somato-
trope function/GH release has also been described in lower verte-
brates (Rousseau et al., 1999; Rousseau and Dufour, 2007).
However, in humans and non-human primates, in the absence of
pathological conditions, there is not much evidence of such effect
to date. Interestingly, in patients suffering from acromegaly, two
independent groups have previously reported an increase in
circulating GH concentration after treatment with either CRH or
dexamethasone (DEX, a synthetic glucocorticoid). However, such
stimulatory effect on GH has not been conﬁrmed by other studies
(Gahete et al., 2009). On the other hand, it has been suggested a role
for CRH in the regulation of gonadotropin secretion based on the
presence of its receptor in pituitary gonadotropes (Kageyama,
2013). However, these results are not conclusive due to the fact
that CRH infusion in male rhesus macaques produced a clear in-
crease on ACTH and cortisol levels, but the LH levels were not
different from those observed in untreated control macaques
(Norman, 1993).
3.1.9. Thyrotropin-releasing hormone (TRH)
TRH is a short neuropeptide (pGlu-His-Pro-NH2) initially iso-
lated from hypothalamic extracts based on its ability to stimulate
the release of thyroid-stimulating hormone. In mammals, it has
been documented that TRH not only stimulates TSH but also PRL
and GH release, although with species-speciﬁc differences (Gahete
et al., 2009; Kanasaki et al., 2015). In humans, TRH induction in-
duces GH release in adenomatous cell cultures from acromegalic
subjects (Gahete et al., 2009; Okinaga et al., 2005). Under this
experimental setting, TRH-induced GH release was dependent on
the calcium inﬂux through L-type calcium channels, with an
attenuation in such calcium events elicited by a PKC inhibitor
(Okinaga et al., 2005). In lactotrope cells, activation of the TRH re-
ceptor by TRH recruits the participation of Gq protein and stimu-
lation of IP production, which in turn activates PKC pathway as well
as the release of Ca2þ from different stores. Other signaling
mechanisms triggered by TRH action includes ERK and MAPK
(Kanasaki et al., 2015).
3.1.10. Neuropeptide Y (NPY)
NPY is a 36-amino acid peptide widely distributed throughout
the central nervous system, with highest density of producing-
neurons located at the hypothalamic arcuate nucleus (Adams
et al., 1987). In some mammalian species, NPY seems to elicit a
stimulatory effect on GH secretion (Gahete et al., 2009). NPYactionsare mediated by multiple receptors that belong to the GPCR family
(Pedrazzini et al., 2003). NPY administration to patients with
prolactin-secreting pituitary adenomas, signiﬁcantly increased GH
levels in 60% of patients. However, in a different study, NPY
administration did not alter GH release when administered to
healthy young men (Lim et al., 2000). In several animal species, it
has been described that NPY indirectly regulates different pituitary
hormones secretion by acting ﬁrst at the hypothalamic level by
regulating the activity of GnRH, CRH, TRH and GHRH neurons
(Pedrazzini et al., 2003; Gaikwad et al., 2005). In fact, it was
described that administration of human NPY to the third cere-
broventricle in ovariectomized (OVX) rhesus monkeys produced a
marked LH suppression through the alteration of GnRH/LH secre-
tory system (Kaynard et al., 1990). Moreover, it was also shown that
NPY acts at the level of the median eminence to stimulate the
release of GnRH or directly enhancing the LH secretion in response
to GnRH through the transportation into the hypophyseal portal
blood. Both of these mechanisms seems to involve the mobilization
of intracellular calcium (Kalra and Crowley, 1992).
3.1.11. Dopamine (DA)
It has been previously reported that either DA precursor or DA
agonist administration stimulated GH release in humans when
administered subcutaneously, while decreased blood PRL concen-
tration (Lal et al., 1973). However, such effect was partially or totally
antagonized by an alpha-adrenergic component in monkeys and
humans (Müller et al., 1999). Conversely, inhibitory actions of DA on
GH release have also been reported (Müller et al., 1999; Garcia-
Tornadú et al., 2010). To date, ﬁve DA receptors (D1-5 receptors)
coupled to diverse downstream signaling pathways have been
described (Beaulieu and Gainetdinov, 2011). Lactotropes present
the highest expression level of DRD2 while, in somatotropes, the
DRD2 expression is signiﬁcantly lower to that observed in adeno-
matous somatotropes (Neto et al., 2009; Taboada et al., 2011; Ben-
Shlomo et al., 2016). Hetero- or oligomerization of SST receptors
and DRs has been studied in non-pituitary cell models andwas thus
suggested as a molecular mechanism in somatotrope cells for the
inhibition of GH release (Ben-Shlomo et al., 2016). In addition,
DRD2 expression was also found in a high percentage of other pi-
tuitary cells, thus indicating that DRD2 expression is not conﬁned
to lactotrope cells. Consistent with the broad pituitary expression of
DRs, one study reported DA can regulate ACTH release (Pivonello
et al., 2007). Although DA receptors have been widely associated
with multiple signaling pathways (Beaulieu and Gainetdinov,
2011), to the best of our knowledge the speciﬁc routes respon-
sible of DA effects on human or primate pituitary gland remain to
be determined.
3.1.12. Oxytocin (OT) and arginine-vasopressin (AVP)
OT and AVP are two hypothalamic hormones well known to
exert post-hypophyseal (systemic) actions. However, OT and AVP
have been also related with the modulation of anterior pituitary
hormones, which could be anticipated by the high concentrations
of both neurohormones found in the hypophyseal portal blood of
non-human primates (Plotsky, 1987; Zimmerman et al., 1973).
Indeed, AVP administration increases ACTH levels in healthy
humans, wherein AVP seems to enhance CRH-stimulated ACTH
release (Liu et al., 1983; DeBold et al., 1984; Hensen et al., 1988;
Meller et al., 1991; Erfurth et al., 1996). In fact, it was reported
that AVP from pituitary portal circulation is more important
altering ACTH levels than AVP derived from peripheral circulation.
Similarly, a stimulation of GH secretion has also been related with
AVP infusion in human and non-human primates (Meller et al.,
1991; Meyer and Knobil, 1966; Gagliardino et al., 1967; Brostoff
et al., 1968; Chiodera and Coiro, 1985) and probably these effects
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mechanisms and/or mediated in part through catecholamines
(Heidingsfelder and Blackard, 1968; Coiro et al., 1985). Regarding
PRL secretion, it was reported a signiﬁcant increase on PRL release
after AVP administration compared with saline infusions (Erfurth
et al., 1996). However, these results are not in agreement with
other reports where no alterations of PRL levels were observed in
response to AVP (Meller et al., 1991; del Pozo et al., 1980; Chiodera
et al., 1988). Finally, the rest of anterior pituitary hormones do not
seem to be signiﬁcantly affected by AVP infusion in humans
(Erfurth et al., 1996; Chiodera et al., 1988).
On the other hand, OT has been described to exert the opposite
role of AVP on ACTH secretion in humans. In this regard, several
studies have reported an inhibition of basal and stimulated ACTH
release in normal human subjects (Legros et al., 1982; Legros et al.,
1984; Gibbs, 1986; Chiodera and Coiro, 1987; Page et al., 1990). In
contrast, other reports have not found changes on plasma ACTH
levels after increasing doses of OT in men even when the OT doses
and administration routes were the same as the studies mentioned
above (Lewis and Sherman., 1985; Nussey et al., 1988; Coiro et al.,
2011). In line with this, OT infusions did not alter basal or CRH-
induced ACTH release in women, but was able to inhibit the
potentiating effect of AVP on CRH-stimulated ACTH release (Suh
et al., 1986). Regarding other anterior pituitary hormones, OT
administration did not relevantly alter GH, PRL, TSH or LH and FSH
responses in healthy humans (del Pozo et al., 1980; Page et al., 1990;
Coiro et al, 1987, 2011; Chiodera et al., 1984a). However, other
studies reported no changes on basal GH release, but a signiﬁcant
reduction on AVP-stimulated GH secretion (Chiodera et al., 1984b).
Additionally, OT administration enhanced PRL release in response
to vasoactive intestinal polypeptide (Chiodera et al., 1998) and TRH
in women (Coiro et al., 1987).
Although the above data demonstrate AVP and OT can mediate
anterior pituitary hormone secretion, in vitro data is lacking
whether these effects are direct or also represent the combined
actions of these peptides on central neuronal function, which may
in part help to explain the contradictory results currently available.
3.2. Other central modulators of pituitary cells function
3.2.1. Melatonin
Melatonin (MT) or N-acetyl-5-methoxy tryptamine is a hor-
mone produced by the pineal gland. The presence of MT receptors
at the pituitary gland suggested a possible inﬂuence of this hor-
mone on the regulation of anterior pituitary hormones (Weaver
et al., 1993; Wu et al., 2006). Indeed, the secretion of pituitary
hormones show a circadian rhythm (Landgraf et al., 1982) and it has
been suggested that these patterns could be a consequence of
nocturnal MT secretion (Forsling et al., 1999). Speciﬁcally, in vivo
studies suggest the inﬂuence of melatonin on the secretion of GH
and other pituitary hormones in primates and healthy humans
(Brandon et al., 2002; Lisoni et al., 1986; Smythe and Lazarus, 1973;
Wright et al., 1986; Kostoglou-Athanassiou et al., 1998). However,
the available data is not consistent. First, MT had a different effect
depending on the stage of human growth. In infants, diurnal cycles
seem to be beneﬁcial for growth, which suggests a negative cor-
relation between MT and GH at this age (Brandon et al., 2002). At
puberty, oral administration of MT treatment resulted in decrease
GH (Lisoni et al., 1986), which may explain a greater growth in this
age range in summer when MT levels are lower (Smythe and
Lazarus, 1973). On the other hand, in adults, MT administration
increased basal GH levels (Wright et al., 1986) and seemed to in-
crease sensitivity to GHRH via altering the SST inhibitory pathway.
However, other studies have shown that in youngmen,MT does not
inﬂuence GH release but correlates with PRL and cortisol(Kostoglou-Athanassiou et al., 1998), which was also observed by
others in bothwomen andmen (Bispink et al., 1990; Rao andMager,
1987). Exogenous MTadministration can also inﬂuence PRL, LH and
TSH secretion in women (Terzolo et al., 1993), wherein MT could
lead to hyperprolactinemia (Okatani and Sagara, 1993). In men, MT
administration has also been associated with a reproductive role,
by regulating LH and FSH secretion. Particularly, MT increases LH
amplitude pulse in a dose-independent manner without altering
FSH values (Cagnacci et al., 1991) and its decrease may lead to
sterility (Li and Zhou, 2015; Luboshitzky et al., 2000). Interestingly,
the effect of MT on pituitary secretions seems to be dose- and time-
dependent, in that MT causes an increase on neurohypophysial
hormones (AVP and OT) and GH at low doses (0,5mg), whereas at
high doses (5mg) the only GH levels are impacted (Forsling et al.,
1999). In addition, an acute MT administration increases GH
levels (Smythe and Lazarus, 1974; Valcavi et al., 1987) and modu-
lates the secretion of other pituitary hormones (LH and/or PRL) in
men and women (Ninomiya et al., 2001; Perras et al., 2005;
Waldhauser et al., 1987). Surprisingly, chronic MT administration,
does not cause any effect on GH (Wright et al., 1986). Studies per-
formed on non-human primates have shown that MTonly was able
to slightly affect the insulin-stimulated GH release without pro-
ducing any change in basal or stimulated PRL, TSH, LH or FSH
secretion (Chrousos et al., 1982). However, it has been recently
described the role of MT on primary pituitary cell cultures obtained
from baboons (Papio anubis), where MT showed clear stimulatory
actions on GH and PRL expression and secretion in a dose and time-
dependent manner through common and distinct signaling path-
ways. Speciﬁcally, the effects of MT on GH and PRL levels were
mediated through AC/PKA and extra-/intra-cellular calcium path-
ways, although the effects on GH, but not PRL release also required
the activation of PLC route. Regarding other pituitary hormones, MT
did not produce any change on ACTH, LH, FSH or TSH synthesis or
release on baboon primary pituitary cell cultures (Iba~nez-Costa
et al., 2015). Finally, it has been suggested that the action of MT
at the pituitary level could be mediated through the MT1 receptor
(Iba~nez-Costa et al., 2015; Dubocovich and Markowska, 2005).
3.2.2. Cortistatin (CORT)
CORT is a neuropeptide produced by post-translational cleavage,
which can lead to the generation of two mature products CORT-17
and CORT-29 in humans (Broglio et al., 2002a). CORT, as well as SST,
is distributed and expressed in wide variety of human and rodent
tissues (including pituitary gland), even more than that previously
assumed (Dalm et al., 2004; Cordoba-Chacon et al., 2016). Addi-
tionally, CORT shares with SST a high structural homology that
explains their similar capacity to bind the same family of receptors
(SST1-5 receptors) (de Lecea et al., 1996; Fukusumi et al., 1997;
Siehler et al., 1998, 2008; Spier and de Lecea, 2000). Despite the
structural and functional similarities of these molecules, they
display crucial differences (Broglio et al., 2008; de Lecea and
Castano, 2006), including the capacity of CORT, but not SST, to
bind to other receptors such as GHSR1a (Deghenghi et al., 2001,
2003), or Mrgx2 (an orphan G-protein-coupled receptor
belonging to Mas-related genes family) (Robas et al., 2003). Also
CORT is able to mediate different/opposite actions compared to SST
such as the effect on immune cells, the increase on slowwave sleep,
the reduction in the synthesis of inﬂammatorymediators, as well as
differential effects on pituitary function (see below) (Gahete et al.,
2008b). At the pituitary level, CORT inhibits GH release through
the activation of SST receptors in young males and, indeed, CORT
and SST show equal inhibition of GH release induced by GHRH,
ghrelin and synthetic analogues (Gottero et al., 2004; Broglio et al.,
2002a, 2002b; Benso et al., 2003; Iba~nez-Costa et al., 2017b).
However, CORT, as well as SST, did not affect ghrelin-stimulated
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showed the same inhibitory effect on ghrelin release (Broglio et al.,
2002b). Interestingly, CORT-8, a synthetic CORT-analogue that
binds GHSR1a but not SST receptors, was not able to modulate
ghrelin- or hexarelin-stimulated GH, PRL and ACTH release, sug-
gesting a predominant role of SST receptors on the known actions
of CORT on GH release (Prodam et al., 2008), which seems to be
further supported by in vitro studies (Deghenghi et al., 2001;
Muccioli et al., 2001). Indeed, in vitro observations in human fetal
pituitary cells using CORT showed an inhibitory effect on GH
release, which was even greater than that elicited by SST (Iba~nez-
Costa et al., 2017b; Rubinfeld et al., 2006). In female baboons
(Papio anubis), CORT blunted GH and ACTH basal secretion and also
decreased GH and POMC mRNA expression. Surprisingly, CORT
stimulated, while SST inhibited, PRL release in baboon primary
pituitary cell cultures without altering mRNA expression. This
stimulatory effect seems to be mediated through GHSR1a, since the
treatment with an antagonist of this receptor completely blocked
this stimulatory response to CORT (Cordoba-Chacon et al., 2011;
Iba~nez-Costa et al., 2017b). Finally, in primate pituitary cell cul-
tures, low concentrations of both CORT-17 and SST-14 (1017 and
1015M) are able to stimulate GH release through SST5 receptor
requiring activation of AC/cAMP/PKA and intracellular Ca2þ path-
ways. Therefore, all this information indicates that CORT directly
modulates the function of different pituitary cell types and these
actions in humans and non-human primate models are dose- and
cell type-dependent and receptor-speciﬁc (Cordoba-Chacon et al.,
2012).
4. Peripheral modulators of pituitary cell function
4.1. Glucocorticoids (GCs)
Glucocorticoids, the end products of the CRH (hypothalamic)
eACTH (pituitary)- adrenal axis, negatively feedback to suppress its
own axis function, where many reports demonstrate GC suppress
ACTH secretion in vivo and in primary pituitary cell cultures
(Waltman et al., 1991; Arvat et al., 1998; La Marca et al, 1999;
Roelfsema et al., 2016). GCs have also been shown to regulate GH
secretion (Mazziotti and Giustina, 2013) in vitro and in vivo in
humans and non-human primates (Luque et al., 2006; Kohler et al.,
1968; Mulchahey et al., 1988). In vivo observations in healthy
humans support the hypothesis that GCs are able to stimulate or
inhibit GH secretion depending on the speciﬁc conditions (dual
effect) (Mazziotti and Giustina, 2013; Pinto et al., 1999; Giustina
et al., 1990a; Casanueva et al., 1990; Burguera et al., 1990;
Kaufmann et al., 1988). Especially, during short-term incubations
(1 h), GCs produce an inhibition of GHRH-stimulated GH secretion
probably due to an increase of endogenous SST secretion (Giustina
et al., 1990a). This inhibitory effect was corroborated using acetyl-
cholinesterase inhibitors, which are known to elicit GH secretion
through a decrease in the hypothalamic release of SST (Massara
et al., 1986; Ghigo et al., 1987; Locatelli et al., 1986). Thus, the
presence of acetylcholinesterase inhibitors, alone or in combination
with GHRH, blocked the inhibitory effect of GCs on GH release
(Giustina et al., 1990b). In contrast, a rise of GH values was detected
after 3 h treatment with DEX (iv. or oral administration) in normal
subjects. Interestingly, after 12 h incubation with DEX, the GH
release was again inhibited (Casanueva et al., 1990; Burguera et al.,
1990). In fact, the GC prednisone was able to blunt GHRH-
stimulated GH response after 4 days of treatment in healthy sub-
jects (Kaufmann et al., 1988). Although the mechanisms behind
these effects are not yet clear, there are potential reasons that could
explain these responses: 1) a rise of GHRH secretion and inhibition
of negative feedback of IGF-I in a short period of treatment; 2) astable increase of SST release due to a sustained hypercortisolemia
and; 3) the time of administration. In contrast, the effects of GCs on
PRL secretion in healthy humans are still unclear inasmuch as
several reports showed a suppression on basal and TRH-stimulated
PRL levels after DEX administration (Dussault, 1974; Sowers et al.,
1977), which is in accordance with in vitro results described in
baboon (Steger et al., 1981). However, TRH-stimulated, but not
basal, PRL is reduced by DEX in women (La Marca et al, 1999), and
no effect on basal or stimulated PRL was found in normal subjects
(Re et al., 1976). These differences between studies could be due to
the dose of GCs, route of administration, experimental design or
even sensitivity limit of PRL radioimmunoassays. In addition, GCs
have been shown to alter TSH secretion in humans, where clear
inhibition has been observed in baseline and TRH-stimulated levels
in response to a short or a long-term GCs treatment and this sup-
pression was reﬂected by a fall in T3 concentration in adults and
preterm infants (Sowers et al., 1977; Re et al., 1976; Wilber and
Utiger, 1969; Otsuki et al., 1973; Faglia et al., 1973; Barbieri et al.,
1985; Brabant et al., 1987; Shimokaze et al., 2012). The use of hy-
pothalamic somatostatinergic and dopaminergic inhibitory com-
pounds revealed that these mechanisms are involved in the TSH
response to GCs treatment (Coiro et al., 2000). In addition to ACTH
and GH, GCs also modulated LH and FSH levels in humans. It has
been reported that DEX cannot alter basal LH or FSH, but decreased
LH levels after GnRH stimulation, but not conﬁrmed in another
study (Sakakura et al., 1978; Veldhuis et al., 1992).
Interestingly, one of the ﬁrst evidences showing the direct effect
of GCs on GH secretion in vitrowas the demonstration of a marked
increase of GH production after the treatment with cortisol in
primary pituitary cell cultures obtained from Macaca mulatta
(Kohler et al., 1968). Interestingly, the use of an inactive analogue
(11 a-hydroxycortisol) blunted the GH response, and the mecha-
nisms behind this effect involved protein and probably RNA syn-
thesis (Kohler et al., 1968). In line with this, treatment with DEX
also produced a signiﬁcant increase in GH secretion when fetal
rhesus monkey pituitary cells were treated (Mulchahey et al., 1988).
These results have been corroborated in another primate model,
Papio anubis, in which DEX and hydrocortisone (HY) caused a clear
increase of GH release in primary pituitary cell cultures after a 24 h
incubation period. Moreover, both GCs signiﬁcantly stimulated GH,
GHRH-R and GHS-R mRNA levels in baboon primary pituitary cell
cultures, which could suggest that the increase in GH mRNA is
translated into an increase of GH production and secretion (Luque
et al., 2006). Furthermore, similar results were obtained in cul-
tures of normal human pituitaries from patients with metastatic
breast carcinoma (Bridson and Kohler, 1970) and in human fetal
anterior pituitary cell cultures (Mulchahey et al., 1988). In both
cases, GCs (cortisol or DEX) were able to produce a marked increase
of GH release under basal and GHRH stimulated conditions in a
time-dependent manner (Mulchahey et al., 1988; Bridson and
Kohler, 1970). In contrast, in the case of PRL secretion, different
concentrations of cortisol signiﬁcantly decreased PRL secretion in
tissue fragments from baboon pituitary glands evenwhen TRH was
used to stimulate PRL release (Steger et al., 1981). To date, the vast
knowledge about the mechanisms and signaling pathways under-
lying these effects have been described mainly in rodents and
involve the activation of cAMP/PKA or PKC signaling pathways and
intracellular free calcium mobilization (Shipston, 1995); however,
whether the actions of GCs on human or primate pituitary hormone
secretions are mediated through these signaling pathways remains
to be fully elucidated.
4.2. Thyroid hormones (THs)
THs are produced and secreted by the thyroid gland and are
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through a direct negative feedback on pituitary gland (Brabant
et al., 1987). In this sense, T3 and T4 administration signiﬁcantly
reduced serum TSH levels without any alteration on its pulsatility
in healthy humans (Brabant et al., 1987). Moreover, TRH-stimulated
TSH response can be suppressed by THs alone or by T3 combined
with ipodate (iodinated radiocontrast agent that inhibits the con-
version of T4 to T3). Conversely, combination of T4 and ipodate did
not alter the TSH response to TRH. These results suggest that the
conversion of T4 to T3 could be important for the THs feedback
action (Brabant et al., 1987; Wenzel et al., 1975). In this regard, it is
important tomention that among thyroid hormone analogues such
as tetraiodothyroaceticacid (TETRAC) or triiodothyroaceticacid
(TRIAC), only TRIAC is known to be able to partially inhibits the
synthesis and secretion of TSH and PRL in normal subjects
(Medeiros-Neto et al., 1980; Menegay et al., 1989). Interestingly,
THs also seem to play a role in the regulation of GH as several
studies have described that an increase in THs levels in humans is
able to produce a strong reduction of pituitary GH release probably
due to a rise of hypothalamic SST tone (which blunted any stimu-
latory effect) or, to a reduction on GHRH release (Giustina and
Veldhuis, 1998; Giustina and Wehrenberq, 1995). However, THs
could also play a direct role in the regulation of somatotropes as T3
can decrease the expression of hGH gene in transfected GC cell
cultures (Cattini et al., 1986). Moreover, the negative effect of T3 on
GH secretion was also described in pituitary cultures from fetal
rhesus monkey and humans. Speciﬁcally, treatment of rhesus
monkey cells with T3 produced a signiﬁcant inhibition of GH
release after GHRH stimulation but did not alter basal GH secretion
(Mulchahey et al., 1988). Conversely, the results with human cells
showed a strong reduction of basal and GHRH-stimulated GH
secretion (Mulchahey et al., 1988). In the same line, T3 treatment
was also able to decrease hGH RNA levels without a clear effect at
the protein level in transgenic (171hGH/CS-TG) mice expressing the
human GH gene (Vakili et al., 2011). However, to the best of our
knowledge, the signaling pathways and mechanisms associated
with the effects of THs and its analogues in humans and non-
human primate pituitaries have not been identiﬁed.
4.3. Insulin and IGF-I
Insulin/IGF-I system comprises a complex family of related
peptides, membrane receptors and high-afﬁnity IGF binding pro-
teins (IGFBP) (Jones and Clemmons, 1995; Rajaram et al., 1997),
which have been directly associated with a strong regulation of
pituitary cell function in several models (Gahete et al., 2013;
Yamashita and Melmed, 1986). Indeed, IGF-I and IGFBP-3 are
positively correlated with spontaneous 24 h GH secretion
(expressed as AUC) in different healthy humans subgroups (sex or
pubertal stage) (Blum et al., 1993). IGF-I in turn acts via negative
feedback to the hypothalamus, as well as the pituitary to control GH
secretion. For example, low doses of recombinant IGF-I infusion
were able to blunt the fasting-stimulated GH secretion in men
fasted for 32 h (Hartman et al., 1993). In the same line, the
administration of recombinant IGF-I at physiological doses dimin-
ished GH response to GHRHwithout any alteration on spontaneous
GH levels (Ghigo et al., 1999). Moreover, it has been shown that
circulating free and not total IGF-I could be a key mediator of GH
secretion since the rise of GH levels after 24 h was negatively
correlated with the reduction of free IGF-I (Chen et al., 2005).
However, a single dose of recombinant IGF-I is not sufﬁcient to alter
basal or pulsatile GH release or impact FSH, LH and PRL levels, but
does suppress TSH (Trainer et al., 1994). This discrepancy between
different studies could be due to the dose or route of
administration.Insulin infusion, like IGF-I, has been shown to reduce GH
response to GHRH in healthy humans (Lanzi et al., 1997). Also, an
increase of insulin concentration observed in healthy humans un-
dergoing overeating, is accompanied by a reduction of GH levels
(Cornford et al., 2011). The action of both IGF-I and insulin could be
in part due to direct suppression of somatotrope function. Specif-
ically, IGF-I and IGF-II dose dependently decreased GH release in
both fetal and adults cultures (Goodyer et al., 1986). In that same
study, IGF also reduced PRL levels in adult, but not in fetal pituitary
cultures, while having no impact on ACTH or LH release (Goodyer
et al., 1986). In another study, IGF-I was able to suppress GH
mRNA levels induced by cAMP plus hydrocortisone and, to reduce
stimulated GH secretion without altering basal GH secretion in
human choriocarcinoma cells transfected with hGH gene
(Yamashita et al., 1987). Moreover, a suppression of somatrotrope
function has been reported in baboon primary pituitary cell cul-
tures wherein IGF-I was able to signiﬁcantly blunt GH release and
mRNA levels in a dose-dependent manner after 24 h of treatment.
Like IGF-I, insulin also inhibited GH secretion and mRNA levels at
physiological concentrations in baboon primary pituitary cell cul-
tures although with a different dose-dependent pattern (Luque
et al., 2006). In another study by the same group, the inhibitory
actions of insulin and IGF-I required distinct intracellular signaling
pathways to suppress somatotrope function in baboon pituitary cell
cultures (i.e. IGF-I acted through PI3K, mTORC1 and MEK routes
while insulin required PI3K), and that these pathways might be
common across mammalian species in that they observed similar
results using mouse primary pituitary cell cultures (Gahete et al.,
2013; Yamashita and Melmed, 1986). Taken together these studies
demonstrate IGF-I and insulin can directly regulate somatotrope
function under normal conditions (Luque et al., 2006), and since
both IGF-I and insulin are regulated by nutritional status, may
suggested changes in circulating GH levels observed during star-
vation or obesity (overeating) may in part be mediated by direct
actions of these hormones on somatotrope function.
4.4. Fatty acids
Free fatty acids (FFAs) have also been described as regulators of
pituitary function. Speciﬁcally, the majority of the information
available about the capacity of FFAs to regulate pituitary gland
function is related with the modulation of GH secretion. Thus, in
primates (rhesus monkeys), it was described a complete inhibition
of acute insulin-induced GH secretion after a soybean oil emulsion,
which produce an elevation of serum FFAs (Blackard et al., 1969).
Consistently, elevation of plasma FFAs produced a strong reduction
in GH release in rhesus and Java monkeys and lowering plasma
FFAs led to an increase in GH secretion, without altering PRL levels
(Quabbe et al., 1990). In healthy humans, as in primates, a reciprocal
relationship between FFAs and GH release has been reported
(Tsushima et al., 1970; Blackard et al., 1971; Fineberg et al., 1972;
Quabbe et al., 1972; Imaki et al., 1985; Casanueva et al., 1987;
Maccario et al., 1994; Pombo et al., 1999). Elevations in FFAs
induced by different types of lipid infusions are able to mediate a
signiﬁcant inhibition of GHRH-stimulated GH secretion, where it
has been hypothesized that this effect is due to suppressing GHRH
and/or stimulating SST secretion, or to a direct effect of FFAs on
somatotrope cells (Tsushima et al., 1970; Blackard et al., 1971;
Fineberg et al., 1972; Quabbe et al., 1972; Imaki et al., 1985;
Casanueva et al., 1987; Maccario et al., 1994; Pombo et al., 1999).
In support of a direct effect was a report showing that 24 h treat-
ment of baboon primary pituitary cell cultures with oleic and
linoleic acids markedly reduced GH release and mRNA levels. In
contrast to GH, no association between FFAs concentrations and
PRL levels has been observed in primates or humans (Quabbe et al.,
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induced elevations in circulating plasma FFAs evoked a strong
inhibitory effect of spontaneous ACTH and cortisol secretion in
humans, although the lipid load did not affect CRH-stimulated
ACTH levels (Casanueva et al., 1987; Lanfranco et al., 2004). In
contrast, another study indicated that FFAs did not alter basal ACTH
and cortisol secretion in normal men even when the FFAs levels
obtained in response to lipid load were comparable in both studies
(Mai et al., 2006). Therefore, further investigations are required to
clearly understand the speciﬁc role of FFAs at the level of the pi-
tuitary gland and the mechanisms involved in such actions.
4.5. Adipokines
Adipokines comprise a family of increasingly important cyto-
kines, mainly released from the adipose tissue, which includes
leptin, adiponectin or resistin. However, although certain studies
have reported the connection between leptin or adiponectin and
pituitary hormones, the precise implication of adipokines on the
modulation of human (or primate) anterior pituitary hormones
remains to be fully characterized. Indeed, exogenous treatment
with leptin in female rhesus monkeys (Macaca mulatta) caused a
rapid rise in LH concentration, which was followed by an increase
in serum estradiol and advanced puberty (Wilson et al., 2003). In
addition, leptin was also associated with an elevation of GH
secretion in this model (Wilson et al., 2003). Similarly, adiponectin
has been directly associated with GH pulse secretion in healthy
men, although it remains to be provenwhether this is a direct effect
(Makimura et al., 2011). Of note, leptin, adiponectin or resistin re-
ceptors are expressed in a wide variety of tissues and organs
including pituitary gland, wherein they seem to be involved in its
regulation (Jin et al., 1999; Psilopanagioti et al., 2009). In order to
determine if leptin mediated changes in pituitary hormone secre-
tion is due to direct pituitary actions, a recent report explored the
impact of adiponectin, leptin and resistin on primary pituitary cell
cultures from two primates species (Macaca fascicularis and Papio
anubis). This study demonstrated that adiponectin reduces GHRH-
stimulated but not ghrelin-stimulated GH release, and that it is able
to increase PRL and decrease ACTH without altering LH/FSH/TSH-
release. Conversely, leptin increased GH, PRL, ACTH and FSH
secretion but did not alter LH or TSH secretion. Finally, resistin, like
leptin, produced an elevation of GH and ACTH levels without any
alteration of PRL, LH, FSH or TSH secretion. In addition, only leptin
was able to increase GH, PRL and POMC at mRNA expression levels.
Interestingly, the direct effects induced by these adipokines were
mediated by common signaling pathways such as AC/PKA, but also
involved distinct and speciﬁc signaling cascades. Indeed, in addi-
tion to AC/PKA, leptin exerted its effects by activating intra-/extra-
cellular calcium and PLC/PKC, adiponectin also involved intra-/ex-
tra-cellular calcium, and resistin also induced its effects through
mTOR pathway (Sarmento-Cabral et al., 2017). Taken together,
these data demonstrate that adipokines could directly modulate
the function of anterior pituitary hormones in non-human pri-
mates, which could help to explain the results obtained in vivo in
humans and primates.
4.6. Obestatin
Obestatin is an amidated peptide hormone encoded by the
ghrelin gene and mainly produced in the gastrointestinal tract
(Zhang et al., 2005; Li et al., 2011). However, the use of human fetal
and adult tissue samples has revealed that obestatin is widely
distributed throughout human tissue, with prominent expression
in lung, pancreas, thyroid, gastrointestinal tract and pituitary gland.
Interestingly, a strong correlation between obestatin and ghrelinmRNA levels has been found in these tissues (Volante et al., 2009).
The data available in the literature about this hormone is confusing,
quite limited andmainly generated in rodentmodels; however, one
study has been recently published exploring the direct, in vitro,
effect of obestatin on the function of all pituitary cell types using
baboon primary pituitary cell cultures as model. Speciﬁcally, obe-
statin treatment did not alter GH or ACTH release or expression
after 4 h. However, GH was inhibited, while ACTH/POMC secretion
and expression was stimulated, in baboon primary cultures after
24 h of treatment. Additionally, obestatin also blunted ghrelin-
stimulated GH release. In contrast, other pituitary hormones (PRL,
FSH, LH and TSH) were not affected by obestatin treatment at any
time point tested. All these observations suggest that obestatin can
directly regulate somatotrope/corticotrope function in primary pi-
tuitary cell cultures from baboons, and that these actions are
mediated through the activation of AC and MAPK routes (Luque
et al., 2014).
4.7. Inhibins
Inhibins are glycoprotein hormones constituted by two different
subunits (a- and bA- or bB-subunit), which are linked to form
inhibin A or inhibin B. These glycoproteins are secreted by the
granulosa and theca cells of the ovary and by the Sertoli cells of the
testis (Ying, 1988). One of the ﬁrst evidence demonstrating the
effect of inhibins on non-human primate models was published by
Medhamurthy et al., where they showed the direct role of inhibins
in the regulation of FSH secretion in the male rhesus monkey
(Macaca mulatta). Speciﬁcally, the administration of ovine anti-
serum against inhibin a-subunit produced a hypersecretion and an
increase of pulse amplitude of FSH, but did not alter LH secretion or
pattern (Medhamurthy et al., 1990,1991). In the same line, pituitary
FSH secretion and expression were maintained at control values by
the infusion of recombinant inhibin in orchidectomized monkeys,
preventing the postcastration hypersecretion and overexpression
of FSH (Majumdar et al., 1995). In addition, a signiﬁcant reduction of
circulating FSH levels was detected after 54 h when recombinant
inhibin was administered by infusion to adult male rhesus mon-
keys. However, and in line with previous results, the infusion of
inhibin A did not alter the circulating LH concentrations in mon-
keys, which suggests that testicular inhibin actions are speciﬁc for
FSH at the pituitary level (Ramaswamy et al., 1998). Likewise,
exogenous inhibin administration to female rhesus monkeys spe-
ciﬁcally reduced FSH secretion during the mid-to-late luteal phase
of themenstrual cycle (Stouffer et al., 1994). Furthermore, the direct
effect of inhibin on FSH and LH secretion in pituitary cell cultures
from male rhesus monkeys and one cynomolgus monkey was
studied during 48 h of incubation, showing a reduction of 50,8% of
FSH release compared with controls while no effect was observed
on LH secretion (Fingscheidt et al., 1998). These results were
corroborated by another study developed with human fetal pri-
mary pituitary cell cultures. In this case, inhibin treatment clearly
reduced FSH levels but the effect on LH was inconsistent
(Blumenfeld and Ritter, 2001). Regarding the presence and role of
inhibins in humans, important gender differences have been
described, being inhibin A and B present at physiological concen-
trations in females, whereas only inhibin B was observed in males
(Hayes et al., 1998). In this sense, inhibin B secretion was found to
be decreased in older ovulatory womenwho showed a monotropic
FSH increase. On the contrary, inhibin A release in these women
was found similar to that in younger women. These results in
women suggest that inhibin B has an important role in the mod-
ulation of the intercycle FSH changes (Klein et al., 1996). In men,
results obtained from an acute sex withdrawal model (declined
testosterone and estradiol levels) showed that inhibin B is the
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2001a). Finally, with regard to the action mechanisms, the knowl-
edge about the inhibin effects is quite limited. One of the hypoth-
esis proposed has been that inhibins could act as a dominant
negative regulator of the activin signal transduction pathways (see
below) through the binding of bA subunit to the activin type II re-
ceptors with lower afﬁnity than activin (Woodruff, 1999). On the
other hand, several reports have found non-overlapping binding
sites for activin A and inhibin A in different tissues suggesting the
existence of inhibin-speciﬁc receptors. In this sense, two different
candidates has been identiﬁed as inhibin receptors, betaglycan
(TGF-b type III receptor) and inhibin binding protein/p120 (INHBP/
P120). However, none of them seem to satisfy all the criteria
required since betaglycan are not expressed in pituitary gonado-
trope cells and INHBP/P120 did not bind to inhibins in receptor
binding assays (Woodruff, 1999; Bernard et al., 2002). For that
reasons, additional studies are necessary to undoubtedly identify
inhibins receptor(s) and signaling mechanisms behind the
observed effects.
4.8. Activins
Activins, like inhibins, are glycoproteins that belong to TGF-b
superfamily. Activins are dimers composed by two different b
subunits, which can generate three isoforms: activin A (bA bA),
activin B (bB bB) or activin AB (bA bB) (Ying, 1988; Ling et al., 1986).
The presence of activins has been detected in some, but not all,
Leydig, Sertoli and granulosa cells of fetal primate gonads
(Rabinovici et al., 1991). Likewise, bA subunit was found in FSH-,
GH- and in a few PRL-positive cells in human pituitary gland
(Uccella et al., 2000). In the same way, bB subunit was detected in
TSH-cells, FSH- and LH-positive gonadotrophs (Uccella et al., 2000).
In primates, the ﬁrst results showing the effect of activins in the
function of pituitary gland were obtained from Macaca fascicularis.
Speciﬁcally, 2-days infusion of activin A to adult male macaques
produced a signiﬁcantly increase of basal FSH levels, without
changes in basal LH levels. However, GnRH-stimulated FSH and LH
levels were signiﬁcantly increased after 48 h of activin A adminis-
tration, showing a physiological role of activins on gonadotropin
secretion in non-human primates (McLachlan et al., 1989). In the
same way, the infusion of exogenous activin to female rhesus
monkeys stimulated FSH and LH production during the early
follicular phase of the menstrual cycle (Stouffer et al., 1993). On the
other hand, the speciﬁc direct role of activins on pituitary glandwas
studied using human fetal primary pituitary cell cultures. In this
case, treatment with recombinant activin A produced a potent in-
crease on FSH and LH release, being activin-stimulated LH secretion
less potent compared to GnRH treatment (Blumenfeld and Ritter,
2001). To date, the knowledge about the mechanisms and
signaling pathways underlying these effects involve the binding of
activins to two activin type II receptors (ActRII and ActRIIB), and
one type I receptor (ActIR/ALK4). Downstream signaling is medi-
ated by the SMAD signaling pathway, where these SMAD proteins
are phosphorylated and translocated to the nucleus as multimeric
complexes to regulate gene transcription (Gregory and Kaiser,
2004; Bilezikjian et al., 2012).
4.9. Follistatin
Follistatin (FST), originally called the FSH suppressing protein, is
a monomeric polypeptide considered a key regulator of the bio-
logical actions of activin. Therefore, this molecule regulates the
expression and secretion of gonadotropins contributing to their
importance as modulators of the reproductive axis (Welt and
Crowley, 1998). FST is secreted from mature gonadal cells,particularly its secretion has been associated to gonadotrophs and
folliculostellate cells probably in an autocrine or paracrine manner
(Welt and Crowley, 1998). Alternative splicing of this molecule
produce two polypeptide variants with different number of amino
acids (FST315 and FST288), although with the same mechanisms of
action (Shimasaki et al., 1988). The long-variant is distributed
throughout the body, while the short-variant is located in secretory
tissues (Sugino et al., 1993). Eachmolecule of FST binds to an activin
subunit. The complex activin-follistatin undergoes internalization
and lysosomal degradation causing an irreversible activin inhibi-
tion, downregulating FSH secretion and avoiding activin-activin
receptor binding (Hashimoto et al., 1997). Regarding to the effect
of FST in non-human primates, castration of rhesus monkeys pro-
duced an increase on FSHb, LHb and a-subunit mRNA levels and an
increase of FSH secretion, which was related to an unaltered pitu-
itary FST expression in these monkeys (Winters et al., 2001). In
humans, a slight decrease of both basal and GnRH-stimulated LH
and FSH concentrations in response to FST was detected in human
fetal primary pituitary cell cultures, which might be due to the fact
that FST could act directly blocking activin actions as it has been
described in other species (Blumenfeld and Ritter, 2001).
4.10. Estrogens
There is increasing evidence demonstrating estrogens directly
regulate pituitary cell function. In fact, estrogen receptors are
expressed in baboon lactotropes and gonadotropes, and to a lesser
extent in somatotropes and thyrotropes (Herbert and Sheridan,
1983; Sprangers et al., 1989). The ﬁrst observations about the
relationship between estrogens and GH levels were not conclusive.
Speciﬁcally, the effect of physiological or pharmacological estradiol
doses on the concentration of IGF-I and GHwas explored in castrate
and intact adult female baboons. These studies demonstrated that
only with intact baboons and physiological doses, estradiol was
able to increase plasma IGF-I levels, associated with an increase in
GH concentrations (Copeland et al., 1984). Likewise, castrated ma-
caques treated with estradiol revealed an increase on GH concen-
trations. However, estradiol treatment on castrated adult female
and male or juvenile female macaques pituitary cell cultures did
not show any effect on GH levels, although adult female monkeys
showed an increase on PRL secretion. Interestingly, only juvenile
male (<2 years), but not adult or juvenile female pituitary cultures
presented a mild increase on GH release, and a double immuno-
cytochemistry corroborated a different cell composition between
adult and juveniles pituitary cell cultures. Based on these results,
the authors suggested that estradiol was acting on a GH-secreting
cell population that was present in young male but not in adult
monkeys, and that this population was probably composed by
mamosomatotrope stem cells, which expressed estrogen receptors
(Bethea and Freesh, 1991). In humans, treatment with estradiol
decreased IGF-I and elevated basal GH and PRL concentrations in
men (Wiedemann et al., 1976). In postmenopausal women, estro-
gen treatment was able to enhance basal and exercise-induced GH
release and decreased IGF-I levels. The mechanisms behind these
effects in humans are not clear although possible options could be
central effects or a negative feedback related with IGF-I levels
(Dawson-Hughes et al., 1986). Regarding the role of estrogens on
other pituitary hormones, a direct effect of estradiol and proges-
terone on PRL secretion has been reported using pituitary cell
cultures from male and female monkeys. Thus, estradiol adminis-
tration signiﬁcantly increased PRL release compared to vehicle-
treated controls. However, estradiol and progesterone combined
treatment did not produce any difference in PRL secretion levels
compared to estradiol treatment suggesting that progesterone did
not exert any effect on PRL secretion (Bethea et al., 1988). In
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cynomolgus monkeys treated with estradiol (Sprangers et al.,
1990). On the other hand, estradiol has been described as the
predominant regulator of FSH secretion in men through the
aromatization of testosterone to estradiol (Hayes et al., 2001b).
Taken together, further studies are necessary to clearly elucidate
the role estrogens play on anterior pituitary hormones and the
signaling pathways underlying these effects.
4.11. Testosterone
In human and monkeys, testosterone acts as a gonadal compo-
nent of the negative feedback that regulate LH and FSH secretion;
however, the precise actions of testosterone on gonadotropin
secretion in humans and non-human primates seem not to be the
same (Fingscheidt et al., 1998; Matsumoto and Bremner, 1984). In
this sense, it has been demonstrated that testosterone replacement
after orchidectomy failed to prevent the postcastration FSH hy-
persecretion in male rhesus monkeys without altering LH levels,
which suggests that circulating testosterone concentrations are not
essential for the testicular inhibition of FSH secretion in rhesus
monkeys (Dubey et al., 1987). In the same line, treatment with
testosterone did not produce any change on basal or GnRH-
stimulated FSH or LH levels in primate pituitary cell cultures
(Fingscheidt et al., 1998; Kawakami and Winters, 1999). In contrast
to these data, the results reported in humans reveal that testos-
terone or its metabolites are able to inhibit FSH and LH secretion
acting at the pituitary and hypothalamus level. Moreover, although
the effect of testosterone on LH release appears to be through a
direct or indirect feedback, the aromatization of testosterone to
estradiol seem to be necessary to produce an effect on FSH secre-
tion (Hayes et al., 2001b; Matsumoto and Bremner, 1984; Sheckter
et al., 1989; Finkelstein et al., 1991). However, the signaling path-
ways associated to these effects have not been described. For these
reasons, further investigations are necessary to clarify the effects of
testosterone on gonadotropin hormones and the mechanisms un-
derlying these effects.
4.12. Endothelin
Endothelin (ET) is a peptide that contributes to constrict the
blood vessel and to rise blood pressure and, consequently, over-
expression of this molecule is associated with heart diseases. In
human, three different ET isopeptides encoded by three different
genes were identiﬁed and designated as ET-1, ET-2 and ET-3 (Inoue
et al., 1989). The presence of ET-3 in gonadotrophs cells has been
detected using immunoreactivity suggesting a potential role of ETs
in gonadotropins secretion (Naruse et al., 1992; Takahashi et al.,
1991; Lange et al., 1994). In vivo assays with healthy human male
volunteers showed that ET-1 intravenous administration produced
an increase on basal serum ACTH levels without altering the rest of
pituitary hormones. However, the increase of pituitary hormones
secretion stimulated by pituitary hormones releasing factors
(GHRH, CRH, GnRH, TRH) was altered in some cases after ET-1
administration. Thus, TSH-stimulated PRL levels and GHRH-
stimulated GH levels were decreased after ET-1 administration. In
contrast, ACTH, FSH and LH were enhanced and TSH was unaltered
in response to ET-1 treatment (Vierhapper et al., 1993). In a
different study, the effect of ET-1 and ET-3 administration was
further studied in men. In this sense, ET-1, but not ET-3, increased
plasma ACTH and PRL levels (Kiefer et al., 2000). Regarding the
mechanisms involved in ET actions, it is known that ACTH and GH
concentrations decreased when nifepidine (a calcium channel
blocker) was administered before ET-1 infusion, without any
alteration on other pituitary hormones. Based on these data, it hasbeen suggested that the effect observed in human in response to ET
could be, at least in part, mediated by calcium mobilization at the
pituitary level (Vierhapper, 1996).
4.13. Opioids
Opioids encompass any endogenous or exogenous agent that
binds to opioid receptors, which are located mainly in the central
nervous system. A signiﬁcant amount of reports have identiﬁed the
main types of receptors as mu-m, kappa-k and delta-d opioid re-
ceptors (Sadee et al., 1982). The effect of opioids at the pituitary
level depends on the cell type implicated. For instance, intrathecal
administration of opioids was able to modulate different pituitary
hormones in a group of 73 patients. The consequence of the chronic
and acute administration was a signiﬁcant decrease on serum LH
concentrations and, only in the chronic administration, FSH levels
(Abs et al., 2000; Delitala et al., 1983; Pende et al., 1986) through the
m-opioid receptor pathway (Mauras et al., 1987). The effect
observed on LH release was dependent on the sexual maturation
stage of patients due to the sex steroid hormones, which are
required for major modulating effects (Petraglia et al., 1986; Kletter
et al., 1991,1997). The effect of chronic opioid administration on PRL
levels is not clear since the information in the literature is contra-
dictory. Likewise, PRL levels were not modiﬁed in chronic patients
(males and females) that received opioids either intrathecally or
orally (Abs et al., 2000; Fraser et al., 2009). However, acute dose of
morphine caused an increase on PRL levels, demonstrating that this
effect is achieved through dopaminergic mechanisms (Delitala
et al., 1983). In this sense, in non-human primates, PRL release
was enhanced by dopaminergic pathways (Wehrenberg et al.,
1981). The use of opioid antagonists showed an increase of LH
levels that could be caused by a change on GnRH levels (Tenhola
et al., 2012). On the other hand, opioids increased plasma GH
level through a reduction of somatostatin tone in healthy males.
This conclusion was obtained after two studies using naloxone
administration (Tomasi et al., 1998; Barbarino et al., 1987). In
addition, TSH was elevated after opioids administration as it is
demonstrated in different studies (Delitala et al., 1983; Pende et al.,
1986; Roti et al., 1984). Speciﬁcally, the use of opioids and their
antagonists had greater effects in modifying the nocturnal pulses of
TSH by altering the circadian rhythm of this hormone (Samuels
et al., 1994; Leslie et al., 1985). However, these results regarding
TSH levels were not corroborated by another study (Abs et al.,
2000). Regarding ACTH levels, several reports indicated that the
use of these compounds reduced the pituitary ACTH response to
CRH through k-receptor (Allolio et al., 1987; Naber et al., 1981; Geer
et al., 2005; Palm et al., 1997; Conaglen et al., 1985; Rittmaster et al.,
1985; Grossman et al., 1986; Pfeiffer et al., 1986). Altogether, the
opiods seem to have a direct role at the hypophyseal level in
humans. Nevertheless, the information found in the literature is
contradictory in many cases, which suggests that additional studies
are necessary to clarify the real effect on pituitary hormones and
the mechanisms involved in these effects.
5. Signaling pathways involved in the regulation of pituitary
gland
As reviewed in detail above, the vast majority of the information
and knowledge regarding the signaling pathways involved in the
regulation of the synthesis and release of the different anterior
pituitary hormones has been generated using primary pituitary cell
cultures from non-human primate species. Indeed, almost all the
studies referenced in this review report the effect of the different
regulators on hormone release; however, not all of them explored
the effect on hormone expression. For this reason, it would be
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better understand the differential regulation of pituitary hormonal
synthesis and release by these regulators. On the other hand, the
major ﬁndings regarding signaling pathways of all studies included
in this review are summarized in Table 1. In particular, in these
studies, the main approach used to explore the signaling pathways
activated or inhibited in response to different pituitary regulators
has been the direct measurement of key second messengers
coupled to the use of speciﬁc pharmacological inhibitors to block
selected components of relevant routes. An overall view of all the
information available reveals that most of the data reported hith-
erto in the literature is mainly focused in the mechanisms involved
in the regulation of GH release by different central and peripheral
modulators (Table 1). When taken together, these data indicate that
the regulation of GH release by different modulators is carried out
through the modulation of multiple, common and distinct,
signaling pathways. Speciﬁcally, most of the GH regulators act
through two common signaling pathways such as AC/PKA (except
for kisspeptins) (Kineman and Luque, 2007; Iba~nez-Costa et al.,
2015; Gahete et al., 2009; Cordoba-Chacon et al., 2012; Mayo
et al., 2000; Cordoba-Chacon et al., 2011; Murakami et al., 2001;
Sarmento-Cabral et al., 2017) and extra- and/or intracellular cal-
cium mobilization (except for PACAP, resistin and obestatin)
(Kineman and Luque, 2007; Iba~nez-Costa et al., 2015; Cordoba-
Chacon et al, 2011, 2012; Luque et al., 2011; Sarmento-Cabral
et al., 2017; Vierhapper, 1996). In addition, most of the modula-
tors of GH secretion simultaneously elicit the activation and/or
inhibition of additional routes. Indeed, ghrelin and kisspeptinsTable 1
Summary of the signaling pathways modulated by different regulators on the secretion
Hormone Signaling pathways Regulators Referenc
GH AC/cAMP GHRH, Ghrelin, CORT, SST, PACAP, MT,
Leptin, Adiponectin, Resistin, Obestatin
(Kinema
Cordoba-
et al., 20
Extra- and/or intra-
cellular Ca2þ
mobilization
GHRH, Ghrelin, CORT, SST, MT,
Kisspeptins, Leptin, Adiponectin,
Endothelin
(Kinema
Cordoba-
1996)
PLC/PKC GHRH, Ghrelin, MT, Kisspeptins (Kinema
et al., 20
PI3K Leptin, Adiponectin, Resistin (Sarmen
MAPK Ghrelin, Kisspeptins, Obestatin (Kinema
mTOR Resistin (Sarmen
NOS/GC GHRH (Kinema
PRL AC/cAMP MT, Leptin, Adiponectin (Iba~nez-C
Extra- and/or intra-
cellular Ca2þ
mobilization
MT, Leptin, Adiponectin (Kinema
PI3K Leptin, Adiponectin (Sarmen
ACTH AC/cAMP Ghrelin, Obestatin, Leptin, Adiponectin,
Resistin
(Luque e
MAPK Ghrelin, Obestatin (Luque e
PI3K Leptin, Adiponectin, Resistin (Sarmen
Extra-cellular Ca2þ
mobilization
Endothelin (Vierhap
LH Extra- and/or intra-
cellular Ca2þ
mobilization
GnRH, Kisspeptins, GnIH (Luque e
PLC/PKC Kisspeptins (Luque e
MAPK Kisspeptins (Luque e
mTOR Kisspeptins (Luque e
PI3K Kisspeptins (Luque e
NOS/GC GnRH (Luque e
SMAD Activins (Gregory
FSH AC/cAMP GnIH, Leptin (Son et a
PLC/PKC Leptin (Sarmen
PI3K Leptin (Sarmen
Extra- and intra-cellular
Ca2þ mobilization
GnIH, Leptin (Clarke a
SMAD Activins (Gregorymodulate GH release also through PLC/PKC and MAPK pathways
(Kineman and Luque, 2007; Luque et al., 2011), while MT also
regulate PLC/PKC pathway (Iba~nez-Costa et al., 2015). Alternatively,
GHRH-mediated GH release required NOS/NO/GC/cGMP pathway
(Kineman and Luque, 2007), obestatin is also able to inhibit GH
release through MAPK signaling pathways (Luque et al., 2014), and
adipokines use PI3K,whereas resistin activates the mTOR pathway
to regulate GH release (Sarmento-Cabral et al., 2017).
Regarding PRL regulation, MT, leptin and adiponectin are able to
exert their effects on PRL secretion through AC/PKA pathway and
extra-/intra-cellular Ca2þ mobilization (Iba~nez-Costa et al., 2015;
Sarmento-Cabral et al., 2017). The stimulation of PRL release by
leptin and adiponectin also involves the activation of PI3K pathway
(Sarmento-Cabral et al., 2017). On the other hand, the regulation of
ACTH is mediated through AC/PKA by ghrelin, obestatin and adi-
pokines, through MAPK by ghrelin and obestatin, through PI3K by
adipokines (Kineman and Luque, 2007; Luque et al., 2014;
Sarmento-Cabral et al., 2017), and also through extracellular Ca2þ
mobilization by endothelins (Vierhapper, 1996). In the case of go-
nadotropins, both LH and FSH hormones are differentially regu-
lated by distinct but also by some common signaling pathways.
Likewise, LH is modulated through PLC/PKC, intracellular Ca2þ
mobilization, MAPK, mTOR and PI3K by kisspeptins, through
extracellular Ca2þ mobilization and NOS/NO/GC/cGMP pathway by
GnRH (Luque et al., 2011), through intracellular Ca2þ mobilization
and AC/PKA by GnIH (Clarke and Parkington, 2014; Son et al., 2012)
and through SMAD signaling by activins (Gregory and Kaiser, 2004;
Bilezikjian et al., 2012). Additionally, FSH release mediated by GnIHof anterior pituitary hormones.
es
n and Luque, 2007; Luque et al., 2014; Iba~nez-Costa et al., 2015; Gahete et al., 2009;
Chacon et al., 2012; Mayo et al., 2000; Cordoba-Chacon et al., 2011; Murakami
01; Sarmento-Cabral et al., 2017)
n and Luque, 2007; Iba~nez-Costa et al., 2015; Cordoba-Chacon et al., 2012;
Chacon et al., 2011; Luque et al., 2011; Sarmento-Cabral et al., 2017; Vierhapper,
n and Luque, 2007; Iba~nez-Costa et al., 2015; Gracia-Navarro et al., 2002; Luque
11)
to-Cabral et al., 2017)
n and Luque, 2007; Luque et al., 2014; Luque et al., 2011)
to-Cabral et al., 2017)
n and Luque, 2007)
osta et al., 2015; Sarmento-Cabral et al., 2017)
n and Luque, 2007; Sarmento-Cabral et al., 2017)
to-Cabral et al., 2017)
t al., 2014; Cami~na et al., 2007; Coiro et al., 2005; Sarmento-Cabral et al., 2017)
t al., 2014; Mousseaux et al., 2006; Cami~na et al., 2007)
to-Cabral et al., 2017)
per, 1996)
t al., 2011; Clarke and Parkington, 2014; Son et al., 2012)
t al., 2011)
t al., 2011)
t al., 2011)
t al., 2011)
t al., 2011)
and Kaiser, 2004; Bilezikjian et al., 2012)
l., 2012; Sarmento-Cabral et al., 2017)
to-Cabral et al., 2017)
to-Cabral et al., 2017)
nd Parkington, 2014; Son et al., 2012; Sarmento-Cabral et al., 2017)
and Kaiser, 2004; Bilezikjian et al., 2012)
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Parkington, 2014; Son et al., 2012), by leptin involve AC/PKA, PLC/
PKC, extra-/intra-cellular Ca2þ mobilization and PI3K (Sarmento-
Cabral et al., 2017) and by activins also involve SMAD signaling
(Gregory and Kaiser, 2004; Bilezikjian et al., 2012). Taken together,
all this information suggests that the central and peripheral mod-
ulators mentioned above, in most cases, converge in multiple and
similar signaling pathways to regulate the function of different
anterior pituitary cell types (Table 1). However, only some selected
signaling pathways have been explored in these studies, which
suggest that more in vitro studies are necessary to understand the
full landscape of signaling pathways involved in the regulation of
pituitary gland function in humans and in non-human primate
models.
6. Concluding remarks
This review summarizes what we know to date regarding both
central and peripheral factors involved in the regulation of pituitary
cell function (Fig. 1), specially focusing on studies performed in
humans and non-human primates, and paying special attention to
intracellular mechanisms underlying this regulation. Although
some regulators seem to exert discrepant results depending on the
study, it seems solidly demonstrated that the regulation of pituitary
function is triggered by an integration of multiple factors acting
simultaneously and/or sequentially at this gland, which converge,
and ultimately result, in the activation and/or inhibition of multi-
ple, common and distinct, signaling pathways to ﬁnely modulate
the synthesis and secretion of the different anterior pituitary hor-
mones. The broad perspective gained through this review highlight
the importance of the pituitary gland, often referred to as the
“master endocrine gland” of the organism, as a true sensor of whole
body function, able to gauge the status of growth, reproduction,
lactation, stress, metabolism and in turn adjust pituitary hormone
synthesis and release to ﬁnely control thewhole-body homeostasis.
This growing number of regulators, interactions and mechanisms,
supports the view that the control of pituitary function is far more
complex than originally envisioned, and that future studies will
need to be implemented in order to elucidate the precise effects of
various regulators mentioned in this review, the complete set of
their underlying mechanisms, and the network of interactions
among them.
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